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Until 1983 the third-generation cephalosporins (3GCs) were thought to be resistant to
hydrolysis by all plasmid-mediated P-lactamases. By the end of the 1980s, however,
transferable TEM- and SUV-derived P-lactamases, known as extended-spectrum
P-lactamases (ESBL), that conferred resistance to the 3GCs, were regularly identified
in clinical isolates.
The gene encoding TEM-E2 (Z>/aT-E2), an ESBL identified in an isolate responsible
for an outbreak of infection in a neonatal unit in 1982, was sequenced. As cloning of
PCR-amplified DNA fragments proved difficult, a new technique for direct DNA-
sequencing of PCR-amplified DNA fragments was developed. From the DNA
sequences of Z>/aT-E2puK721 generated by this method, a mutant adenine residue was
identified at DNA residue number 692. pUK721 encoded both TEM-1 and TEM-E2,
the latter enzyme being identical to the TEM-12 P-lactamase.
Silent mutations, or minimally important mutations, occur frequently with little
functional consequence, but may prepare bacteria for a more drastic change when
challenged with a 3GC: acquisition of a single innocuous mutation facilitates the
occurrence of a more dangerous double mutation. Clavulanic acid, in combination
with amoxycillin, has been shown to promote back-mutations in ESBL by a
mechanism of gene duplication facilitated by intramolecular transposition.
Escherichia coli J62-2 (TEM-5pcFF14) was subcultured in liquid media containing
limiting concentrations of ampicillin or amoxycillin/clavulanic acid (ratio 2:1) for five
days. The minimum inhibitory concentrations (MICs) of various P-lactam antibiotics
revealed some strains with increased resistance to amoxycillin/clavulanic acid,
ceftazidime and cefotaxime. Increased resistance corresponded to multiple
P-lactamase expression (three enzymes with isoelectric points (pi) of 5.57, 5.5
and 5.25). Enzyme kinetics of each P-lactamase showed significant similarity to the
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TEM-10 (pi 5.57), TEM-5 (pi 5.5), and TEM-12 (pi 5.25) P-lactamases; this
suggested that these were the identities of the mutant P-lactamases. Southern blotting
of restricted plasmid DNA showed that gene duplication had occurred to create the
mutant plasmid, pUK3007, from the parent plasmid (pCFF14).
Strains of E. coli J62-2 containing the mutant plasmid (pUK3007) or the parent
plasmid (pCFF14) were passaged in liquid media containing limiting concentrations of
ampicillin or amoxycillin/clavulanic acid (ratio 2:1) for a further 20 day period.
Analysis of passaged strains revealed that anomalous changes in the MICs of
amoxycillin/clavulanic acid, cefotaxime and ceftazidime corresponded to the presence
of one of two P-lactamases (pi 5.5, and 5.4). Each strain was shown to harbour a
single plasmid, and Southern blotting showed the presence of one TEM P-lactamase
gene or two TEM P-lactamase genes despite each strain expressing only a single
p-lactamase. Enzyme kinetics of each P-lactamase confirmed that the novel enzymes
were TEM-5 (pi 5.5) and TEM-1 (pi 5.4). The combination of amoxycillin with
clavulanic acid promotes the selection of either a 'terminus' ESBL or a
narrow-spectrum prototype enzyme within an individual strain.
I suggest the hypothesis that the evolution of the parent P-lactamase to ESBL can
consist of both forward and backward mutations at well defined locations. My results
have shown that amoxycillin in combination with clavulanic acid selected back
mutations to TEM-1 or the intermediate ESBL. The back mutations were facilitated
by gene duplication. The point-mutations occur in the TEM-gene during duplication
of the gene. In a non-selective environment one of the duplicate genes is usually
deleted.
Escape into the environment may result in challenge of the host organism with a
penicillin and a P-lactamase inhibitor. Such a biological pressure would select against
the ESBL, and may induce back mutations to the more innocuous enzymes, for
example TEM-17 or SHV-3. These results would also help explain the evolution of
such a diversity of "terminus" enzymes, such as TEM-3, TEM-5, TEM-9 and
TEM-24, that essentially provide the same service to the host strain.
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The common abbreviations used throughout the text of this thesis are listed
alphabetically below. Standard amino acid abbreviations are listed in the table on
page xvi, and the genetic code is given in the table on page xvii.
%c total crosslinking monomer
concentration per 100ml
%T total monomer concentration
per 100ml
%v/v volume (ml) per 100ml
%w/v weight (g) per 100ml




A260 absorbance at X = 260nm
A280 absorbance at X = 280nm




blctT TEM P-lactamase gene
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BSA bovine serum albumin
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X wavelength of light
X DNA lambda phage DNA
lac lactose non-fermentor
lacZ P-galactosidase gene
lacZ' portion of the lacZ gene
encoding a-protein
LB Luria-Bertani medium
M.Wt. molecular weight (mass)
mA milliAmperes
MCS multiple cloning site







OD550 optical density at X = 550nm
OMP outer membrane protein
ORF open reading frame
p.o. oral administration (per oris)
PBP penicillin-binding protein
PCR polymerase chain reaction
PEG polyethylene glycol






RNase A ribonuclease A
rpm revolutions per minute
SDM site-directed mutagenesis
SDS sodium dodecyl sulphate




















Vv max maximum rate of hydrolysis
w Watts





Amino acid Three-letter One-letter Molecular
abbreviation abbreviation weight
Alanine Ala A 89
Arginine Arg R 174
Asparagine Asn N 132
Aspartic acid Asp D 133
Asparagine or aspartic acid Asx B -
Cysteine Cys C 121
Glutamine Gin Q 146
Glutamic acid Glu E 147
Glutamine or glutamic acid Glx Z -
Glycine Gly G 175
Histidine His H 155
Isoleucine lie 1 131
Leucine Leu L 131
Lysine Lys K 146
Methionine Met M 149
Phenylalanine Phe F 165
Proline Pro P 115
Serine Ser S 105
Threonine Thr T 119
Tryptophan Trp W 204
Tyrosine Tyr Y 181
Valine Val V 117
Abbreviations & molecular weights of amino acids
xv i
Abbreviations
First base Second base
Third base of codon
of codon of codon
G A C T
G G Gly Gly Gly Gly
A Glu Glu Asp Asp
C Ala Ala Ala Ala
T Val Val Val Val
A G Arg Arg Ser Ser
A Lys Lys Asn Asn
C Thr Thr Thr Thr
T Met lie lie lie
C G Arg Arg Arg Arg
A Gin Gin His His
C Pro Pro Pro Pro
T Leu Leu Leu Leu
T G Trp UGA Cys Cys
A Stop (amber) Stop (ochre) Tyr Tyr
C Ser Ser Ser Ser
T Leu Leu Phe Phe
The genetic code
Abbreviations: A, adenine; C, cytosine; G, guanine; T, thymine; U, uridine. The three letter amino acid
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T I O N
1. Prologue
There are primarily three mechanisms of p-lactam antibiotic resistance in bacteria:
• The target enzymes of P-lactams, collectively known as the penicillin binding
proteins, can become insensitive to the antibiotic.
• The bacterial cell envelope can become impermeable to the P-lactam antibiotic
through loss or mutation of certain outer membrane proteins (OMPs) or porins.
• Thirdly, and by far the most predominant method of P-lactam resistance, is the
enzymatic destruction of the antibiotic. These enzymes are known generically as
P-lactamases, but they are also called penicillinases if they only hydrolyse
penicillins, or cephalosporinases if they only hydrolyse cephalosporins.
P-lactamases confer resistance to penicillins, cephalosporins and related P-lactam
antibiotics by their ability to bind and hydrolyse these drugs before they reach their
target sites. In bacteria these targets are known as penicillin-binding proteins (PBPs),
and in Gram-negative bacteria are located on the inner membrane of the cell envelope.
The P-lactamases of bacteria are cell bound, periplasmic, or secreted. In Gram-
negative organisms the p-lactamases are located in the periplasm, between the outer
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layer and the membrane, ready to intercept incoming P-lactam molecules. The
P-lactamases of staphylococci and enterobacteria are the most studied of this class of
enzyme because of their obvious role in the emergence of resistance to P-lactam
antimicrobials in the clinical setting; P-lactamases are produced by many other genera,
including Mycobacterium, Legionella, Actinomyces, and Nocardia [1], Certain
mammalian cell enzymes have also been shown to exhibit some P-lactamase function,
for example renal dehydropeptidases [1],
Although many P-lactamases of clinical importance are encoded by genes on the
bacterial chromosome, the most prevalent and successful resistance genes are carried
by plasmids and usually within transposons. Unlike their chromosomally-encoded
counterparts, the plasmid-mediated enzymes in Gram-negative bacteria are usually
produced constitutively so that any change in the ability to confer resistance will
probably stem from changes in the structure of the molecule rather than changes in
expression of the gene.
The discovery and evolution of P-lactamases has paralleled the discovery and clinical
use of P-lactam antimicrobial agents. The plasmid-mediated TEM- and SHN-derived
extended-spectrum p-lactamases (ESBL) have evolved over a short period of time
from the TEM-1 and SHV-1 P-lactamases. The plasmid-mediated TEM- and
SHV-(y/?<? P-lactamases are the most common mechanism of resistance to the
p-lactam group of drugs in Gram-negative bacteria [2, 3], These two ubiquitous
enzyme types have a broad spectrum of activity and preferentially hydrolyse the
penicillins together with some first- and second-generation cephalosporins. The
ESBL, the substrates of which include the so called 'P-lactamase-stable' third-
generation cephalosporins (3GCs), have emerged in clinical bacteria on every
continent, and have become an enormous clinical threat to this class of
pharmaceutical. The ESBL that are appearing sporadically are a response of the
bacteria to treatment of infections by the 3GCs, ceftazidime and cefotaxime.
The p-lactam antibiotics have played a key role in reducing the impact of life
threatening diseases. Serious infections, however, remain a major and potentially life-
threatening problem among vulnerable patients. Intensive Therapy Units (ITUs), for
example, provide an environment that is especially favourable to the development and
spread of pathogens [4] and the ESBL.
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2. The history of antimicrobial agents
Often traditional and folk remedies, many of which have been formulated through
centuries of experience, can be shown to have a sound pharmacological basis for their
ascribed action. A Mesopotamian pharmacopoeia, the earliest known and dating from
about 2100BC [5], describes preparations for the control of sepsis, which work by
osmotic effects. Honey was frequently used as a component of ancient nostrums for
its anti-inflammatory and antimicrobial attributes. Osmotic desiccation can account for
part of the observed efficacy, however, the non-monosaccharide components of honey
have a more direct antimicrobial action [5], In recent years, sugars, in the form of
granulated sugar in combination with debriding agents, have had a resurgence in
popularity for the treatment ofwound infections [6-8],
Substances with better and more efficient antimicrobial agents have always been
sought, therefore, even the most unlikely substances have been investigated. Fungi
have been used in herbal medicine for many hundreds of years, partly for their
antimicrobial action. The therapeutic use of hyssop by ancient civilisations may be
significant when considering that the first description ofPenicillium notatum followed
its isolation from this small bushy aromatic herb [9], Thomas Phayre's 'Boke of
Chyldren' (1545), however, probably contains the first specific reference for the
therapeutic use of a fungus for the treatment of bacterial infections. Further references
for the use of fungi from various sources were made at intervals until the latter half of
the 19th century [10, 11], when scientists began to investigate the attributed actions
ofmoulds and fungi more thoroughly.
John Burdon Sanderson was the first to note, after a series of microbiological
experiments in 1870, that bacteria did not grow in media with visible 'penicillum'
mould growth. He misinterpreted the results and did not suspect that the mould itself
had an antibacterial action. Lister in some of his pioneering bacteriology experiments,
prompted by Sanderson's publications in 1871, also noted that Penicillium could
inhibit the growth of some bacteria, but fully recognised the inhibitory effect of the
mould on bacteria. In a letter in 1872 Joseph Lister expressed the intention to use
Penicillium glaucum therapeutically in humans, and there is some evidence that he did
in 1884 [12], Several other workers, notably William Roberts, John Tyndell and
Thomas Henry Huxley, also contributed to the pioneering work on Penicillium during
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this decade. It was not, however, until the detailed report published by Fleming in
1929 on the antibacterial effects ofPenicillium notation [13], that Chain etal. were
prompted to re-examine the phenomenon [14],
Paul Ehrlich's work in the first decade of this century must also be mentioned. Almost
all the concepts which have governed subsequent work on synthetic antimicrobial
agents were proposed by Ehrlich during his studies. Ehrlich believed that infectious
disease could be treated with synthetic chemicals. He proposed that if enough
variations of a compound group were synthesised, some would be made that would
have sufficiently low toxicity to be safe for use as chemotherapeutic agents. A massive
search for an organo-arsenical compound for the treatment of syphilis ensued, leading
to the discovery of salvarsan in the 1900s [15], Salvarsan, and its derivative
neo-salvarsan, together with bismuth therapy were the standard treatment for syphilis
until the introduction of penicillin in the 1940s.
3. The discovery & development of penams
The discovery of penicillin is credited to Alexander Fleming, who noted in 1929 that a
culture of Penicillium notatum inhibited the growth of Staphylococcus aureus [13],
Several other scientists, as described above, over the previous 60 years had also
observed the antibacterial activity of Penicillium moulds. Fleming was the first,
however, to realise that the inhibition resulted from the action of a small molecular
mass compound produced by the mould, and suggested its use as an inhibitor in the
isolation of certain types of bacteria, especially Haemophilus influenzae. He also
noted that broth containing the substance, which he called penicillin, when injected
into animals was no more toxic than an injection of plain broth. Fleming suggested
that penicillin could be used as an antiseptic. The unstable nature of penicillin,
however, thwarted early attempts at purification and hence prevented exploitation.
The clinical success of the sulphonamides [16, 17] renewed scientific interest in the
chemotherapy of bacterial infections and stimulated Florey and Chain, in 1939, to
re-examine 'penicillin' [14], Chain and co-workers managed, where others had failed
over the previous decade, to isolate an impure but highly anti-bacterial penicillin
powder [14, 18], Early clinical trials of penicillin [19] demonstrated its effectiveness,
and, because ofWorld War II, stimulated perhaps the biggest chemical and biological
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joint research programme ever undertaken between companies in the UK and the
USA. The collaboration led, not only to a vast output of penicillin, but also the
foundation of the modern pharmaceutical industry. Since the 1940s, penicillin has
been widely used for the treatment of various infections, and numerous penams have
been discovered or synthesised [20] (Table 1.1 page 6). The identification of the anti¬
bacterial activity of penicillin by Fleming instigated the discovery of one of the largest
and most important classes of antimicrobial agents, known as the P-lactam antibiotics,
which are unrivalled in the treatment of bacterial infections. Their only serious defect
is their characteristic induction of immunological sensitisation in a small percentage
(usually about 10%) of the population, a side effect which precludes their use in those
affected.
3.1. The natural penicillins
The original penicillins, isolated directly from mould fermentations, were mixtures
of compounds with different side-chains. Addition of adjuncts to the fermentation
ensured that the product was predominantly a single compound. Penicillin G
(benzylpenicillin) was the parent drug of this family produced by the addition of
phenylacetic acid to the mould growth medium [21], The first successful variant,
phenoxymethylpenicillin (penicillin V), was obtained by adding phenoxyacetic acid
to the medium rather than phenylacetic acid [22], although many compounds were
tried as adjuncts. The main advantage of the side-chain modification of penicillin V
over penicillin G was the improvement in acid stability. The ready inactivation of
penicillin G at low pH limited its usefulness when given orally.
Phenoxymethylpenicillin thus improved the reliability of oral administration. The
early penicillins were very active against Gram-positive bacteria and gave excellent
results in streptococcal and staphylococcal infections, and in pneumonia.
Penicillin G and V are much less active against the more typical Gram-negative
bacterial infections, except Neisseria gonorrhoeae. A tribute to the longevity of
these compounds is that both penicillin G and penicillin V are still used regularly in
clinical practice more than half a century after their introduction into medicine.
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3.2. PENICILLINASE-RESISTANT PENICILLINS
Penicillinase, an enzyme which could inactivate penicillin by hydrolysis, was
identified in Escherichia coli in 1940 by Abraham & Chain [23], the same year as
the initial reports of the therapeutic potential of penicillins were published [13],
Although the discovery of penicillinase was an important consideration in the
development of the [3-lactams, the increased use and success of penicillins in the
treatment of staphylococcal infections between 1945 and 1960, led to the
emergence of penicillinase-producing staphylococci that rendered the natural
penicillins ineffective. Barber's observation, in 1949 [24], that penicillin-sensitive
Type of penam Generic name































Table 1.1 Classification of the penicillins
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strains could acquire resistance after contact with penicillin-resistant strains led to
the discovery of penicillinase encoding plasmids in Gram-positive bacteria [25],
Prior to this the transferable R-factors had only been observed in Gram-negative
bacteria [26],
Enzymatic removal of the 6-P-benzyl side-chain of penicillin G allowed the
isolation of the nucleus 6-aminopenicillanic acid (6-APA) (Figure 1.1), which could
subsequently be modified by chemical means to create various semi-synthetic
derivatives [27], Development of semi-synthetic penicillins with an acyl side chain
that sterically inhibited the action of penicillinase ensued. Methicillin was the first
of this group, followed by, among others, oxacillin and the oral drug cloxacillin.
These penicillins were widely used as the first line therapy of staphylococcal
infections until the emergence of Methicillin-resistance Staph, aureus (MRSA) in
the 1980s (for a recent review see Mulligan et al. [28]). Penicillinase-resistant
penicillins have activity against the species Streptococcus and Staphylococcus but,
unfortunately, little activity against Gram-negative organisms.
3.3. Extended-spectrum penicillins
Increasing the antibacterial spectrum of penicillin derivatives has been the aim of
antimicrobial research for many years. The need for penams with activity against
Gram-negative bacteria prompted further modification of the 6-APA nucleus. The
aminopenicillins were the first new group to be produced, followed by some
i
Figure 1.1: 6-Aminopenicillanic acid (6-APA)
Numbering of atoms starts from sulphur of five-membered thiazolidine ring (top right); continues
clockwise to four-membered (3-lactam ring through bridgehead nitrogen and tetrahedral carbon atoms
(N-4 and C-5 respectively).
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carboxypenicillins and ureidopenicillins. These classes of penicillin are not resistant
to staphylococcal P-lactamases but are resistant, in variable degrees, to the
chromosomally-encoded P-lactamases of Gram-negative bacteria. Improved
antimicrobial activity is derived from increased penetration through the outer
membrane of Gram-negative organisms and greater affinity for the targets of
penicillin, the PBPs.
3.4. The amdinopenicillins
Amdinocillin, another 6-APA derivative but with a 6-p-amidino side-group, has the
unique property of binding preferentially to penicillin-binding protein type 2
(PBP-2), in contrast to other penicillins that bind to PBP-1 and PBP-3. In addition,
amdinocillin is hydrolysed slowly by P-lactamases.
3.5. Penicillins plus P-lactamase inhibitors
Further development of the penicillins has been impeded by the limitation of
possible modifications of the 6-P-acyl side-chain, unlike the cephalosporins which
can be modified at the 7-carbon (sterically equivalent to C-6 of 6-APA) and the
3-carbon of the 7-aminocephalosporanic acid (7-ACA) nucleus (Figure 1.3
page 10). Variation of the 6-acyl side-chain is limited by the stability, spectrum of
activity, P-lactamase susceptibility, pharmacokinetics, and toxicity of the resultant
penicillin. Hence, because of these limitations new strategies were explored.
The use of an inhibitor, with high-affinity and irreversible binding to bacterial
P-lactamase, was introduced after the discovery of the P-lactamase inhibitor
clavulanic acid [29, 30] (Figure 1.2 page 9) and provided an opportunity to
co-administer a P-lactam with P-lactamase-susceptible penicillins such as
amoxycillin, or ticarcillin. Other inhibitors have subsequently been discovered, for
example, sulbactam and tazobactam, and used in combination with penicillins:
ampicillin and sulbactam; piperacillin and tazobactam. Combinations of penicillins
with p-lactamase inhibitors can prevent the most common method of bacterial






Figure 1.2: Clavulanic acid
CH2OH
H
Clavulanic acid is an exo-double bond isomer of the 1-oxa-2-penems. The sulphur atom of the five-
membered thiazolidine ring of 6-APA has been replaced with an oxygen and the dual 2-methyl
groups substituted with a hydroxyethylidene side-chain
4. The discovery & development of cephems
An antibiotic producing strain of Cephalosporinm acremonium was isolated from a
sewage outflow in Sardinia by Guiseppi Brotzu in 1945 [31] and he had some
success, with crude preparations from this organism, against bacterial infections.
Brotzu sent a culture of the mould to Sir Howard Florey in Oxford where the first
substances were isolated from the organism. These compounds were a series of acidic
steroids, collectively called cephalosporin P, that only had activity against Gram-
positive bacteria [32], The search for a second antibiotic isolated penicillin N (initially
called cephalosporin N), closely related to the penicillins in structure [33], with
activity against both Gram-positive and Gram-negative bacteria [34], The antibacterial
action of penicillin N was undoubtedly the cause of the antibiotic activities observed
by Brotzu [35], A small amount of a third antibiotic was observed during the analysis
of penicillin N. The third compound, named cephalosporin C, possessed a [3-lactam
ring, but not the five membered thiazolidine ring characteristic of the penams [36],
Cephalosporin C was observed to have similar antibacterial activities to penicillin N,
but was resistant to hydrolysis by penicillinase, hence provided potential clinical
interest.
The isolation of the cephalosporin C nucleus, 7-amino-cephalosporanic acid (7-ACA),
in the early 1960s [37] (Figure 1.3 page 10), has enabled the development of
compounds that could be given orally, and that exhibit high activity against a range of
penicillin resistant Gram-negative bacteria.
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Prior to 1975 only a few cephalosporins were available for clinical use to the medical
profession and it was relatively easy to distinguish between the compounds on the
basis of antibacterial activity and pharmacology [38], The production of successive
'generations' of cephalosporins since 1975 has suggested that each new group has
provided general advances in every aspect of the cephems properties. A summary of
the three recognised generations is given in Table 1.2 (page 11).
4.1. First-generation cephalosporins
Many of the first semi-synthetic cephalosporins are analogous in structure to the
successful penicillins [39], and were highly active against a number of
Gram-positive species at the time of their introduction. Although the first-
generation cephalosporins showed significant activity against some Gram-negative
bacteria, including various Salmonella, Shigella, and Klebsiella, their value for the
treatment of a number ofGram-negative mediated infections was limited, and many
of them were still susceptible to the TEM- and SHW-type of P-lactamases.
4.2. Second-generation cephalosporins
Modification of the side chains (C-3 and C-7) around the 7-ACA nucleus
generated cephalosporins that were active against bacteria which had shown
resistance to their predecessors. As the second-generation cephalosporins, in turn,
fell foul of novel P-lactamases, compounds with a wider spectrum of activity and
high stability against P-lactamase degradation were sought.
ch2—o—c—ch3
o
Figure 1.3: 7-Aminocephalosporanic acid (7-ACA)
Six-membered dihydrothiazine ring equivalent to the five-membered thiazolidine ring of 6-APA.
Substitutions at positions 3 and 7 of 7-ACA are sterically equivalent to positions 2 and 6 of 6-APA.
Introduction Page 11






Cephadrine i.m., i.v., p.o.
















Table 1.2: Classification of the cephalosporins
* Route of administration: i.m., intramuscular; i.v., intravenous; p.o., oral
4.3. Third-generation cephalosporins
The most recent cephalosporins possess a broad spectrum of activity against
Gram-negative bacteria, including some Pseudomonas aeruginosa strains. This
group of cephalosporins were considered, at the time of their introduction, to be
examples of the ultimate ability to overcome antimicrobial resistance, especially
that mediated by TEM-1. Among these cephalosporins the increase in activity
against Gram-negative bacteria is attributed to a modification of the side-chain,
attached to the 7-carbon of the 7-ACA nucleus, containing a 2-aminothiazole
group (e.g. cefotaxime, ceftazidime, ceftriaxone, ceftizoxime and cefmenoxime).
These five cephalosporins also contain an O-substituted oxyimino group on the
7-f3-acyl side-chain. Perhaps this group of cephalosporins can be epitomised by
ceftazidime with a carboxylic alkoxyimino group, resulting in slow outer membrane
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penetration but conferring a significant degree of anti-pseudomonas activity, and
cefotaxime with a methoxyimino side-group, which gives the molecule faster
penetration but little anti-pseudomonas activity. Ceftriaxone has similar properties
to cefotaxime but has a much longer plasma half-life.
4.4. Fourth-generation cephalosporins
Recently, the term 'fourth-generation cephalosporins' has been coined for the
marketing of the previously designated third-generation cephalosporins cefpirome
and cefepime. The fourth-generation cephalosporins have been identified by their
'bullet shaped' structure and a quaternary ammonium group, giving zwitterionic
properties, at the 3-position of the cephem nucleus. Other cephalosporins (e.g.
cephaloridine), however, also contain quaternary ammonium side-chains at the
3-position and are zwitterionic [20], The bullet shape in combination with the
positive charge at the 'point' of the bullet is believed to orientate the cephem when
penetrating the outer membrane of the bacterium [40],
5. Penicillin & cephalosporin biosynthesis
Examples of the P-lactam class of antibiotics are produced by a wide variety ofmicro¬
organisms (Table 1.3 page 14), including some filamentous fungi, and a few Gram-
positive and Gram-negative bacteria [41], Eukaryotes and prokaryotes both produce
penicillin and cephalosporin antibiotics by very similar biosynthetic pathways, a
generic example of which is illustrated in Figure 1.4 (page 15). Various species of
bacteria produce a range of cephalosporins or cephamycins, but none have been found
to synthesise penicillins. In contrast, the fungi have only been found to contain genes
for penicillin or cephalosporin biosynthesis. It is generally accepted that the genes
associated with P-lactam biosynthesis, collectively known as the p-lactam synthetase
genes, exist in gene clusters on the chromosome of the respective micro-organism, as
first demonstrated by Malpartida & Hopwood [42],
5.1. The origin of the P-lactam synthetase gene
In general, the genes controlling successive steps in antibiotic biosynthesis, are
clustered and there are no currently proven exceptions [43], This is certainly true
for the genes involved with P-lactam synthesis. Clustering of functionally related
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genes implies that they have evolved as a unit, and enhances the probability that
transfer of all the genes associated with biosynthesis occurs simultaneously [44],
This, together with high sequence similarity and narrow distribution of the
(3-lactam synthetase genes amongst micro-organisms, has led to a debate on the
evolution of these genes. The currently accepted theory estimates that the genes
transferred between species about 370 million years ago [45], after the
eukaryote/prokaryote split (2 billion years ago [46]) but before the Gram-
positive/Gram-negative split (1.5 million years ago [46]), rather than developing
independently in parallel.
Bacteria possess a greater capacity to synthesise (3-lactams than fungi, and are
believed to be the donors in the ancient transfer event [47], For transfer to occur
the micro-organisms would have be in close contact, probably in the soil as all
three participants (Gram-positive bacteria, Gram-negative bacteria, and fungi) are
known to exist in this environment [48], Conjugation in the soil environment has
been demonstrated but is dependant on many factors, including geological factors
and chemical interference from other soil micro-organisms [49],
5.2. The ecology of P-lactam production in micro-organisms
Metabolism can be divided into two types: primary and secondary. Primary
metabolic processes, essential for cell life, are generally far less complex than
secondary metabolic pathways. Secondary metabolites, which include the
antibiotics, are generally small molecular mass compounds, and are produced by a
number of organisms including bacteria, plants and lower animals. Biosynthesis of
secondary metabolites is not essential for the survival of the producing organism in
a non-selective environment, but it has been proposed that they confer a selective
advantage on the producing organism under certain conditions [44], The chemical
structures of secondary metabolites are responsible for their biological activity, and
this activity is thought to confer a chemically-mediated defence mechanism on the













































Table 1.3: Micro-organisms that produce |3-lactam antibiotics
§ Only certain species within the micro-organisms listed make the indicated p-lactam antibiotic.



































Figure 1.4: Generic pathway for the biosynthesis of p-lactam antibiotics
Many of the enzymes of the pathway are multi-functional; type of activity exhibited at each step is
noted, not the specific enzyme. Modified from Aharanowitz, Cohen & Martin. (1992) [41],
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Antibiotics are thought to have evolved to hinder the growth of other micro¬
organisms competing for the same nutrients, hence production would confer a
selective advantage on the host organism [2], Certainly, soil is estimated to harbour
a large number of micro-organisms [48], and antibiotic production of some soil
dwelling bacteria has been associated with vulnerable stages of the life-cycle of
those organisms [50], Hence, production of growth-inhibitors may be
advantageous to the producer [44],
In order to avoid the potentially lethal effects of antibiotic synthesis, micro¬
organisms have had to develop mechanisms of defence against their own secondary
metabolite production [2, 51, 52], There are principally three methods of
protection against intracellular metabolites during antibiotic biosynthesis [51]:
• Modification of the target-site to render it insensitive to a particular metabolite.
• Production as inert derivatives which are activated during or after export from
the cell.
• Confinement of toxic products within discrete sub-cellular compartments during
biosynthesis.
Obviously, although certain eukaryotes may exploit the third method, prokaryotes
cannot. Self-defence in antibiotic-producing Streptomyces is well documented to
occur by the former two mechanisms: target-site modification or metabolite
inactivation [51-53], Sequence similarities between the genes that encode enzymes
for biosynthesis and antibiotic-inactivation within clusters in Streptomyces suggest
that resistance has evolved from the biosynthetic genes [2, 43, 44], Point mutations
of the relevant DNA, facilitated by gene duplication, eventually created enzymes
that modified the Streptomyces antibiotic streptomycin and its active-intermediates
to a less active form [42, 44], Resistance is, therefore, conferred on the host by an
extra step in the synthesis of the secondary metabolite.
The genes encoding self-resistance are frequently interspersed into the
biosynthetic/regulatory gene cluster, and often transcription of the proteins
mediating resistance is part of the regulatory mechanism of biosynthesis [54], In
these pathways, self-resistance is established preceding antibiotic production.
Integration of DNA encoding self-resistance into the gene cluster also guarantees
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co-transfer between micro-organisms and ensures resistance in the recipient. The
observation that antibiotic biosynthetic gene clusters appear to have little DNA
unassociated with biosynthesis, regulation or resistance [44], adds weight to the
theory that antibiotic production would confer a selective advantage on the
producing-organism in a competitive environment.
In conclusion; antibiotics are thought to have evolved in the soil environment to
provide a chemical defence mechanism to the host. Organisms, which produce
these secondary metabolites, have also evolved an integral resistance mechanism to
prevent the fatal effects of self-intoxication, often by modification of the
biosynthetic enzymes. Resistance mechanisms associated with antibiotic
production, however, are not the only sources of clinical resistance genes, other
mechanisms appear to have evolved separately [2],
6. The structure & activity of the (3-lactam
antibiotics
The P-lactam antimicrobial agents are the most extensively studied and are,
consequently, the most structurally varied class of drug. This is partly because of the
ease with which the biological activities of the P-lactams can be varied by
modification of the penicillin and cephalosporin rings. Each of the seven or eight
positions on the bicyclic 6-APA or 7-ACA nuclei have undergone modification with
the exception of the 4(5)-bridgehead nitrogen atom. Not only have the type of
substituents of the nuclei been altered, but also the configuration of ring substituents,
size and atom content of the rings, and position and configuration of ring junctures, in
the search for better antimicrobial, pharmacokinetic, and pharmacological properties
of the P-lactam.
6.1. The consensus structure of the (3-lactam antibiotic
P-lactams usually have a fiised-ring at the heart of their structure, but this is not
essential. The four membered lactam ring, present in all this class of antimicrobial
agent, however, is essential for antibiosis. Except for the monobactams and the
nocardicins, the P-lactam ring is fused through the bridgehead nitrogen atom
(N-4(5)) and adjacent tetrahedral carbon atom (C-5(6)) to a second five or six
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membered ring. Stereochemistry of the bicyclic nucleus around the P-lactam rings
of the penicillins and cephalosporins is the same. The asymmetric centres at C-5
and C-6 of the penicillins correspond to C-6 and C-7 of the cephalosporins. Nearly
all P-lactam compounds have a carboxyl group attached to the C-3(4) (adjacent to
the bridgehead nitrogen) that is on the a-side of the ring system. Even the
nocardicins, which lack the fused-ring structure, possess a carboxyl group that is
congruent with the stereochemistry of the penams and cephems.
6.2. Structural aspects of activity
The activity of the P-lactam antimicrobial agents is the result of the inhibition of
the growth of the bacteria, and is usually bactericidal. Bacteriostasis and/or
bactericide is achieved through the interaction of the P-lactam compound with the
complex dynamic processes involved in bacterial cell-wall synthesis. In both the
penicillins (Figure 1.5a: X = S, R2 & R3= H) and cephalosporins (Figure 1.6a page
21: Z = S, Rg = H) a 6(7)-P-acylamino side-group (or equivalent) is necessary for
antibiosis of bacteria. Manipulation of this group has created the most clinically
useful agents in this class of drugs [55],
Figure 1.5: Generic structure of p-lactam antimicrobial agents I:
penams, clavams & penems
Nomenclature: numbering of ring atoms according to that of 6-APA; a, denotes side-group "below"
the plane of the fused-ring (i.e. into page); (3, denotes side-group "above" the plane of the fused-ring
(i.e. out of page), a) Penams (X = S), penems (X = S, C2-C3 double bond), sulfones (X = S-On),






The prerequisite for the presence of a 6(7)-P-acylamino side-group (Figure 1.5:
R, = -CONH-) for antibacterial activity is illustrated by the absence of antibiosis of
clavulanic acid (see Figure 1.2 page 9 and Figure 1.5b) which lacks this side-group.
The high antibacterial activity of the thienamycins (Figure 1.5c: groups R2 or R, =
6-a- or 6-P-hydroxyethyl side-chains respectively), therefore, is unexpected [55],
Good antimicrobial activity is thought to result from optimal chemical reactivity of
the P-lactam ring. Penicillin and cephalosporin fused-ring systems require
additional activation through the 6(7)-P-acylamino substitution to raise the level of
antibacterial activity of the compound [56], however, this activation has also been
achieved with a 6-P-amidino group (Figure 1.5a: R, = -C(7?)=N-) [57],
Unless a compound retains in vivo antimicrobial activity, and the appropriate
pharmacokinetic and pharmacological properties, after introduction of a
modification, the drug will not be useful clinically.
The penicillins.
A majority of the clinically useful penicillins are 6-P-acylamino substituted, and
of those high antibacterial activity is narrowly confined to additional substitution
with carboxamides [58-63], As a consequence, only minor differences between
analogues are observed [64], Most 6-P-side-groups are derived from mono- or
///'-substituted acetic acids [21, 22, 65-68] which have improved acid stability,
oral absorption, resistance to staphylococcal P-lactamases, and broadened
Gram-negative activity. Other side-groups can considerably change activity: the
6-P-amidinopencillins, for example, have very low Gram-positive activity, but
are very active against strains of E. coli, including those expressing plasmid-
mediated P-lactamases (partly explained by low enzyme affinity) [57, 69],
Staphylococcal penicillinase susceptibility has principally been reduced by
increasing steric hindrance around C-6 or by the introduction of an extra bond
into the five-membered ring, for example, the 6-membered dihydrothiazine ring
of the cephalosporins. Unfortunately, many of the changes in penicillin structure
have had a deleterious effect on one or more of the desired properties. For
example, penicillinase-resistant penicillins (e.g. methicillin, oxacillin) are
virtually devoid of Gram-negative activity at the expense of good Gram-positive
activity and penicillinase-resistance [64],
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In general, substitution of the highly ionic acidic groups or hydrophilic groups
on the a-carbon of the 6-P-side chain decreases the minimum inhibitory
concentrations (MICs) towards Gram-positive bacteria but raises the anti-
Gram-negative effect and extends the spectrum of activity in this genera [55],
Inclusion of alkyl groups into the 6-P-side-group can also help to optimise
Gram-negative activity, but unsaturated 6-P-groups will improve Gram-positive
activity, as does the introduction of heterocyclic or aromatic rings (usually at
the expense of Gram-negative activity). Hetero atoms in the cyclic analogues
have variable effects, but properly placed can invert the ratio of Gram-positive
to Gram-negative activity. Also, /rarra-hydroxy substitutions of 6-P-aromatic
groups can increase oral absorption as does the formation of pro-drugs through
conjugative esterification of various positions of the 6-P-side group.
Substitution of the 6-a-position of the penicillin nucleus generally will result in
total loss of antibacterial activity. The anomalous temocillin, a 6-a-methoxy-
penicillin, however, has a wide range of activity against Enterobacteria, but
exhibits a very low level Gram-positive activity [70, 71],
The cephalosporins & cephamycins.
Like the penicillins, the cephalosporins usually have a low level of toxicity, and
cross-allergenicity is sufficiently low (about 10%) to allow their use in
penicillin-sensitive patients [72], Natural cephalosporins, for example
cephalosporin C [36], exhibit a better ratio of Gram-negative/Gram-positive
activity than the penicillins, but the intrinsic antibacterial activities of the former
are generally lower than the corresponding penicillins. Differences in activity,
independent of permeability and P-lactamases, can be correlated to PBP binding
characteristics [55], Although the cephalosporins are resistant to the Gram-
positive penicillinases, there are a profusion of Gram-negative P-lactamases that
degrade the cephalosporins. The major objectives of research have, therefore,
been to increase the intrinsic antibacterial action and broaden the spectrum of
activity, partly by improving P-lactamase stability, and pharmacokinetic
properties.
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Figure 1.6: Generic structure of the p-lactam antimicrobial agents II:
cephems, cephamycins, & non-classic p-lactams
Numbering of ring atoms accords with that of 7-ACA, except monocyclic p-lactams which are
numbered clockwise from the lactam bond nitrogen (bottom left), a) Cephems (Z = S, Rq = H),
cephamycins (Z = S, Rg = OCH3), oxacephems (Z = O, Rg = H, OCH3) b) Monocyclic P-lactams
(C-3 side-groups and the N-1-^Ry bond are sterically equivalent to the C-6(7) side-groups and
C-3(4)-»N-4(5) bond of bicyclic p-lactams respectively): monobactams, sulfazecins, nocardicins.
The cephalosporins [20] (Figure l ,6a: Z = S, Rg = H), have fewer constraints on
the structural modifications that improve biological performance than the
penicillins [37, 39], Careful manipulation of the 3-substituent (R4), the
7-(3-acylamino group (R5), and substitution of the 7-a-position (Rg) can increase
P-lactamase stability and retain useful biological activity. The oxacephalosporin,
moxalactam, shows that replacement of the sulphur atom of the dihydrothiazine
ring by an oxygen (Figure 1.6a: Z = O) leads to an improvement in antimicrobial
activity, whereas this exchange in the 5-membered thiazolidine ring is
detrimental to activity. While the opportunity for the modification of
cephalosporin nucleus is broader, there are some constraints, for example the
use of esters as pro-drugs has not been as successful with the cephalosporins as
with the penicillins. The nature of the 7-P-acyl group mainly determines the
level and degree of antibacterial activity; the effect on pharmacokinetic
properties is less substantial, with the exception of oral absorption, achieved by
incorporation of a 7-P-arylglycl group. Changes at the 3-position have
occasionally resulted in broadening of the spectrum of activity, but
modifications at this position have more influence on the level of activity and
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pharmacokinetic properties. Variation of the third important locus of substituent
modification, the 7-a-position, is extremely limited, and constrained to a
hydrogen (Rg = H = cephalosporin) or a methoxy group (R<; = OCH3 =
cephamycin); the latter increases resistance to p-lactamases by steric hindrance
The first-generation cephalosporins are unstable in the presence of Gram-
negative P-lactamases, and those with a 3'-acetoxy group (Figure 1.6a:
R4 = CH2COOH) are susceptible to metabolic hydrolysis. The general rules
governing activity of the penicillins to some extent apply to the cephalosporins,
most notably the reduction of Gram-negative activity with the introduction of
hydrophobic groups to the side-chain, and the positive effect of some
a-substituents (OH, NH2) on Gram-negative activity. The 3'-acetoxymethyl
grouping (Figure 1.6a: R4 = CH2OCOCH3), which is present in some the
p-lactamase-sensitive cephalosporins, and the 3GC, cefotaxime, is subject to
metabolic hydrolysis to give the corresponding 3'-alcohol, with significantly
lower antibacterial activity of that of the parent. Whilst detrimental to the earlier
cephalosporins' activity and half-life, the result is different with cefotaxime; the
activity of the deacetyl derivative of cefotaxime is reduced against the
Enterobacteriaceae, but still compares favourably to that of other
cephalosporins. In addition to avoiding metabolic hydrolysis, modification of the
3-substituent can increase the intrinsic antibacterial activity and improve the
pharmacokinetic properties of the cephalosporin. In general, esterification of the
3-substituent has been unprofitable, but one exception is the carbamoyloxy side-
group (Figure 1.6a: R4 = CH2OCONH2), which occurs naturally in some
cephamycins (Figure 1.6a: Rg = OCH3), has been retained in cefoxitin and
incorporated into cefuroxime to help prevent metabolic hydrolysis.
The inclusion of nitrogen nucleophiles, for example pyridines, at the 3-position
can increase metabolic stability, and the substitution of sulphur nucleophiles at
the same position will provide similar changes in properties. Differences in the
intrinsic activities of the penicillins and cephalosporins are attributed to the
relative strain of the (3-lactam ring, to give different levels of chemical
reactivity [55], Chemical reactivity can be optimised by the choice of side-chain
substituents and the rate of ring opening is directly proportional to activity of
the cephalosporins against Gram-negative bacteria [73], Good oral absorption
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of cephalosporins, an unusual characteristic of these compounds considering the
increased acid stability compared to the penicillins, requires an a-amino
substituent on the 7-(3-acyl side-chain and small uncharged groups at the
3-position. As observed with the penicillins, resistance to p-lactamase hydrolysis
can be improved by steric hindrance around the 7-P-amide group by
manipulation of the a-carbon substituents. Incorporation of an a-oxyimino
group into the 7-P-acylamino side-chain is a particularly effective method of
conferring high level P-lactamase resistance without reduction in antibacterial
activity. At this position methoxyimino groups are pharmacokinetically superior
to hydroxyimino derivatives. The substitution of a methoxy (or carboxy) group
at the 6(7)-a-position [74], as seen in the cephamycins, protects the molecule
more efficiently from P-lactamase degradation than any 6(7)-P-position
modification. It is interesting to note that 7-a-methoxy groups only protect the
oxacephalosporins (Z = O) from penicillinase activity.
Non-classic P-lactams.
The stereochemistry of the non-classic P-lactams has been shown to conform to
the constraints required for activity observed in the penicillins, cephalosporins,
and cephamycins. The increased reactivity of the ring system in the penems
(Figure 1.5c page 18: X = CH2 and the conjugated C-2—»C-3 double bond)
results in the contribution of 6-substituents (R, & R2) being reversed, i.e. the
6-unsubstituted penems and carbapenems are more active than the
6-P-acylamino derivatives. The potent antibacterial activity of the penems is
attributed to the ring strain and the electronic effects of the double bond.
Monocyclic P-lactam stereochemical configurations of the 3-P-acylamino group
and the carboxyl group (Figure 1.6b page 21: R7) are the same, or similar to, the
corresponding positions of the penams and cephems. Changes in activity of
various side-chain substituents broadly follow the same trends as seen in the
classic P-lactams (e.g. 3-oc-methoxy substitutions enhance P-lactamase
resistance). The introduction of an a-oxyimino-2-aminothiazol-4-ylacetyl group
at the 3-P-position (R8) into the monobactam structure (Figure 1.6b: Rg = H
or OCH3, R,0 = H), will confer high levels of activity against Gram-negative
bacteria, as observed in the 3GCs where this type of group has been substituted
at the 7-P-position [75, 76],
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P-Lactamase inhibitors.
Apart from the incorporation of structural features in the P-lactam molecule to
help prevent inactivation by P-lactamases, specific P-lactamase inhibitors can
also be combined with a P-lactam for therapeutic use. Compounds, without a
P-lactam ring, exist that are specific or non-specific inhibitors of P-lactamases,
however, the most successful candidates for clinical use are based on a P-lactam
fused-ring structure. Of the P-lactam containing inhibitors two groups exist
[77]:
• Penicillins and cephalosporins that bind, usually reversibly, to the
P-lactamase and are hydrolysed, by the normal enzymatic process, to
respective penicilloic acid and cephalosporic acids at a very slow rate.
P-Lactams in this class are generally competitive inhibitors with a high
affinity for the enzyme (low Km) but with a low Vmax.
• P-lactam compounds, named 'suicide' inhibitors, bind to the P-lactamase
active-site and during the course of a normal hydrolytic action undergo a
secondary reaction to stabilise the enzyme-substrate complex. This results in
irreversible inhibition of the P-lactamase.
Compounds in the former group require high concentrations to afford
protection to the 'antimicrobial' p-lactam with which it is being
co-administered. As a consequence the biological activity of this particular
combination is variable. Inhibition depends on competitive inhibitor-enzyme
binding, but the effect can be transient as a result of the slight hydrolytic
susceptibility of the inhibitor.
The second group of agents, also known as 'progressive' P-lactamase inhibitors,
can exhibit synergistic antibacterial properties when combined with
'antimicrobial' P-lactams. Clavulanic acid (Figure 1.5b page 18: X = O,
R, = NH3, R2 & R3 = H), sulbactam (Figure 1.5a: X = S02, Rb R2 & R3 = H ),
tazobactam (Figure 1.5b: X = S02, ,Rb R2 & R3 = H, and a 2-p-triazol-
1-ylmethyl group), certain carbapenems and several semi-synthetic P-lactam
derivatives are members of this class of inhibitor. These inhibitors all contain a
P-lactam ring that undergo enzyme attack to form the normal acyl-enzyme
complex, but then undergo hydrolysis of the P-lactam bond at a slow rate. An
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elimination reaction that results in the formation of a double-bond between C-5
and C-6 is facilitated during (3-lactam-bond hydrolysis by the acidic 6-a-proton
and good 6-P-leaving group of these compounds. The unsaturated acyl-enzyme
complex is sufficiently stable to prevent elimination of the hydrolysed product
from the active site of the enzyme. The most efficient drugs of this type have
high affinity for the P-lactamase active-site, but undergo slow hydrolysis and
release of the penicilloic acid product. Describing these agents as 'irreversible'
inhibitors is not entirely true as partial recovery has been observed under certain
conditions [78], Esterification of this type of inhibitor does not appear to greatly
lower the p-lactamase inhibiting properties [77],
7. The bacterial cell wall
The differences that exist between the bacteria and mammalian cells are ideal targets
for antimicrobial agents. In theory, chemicals that will inhibit a process that only takes
place in bacteria will not affect a mammalian cell. The obvious distinction between
bacteria and animal cells is their structure. Ironically, the evolution of a protective cell
wall by bacteria has served as a means of its own destruction. A number of effective
antimicrobial agents owe their action to their ability to inhibit bacterial cell wall
synthesis, a process with no parallel in animal cells. The biosynthesis of peptidoglycan
in both Gram-positive and Gram-negative bacteria is essentially the same; not
surprising considering both "types" ofbacteria are believed to have evolved from a
common ancestor [46],
7.1. Peptidoglycan synthesis
The peptidoglycan biosynthesis pathway has been divided into three stages [79]
depending on the location within the bacterium of the reactions: cytoplasm,
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7.2. Inhibitors of peptidoglycan synthesis
Inhibitors of peptidoglycan anabolism will not have any deleterious effect on an
eukaryotic host, except for the undecaprenyl-phosphate inhibitors which may
interfere with glycoprotein or sterol biosynthesis. Peptidoglycan synthesis
inhibitors may be categorised into three groups, each corresponding to the three
stages of biosynthesis: cytoplasmic, cytoplasmic membrane, and the cell wall. The
earlier the point of inhibition in the pathway, however, the deeper into the cell the
inhibitor will have to penetrate.
P-Lactam antibiotics act on the final stage of the peptidoglycan biosynthetic
pathway. The site of this reaction, the inside of the outer cell membrane, requires
that these antimicrobial agents only have to penetrate a single membrane, often by
passive diffusion through porins. P-Lactams act on the transpeptidation reaction
that cross-links the peptidoglycan after transglycosylation. These antibiotics have
been shown to be analogues of the D-alanyl-D-alanine terminus of the A-AMA-
TV-AGA-pentapeptide [80] (Figure 1.8), a normal substrate of some PBPs.
H
Figure 1.8: Structural comparison of a penicillin with D-alanyl-D-alanine
Chemical structures of a penicillin (left) and the D-alanyl-D-alanine end group of the peptidoglycan
precursor (A/-AGA-A/-AMA-pentapetide) (right). After Strominger et al (1967) [80]
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Gram-positive bacteria have about four or five PBPs but Gram-negative organisms
have about six main types, and different P-lactam agents have varying affinities for
each PBP which can be correlated with the morphological effects observed through
PBP inhibition. The properties of the various PBPs present in E. coli have been
elucidated [81] (Table 1.4). Access to the PBPs of Gram-positive bacteria is not a
problem. Penetration through the outer cell wall of Gram-negative bacteria,
however, could be a problem for small polar (hydrophilic) molecules if it were not
for the OMPs that form water filled channels called porins.
Porin channels in the Enterobacteriaceae do not restrict penetration of these
antibiotics through the outer membrane to any significant extent [83], but
differences in the rate of penetration can explain some of the differences in MICs
of P-lactam antibiotics. The penetration rate of a drug through the outer membrane
is also important when P-lactamases are present in the bacterium. A slow rate of
diffusion into the cell, through loss or mutation of certain porins or poor drug
design, may result in a resistant phenotype in the presence of a P-lactamase, when
the enzyme alone may not be sufficient to confer resistance on the host. Mutation
of the active-site of the PBPs may affect binding of the peptidoglycan synthesis
inhibitors and thus also result in resistance of the p-lactam target.
PBPt M. Wt§ Enzyme activity Function
1 A, 1B 91000 Transpeptidase (wall)
Transglycosylase
Cell elongation
2 66000 Transpeptidase Longitudinal growth
3 60000 Transpeptidase (septum)
Transglycosylase
Septum formation
4 49000 Carboxypeptidase Lipoprotein attachment
5 42000 DD-Carboxypeptidase Limitation of cross-linking
6 40000 DD-Carboxypeptidase Limitation of cross-linking
Table 1.4: The penicillin-binding proteins of Escherichia coli
i PBP, penicillin-binding protein. § M.Wt, molecular weight. From Franklin & Snow(1989) [82]
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8. The classification of (3-lactamases
Abraham & Chain [23] were the first to describe the phenomenon of enzymatic
degradation of penicillin by 'penicillinases' in 1940; the same year as penicillin was
first purified in a sufficiently stable form in order that it could be used clinically
[14, 18], Abraham & Chain [23] identified the presence of penicillinase in a penicillin-
resistant Gram-negative bacilli and in a penicillin-sensitive Micrococcus and thus
postulated that the presence or absence of [3-lactamases was not the sole factor in
determining the penicillin-resistance phenotype. Staphylococcal penicillinases were
described a few years later [84, 85] which, as a result of their selection to epidemic
proportions through penicillin use, have commanded a huge research effort, even to
the present day [28], It rapidly became apparent that [3-lactamases from different
sources were not the same and exhibited variations in enzymatic properties [86, 87],
The introduction of semi-synthetic penicillins highlighted the variations in substrate
profiles, especially between Gram-positive- and Gram-negative-derived
enzymes [88, 89],
Although transferability of antibiotic-resistance had been noted in the 1940s [24] a
majority of the early work on transmissible drug resistance was done in post-war
Japan [90], Epidemic multiple-drug resistant shigellosis in Japan prompted a huge
research effort and led to the formulation of an explanation for resistance transfer by
two groups of workers simultaneously [91, 92], Despite some earlier reports in
English [93-96], it was not until Watanabe reviewed the topic in 1963 [26] that the
scientists in Europe and North America were comprehensively introduced to
'R-factors': extra-chromosomal genetic elements, or plasmids, consisting ofDNA that
encode resistance determinants. Even then it was not until Datta & Kontamichalou
first described penicillinase-mediated penicillin-resistance encoded on R-factors in
1965 [97] that the multiplicity of the [3-lactamase phenomenon began to be fully
realised.
Once it was apparent that there were many different [3-lactamases in the environment
classification schemes began to be introduced to attempt to group these enzymes
either by biochemical characteristics, by structure, or by amino acid sequence
depending on the needs of the classifier.
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8.1. The Richmond & Sykes classification of p-lactamases
The earliest schemes were, as would be expected, very simple, sub-dividing the
enzymes into relatively few groups [98-101], As the number of characterised
penicillinases and cephalosporinases increased the complexity of the classification
schemes also increased until Richmond & Sykes produced a more comprehensive
strategy in 1973 [102], The 'Richmond & Sykes classification', as it has become
known, is still used today by some workers, especially those studying
chromosomally-encoded P-lactamases.
The scheme (outlined in Table 1.5 page 31) initially divided P-lactamases into five
classes (designated by roman numerals I to V) depending upon the substrate profile
of the enzyme. The first class (I) was divided further into four sub-groups: a, b, c,
and d. Neu [103] introduced an extra class (VI) to accommodate the P-lactamases
ofBacteroides spp. in 1986. The major disadvantages of this classification scheme
are that it is entirely based on biochemical characteristics. P-Lactamases that are
entirely unrelated, apart from in the substrate profile, are grouped together. It
would be reasonable to assume that enzymes may have evolved from different
species under the same selective pressures, therefore, the biochemical properties of
the enzymes are similar but protein structures are quite distinct
As the techniques for analysing P-lactamases improved and as new techniques
became available the criteria for categorising the enzymes could become more
stringent. The most significant advance in aids for the study of P-lactamases in the
1970s was the discovery of the chromogenic cephalosporin, nitrocefin [104],
followed by the development of the technique of isoelectric focusing (IEF) [105],
This allowed the presence of P-lactamases to be easily ascertained and also the
ready determination of isoelectric point (pi) of the enzyme.
Sykes & Matthews [106] modified the classification of P-lactamases derived from
Gram-negative bacteria through the use of these techniques and also included the
molecular weight of the enzyme. Sykes & Matthew initially divided Gram-negative
p-lactamases into chromosomally- or plasmid-mediated enzymes and then sub¬
divided the former into three groups: a, b, and c (penicillinases, cephalosporinases,
and broad-spectrum enzymes). Plasmid-mediated P-lactamases were divided into
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two groups (a & b) depending on substrate profile (hydrolysis, or not, of
methicillin and isoxazoyl penicillins). A final plasmid-mediated group (c) was
added to contain the P-lactamases that do not fit into either group a or b [107],
As the number of plasmid-encoded p-lactamases identified increased the Richmond
& Sykes classification became insufficient to deal with the profusion of
hydrolytically similar enzymes. The Sykes & Matthew modification compensated
slightly for this shortfall, but was not extensive enough. Several classification
schemes for both plasmid-mediated and chromosomally-mediated enzymes have
been devised separately, but have led to some confusion over nomenclature [108],
8.2. The Ambler classification of P-lactamases
The description of a classification, based on comparisons of the amino acid
sequences of enzymes, by Ambler in 1980 [109], was a major advance in
P-lactamase characterisation. Most of the preceding classifications, apart from the
Class Activity^ Source Other features
I a Cephalosporinase Chromosomal Inducible e.g. P99 from Enterobacter
cloacae
b Constitutive e.g. AmpC from E. coli
c Inducible e.g. cefuroximase &
cefotaximase from Proteus vulgaris
d Inducible e.g. Sabath-Abraham
enzyme from Pseudomonas
aeruginosa
II Penicillinase Chromosomal Rare enzymes but noted in Proteus
mirabilis
III Penicillinase & Plasmid Inhibited by cloxacillin & pCMB e.g.
Cephalosporinase TEM- & SHV-fype enzymes
IV Penicillinase & Chromosomal Resistant to inhibition by cloxacillin
Cephalosporinase but inhibited by pCMB.
V Penicillinase Plasmid Resistant to inhibition by cloxacillin &
pCMB e.g. OXA- & PSE-type
enzymes
VI Cephalosporinase Chromosomal Found in Bacteroides spp.
Table 1.5: Richmond & Sykes classification scheme for p-lactamases
§ Activity predominantly, but not necessarily absolutely, penicillinase or cephalosporinase in nature
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Richmond & Sykes method [102], are insufficiently broad or detailed to encompass
the increasing number of P-lactamases and are no longer used.
Five classes have now been attributed to the Ambler classification (Table 1.6
page 33). Originally two classes (A and B) were described [109] based on the
amino acid sequence differences of six P-lactamases: Bacillus cereus 569/H type I
and type II, B. licheniformis 749/C, Staph, aureus PCI, TEM-1pbr322 and
TEM-2rp4_ Sequence homology suggested that five of these P-lactamases
belonged to the same evolutionary distinct group: active-site serine penicillin-
recognising enzymes. The sixth P-lactamase, B. cereus 569/H type II, a
metalloenzyme, lacked a significant degree of sequence homology. Additional
classes C [110], D [111], and E [112, 113] have been added in the last 13 years. It
maybe interesting to note that in the literature Bush [114] is often quoted as
proposing a modification to the Ambler classification: the paper actually proposes
a scheme based on biochemical characteristics, i.e. a Richmond & Sykes style
classification.
Enzymes belonging to Ambler classes A, C, and D, as well as the PBPs, are
members of a superfamily of active-site serine penicillin-recognising
enzymes [115], P-Lactamases of classes A and D are thought to have evolved from
the penicillin-sensitive D-alanyl-D-alanine carboxypeptidases (DD-peptidases)
involved in bacterial wall peptidoglycan anabolism [80], Kelly et al. [116] and
Samraoui et al. [117] compared the primary and tertiary structures of the
Streptomyces R61 DD-peptidase with the B. licheniformis 749/C and B. cereus
type III P-lactamases respectively. Although the p-lactamases and
carboxypeptidases have different biochemical properties (but recognise the same
substrates) and primary structures, they show significant similarity in the spatial
arrangement of the secondary structure (Figure 1.9 page 34). Until recently only
classes A and D contained examples of plasmid-mediated P-lactamases; however
class C plasmid-mediated resistance has recently been observed [118, 119],
Class A P-lactamases
Class A enzymes differ widely in biochemical and physical properties but
preferentially hydrolyse penicillins and contain about 260-270 amino acid
residues. These P-lactamases have a serine residue at the active-site, show
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considerable sequence homology with the DD-peptidases [116, 117] and include
the TEM- and SH\-type P-lactamases (acronyms of a patients name,
'Temoneira', and the biochemical characteristic 'Sulphydryl variable' [108]).
Huletsky et al. [120] constructed a phylogenetic tree of the class A
P-lactamases. The cladogram obtained by the analysis of 18 P-lactamases
(Figure 1.10 page 35) showed that class A enzymes divide into Gram-negative
and Gram-positive derived branches. The only anomaly in this sub-division was
the plasmid-mediated ROB-1 P-lactamase of H. influenzae. The close
relationship of this Gram-negative species' enzyme to Gram-positive enzymes
may be the result of horizontal gene transfer [120, 121], Considering that gene
transfer is entirely possible, especially associated with antibiosis [45], it is
surprising that of the 18 P-lactamases studied by Huletsky et al. [120] only one
is 'misplaced'.
Class M. Wt Type Activity Source Examples













D Variable Active-site serine Carbenicillinase or Plasmid OXA-type
oxacillinase PSE-type
E -120,000 Metalloenzymes Inhibited with EDTAChromosomal Xanthomonas
(Znll) p-Lactamase maltophilia L1
inhibitor resistant
Table 1.6: Summary of the Ambler p-lactamase classification
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Figure 1.9: Comparison of the tertiary structure of a Class A
p-lactamase & a DD-peptidase
Comparable a-helices of enzymes are denoted with the same letters (A to G). Diagram modified from
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The Gram-positive-JemW enzymes are mostly chromosomally mediated
(except the plasmid-mediated ROB-1 and Staph, aureus PCI enzymes), which
compares with the predominantly plasmid-mediated nature of the
Gram-negati\t-derived group (exceptions include the chromosomally mediated
Klebsiella pneumoniae enzyme LEN-1) [108, 120], Evolutionary distances
between Gram-positive enzymes are typically much longer than those of the
Gram-negative enzymes. Huletsky et al. [120] noted that despite this there was
no fundamental change in substrate profile and concluded, in agreement with
Woese [122], that the divergence of genotype was not mediated by an external
selective pressure. It was concluded that the Gram-positive enzymes appeared
earlier in evolution than the Gram-negative enzymes, but both groups had
evolved in parallel from a common ancestor [120],
Comparison of the tertiary structures of the Gram-positive class A enzymes,
Staph, aureus PCI [123], B. licheniformisl49/C [116, 124], and B. cereus
type I [117, 125] with that of the Gram-negative plasmid-mediated P-lactamase
TEM-1 [126, 127] reveals considerable conservation of the spatial arrangement
of secondary elements, lending additional weight to the 'common ancestor'
hypothesis. Several amino acids have multiple codons, but serine is unique in
having a large set of codons which divide into two groups, TCN and AGY, that
cannot be converted to the other via a single nucleotide change. Class A
p-lactamases (and class C and D) possess a serine residue at the active-site. This
residue, as a result of its role in catalysis, is highly conserved and loss results in
a reduction of activity if not total inactivity [128, 129], Brenner [130] proposed
that two evolutionary distinct groups (those with a TCN serine codon and those
with an AGY serine codon) of active-site serine proteins have evolved from a
common ancestor. He proposed that of the two possible ancestral codons, ACN
for threonine and TGY for cysteine, the latter was the most probable on the
basis of catalytic function. Replacement of the TEM-1 pbr322 active-site serine
with cysteine reduces, but does not totally abolish activity [128], as observed
when the serine is replaced with threonine [129], Comparison of the active-site
serine codons of the class A enzymes analysed by Huletsky et al. [120] shows
that in general the Gram-negative-t/er/wc/ P-lactamases use the AGY
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serine-codon and the Gram-positive-derived enzymes serine-codons are of the
TCN-type suggesting dual pathways of descent.
Class B P-lactamases
Class B enzymes are metalloenzymes that require a divalent zinc atom bound to
two histidines and a cysteine residue at the active site [109], Class B enzymes
are generally slightly smaller than class A enzymes and lack sequence homology
(either DNA or amino acid) suggesting the two classes had independent origins.
Class C P-lactamases
Only classes A and B were proposed by Ambler in the original classification of
the P-lactamases he analysed. He did, however, foresee the expansion of the
scheme to include enzymes that did not fit into the original two groups [109],
Jaurin & Grundstrom [110] were the first to modify the Ambler classification
after analysing the chromosomal ampC P-lactamase of E. coli. Class C enzymes
lack sequence identity with either class A or class B enzymes. Like class A
enzymes, class C P-lactamases are active-site serine enzymes but they are much
larger than the preceding two classes, and preferentially cephalosporinases [110,
131, 132] even to the extent of conferring resistance to 3GCs and P-lactamase
inhibitors [118, 119],
Class D P-lactamases
As the DNA and amino acid sequences of an increasing number of P-lactamases
were determined it became apparent that another group needed to be added to
the Ambler classification. PSE-2 P-lactamase [133] was found to have
significant similarity to the OXA-1 and OXA-2 P-lactamases [111, 134], all of
which were sufficiently different from class A, B, and C, for Ouellette et al.
[Ill] to propose a new class. Class D was designated to include the plasmid-
mediated PSE- and OXA-type enzymes (acronyms of 'Pseudomonas-specific'
and 'oxacillin-hydrolysing' respectively [108]) and other enzymes that exhibit
carbenicillinase or oxacillinase activities. The PSE-4 P-lactamase, although
exhibiting the same characteristics of other PSE-type enzymes, has been
allocated to class A on a basis ofDNA sequence homology [135],
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Class E P-lactamases
Class E is the most recent addition to the Ambler classification. The LI
P-lactamase of Xanthomonas niciltophilia [112, 136] is a metalloenzyme
requiring a divalent zinc ion at the active-site for activity, as in class B. The
differences in biochemical properties and lack of sequence homology with
class B enzymes has prompted the suggestion by Sanders [113] that this fifth
class be created to accommodate this unique P-lactamase.
8.3. The Bush classification of P-lactamases
After Bush & Sykes [137] detailed guidelines for the study of the biochemical
characteristics of P-lactamases a classification with a more sensitive analysis of
enzyme kinetic parameters needed to be outlined. A modification of the
biochemical classification of P-lactamases [100, 102, 106] was proposed by Bush
in 1988 [114], This 'Bush classification' catalogued a large number of
P-lactamases in great detail [138-140] (Table 1.7 page 40). An initial review [114]
defined three classes (1, 2, and 3) in which class 2 was further divided into five
sub-groups (annotated a to e). The more detailed description [138-140] expanded
the scheme to include two extra classes: class 2b' and class 4. The classification
tried to take account of molecular aspects as well as biochemical characteristics,
but was not particularly successful in this respect.
Class 1 (CEP-N) P-lactamases
CEP-N (Cephalosporinase not inhibited by clavulanic acid) are preferentially
cephalosporinases and are not inhibited by lOpM clavulanate or
ethylenediaminetetraacetate (EDTA). Representative enzymes of this class are
the chromosomal P-lactamases of Gram-negative bacteria, for example the
E. coli ampC enzyme, or the Sabath & Abraham enzyme of Ps. aeruginosa and
Serratia marcescens. This group does not exclude plasmid-mediated
P-lactamases, for example CEP-1r22K from Proteus mirabilis.
Class 2 P-lactamases
This large group, divided into six sub-classes, consists of a variety of
P-lactamases all inhibited by clavulanic acid (hence the 'Y' suffix of each sub¬
title). Class 2a (PEN-Y) enzymes are classical penicillinases characteristically of
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Gram-positive origin. Although predominantly chromosomally encoded a few
notable exceptions are plasmid-mediated, for example the PCI P-lactamase of
Staph, aureus. Class 2b (BDS-Y), broad-spectrum enzymes with both
cephalosporinase and penicillinase activity, are predominantly plasmid-mediated
and contain the ubiquitous TEM-1 and SHV-1 P-lactamases. These enzymes,
however, do not exhibit any ESBL activity. The later designation of class 2b'
(EBS-Y) was added to the Bush classification to accommodate the novel
extended-spectrum enzymes, e.g. TEM-3, TEM-5, SHV-5, which readily
hydrolyse the 3GCs. Classes 2c (CAR-Y) and 2d (CLX-Y) include
penicillinases that also exhibit carbenicillinase and oxacillinase activity
respectively. Examples of these classes, again predominantly plasmid-meditated,
include some of the PSE-type enzymes, CARB-(y/?c enzymes and the OXA-type
enzymes. The final class 2 group, 'e' (CEP-Y), are cephalosporinases that
uniquely exhibit immunological properties similar to those of the penicillinases.
Class 3 (MET-N) P-lactamases
Class 3 enzymes are all metalloenzymes, usually requiring a Znll ion at the
active-site for activity. Since the criteria for designation into this class is being a
metallo-P-lactamase the hydrolytic properties are distinctly varied; however,
none are inhibited by clavulanic acid, and as would be expected all are inhibited
in the presence of the chelating agent EDTA. This group includes the
Xanthomonas maltophilia LI and the B. cereus type II metalloenzymes that
have been separated under the Ambler classification (see Section 8.2
pages 31-38).
Class 4 (PEN-N) P-lactamases
The PEN-N class has been added to the original Bush classification to include
those enzymes that are predominantly penicillinase in activity but are not
inhibited by clavulanic acid. The inhibition characteristics of EDTA on this










































Variable 26 -> 85 Pseudomonas
aeruginosa
LCR-1
Table 1.7: Summary of the Bush classification of p-lactamases
Abbreviations: BDS- prefix, broad spectrum p-lactamase; CAR- prefix, carbenicillin hydrolysing; CEP-
prefix, cephalosporinase; Clav, 10pM clavulanic acid; CLX- prefix, cloxacillin hydrolysing; EBS- prefix,
extended spectrum p-lactamase; MET- prefix, metallo-P-lactamase; M. Wt., molecular weight; -N
suffix, not inhibited by clavulanic acid; PEN- prefix, penicillinase; -Y suffix, inhibited by clavulanic
acid. After Bush (1989) [138]
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8.4. The Richmond & Sykes, Ambler, and Bush
classifications: A critique
Although each of the three of the above classifications, presented chronologically,
has its advantages each also has specific disadvantages. The Bush classification,
despite being originally proposed as a modification to the Richmond & Sykes
scheme, is sufficiently different to be considered as a classification scheme in its
own right.
Both the Richmond & Sykes and the Bush methods essentially use the biochemical
characteristics of the enzymes studied to classify them. The latter of these two
classifications, primarily as a result of the improvements in scientific techniques in
the 15 years between the two descriptions, requires a much more detailed
examination of the kinetics of a particular enzyme for categorisation than the
former. The Ambler system primarily relies on sequence homology to define the
classification but does, to some extent, also rely on the identification of
biochemical properties. To categorise a particular enzyme by the Ambler scheme
requires the DNA or amino acid sequence to be determined. This is not the
problem it was when Ambler introduced the concept of this categorisation in 1980
[109], Advances in molecular biology techniques have allowed the rapid and
efficient determination of DNA sequences on a routine basis. The Bush
classification makes some attempt to include the genetic details of the enzymes
catalogued [138-140], but as can be seen from the inclusion of molecular weights
of enzymes (Table 1.7 page 40), each class contains enzymes of very varied size,
hence varied ancestry. This adds further weight to the suggestion that many
P-lactamases have undergone convergent evolution under the selection of a
common antibiotic. Correlation of classification, however, under the Richmond &
Sykes and Bush schemes with the evolutionary categorisation of Ambler system is
poor.
It is probably the Ambler classification that will ultimately become the standard
method of classification of P-lactamases, but as discussed below, this will be
supplemented by other systems within each class (A, B, C, D, and E). The
determination ofDNA sequence is the ultimate method of defining the novelty of a
particular P-lactamase [141].
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9. TEM- & SHV-DERIVED (3-lactamases
The most prevalent and successful p-lactamase genes are carried by plasmids which,
unlike their chromosomally-encoded counterparts, are usually produced constitutively
so that any change in the ability to confer resistance stems from alterations in the
structure of the molecule rather than in the regulation of gene expression. The most
successful plasmid-encoded p-lactamases are the members of the TEM- and
SHV-families [2], Expression of the TEM-1 P-lactamase is the most common
mechanism of resistance to the P-lactam group of drugs in Gram-negative bacteria.
This successful resistance gene has most regularly been identified in
Enterobacteriaceae but is not confined to it. The gene is usually located on the
promiscuous transposon Tn3, and a series of transposition and rearrangement events
have allowed the TEM-1 gene's migration into many bacterial species [107] including
Haemophilus [142], Neisseria [143] and Vibrio spp. [144], The SHV family of
P-lactamases, on the other hand, appear to have been derived in Klebsiella. The gene
of the prototype SHV-1 shares about 65% identity with the TEM-1 gene [120], Both
are classified as Ambler Class A P-lactamases [109] in which the basic shape of the
enzyme molecule is conserved [116] and TEM-1 and SHV-1 have very similar
biochemical properties.
It is not obvious why TEM-1 should be so prevalent, accounting for about 80% of all
plasmid-encoded P-lactamases in clinical Enterobacteriaceae, whereas SHV-1
accounts for little more than 1% [3, 145-148], The transposon, on which the TEM-1
gene resides, may be far more mobile than the DNA that surrounds the SHV-1 gene
but this may not be the explanation. The gene of the P-lactamase TEM-2, a very close
relative of TEM-1 which differs from it only by a substitution of a single amino acid
(glutamic acid to lysine) at position 39 [149, 150], is also located on a transposon.
The TEM-2 enzyme never accounts for more than 10% of all plasmid-encoded
p-lactamases. There are probably subtle structural differences between the TEM-1
enzyme and either TEM-2 or SHV-1, which produce changes in the biochemical
function of the active site of the enzyme that even modern assay techniques are too
crude to distinguish. It seems that the active site of the TEM-1 p-lactamase is
exquisitely suited to the binding and hydrolysis of the most common penicillins in
clinical use.
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The earliest clinical strain known to possess an extended-spectrum (3-lactamase was
isolated in England in 1982 [151], A strain ofKlebsiella oxytoca was responsible for
an outbreak of infection in a neonatal unit in Liverpool. This strain was originally
gentamicin resistant but ceftazidime sensitive and it produced the TEM-1
p-lactamase. Ceftazidime was used to control it, but subsequent isolates of Kleb.
oxytoca from this unit showed that the strain had become ceftazidime resistant. The
ceftazidime resistance gene was transferable and carried on a 141-kb plasmid [151],
Subsequent detailed biochemical analysis showed that the ceftazidime resistance was
mediated by a new P-lactamase which hydrolysed ceftazidime with low, but
significant, efficiency [151],
Despite the fact that the earliest transferable extended-spectrum P-lactamase has now
been shown to have originated in an English strain, it is on the mainland of Europe
where most of these enzymes have been found and where they were first
reported [152, 153], In 1983, three strains of Kleb. pneumoniae and one Serratia
marcescens isolated in West Germany were demonstrated to confer transferable
resistance to cefotaxime [154], The plasmid mediated P-lactamase was a modification
of the Klebsiella enzyme SHV-1 and was designated SHV-2 [155], The nucleotide
sequence of SHV-2 showed a single nucleotide point mutation changing the amino
acid at position 238 from a glycine to a serine [120], These observations spawned a
series of reports of transferable plasmid-encoded resistance to 3GCs and almost all
these broad spectrum enzymes have been found to be modifications of either the TEM
or SHV groups of P-lactamases [156], The extended-spectrum SHV- and
TEM-derived enzymes have been identified in clinical isolates on every continent
[108, 152], These enzymes have been found in many Enterobacteriaceae, but
predominantly in Klebsiella, and are often encoded on large transferable plasmids.
These could have arisen either from direct selection, or by in vivo conjugation.
9.1. Mutations of the TEM- and SHV-P-lactamases
From the first example of cephalosporin selection of TEM-derived mutants in
Liverpool [151], the extended-spectrum P-lactamases seem to have emerged
spontaneously as a response by clinical isolates to the selective pressure of the
7-oxyimino cephalosporins. Many of the extended spectrum P-lactamases have
now been sequenced, or the mutations have been deduced after oligonucleotide
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probing ('oligotyping') [157], and relatively few point mutations have occurred in
the genes of the TEM- and SHV-type enzymes (Table 1.8 and Table 1.9 page 45).
p-Lactamases defined as Ambler Class A have differed in the numbering of amino
acid residues depending on whether a 'natural' or 'sequential' method is used. The
TEM- and SElV-enzymes have generally been numbered, at the level of amino acid
sequence by one of two methods. Sutclifife's numbering system [150] is derived
from the natural sequence, after the determination of the sequence of
TEM-1 pBR322i and places the active-site serine at residue number 68. The second
method used regularly is based upon the consensus sequence obtained by
Ambler [109] when his P-lactamase classification was first proposed. This latter
system places the active-site serine at residue number 70. The Sutcliffe system
generally numbers residues at two less than the Ambler system, but numbers vary
towards the C-terminal end of sequences because of deletions. For example, in
TEM-1, residue 261 under the Sutcliffe numbering system is equivalent to residue
265 of the Ambler system. As a result of the confusion these dual methods were
causing, Ambler el al. [158] proposed that the standard numbering system places
the active-site serine at residue 70 and that standard numbers be indicated by the
'ABL' prefix (Class A Beta-Lactamase). The Ambler standard numbering
system [158] is used throughout this thesis, but the 'ABL' prefix is not used.
Enzymes Amino acid at position^
205 238 240
SHV-1 Arg Gly Glu
SHV-2 Ser
SHV-3 Leu Ser
SHV-4 Leu Ser Lys
SHV-5 Ser Lys
SHV-8 Lys
Table 1.8: Molecular basis of the SHV-cfer/Vecf p-lactamases
t Amino acid numbering according to Ambler et al. (1991) [158], Abbreviations: Arg, arginine; Glu,
glutamic acid; Gly, glycine; Leu, leucine; Lys, lysine; Ser, serine.
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Enzyme Amino acid at position*
39 104 164 237 238 240 265
TEM-1 Gin Glu Arg Ala Gly Glu Thr
TEM-2 Lys
TEM-3 Lys Lys Ser
TEM-4 Lys Ser Met
TEM-5 Ser Thr Lys
TEM-6 Lys His
TEM-7 Lys Ser
TEM-8 Lys Lys Ser Ser





TEM-14 Lys Lys Ser Met
TEM-15 Lys Ser




TEM-24 Lys Lys Ser Thr Lys
TEM-26 Lys Ser
Table 1.9: The molecular basis of the TEM-der/Ved extended-spectrum
p-lactamases
^ Amino acid numbering according to Ambler et at. (1991) [158], Abbreviations: Ala, alanine; Arg,
arginine; Gin, glutamine; Glu, glutamic acid; Gly, glycine; His, histidine; Lys, lysine; Met, methionine;
Ser, serine; Thr, threonine.
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The point mutations of the SHV- and TEM-derived P-lactamases are clustered in
five areas of the enzyme (Figure 1.11 page 47), each adjacent to one of seven
evolutionary conserved boxes described by Joris et al. [115]; area 1 is at position
104 (adjacent to the a-3 helix), area 2 is at position 164 (adjacent to the a-7 helix),
area 3 is at position 205 (on the a-9 helix), area 4 is at positions 237-240 (on the
p-3 strand) and area 5 is at position 265 (on the P-5 strand). Each of these areas
are located in close proximity to the active-site cavity (Figure 1.11) and are
thought to open up novel enzyme-substrate interactions involving, in particular the
oxyimino substituents of 3GCs [159],
9.2. The Payne & Amyes classification of extended-spectrum
P-lactamases
It is current practice to classify P-lactamases by their nucleotide sequence and for
most enzymes this works well; however, all the extended-spectrum P-lactamases
fall into class A [109] and encompass enzymes whose genes share as little as 35%
identity but retain the same overall shape. The lack of correlation between
sequence and enzyme function is epitomised with the prototype enzymes TEM-1
and SHV-1; these enzymes are impossible to distinguish biochemically. On the
other hand, the gene of TEM-5 has only three nucleotide changes from that of
TEM-1 [160] (i.e. > 99.5% identity). The biochemical difference of the resultant
TEM-5 P-lactamase and the resistances that it confers are of immense clinical
importance. So a classification scheme based entirely on the structure is unhelpful.
A categorisation scheme devised by Payne & Amyes [152], for the plasmid-
mediated ESBL, based on the biochemical properties and the resistances that the
enzymes confer, shows that the mutations produce three major changes in function.
A summary of the original classification is given in Table 1.10 (page 48). Most of
the enzymes included in the original classification [152] are members of Ambler
class A, however, some have subsequently been found to be members of other
classes (e.g. BIL-1 and MIR-1 have now been allocated to Ambler class C).
Figure 1.11: Ribbon diagram of the TEM-1 ^-lactamase
Numbering of amino acid residues according to the recommendations of Ambler et al. (1991) [158],
Diagram is based on the crystal structure of the TEM-1 p-lactamase described by Jelsch et al.
(1992) [126] and Jelsch et al. (1993) [127], The active site is centred around the serine-70 and
bounded by the a3 and a7 helices, p3 sheet, the SDN loop (named after the conserved Serine-
Aspartic acid-Asparagine motif found on the turn), and the Q-loop (named after the shape of the
loop). Abbreviations: Ala, alanine; Arg, arginine; Glu, glutamic acid; Gly, glycine; Ser, serine; Thr,
threonine.
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Extended-spectrum P-lactamases in group 1, which give low level resistance to
cefotaxime or ceftazidime, possess amino acid substitutions that increase the ability
of the enzyme to hydrolyse ceftazidime faster than cefotaxime. Groups 2 and 3 will
produce high levels of resistance to both ceftazidime and/or cefotaxime. Enzymes
in group 2 hydrolyse ceftazidime to a greater extent than cefotaxime, whereas
group 3 enzymes hydrolyse cefotaxime better than ceftazidime. Group 4 contains
those P-lactamases that hydrolyse the 3GCs and are resistant to inhibition by the
P-lactamase inhibitors such as clavulanic acid. Often the in vitro ability to
hydrolyse cefotaxime is greater than that to hydrolyse ceftazidime, but the fast
penetration of cefotaxime ensures that this hydrolysis is insufficient to overcome
the drug's antibacterial activity [20, 40, 72, 83],
The Payne & Amyes classification was the best system available to concisely
describe the plasmid-mediated SHV- and TEM-derived P-lactamases at the start of
this thesis. No account, however, is taken of the amino acid sequence of these
closely related ESBL.
II Phenotype Activity Examples...
CAZ CTX Clav
1 Low 3GC resistance ++ + TEM-E2, TEM-2,
TEM-7, TEM-12
2 High 3GC resistance ++++ +++ TEM-E3, TEM-6,
TEM-9, TEM-10
3 a High 3GC resistance ++++ +++++ TEM-3, TEM-4, TEM-5,
TEM-8
b SHV-2, SHV-3, SHV-4,
SHV-5
c FEC-1, DJP-1
4 3GC resistance ++++ +++ ++ MIR-1, BIL-1
Table 1.10: Summary of the Payne & Amyes classification of plasmid-
mediated extended-spectrum p-lactamases
Abbreviations: 3GC, 3rd generation cephalosporins; CAZ, ceftazidime; Clav, clavulanic acid,
t Group 3 is subdivided into TEM-derived (a), SHV-der/Ved (b), and those of unknown origin (c)
according to the data available when the classification was devised Payne & Amyes [152].
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10. Concluding remarks
The evolution of the P-lactamases have been studied in detail by a number of workers
since the enzymes discovery in 1940. The Ambler class A p-lactamases, specifically
the ubiquitous SHV- and TEM-type enzymes, are of particular clinical importance and
an understanding of the environmental pressures that have selected the enzymes is
useful in the design of new P-lactam antimicrobial agents. The parental enzymes
(TEM-1, TEM-2 and SHV-1) can be readily mutated to extended-spectrum enzymes
in the laboratory environment when challenged with a 3GC [161, 162], This
phenomenon, however, proposes the question: " If the ESBL mutations occur so
readily, why are the reported incidences of ESBL-mediated resistance to the 3GCs so
few?"
The epidemic of ESBL-mediated resistance promised by certain groups [107, 153,
163-165] in the 1980s failed to materialise [152], One of the proposed reasons for this
was the limitation of 3GC use to hospitals. The introduction of orally active 3GCs has
allowed an increase in the number bacteria to be challenged with this selective
pressure. The oral 3GCs are no more likely to select ESBL-mutations than the
parenteral 3GCs [166], but the incidence of 'challenge events' will increase as the
drugs become more widely prescribed. A pool of 3GC resistant strains may then
develop in the general population. The sporadic nature of reports describing ESBL,
however, suggests that the TEM- and SH\-derived ESBL are somehow unstable
compared to the parental enzymes. This phenomenon has not been investigated or
explained.
Most researchers have either examined the clinical implications ofESBL or the effect
of the ESBL-mutations on substrate binding. The clinical aspects of the ESBL have
rarely been studied in combination with a detailed analysis of the molecular and
biochemical characteristics of the ESBL-mutations. There has been no satisfactory
explanation for the multiplicity of the TEM- or SH\-derived enzymes to date. Much
of the research, like the combinations of the ESBL-mutations (Table 1.8 page 44,
Table 1.9 page 45 and Figure 1.11 page 47), appears to have been random with
respect to evolutionary considerations. Although this approach has been useful in
elucidating the substrate binding of many class A P-lactamases, the contribution of
each individual clinical mutation, separately or in clinically observed combinations, has
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not been fully investigated. There are 23 SHV- and TEM-derived ESBL that have
been shown to be genotypically and phenotypically distinct: the classification schemes
described above (see Section 8 pages 29-41 & Section 9.2 pages 46-48) do little,
unfortunately, to accommodate the inter-relationships of these closely related
enzymes.
11. Aims of this thesis
1. To evaluate the inter-relationships of the SHV- and TEM-derived (^-lactamases,
and to establish a rationale for the study of the ESBL.
2. To study the various TEM-derived ESBL enzymologically, to relate the
enzymes structural variations to changes in function, and to elucidate the effects
of the various point mutations present within the ESBL on the binding of the
7-oxyimino cephalosporins.
3. To identify the possible evolutionary course of events, promoted by the
selective pressure applied through the clinical use of the 3GCs, that led to the
selection ofmany of the ESBL.
4. To investigate the relative instability of the SHV- and TEM-derived ESBL
genes compared to the parental TEM-1, TEM-2 and SHV-1 P-lactamase genes.
5. To relate the molecular and biochemical aspects of the SHV- and TEM-derived
P-lactamases to the possible selective pressures applied by antimicrobial




1. Reagents & antimicrobial agents
Chemicals and reagents were all supplied by Sigma Chemicals (Poole, Dorset) unless
otherwise indicated. The antimicrobial agents were supplied by Sigma chemicals
unless otherwise stated (Table 2.1 page 52). Solutions of antimicrobial agents
prepared from non-sterile powders were filter sterilised through a 0.22pm pore
membrane (Acrodisc 0.2pm sterile syringe filters; Gelman Sciences, Ann Arbor,
Michigan, USA) prior to use. All solutions of antimicrobial agents were freshly
prepared with sterile ultra-pure deionised water unless otherwise indicated.
2. Bacterial strains
The standard bacterial strains used for the experiments that comprise this thesis are
shown in Table 2.2 (page 53) and the standard vector plasmids are detailed in
Table 2.3 (page 53). Details of strains expressing standard P-lactamases are listed in
Table 2.4 (page 54).
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Antimicrobial agent Abbreviation Supplier
Generic name Proprietary name used in text
Ampicillin - Amp Sigma Chemicals
Amoxycillin Amoxil Amx Bencard
Cefotaxime Claforan Ctx Roussel Laboratories Ltd
Ceftazidime Fortum Caz Glaxo Laboratories Ltd
Cefuroxime - Cfx Sigma Chemicals
Cephaloridine - Cep Sigma Chemicals
Chloramphenicol - Cm Boehringer Mannheim UK
Clavulanic acid - Clav Glaxo Group Research Ltd
Kanamycin - Kan Boehringer Mannheim UK
Nalidixic acid S: Nal Sigma Chemicals
Nitrocefin - Ncfn Glaxo Group Research Ltd
Penicillin G - PenG Sigma Chemicals
Rifampicin Rifadin Rif Ciba Laboratories
Streptomycin - Sm Sigma Chemicals
Tetracycline Achromycin Tet Lederle Laboratories
Table 2.1: Antimicrobial agents
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All strains were stored at -70°C in cryovials (Alpha Laboratories, Eastleigh, Hants.).
The required strain was inoculated into nutrient broth and incubated, with shaking,
overnight at 37°C. An aliquot of the overnight culture was thoroughly mixed with
sterile glycerol to a final concentration of 10%v/v and immediately frozen at -70°C.
Strains were sub-cultured directly from stock onto solid media, for verification of
phenotype and purity prior to use, but were never passaged.
Strain Genotype Source Reference
E. coli K12 J53-2 pro, met, RifR
E. coli K12 J62-1 pro, his, trp, lac, NalR
E. coli K12 J62-2 pro, his, trp, lac, RifR
E. coli K12 TG1 thi, A(lac-proAB), F[lac\i /acZAM15]







Table 2.2: Standard bacterial strains
Plasmid Size Markers Reference
pAT153 3.7-kb AmpR, TetR [170]
pBGS18+ 4.4-kb KanR, lacZ' [171]
pBR322 4.4-kb AmpR, TetR [172]
pKK233-2 4.6-kb AmpR [173]
pSG-2 4.4-kb KanR [174]
pSG-TEM-1 5.3-kb AmpR, KanR [174]
pUC8 2.7-kb AmpR, lacZ' [175]
pUC18 2.7-kb AmpR, lacZ' [176]
Table 2.3: Details of vector plasmids
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p-Lactamase PI Bacterial strain Plasmid Source? Reference
OXA-2 7.7 E. coli J53-2 R46 SA319 [177]
SHV-3 7.0 E. coli J53-2 pUD16 DP191 [178-180]
TEM-1 5.4 E. coli JM108 pUC8 SA1489 [175]
E. coli JM83 pUC18 SDB73 [176]
E. coli TG1 pAT153 SDB101 [170]
E. coli 1009 pBR322 SA473 [172]
E. coli J53-2 R6K SA471 [181]
E. coli J62-2 R1 SA17 [182]
TEM-2 5.6 E. coli J62-2 RP4 DP43 [-181]
TEM-3 6.3 E. coli J62-1 pCFF04 DP189 [180, 183]
TEM-5 5.5 E. coli J62-2 pCFF14 DP70 [180, 184]
TEM-6 5.9 E. coli J53-2 pMG226 DP314 [180, 185]
TEM-7 5.41 E. coli J62-1 plF100 DP187 [180, 186]
TEM-9 5.5 E. coli J53-2 pMG228 DP41 [180, 187]
TEM-10 5.57 E. coli J53-2 pJPQ100 DP211 [188]
TEM-12 5.25 E. coli MG32 Chromosomal SDB68 [189]
TEM-26 5.58 E. coli DH5a PJPQ101 SDB157 [190]
TEM-E1 5.41 E. co//J53-2 pUK720 DP63 [141, 191]
TEM-E2 5.25 E.coli J53-2 pUK721 DP67 [141, 151]
TEM-E3 5.57 E. coli J53-2 pUK722 DP61 [141, 192, 193]
E. coli J53-2 pUK723 DP315 [141, 192, 193]
TEM-E4 5.61 E. coli J53-2 pUK724 DP59 [141, 194]
Table 2.4: Bacterial strains producing standard ^-lactamases
§ Source of host organism (culture collection number: DP prefix refers to D.J. Payne's culture
collection; SA prefix refers to S.G.B. Amyes' culture collection; SDB prefix refers to S.K. Du Bois'
culture collection).
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3. Growth media
Unless otherwise stated all growth media, and components thereof, were sterilised by
autoclaving for 15 minutes at 121°C. The standard working concentrations of
antibiotic supplements for addition to both minimal and complex media are listed in
Table 2.5.
3.1. Minimal media
Minimal salts medium was prepared as a double strength solution, as described by
Davis & Mingioli [195] (double-strength DM) (Table 2.6 page 56). A single-
strength minimal salts medium (single-strength DM) was prepared by dilution of
double-strength DM with an equal volume of sterile distilled water. Single-strength
DM was used for the dilution of bacterial cell suspensions. For the preparation of
minimal salts growth media D-glucose was added to a final concentration of





Ampicillin 50mg/ml Water 50-100mg/l
Ceftazidime 10mg/ml Water 2-8mg/l
Kanamycin 20mg/ml Water 50mg/l
Nalidixic acid 2.0mg/ml Water 20mg/l
Rifampicin 2.5mg/ml Water 25-50mg/l
Tetracycline 5mg/ml Ethanol 50mg/l
Table 2.5 : Antibiotics used for the selection of resistant
Escherichia coli cells
* Solutions were freshly prepared and sterilised by filtration (Acrodisc 0.2pm syringe filter, Gelman
Sciences). 1 Concentrations of antibiotics varied according to plasmid copy number and resistance
mechanism.
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Single-strength DM supplemented with glucose and thiamine is called MGT
medium throughout this thesis, and was primarily used for the maintenance of
E. coli TGI strains.
Solid media was prepared by adding the required auxotrophic supplements,
selective antibiotics, and glucose to a 50ml aliquot of double-strength DM and
making up to 60ml. The enriched solution was then mixed with 40ml sterile molten
Bacteriological Agar No. 1 (37.5g/l) (Oxoid, Basingstoke, Hants.) immediately





^/-Potassium hydrogen phosphate k2hpo4 14.0g/l 7.0g/l
Potassium dihydrogen phosphate kh2po4 6.0g/l 3.0g/l
fry-Sodium citrate Na3C6H507 0.94g/l 0.47g/l
Magnesium sulphate MgS04-7H20 0.2g/l 0.1 g/l
Ammonium sulphate (NH4)2S04 2.0g/l 1 0g/l
Table 2.6: Davis & Mingioli minimal salts medium






L-Histidine 5.Og/I 50mg/l Steaming/30min.
L-Methionine 5.Og/I 50mg/l Steaming/30min.
L-Proline 5.Og/I 50mg/l Steaming/30min.
L-Tryptophan 2.Og/I 50mg/l Steaming/30min.
Thiamine hydrochloride 1 -Og/I 2mg/l Filtration^
Table 2.7: Supplements for minimal media
t Acrodisc 0.2|jm syringe filter (Gelman Sciences)
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3.2. Complex media
The following complex media were used: Isosensitest Broth (CM473), Nutrient
Broth No. 2 (CM67), Isosensitest Agar (CM471) and MacConkey Agar (CM7b),
all supplied by Oxoid (Basingstoke, Hants.).The following media were also used
(quantities for a final volume of one litre):
SOC MEDIUM: 20g Bacto tryptone (Difco, Detroit, Michigan, USA), 5g Bacto
yeast extract (Difco), and 0.5g sodium chloride, with final concentrations of
25mM potassium chloride and 20mM glucose. The pH was adjusted to 7.0 with
sodium hydroxide.
LURIA-BERTANI (LB) MEDIUM: 10g Bacto tryptone (Difco), 5g Bacto yeast
extract (Difco), and lOg sodium chloride. LB Agar was prepared with the
addition of 15g Bacteriological Agar No. 1 (Oxoid) to the medium before
making the volume up to one litre. LB 'top agar' (for overlaying agar plates)
was prepared as for LB broth except for the addition of 7g Bacteriological Agar
No. 1 (Oxoid) per litre.
4. Antibacterial susceptibility testing
Minimum inhibitory concentrations (MICs) were performed on Isosensitest (1ST)
agar following the British Society for Antimicrobial Chemotherapy (BSAC) guidelines
for susceptibility testing where applicable [196], Antibiotic sensitivity discs were
supplied by Mast Laboratories Ltd. (Merseyside). MICs were determined by agar
double dilution of the antimicrobial agent. Agar, containing the appropriate
concentrations of antimicrobial agent, was inoculated with a 2pl spot of each
organism, delivered from a multipoint inoculator (Denley, Billinghurst, Surrey).
Bacterial strains to be tested were inoculated into nutrient broth and incubated in a
static environment for 12 hours at 37°C, before dilution in single-strength DM to give
an inoculum of 104 colony forming units (cfu)/spot in each case (unless otherwise
stated). Inoculated agar plates were incubated overnight at 37°C in stacks of no more
than three Petri dishes. MICs of co-amoxiclav (amoxycillin/clavulanic acid ratio 2:1)
are expressed in terms of the amoxycillin concentration.
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5. Transconjugational transfer of plasmids
The method of conjugal transfer of plasmids employed was as described by Amyes &
Gould [197], Broth cultures of donor and recipient strains were always incubated
statically at 37°C. The donor and recipient strain were cultured overnight in nutrient
broth, then 4.5ml of fresh, pre-warmed, nutrient broth was inoculated with lOOpl of
the donor strain and 1.0ml of the recipient strain, and gently mixed. The mixture was
incubated at 37°C for six hours. The bacterial cells were then harvested using a
Heraeus Labofuge 6000 by centrifugation at 4500rpm (3000xg) for 20 minutes. The
cell pellet was resuspended in 5ml of single-strength DM and a series of ten-fold
dilutions prepared. A lOOpl aliquot of each dilution was spread onto minimal media
containing the appropriate auxotrophic supplements and selective antibiotics. The
inoculated plates were incubated at 37°C for 48 hours. All potential transconjugants
were verified by checking the auxotrophic requirements and resistance markers.
To select ampicillin or ceftazidime resistant E. coli K12 J62-2 transconjugants,
minimal media containing the auxotrophic requirements of this strain (proline,
histidine, and tryptophan; see Table 2.7 page 56), plus 25mg/l rifampicin and
50mg/l ampicillin or 4mg/l ceftazidime, as appropriate for selection, was used.
6. Purification of (3-lactamases
The three different methods of [3-lactamase purification employed are described
below. Each method was based on the initial disruption of the bacterial cells with
ultrasound [97, 198], A Sorvall RC-5B Refrigerated Superspeed Centrifuge (DuPont
Instruments, Stevenage, Herts) was used for all the centrifugation described in this
section, unless otherwise stated. The specific Sorvall fixed-angle rotor (SM-24,
SA-600, or GS-3: all supplied by DuPont Instruments) used in the Sorvall RC-5B
Centrifuge for each centrifugation step is stated where appropriate.
6.1. Crude, cell free, P-lactamase preparations
Each bacterial strain investigated was streaked onto nutrient agar slopes and
incubated overnight at 37°C. Cell growth was then washed off the surface of the
nutrient agar slope with 1.0ml of 50mM sodium phosphate buffer (pH 7.0),
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transferred to a fresh sterile container, and cooled on ice for 5 minutes. Bacteria
were disrupted by sonication (MSE Soniprep 150, MSE Instruments, Crawley,
Sussex) with the cell suspensions cooled on ice [198, 199]: two 30 second pulses
of 7-8pm amplitude separated by a 30 second cooling period. The lysate was
cleared of cell debris by centrifiigation at 4°C in an MSE Micro Centaur centrifuge
at 13000rpm (11600xg) for 20 minutes. The cell free supernatant was stored at
-20°C until required.
Assessment of 0-lactamase activity enzyme preparations
The time, in seconds, for a 33pi aliquot of each [3-lactamase preparation to
change lOOpl of a lOOpM solution of nitrocefin from a yellow colour to red
was taken as an indication of P-lactamase activity. Measurements were
performed in a microtitre plate against a white background. This empirical
assessment is referred to as the 'nitrocefin spot test' throughout this thesis.
6.2 Partial purification of P-lactamases
The required bacterial strain was inoculated into 5ml of LB broth and incubated at
37°C with vigorous shaking (~200rpm) for 6 hours. This seeder culture was added
to 500ml of LB broth, in a 21 conical flask, which was then incubated overnight at
37°C with vigorous shaking (~180rpm). The overnight cell culture was harvested
by centrifogation at 7500rpm (6000xg) for 15 minutes at 4°C in a GS-3 rotor. The
resultant bacterial pellet was resuspended in 20ml of 50mM sodium phosphate
buffer (pH 7.0), and re-pelleted at 4500rpm (3000x^) for 30 minutes at 4°C, with
the SA-600 rotor. One ml of 50mM sodium phosphate buffer (pH 7.0) was added
to the final cell pellet (~2ml in volume) and the cells resuspended to form a thick
slurry. This sample was dispensed into ~1.5ml aliquots and suspended in an
ice/water bath.
The cells were disrupted by sonication [198, 199] at 7-8pM amplitude (MSE
Soniprep 150): three 30 second pulses separated by 30 second cooling periods.
The separate aliquots were pooled and cooled on ice for 5 minutes. Nucleic acids
were removed by precipitation with the addition of 0.1 volumes of
10%w/v streptomycin sulphate. The cell lysate was cleared by centrifogation at 4°C
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at 16000rpm (32000xg) for 1 hour with an SM-24 rotor. The supernatant was
removed and used immediately, or stored at -20°C and thawed on ice before use.
Preparation of a Sephadex G-75 gel filtration column
The method of column preparation was based upon that described by
Andrews [200], Fine grade Sephadex G-75 (Pharmacia, Uppsala, Sweden)3 was
swollen in an appropriate volume of 50mM sodium phosphate buffer, (pH 7.0)
by maintainance at 100°C for 3 hours. The slurry was cooled to 4°C and poured
into a 2cm2x90cm acrylic column (Amicon, Ltd, Stonehouse, Glos.) which was
maintained at 4°C. When fully packed, an LKB 10200 Perpex peristaltic pump
(Pharmacia) was connected, and the Sephadex was washed with 50mM sodium
phosphate buffer (pH 7.0), at a flow rate of 0.2ml/minute for 48 hours. When
not in use the Sephadex column was maintained by continuous recycling of a
one to two litre reservoir of 50mM sodium phosphate buffer. After use the
column was washed with a minimum of two column volumes (180ml) of 50mM
sodium phosphate buffer (pH 7.0) before maintainance with continuous
recycling of buffer.
Calibration of the Sephadex G-75 gel filtration column
The Sephadex column was calibrated according to the method of
Andrews [200], Three proteins of known molecular weight (lOmg/ml each of
cytochrome C, chymotrypsinogen, and ovalbumin) were applied to the column
in a 1ml aliquot and eluted at a rate of 0.2ml/minute in 50mM sodium phosphate
buffer. Fractions were collected in 2ml aliquots with a LKB 2070 Ultrorac II
fraction collector (Pharmacia). The elution volumes of the proteins were
determined by measuring absorbance (X = 280nm) of the fractions with a
Perkin-Elmer UV/Vis Lambda 2 Spectrophotometer (Beaconsfield, Bucks.).
Absorbance of each fraction was plotted against elution volume; this standard
curve was used to estimate the elution volume of the (3-lactamases passed
through the column.
The total crude, cell free, lysates were applied to the Sephadex column and eluted
with 50mM sodium phosphate buffer (pH 7.0) at a flow rate of 0.2ml/minute, until
a Dry bead diameter 10-40pm: Bed volume 12-15ml/g of dry Sephadex G-75: Recommended for
the fractionation of peptides & globular proteins of a molecular mass between 3xl03 and 7><104.
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at least one column volume had been collected in 2ml fractions. Each fraction was
subjected to a nitrocefin spot-test assay to ascertain the fractions containing the
eluted p-lactamase. Fractions exhibiting peak P-lactamase activity were pooled and
proteins precipitated by the addition of 70%w/v ammonium sulphate. The
precipitated proteins were pelleted by centrifiigation at 12000rpm (20000xg) at
4°C, in an SA-600 rotor for 30 minutes. The (NH^SC^ precipitate was dispersed
in 1.0ml of 50mM sodium phosphate buffer (pH 7.0) and the resultant slurry
dialysed against 21 of 50mM sodium phosphate buffer (pH 7.0) at 4°C for
12 hours. The activity of each partially purified P-lactamase preparation was
assessed with a nitrocefin spot test. Partially purified preparations were stored at
-20°C until required.
6.3. Preparative isoelectric focusing of P-lactamases
Preparative IEF of partially purified enzymes was required to separate individual
P-lactamases of multiple P-lactamase producing strains, in order that the enzyme
kinetics of the different P-lactamases could be determined. The method employed
was modified from that described by Vecoli et al. [201] and Hood [202] for use
with an LKB 2217 Ultraphor Electrofocusing unit (Pharmacia).
Agarose for Isoelectric focusing Type VIII (1.5g) was dissolved in 75ml sterile
deionised water by heating to 121°C, followed by cooling to 55°C. Twenty ml of
50%w/v D-sorbitol, 2.5ml of 40%w/v carrier ampholytes pH 4-6, and 2.5ml of
40%w/v carrier ampholytes pH 3.5-10 were pre-warmed to 55°C and mixed with
the molten agarose.
An LKB Gelbond film (for agarose gels) (Pharmacia) was placed onto the cooling
plate of an LKB Ultraphor Electrofocusing unit. The cooling plate was warmed to
45°C by connecting the unit to a thermostatic circulator and the molten IEF
agarose solution poured evenly onto the Gelbond film. The unit was then cooled to
15°C, and agarose solidified, prior to the application of electrode strips, soaked in
the appropriate buffer (1M H3PO4 for the anode and 1M NaOH for the cathode),
close to the short edges of the gel. One ml of a partially purified P-lactamase
preparation was applied evenly to the surface of the agarose, to within 10mm of
the gel edges and electrode strips. The P-lactamases were focused for 3 hours at
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15°C at a constant power of 20 Watts (Power supply settings: voltage = 1500V,
current = 30mA, power = 20W). The two edges of the agarose gel between the
electrode strips, were visualised by overlaying the gel with strips of filter paper
soaked in ImM nitrocefin solution. When the regions of P-lactamase activity were
identified the focused enzyme bands were excised. One ml of 50mM sodium
phosphate buffer (pH 7.0) was added to each agarose gel slice (between 5-10mm
in width), after slicing into smaller fragments, and dialysed overnight against 21 of
50mM sodium phosphate (pH 7.0) at 4°C. The agarose fragments were then
pelleted at 16000rpm (32000x,g) at 4°C in an SM-24 rotor. The supernatant was
removed and was stored at -20°C for up to one month prior to use. The activity of
each preparation was estimated with a nitrocefin spot test. Purity of preparations
were verified by analytical IEF (see Section 7 below).
7. Analytical isoelectric focusing
P-Lactamases were identified by analytical IEF as described by Matthews et al. [105],
The P-lactamase preparations were focused on horizontal thin layer polyacrylamide
gels [203] containing broad range carrier ampholytes of pH 3.5-10, or a mixture of
broad range (pH 3.5-10) and narrow range (pH 4-6) carrier ampholytes (ratio 1:1).
Thin layers of polyacrylamide gel, 200m x 150mm x 1mm, were prepared by
polymerisation of the gel solution, described in Table 2.8 (page 63), catalysed by
riboflavin [204] in the presence of ultra-violet light between two glass plates 1mm
apart. To promote adhesion of the polyacrylamide gel to one of the two glass plates,
it was necessary to coat one glass plate with a binding solution. The remaining glass
plate was siliconised, to reduce adhesion, with Sigmacote silconising solution.
The binding solution was prepared by dissolving 0.5%w/v gelatine (ca. 225 bloom
from calf skin: Aldrich Chemical Co. Ltd., Gillingham, Dorset) and
0.5%w/v chromium potassium sulphate dodecahydrate (Aldrich Chemical Co. Ltd.) in
sterile distilled water. Glass plates (210mm x 160mm) were submersed in the coating
solution for 10 minutes, before removal from the solution and air-drying for 1 hour
prior to use.
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Samples of p-lactamase preparations were loaded close to the anode on the surface of
the gel (volumes in pi equivalent to the nitrocefin spot test time, up to a maximum of
50pl were applied). In all cases P-lactamases of known isolectric point (see Table 2.4
page 54) were focused alongside novel enzymes.
Analytical IEF gels were focused at a constant power of 1 Watt overnight at room
temperature (Power supply settings: voltage = 500V, current = 20mA, power =
1.0W). The focused P-lactamase bands were visualised by overlaying the
polyacrylamide gel with sheets of filter paper soaked in ImM nitrocefin [104],
Isoelectic points of unknown or novel enzymes were estimated from the focused
bands of enzymes of known pi.
8. Enzyme kinetics
The SHV- and TEM-type P-lactamases catalyse P-lactam hydrolysis (Figure 2.1
page 64) by a double displacement mechanism, via an acyl-enzyme intermediate
[205,206] that obeys the principles of Michaelis-Menten kinetics [137,207]
(Figure 2.2 page 64). The progress of enzyme catalysed reactions could be monitored
by measuring the change in absorption of light (A) over time [104, 208, 209],





Sterile distilled water 25.0 - -
5%v/v A/,/V,/V',/\/-tetramethyl-
ethylenediamine (TEMED)
0.2 0.05%v/v Sigma Chemicals
40%w/v carrier ampholytes:
pH 3.5-10
pH 3.5-10/pH 4-6 (Ratio 1:1)
2.0 2.0%w/v Sigma Chemicals
33.9%T, 2.7%C acrylamide/
N,N'-methylene 6/s-acrylamide
9.0 7.6%T, 2.7%C BDH Chemicals
0.002%w/v riboflavin 4.0 0.0002%w/v Sigma Chemicals
Table 2.8: Composition of analytical IEF gels
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All spectrophotometric studies of P-lactamases were performed on either a Perkin-
Elmer UV/Vis Lambda 2 Spectrophotometer or a Perkin-Elmer UV/Vis 554
Spectrophotometer. Ail assays were carried out at 37°C in 50mM sodium phosphate
buffer (pH 7.0). Substrate solutions were prepared in 50mM sodium phosphate buffer
(pH 7.0).
The wavelength (A) at which enzymatic-degradation of a given P-lactam substrate
was measured, was that which gave the maximum difference in absorbance between
unhydrolysed and hydrolysed substrate. Details of the wavelength used for
P-lactamase assays of the various P-lactam substrates (Amax) is given in Table 2.9
(page 65).
8.1. Measurement of p-lactamase activity
The rate of hydrolysis for a fixed concentration of substrate (ImM for penams,
O.lmM for cephems) was measured to give an indication of enzyme activity. An
Figure 2.1: Hydrolysis of the p-lactam bond of cephems
Enzymatic degradation of the p-lactam antimicrobial agents by p-lactamases adds a water molecule
across the p-lactam bond.
k} k2 k3
E + S E-S —> E-S—E + P
k.,
Figure 2.2: The mechanism of p-lactamase hydrolysis of p-lactam
antimicrobial agents
The enzymatic hydrolysis of p-lactam antimicrobial agents follows Michaelis-Menten kinetics.
Abbreviations: E, enzyme; S, substrate; E-S, noncovalent Michaelis complex; E-S, acyl-enzyme
complex; P, ring opened product; kn, rate constants. From Bush & Sykes (1986) [137].
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aliquot of a P-lactamase preparation was added to a test cuvette containing the
substrate, and the decrease in absorbance over time (in minutes), was measured
with reference to a blank solution containing the same concentration of enzyme but
no substrate. Rate of hydrolysis was defined as micromoles of substrate hydrolysed
per minute, per millilitre of enzyme preparation [104]:
_ AA xnx d
K =
A0 x t
where: R = initial rate of hydrolysis (pmoles/minute/ml of enzyme)
AA = change in absorbance over time, t (minutes)
n = number of micromoles of substrate added to cuvette
d = factor adjusting enzyme volume to lml
A0 = absorbance of intact substrate solution at t = 0
The change of absorbance over time was measured for the initial 10% of the
degradation reaction, where AA remained proportional to time. The values
obtained by this method were normalised with respect to ampicillin or nitrocefin, to
obtain the 'relative rate of hydrolysis' for each substrate, as proposed by Bush &
Sykes [137],







Penicillin G (benzylpenicillin) 356.4 238nm
Table 2.9: Optimum wavelengths for the measurement of p-lactam
hydrolysis
t Molecular mass of sodium salt, except for nitrocefin (free base).
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8.2. Determination of enzyme kinetic parameters
The initial rate of hydrolysis (v0) for a range of substrate concentrations (S), at
which the Beer-Lambert law was obeyed, were determined photometrically. The
results were analysed by the method of Lineweaver & Burke [210] and the
maximum rate of reaction (Vmax) and the Michaelis constant (Km) were calculated
from a plot of l/v0 against 1/S. The efficiency of hydrolysis was calculated by
dividing the Vmax by the Km [75, 211],
The I5o value was defined as the concentration of inhibitor required to inhibit
enzyme activity by 50%. The initial rate of hydrolysis of ImM penicillin G was
determined in the absence of inhibitor. The (3-lactamase inhibitor clavulanic acid
was incubated with enzyme for 5 minutes at 37°C, before initiation of the reaction
by addition of penicillin G to a final concentration of ImM. The percentage
inhibition for clavulanic acid concentrations increasing from lOnM to ImM were
determined. Percentage inhibition was then plotted against the logarithm (to the
base 10) of the inhibitor concentration, and the I50 value determined by
interpolation.
9. The isolation and purification of DNA
A number of different methods were used for the isolation of DNA depending on its
nature, or source, and the proposed use of the isolated DNA.
9.1. Isolation of small bacterial plasmids
Small molecular weight plasmids (2-kb to 10-kb) were isolated from cultures of
E. coli by a procedure based on the 'Rapid boiling method' of Holmes &
Quigley [212], Bacteria from a small volume (1-1.5ml) of an overnight LB broth
culture, were harvested and suspended in STET buffer (8%w/v sucrose,
50mM Tris-Cl pH 8.0, 50mM EDTA, 5%v/v Triton X-100), and boiled for
1 minute in the presence of l%w/v lysozyme. An insoluble clot of cell debris and
genomic DNA was removed by centrifugation (13000rpm (11600x^) for
10 minutes in an MSE Micro Centaur centrifuge). Plasmid DNA was recovered
from the supernatant by precipitation with an equal volume of isopropranol at
-70°C for 10 minutes. The precipitate was collected by centrifugation (9500xg for
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10 minutes) and resuspended in a 300mM sodium acetate solution (pH 5.5),
followed by a repeat centrifugation step to remove any remaining insoluble
material. Plasmid DNA was precipitated at -70°C for 30 minutes after the addition
of two to four volumes of ethanol. The precipitated plasmid DNA was pelleted by
centrifugation (11600xgfor 10 minutes), washed in a small volume of ethanol, and
dried under vacuum for 10-20 minutes. The dried DNA-pellet was resuspended in
20pil ofTE buffer (lOmM Tris-Cl pH 7.5, 0.1mM EDTA).
This method was used for the isolation of cloning vector plasmids and double-
stranded Ml3 phage DNA.
9.2. Isolation of large bacterial plasmids
Overnight LB broth cultures (4.5ml) were harvested by centrifugation for
30 minutes at 3100rpm (2000xg-) in a Sorvall RT6000D Refrigerated Centrifuge
with H1000B rotor (DuPont Instruments). A modification of the alkaline lysis
method described by Takahashi & Nagano [213] was used to isolate large bacterial
plasmids of clinical origin. The harvested cells were suspended in TAER buffer
(50mM Tris-acetate pH 8.0, lOmM EDTA, lOOpg/ml RNase A) and lysed at room
temperature with the addition of an equal volume of 200mM NaOH/l%w/v sodium
dodecyl sulphate (SDS) for 5 minutes. An additional aliquot (equal to half the total
volume) of 3M sodium acetate (pH 5.5) was added to neutralise the lysing
solution. The insoluble clot of cell debris and genomic DNA was removed by
centrifugation (13000rpm (11600xg) in an MSE Micro Centaur centrifuge at 4°C).
The supernatant was extracted with an equal volume of chloroform, before
precipitation of the plasmid DNA on ice for 10 minutes after the addition of two
volumes of ehtanol. The precipitate was pelleted by centrifugation (11600xg for
10 minutes at 4°C), washed in a small volume of ethanol, and dried under vacuum
for 10 minutes. The dried DNA pellet was redissolved in 20-50pil of an appropriate
buffer.
DNA extracted by this modified alkaline lysis method was typically used to isolate
plasmids up to ~150-kb in size, and often subjected to restriction analysis (see
Section 11.2 page 73).
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9.3. Isolation of total genomic DNA
Genomic DNA was isolated by an SDS-proteinase K treatment of E. co/i cells
similar to that described by Towner [214], DNA prepared by this method was
added to polymerase chain reactions as template DNA.
Cells were harvested from 1.5ml of an overnight LB broth culture, centrifuged
(11600xg- for 10 minutes in an MSE Micro Centaur centrifuge), and resuspended
in 200pl of TESUC buffer (50mM Tris-Cl pH 8.0, lOmM EDTA, 7%w/v sucrose).
Forty pi of 0.1%w/v lysozyme and 20pl of 0.2%w/v proteinase K were added and
the sample incubated at 37°C for 30 minutes. SDS, to a final concentration of
l%w/v, was added, followed by a second incubation for 30 minutes at 37°C. The
sample was then extracted five times with an equal volume of
phenol/chloroform/isoamyl alcohol (ratio 25: 24: 1, saturated with TESUC buffer).
Two volumes of ice-cold ethanol were added to the sample and the precipitate
collected by centrifugation (11600xg for 10 minutes). The DNA was washed in
ethanol and the pellet air-dried for 20-30 minutes. The DNA was redissolved in
50pl of TE buffer (pH 8.0).
9.4. Isolation of single-stranded M13 phage template DNA
Single-stranded template M13-DNA was prepared for use in site-directed
mutagenesis experiments, or DNA sequencing reactions, by a modification of the
polyethylene glycol (PEG) precipitation methods, described in the 'Ml3 cloning
and sequencing handbook' (Amersham International pic [168]) and by Howe &
Ward [215],
A single colony ofE. coli TGI (plasmid and phage free) was inoculated into 50ml
MGT media (single-strength DM medium supplemented with thiamine and glucose
at the concentrations described in Section 3.1 page 55) and incubated overnight at
37°C with vigorous shaking (~180rpm). An aliquot (1 OOpil) of the overnight
culture was inoculated into 50ml ofLB broth and incubated at 37°C with vigorous
shaking (~180rpm) for 1-2 hours until cell growth was just visible (OD550 ~ 0.3).
Two hundred pi of phage-containing supernatant, or purified Ml3 phage DNA,
was added to the E. coli TGI culture and incubated at 37°C for 5-8 hours with
vigorous shaking (~180rpm). The culture was then cooled on ice for 5 minutes,
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prior to pelleting the bacterial cells by centrifugation at 12000rpm (20000xg) at
4°C, in a Sorvall RC-5B centrifuge with an SA-600 rotor, for 15 minutes. The
single-stranded M13 phage DNA, present in the cell free supernatant, was
precipitated for 30 minutes on ice by the addition of PEG 6000 and sodium
chloride to final concentrations of 5%w/v and 500mM respectively [216], The
precipitate was collected by centrifugation for 15 minutes at 8000rpm (8000x,g) in
a Sorvall RC-5B centrifuge with an SM-24 rotor. The DNA pellet was
resuspended in TES buffer (20mM Tris-Cl pH 8.0, lOmM NaCl, O.lmM EDTA)
and extracted once with an equal volume of phenol (saturated with TE buffer),
once with an equal volume of phenol/chloroform (ratio 1:1, saturated with TE
buffer), and three times with an equal volume of isoamyl alcohol/chloroform (ratio
1:24, saturated with TE buffer). The single-stranded DNA was then precipitated at
-70°C for 90 minutes by the addition of one-tenth of a volume of 3M sodium
acetate (pH 5.5) and two volumes of ethanol. The precipitate was pelleted by
centrifugation at 13000rpm (9500xg) at 4°C for 8 minutes (MSE Micro Centaur
centrifuge). The pellet was washed in ethanol and dried under vacuum for
10-20 minutes. The dried DNA pellet was redissolved in 50p.l of TE buffer
(pH 8.0).
9.5. Preparation of double-stranded plasmid DNA for
cloning and DNA sequencing reactions
Double-stranded plasmid DNA was prepared with the Qiagen Plasmid Midi
Preparation Kit (Qiagen, Chatsworth, California, USA). DNA yields of between 50
and lOOpg were obtained from overnight LB broth cultures of 100-150ml.
Bacteria were lysed by an alkaline-lysis method (similar to that described by
Takahashi & Nagano [213]) with the reagents supplied with the Qiagen kit.
Plasmid DNA was isolated by the selective nucleic acid binding characteristics of
the Qiagen-tip 100 (a disposable modified anion-exchange resin column). Double-
stranded DNA obtained by this method was reputed by the manufacturer to be
equivalent in purity to that obtained by caesium chloride density gradient
purification (as described by Sambrooke, Fitsch & Maniatis [217]).
The number of vector plasmids per chromosome were increased, when required for
plasmid preparation, by the addition of chloramphenicol (34mg/ml in ethanol) to a
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final concentration of 170mg/l after ~8 hours of incubation of the cultures at 37°C
(with vigorous shaking). Cultures were then incubated for a further 8-12 hours at
37°C with vigorous shaking (~200rpm) before harvesting.
9.6. Isolation of DNA from agarose gel slices
The Geneclean II Kit (Bio 101 Inc., La Jolla, California, USA) was used to recover
DNA fragments from agarose gels (see this chapter Section 11.1 page 72). The
protocol supplied by the manufacturer, based on the findings of Vogelstein &
Gillespie [218], was followed throughout. Bands of DNA fragments were excised
from agarose gels (0.7-1,5%w/v) after electrophoresis for separation purposes.
DNA fragment purification by this method relied on the selective adsorbtion of
DNA to the surface of small beads of a silica matrix (Glassmilk) supplied with the
kit. DNA was eluted from the Glassmilk beads into lOpl ofTE buffer.
9.7. the assessment of concentration & purity of DNA
The absorbance of DNA solutions was measured at 260nm (A260) and 280nm
(A28o) with a Perkin-Elmer UV/Vis Lambda 2 Spectrophotometer, according to
the method described by Towner [214], One absorbance unit at 260nm was taken
to be equivalent to a concentration of 50(.ig/ml of double-stranded DNA and
35ng/ml of single-stranded DNA. The ratio of the A260 and A280 value provided
an estimation of purity: a ratio A260/A28o of 1:1.8 indicated pure double-stranded
DNA free from contaminating protein.
10. Amplification of DNA with the polymerase
chain reaction (PCR)
Polymerase chain reaction (PCR) amplification of the open-reading frame (ORF) was
based on the method provided by Disney & Dove [174], Each PCR reaction was
performed in a total volume of 1 OOpil (Table 2.10 page 71) prepared in a 0.5ml
polypropylene microcentrifuge tube (Alpha Laboratories) with a Techne PHC-2 Dri-
Block Cycler (Cambridge, Cambs.). Reaction mixtures were overlaid with one or two
drops of mineral oil to reduce evaporation, and the tips of the tubes were smeared
with a thin film of silicone grease to improve thermal contact with the heating block.
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Each reaction was then subjected to between 21 and 25 cycles, each of three steps
(denaturation, annealing, and extension) as defined in Table 2.11 (page 72).
After completion of the PCR reaction (-2.5 hours) samples were placed on ice to
'quench' any further reaction. PCR reactions were then ethanol precipitated before
verification of DNA amplification by agarose gel electrophoresis. PCR-amplification
of TEM ORFs generated DNA fragments of ~900-bp in size. The biotinylated primer,
Biotin-Bla 4', was used for the amplification of DNA for use with the Dynabeads
M-280 Streptavidin (Dynal, Norway) direct sequencing protocol (see Chapter 3
below) or for use as DNA probes in Southern hybridisation procedures (see
Section 11.4 page 75).
Component Quantity Supplier
10y-Taq reaction buffer (Mg2+ free) 10pl Promega (Southampton, Hants.)
25mM magnesium chloride 10pl Promega
4mM dNTP stock solution* 5(j I Boehringer Mannheim UK
Bla 3' PCR primer§ 10pmoles Glaxo Group Research Ltd.
Bla 4' PCR primer or
Biotin-Bla 4' PCR primer*
10pmoles Glaxo Group Research Ltd.
Genomic DNA preparation or a
Washed E. coli cell suspension
1-2pl -
Taq DNA polymerase 1 unit Promega
Deionised distilled water to 100pl -
Table 2.10: PCR reaction components
* 4mM dNTP stock solution: 1mM dATP, 1mM dTTP, 1mM dGTP, 1mM dCTP in 10mM Tris CI
(pH 7.5). § Bla 3' PCR primer: 5'-CTC TCT AGA AAA AGG AAG AGT ATG ATT-3'. * Bla 4' & Biotin-
Bla 4' PCR primers: 5'-CTC GCA TGC GTA AAC TTG GTC TGC CAG TTA-3'.
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11. The analysis of DNA
11.1. Gel electrophoresis of dna
Intact plasmid DNA, restriction endonuclease digested plasmid DNA, or PCR-
amplified DNA species were separated at neutral pH values in 0.7-1.5%w/v
agarose gels in TAE buffer (40mM Tris-acetate pH 7.6, ImM EDTA). Under
these conditions duplex-DNA is negatively charged, hence loaded near the
cathode, and migrates towards the anode when an electric field is applied [219],
Horizontal slab gel electrophoresis was carried out in a Bethesda Research
Laboratories Horizon 20-25 gel tank (Life Technologies Inc, Petersburg, Florida,
USA) or a Pharmacia GNA-I00 Mini tank at constant voltage (between 50V for
12 hours and 200V for 1 hour, depending on the experiment and apparatus).
A phage-DNA digested with Hind III (Sigma Chemical Co.) was run alongside
samples during electrophoresis, as an indicator of molecular weight of linear
duplex-DNA. Each sample was mixed with one-sixth of a volume ofGBX loading
buffer (30%v/v glycerol, 0.25%w/v bromophenol blue, 0.25%w/v xylene
cyanol)[217] prior to loading on to the gel. The DNA was visualised after
electrophoresis by staining for one hour in a 50p.g/l ethidium bromide solution and
viewed on a UV transilluminator (UV Products, Cambridge).
Segment Temperature Time Ramp rate Repeats Function
1 96°C 30 sec 48°C/min 1 DNA denaturation
50°C 60 sec 10°C/min \ x1 Primer annealing
72°C 90 sec 30°C/min J Primer extension
2 96°C 15 sec 48°C/min 1 DNA denaturation
50°C 30 sec 10°C/min V X20-24 Primer annealing
72°C 90 sec 30°C/min J Primer extension
3 72°C 5 min - x1 Final extension
Table 2.11: The PCR heating cycle protocol
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11.2. Restriction endonuclease digests
The restriction endonucleases utilised for the digestion of DNA in this thesis are
given in Table 2.12. Plasmid DNA was digested with 5-10 units of enzyme in
volumes of 10-30pl, with the manufacturer's recommended incubation buffer, at
37°C for between one and three hours depending on the purity of DNA and the
efficiency of the specific enzyme.
11.3. Dot-blot hybridisation of M13 vector DNA
The dot-blot hybridisation procedure followed was obtained from Mrs Erica
Christadoulou (Glaxo Group Research Ltd, Greenford, Middx). The method
required the use of a NEN GeneScreen hybridisation transfer membrane (DuPont
Instruments) in conjunction with the Schleicher & Schuell Minifold II dot-blot
manifold (Anderman & Co. Ltd., Kingston-upon-Thames, Surrey). The apparatus
was assembled according to the manufacturer's instructions.
Bacteria infected with the M13-phage were incubated overnight in 2ml of LB
broth, before the phage containing supernatant was cleared by centrifugation at
Restriction endonuclease Recognition sequence Supplier
Alf II CTTAAG Boehringer Mannheim UK
BamH I GGATCC Gibco BRL
fig/II AGATCT Gibco BRL
EcoR I GAATTC Gibco BRL
Hind III AAGCTT Gibco BRL
Pst I CTGCAG Pharmacia
Sea I AGTACT Northumbria Biologicals Ltd
Sph I GCATGC Boehringer Mannheim UK
Xba I TCTAGA Boehringer Mannheim UK
Table 2.12: Restriction endonucleases
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13000rpm (11600xg) for 10 minutes (MSE Micro Centaur centrifuge). Fifty p.1 of
each phage containing supernatant was pipetted into wells of the Minifold II and
allowed to pass through the hybridisation membrane. Up to 66 samples were
applied to the membrane, together with three positive and three negative control
samples. After all the samples had been applied and passed through the membrane
the hybridisation filter was removed from the apparatus. The GeneScreen
membrane was soaked in a denaturing solution (0.5M NaOH, 2.5M NaCl) for
15 minutes, before neutralisation in 3M sodium acetate (pH 5.5) for 15 minutes.
The membrane was carefully blotted dry and the DNA cross-linked to the
membrane by UV irradiation (Auto-crosslink setting, total energy = 1200 joules;
Stratalinker, Stratagene, La Jolla, California, USA).
The membrane was incubated with an aqueous pre-hybridisation solution
(0.2%w/v bovine serum albumin (BSA), 0.2%w/v Ficoll 400,
0.2w/v polyvinylpyrrolidine (PVP), l%w/v SDS in 2><SSC buffer3) at 37°C for one
hour. DNA probes were prepared by labelling the oligonucleotide primers
(manufactured by Glaxo Group Research Ltd.) used for the SDM experiments
(listed in Chapter 3): a solution containing lOpmoles of oligonucleotide DNA,
50mM Tris-Cl (pH 7.6), lOmM magnesium chloride, 5mM dithiothreitol (DTT),
O.lmM spermidine, O.lmM EDTA (pH 8.0), 1 unit of polynucleotide kinase, and
lpl of 32P-y-ATP (370MBq/ml, 3000Ci/mmole: Amersham International pic) was
prepared and incubated at 37°C for 30 minutes. The membrane was then
hybridised with the DNA probe in fresh pre-hybridisation solution for 60 minutes
at 37°C.
The membrane was initially washed with 2><SSC/0.1%w/v SDS at 37°C for
5 minutes. The filter was washed with increasing stringency (decreasing salt
concentration and increasing temperature) and monitored with a Geiger-Mtiller
tube, until negative control samples gave significantly fewer counts than the
positive controls. The membrane was then autoradiographed, by exposure to
Hyperfilm MP X-ray film (Amersham pic), overnight at -70°C. The X-ray film was
then developed with an automatic film processor.
3 20xSSC buffer: 3.0M sodium chloride, 0.3M /n-sodium citrate.
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11.4. Southern blotting
Plasmid DNA was digested with restriction endonucleases and the resulting DNA
fragments were separated by agarose gel electrophoresis in lxTAE buffer at 50V
for 12 hours. DNA was then transferred onto Hybond-C Extra membrane
(Amersham International pic) by a capillary blotting method, based upon the
procedure described by Southern [220], recommended by the manufacturer. After
overnight blotting the membrane was baked at 80°C under vacuum for two hours.
DNA probes were prepared by the PCR-amplification (see Section 10 page 70) of
the TEM-1 P-lactamase gene {bldY-\) ORF, with one of the two PCR-primers
biotinylated (Biotin-Bla 4', see Section 10 page 70).
Prior to hybridisation of the DNA fragments with a biotin-labelled blal-\ probe,




Deionised formamide§ 50%v/v %v/v
SSC buffer 5x 5x
Denhardt's solution* 5x 1 x
Sodium phosphate buffer (pH 6.5) 50mM 20mM
SDS 0.1%w/v 0.1%w/v
Sheared herring sperm DNAt 0.1%w/v 0.05%w/v
Sodium dextran sulphate - 5%v/v
Table 2.13: Pre-hybridisation and hybridisation solutions for Southern
blotting
All solutions were prepared with deionised distilled water. § Deionised before use with Amberlite
Monobed resin M.B.1 (BDH Merck, Poole, Dorset). 1100><Denhardt's solution: 2%v/v BSA,
2%v/v Ficoll 400, 2%v/v PVP in 3xSSC buffer, t Boiled for 10 minutes, then cooled on ice for
10 minutes immediately prior to addition to solutions.
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pre-hybridisation solution (Table 2.13 page 75) for 2 hours at 42°C. The pre-
hybridisation solution was replaced with the hybridisation solution (Table 2.13)
containing probe DNA (denatured by boiling for 10 minutes, and cooled on ice for
10 minutes immediately prior to use). Hybridisation was carried out at 42°C
overnight.
The membrane was washed twice with 2><SSC/0.l%w/v SDS for three minutes at
room temperature, twice with 0.2><SSC/0.1%w/v SDS for three minutes at room
temperature, and twice with 0.16*SSC/0.1%w/v SDS for 15 minutes at 50°C. The
Hybond-C Extra membrane was finally washed briefly with 2><SSC at room
temperature. Positive hybridisation signals were then visualised by means of the
BIuGene biotin detection kit (Gibco BRL), following the manufacturer's
recommended procedure.
11.5. DNA SEQUENCING
DNA was sequenced with the USB Sequenase Version 2.0 DNA Sequencing Kit
(Cambridge Bioscience, Cambs.), based on the chain-termination method of
Sanger et al. [221], The Sequenase Version 2.0 polymerase is a genetic variant of
T7 DNA polymerase lacking all 3'—>5' exonuclease activity [222, 223], Sequencing
reaction products were radiolabeled with 35S-a-dATP or 33P-a-dATP
(Amersham International pic), and separated by electrophoresis in a denaturing
polyacrylamide gel (8%T, 5%C acrylamide/AA-acrylamide, 7M urea) with the
Sequi-Gen Nucleic Acid Sequencing Cell (BioRad, Watford, Herts.), in an
electrolyte gradient [224], The recommended USB Sequenase Version 2.0 Kit
protocols [225] for the sequencing of single-stranded template DNA (see
Section 9.4 page 68 for preparation) and double-stranded plasmid DNA (see
Section 9.5 page 69 for preparation) were followed. Other sequencing methods
were employed [226-228] for specific purposes, and are described in more detail
under the relevant section in Chapter 3. The details below refer to the preparation
and running of a 210mm x 500mm x 0.4mm polyacrylamide gel.
The Sequi-Gen Cell was cleaned and assembled according to the manufacturer's
recommendations: the integral/plate chamber (IPC) and outer glass plate were
sequentially cleaned with deionised water, ethanol, chloroform, ethanol and finally
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deionised water, to remove all traces of acrylamide and grease. The IPC was
siliconised with Sigmacote prior to each experiment. The two 0.4mm spacers
required for assembly were thoroughly cleaned with deionised water.
The 8%T, 5%C acrylamide/7M urea solution required for the preparation of the
denaturing polyacrylamide gel is described in Table 2.14. The bottom of the
electrophoresis gel was sealed by impregnating a Sealing Strip (BioRad) with the
plug solution (Table 2.15). The polyacrylamide gel (Table 2.15) was poured, with
the apparatus at -20° to the horizontal, and left to polymerise for one hour.
Ingredient Stock solution conc. Supplier
Urea 7M Sigma Chemicals
10*TBE buffer* 1x Sigma Chemicals
40%T, 5%C acrylamide/
/V,/V'-methylene-b/'s-acrylamide
8%T, 5%C Sigma Chemicals
Table 2.14: Denaturing acrylamide/b/s-acrylamide stock solution
All solutions were prepared with deionised distilled water. * 10><TBE
(pH 8.3), 20mM EDTA.
buffer: 0.89M Tris-borate
Component Plug solution^ Gel solution!
8%T, 5%C acrylamide/
b/s-acrylamide, 7M urea stock
solution
20ml 55ml
25%w/v ammonium persulphate 140pl 220pl
TEMED 50pl 7|il
Table 2.15: Recipes for the denaturing polyacrylamide gel
§ Polymerisation time -10 minutes, t Polymerisation time 30-60 minutes.
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The Sequi-Gen unit was mounted in the Universal Base (lower buffer chamber),
the IPC filled with 0.5xTBE, and the lower buffer chamber filled with 400ml of
lxTBE buffer. The polyacrylamide gel was pre-run for 30-40 minutes at constant
power (Power supply settings: voltage = 3000V, current = 50mA, power = 60W)
to warm the apparatus to the required running temperature of 50-55°C. Samples
were loaded and the gel run for 1 hour before the addition of 200ml of 3M sodium
acetate (pH5.5) to the lower buffer chamber. Electrophoresis was continued at
60 Watts for a further two to three hours.
The polyacrylamide gel was removed from the apparatus and soaked in a solution
of 10%v/v methanol/10%v/v acetic acid for 45 minutes before drying at 80°C for
two hours under vacuum in a flat-bed gel drier. Autoradiography was carried out
by exposure to Hyperfilm MP X-ray film (Amersham International pic) at room
temperature for 12-48 hours, before developing the film in an automatic film
processor.
12. Cloning of DNA fragments
12.1. Ligation of DNA
The vector and target DNA were digested with the appropriate restriction
endonucleases (see Section 11.2 page 73) and the fragments separated by agarose
gel electrophoresis (see Section 11.1 page 72). The required DNA fragments were
excised from the agarose gel and purified with the Geneclean II Kit (see
Section 9.6 page 70). The target DNA fragment and vector DNA fragment (in
excess) were diluted in 20pl of Ligation buffer (Gibco BRL) with 0.1 units of
T4 DNA ligase (Gibco BRL). Ligation was carried out for 12 hours at 16°C, after
which a portion of the ligation products were transformed into E. coli.
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12.2. Transformation of Escherichia coli
Recombinant DNA was transformed into one of two E. coli strains depending on
the experiment.
Preparation of competent e. coli TG1
A single colony of E. coli TGI (phage and plasmid free) was inoculated into
50ml ofMGT medium and incubated overnight at 37°C with vigorous shaking
(~180rpm). Fifty ml of LB broth was inoculated with 200pl of the overnight
culture and incubated at 37°C with vigorous shaking (~180rpm) for about
2 hours until very slight turbidity was observed (OD550 « 0.3). The bacteria
were harvested by centrifugation at 4500rpm (3100x_g) in a Heraeus Labofuge
6000 for 15 minutes. The cells were then resuspended in 20ml of cold (4°C),
sterile lOOmM calcium chloride solution and incubated on ice for
40-60 minutes, before re-pelleting the bacteria at 3100x,g for 15 minutes at 4°C.
The bacterial cell pellet was finally resuspended in 4ml of cold lOOmM calcium
chloride solution and stored on ice for 2-4 hours prior to use.
Transformation of e. coli tgi
Approximately half of the ligation products solution was mixed with 200pl of
competent E. coli TGI and incubated on ice for 40 minutes. The transformation
mix was heat shocked at 42°C for 2 minutes, prior to the addition of 800pil of
pre-warmed (to 37°C) LB broth. The mix was incubated at 37°C for 55 minutes
then plated out onto selective media. For 'Lac (blue-white) selection' of
recombinant clones, 50pl of 2%w/v of 5-bromo-4-chloro-3-indoyl-
P-D-galactopyranoside (X-gal) in A,7V-dimethylformamide (DMF) and 1 Opil of
0.24%w/v of isopropyl-P-D-thiogalactopyranoside (IPTG) were added to the
transformation mix, immediately prior to plating out onto selective agar.
For the Lac selection of recombinant Ml3 vectors, 200pl of a culture of
E. coli TGI (in the mid-log phase of cell growth), 50pl of 2%w/v X-gal (in
DMF), and 10pl of 0.24%w/v IPTG were added to the transformation mix after
heat shock, in place of the 800pl of LB broth described above. Molten LB top
agar (2ml cooled to ~55°C) was mixed with the transformed cells and poured
evenly over the surface of a pre-warmed (37°C) LB agar plate. The top agar
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was left to solidify at room temperature, before incubation of the plates at 37°C
overnight. Plaques of transfected E. coli TGI were 'picked' with a sterile glass
Pasteur pipette by removing an agar plug containing the entire plaque, which
was then transferred to a suitable growth medium.
Transformation of E. coli DH5a
MAX Efficiency DH5a Competent Cells (Gibco BRL) were used for the
transformation of recombinant plasmids containing PCR-amplified DNA. The
MAX Efficiency DH5a Competent Cells were prepared by Gibco BRL from
E. coli DH5a with a modification of the procedure described by
Hanahan [169], The transformation procedure recommended by the
manufacturer was followed.
13. Site-directed mutagenesis
The 'Oligonucleotide-directed in vitro mutagenesis system (Version 2.1)' (Amersham
International pic) was used for the introduction of point mutations into the blaT-l
gene. The system is based on the findings of Eckstein and co-workers [229-232],
Figure 2.3 (page 81) summarises the manufacturer's recommended protocol [168],
All oligonucleotide primers for SDM were supplied by Glaxo Group Research Ltd.,
and the specific sequences of the primers are given under the relevant section in
Chapter 3. For each SDM experiment an oligonucleotide primer, with a single
mismatched nucleotide to the target sequence, was annealed to the single-stranded
Ml3 DNA template (see Section 9.4 page 68 above for preparation of templates).
Heteroduplex DNA was then formed by polymerisation of a DNA strand with Klenow
fragment and T4 DNA ligase. The newly synthesised DNA strand contained
phosphorothioate, and was thus protected from Nci I digestion [229, 231], The non-
mutant DNA strand was 'nicked' with Nci I (recognition site ~500-bp from the Ml3
multiple-cloning site) and degraded in the 3'—>5' direction from free 3-DNA ends with
the exonuclease Exo III [232], Re-synthesis of the double-stranded closed-circular
DNA ensured homoduplex formation, hence each strand encoded the point mutation
required. The mutant homoduplex DNA was used for the transformation of
E. coli TGI as described above (Section 12.2 page 79).
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Figure 2.3: Summary of the Amersham oligonucleotide-directed in vitro
mutagenesis system
Abbreviations: MCS, multiple cloning site; SDM, site-directed mutagenesis; ssDNA, single-stranded




The results of the research executed for the completion of this work has been divided
into seven sections. The first section describes the identification and characterisation
of ten clinical isolates of 3GC resistant Klebsiella from a London hospital (the results
of which have been published [232]). These isolates contained an example of the
ESBL mutations that are the subject of this thesis, and are a reminder of the clinical
relevance of the need to identify the mechanisms of ESBL mutation and why such
mutations have not become ubiquitous. In essence, the ESBL mutations do not appear
to be self-perpetuating; but appear to be 'unstable' in nature, according to the relative
rarity of published reports.
The subsequent sections describe the design of a classification scheme for the TEM-
and SHV-derived P-lactamases and how this scheme was used to investigate the
relationships of the TEM-derived P-lactamases. The elucidation of the DNA sequence
of the first known ESBL, TEM-E2, is described; and the nature of the ESBL mutation
holds crucial significance in the development of the ESBL during the 1980s and




2. Identification of P-lactamases from clinical
isolates
Ten clinical isolates ofKlebsiella pneumoniae were received from the Department of
Medical Microbiology, Royal Free Hospital, Pond Street, London NW3 2QG in
Autumn 1990. Identification of the resistance mechanisms of the strains, sequentially
numbered KR1 to KR10 (for 'Klebsiella Resistant'), was carried out. The origin of
the ten strains was not known until identification of the P-lactamases present in each
had been completed. The 'blind' nature of the identification was not the intention of
either Dr MacDonald or myself, but was introduced by other parties for an unknown
reason. The lack of information regarding the origin of isolation of the strains
influenced the methodology of study.
Resistance phenotypes were initially determined by measuring the zone of inhibition of
antibiotic discs for ampicillin, ceftazidime, and cefotaxime. Crude extracts of each of
the ten strains were prepared and the pi of any P-lactamase produced was determined
by IEF. Crude cell free P-lactamase extracts were then used to determine the specific
activity of each enzyme preparation, and compared with standard P-lactamase
preparations.
2.1. Case Histories
The ten strains were isolated from three patients, eight from Case 1 (KRI—>KR8),
and one each from Case 2 (KR9) and Case 3 (KR10). The case history of each
patient was supplied by Dr MacDonald and each is summarised below.
case 1: A 17 year old man received chemotherapy of Acute Myeloid
Leukaemia in Turkey after diagnosis in mid-1989, and remission was achieved.
In late-1989 he was admitted to the Royal Free Hospital (RFH) for further
chemotherapy, in preparation for bone marrow transplantation (BMT). Whilst in
hospital the patient, suffering from neutropenia, experienced two separate
episodes of pyrexia. Four antibiotics (colistin, ciprofloxacin, aztreonam and
azlocillin) were administered at this time: the two former agents for prophylaxis
and the latter two agents for treatment of the pyrexia. A ciprofloxacin and
trimethoprim resistant Kleb. pneumoniae was isolated from surveillance culture
of stools. Prior to re-admission to the RFH, for the proposed BMT in Spring
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1990, the patient received a short course of pivampicillin for the treatment of an
infected ingrown toenail.
Figure 3.1 represents the drug treatment administered to the patient during re-
admission to the RFH for the BMT. The day of isolation for each of the eight
Klebsiella strains (KRI—»KR8) is indicated in the diagram. Ten days after the
BMT, and whilst still neutropenic, the patient developed a pyrexia and was
treated with amikacin and azlocillin. Kleb. pneumoniae were isolated from
blood cultures, but not from sputum, urine or stools, on four separate occasions
during this episode (Figure 3.1). The patient was then treated with low dose
imipenem (500mg i.v. qds) to which the fever initially responded. Pyrexia had
developed again after four days and a final Kleb. pneumoniae was isolated from
the blood three days later. Increasing the dose of imipenem (lg i.v. qds)
abolished fever. Imipenem was given orally on return of a normal neutrophil
CIP 500mg bd p.o.
AZL5gktel.v.
AMK 450mg bd l.v.
AZT 2g tie I.v.
->l
GEN 50mg tcte i.v.
CAZ2g stati.v.
HH
IMP 500mg qds I.v.











No. of days from initial pyrexia
Figure 3.1: Diagram representing the case history of Case 1 from the
Royal Free Hospital.
Scale in days from start of initial pyrexia experienced during the second admission to the RFH.
Abbreviations: AMK, amikacin; AZL, azlocillin; AZT, aztreonam; bd, twice daily; CAZ, ceftazidime;
CIP, ciprofloxacin; GEN, gentamicin; i.v., intravenous infusion; IMP, imipenem; Incr. TEMP., periods
of pyrexia; qds, four times daily; p.o., oral administration; stat, single dose; tds, three times daily.
Strains of Klebsiella pneumoniae KR1 to KR8 were isolated from blood cultures taken on the days
indicated.
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count, but the patient became pyrexial again for two days after termination of
antibiotic treatment. The fever responded on re-instigation of oral imipenem
therapy. Imipenem was given for a total of 60 days during this prolonged
episode of intermittent Kleb. pneumoniae septicaemia.
CASE 2: A previously healthy 16 year old girl developed Guillamune-Barre
Syndrome after an upper respiratory tract infection. The girl was treated for
four weeks in an Athens ITU where she developed a large sacral sore. Two
weeks later the patient was transferred to the RFH, and was admitted on the
same day as the above patient (Case 1) for treatment of the sore and
convalescence. On arrival her medications, which included imipenem, were
stopped. Urine specimens, taken soon after admission, grew multiply resistant
Kleb. pneumoniae. The patient remained well during the two months of hospital
treatment, required no antibiotic therapy and was discharged following a
successful skin graft. The patient was treated in isolation because of continued
urinary colonisation of the Klebsiella. Strain number KR9 was taken as a
representative strain of the multiply resistant Kleb. pneumoniae isolated from
the urine of this patient.
CASE 3: A 28 year old paraplegic man (since a C5 crush fracture of the cervical
spine in 1985) was admitted to the RFH with urinary retention and fever in mid-
1990. The indwelling electronic device controlling the ureteric and anal
sphincters had malfunctioned. Kleb. pneumoniae were isolated from both blood
and urine specimens, and the infection did not respond to 24 hours of
cefotaxime treatment. The patient was subsequently successfully treated with
amikacin followed by oral trimethoprim. The patient was nursed in isolation
until three consecutive urine specimens were found to be clear of the organism.
Since 1985 this patient had been an inpatient at two other London hospitals and
had no history of foreign travel. Strain number KR10 was representative of the
initial isolates ofKleb. pneumoniae from blood and urine.
2.2. MICS FOR THE CLINICAL STRAINS KR1 TO KR10
The resistance phenotype for each of the ten strains was determined by
measurement of zone of inhibition of growth of ampicillin, ceftazidime and
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cefotaxime sensitivity test discs. 1ST agar plates were flood seeded with overnight
cultures of the organism under test. The results, given in Table 3.1, followed the
trend of the results of the MIC determinations for the ten strains provided by
Dr Alan MacDonald (RFH) (see Table 3.2 page 87). Dr MacDonald determined
the MICs of the ten clinical isolates for a range of P-lactam antimicrobial agents
alone, and in combination with clavulanic acid (2mg/l), at two inoculation
concentrations (104cfu/spot and 106cfu/spot) (Table 3.2 page 87).
Strain number Zone of inhibition (0 mm)4 Phenotype§
AMP CAZ CTX AMP CAZ CTX
KR1 Nil 20 21 R S s
KR2 Nil 26 36 R s s
KR3 Nil 13 15 R I s
KR4 Nil 10 19 R R s
KR5 Nil 12 22 R I s
KR6 Nil 14 13 R R I
KR7 Nil 30 33 R S s
KR8 Nil 23 19 R S s
KR9 Nil 7 13 R R R
KR10 Nil Nil 21 R R S
Controls4:
OXA-2 12 27 36 I S S
TEM-1 Nil 30 35 R S S
Table 3.1: Antibiotic sensitivity of clinical isolates of ceftazidime
resistant Klebsiella pneumoniae from the Royal Free Hospital.
Antibiotic sensitivity testing with antibiotic sensitivity discs following the BSAC guidelines [196],
Abbreviations: 0, diameter; AMP, ampicillin; CAZ, ceftazidime; CTX, cefotaxime; Nil, no zone of
inhibition of growth, 4 Zone diameters given in mm (disc diameter 6mm) for the following disc
concentrations: 25pg ampicillin/disc, 30pg ceftazidime/disc, 30pg cefotaxime/disc. § Phenotype:
I, intermediate (zone 0 > 10mm, < 14mm); R, resistant (zone 0 < 10mm); S, sensitive
(zone 0 > 14mm). 4 E. coli J62-2 expressing the given (3-lactamase.
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MIC (mg/l) for strain no.
biotic KR1 KR2 KR3 KR4 KR5 KR7 KR8 KR9 KR10 NCTC
CAZ 0.5 4 32 128 128 64 32 64 512 0.125
0.5 16 128 512 512 512 64 512 >1024 0.125
CAZ/ 0.25 0.5 1 1 1 64 8 0.25 4 0.125
Clav 0.5 4 4 8 8 128 32 0.5 4 0.125
CTX 0.25 2 16 4 4 256 64 2 16 0.015
0.5 256 512 256 256 >1024 1024 32 64 0.25
CTX/ 0.25 0.25 0.25 0.25 0.25 128 16 0.063 2 0.016
Clav 0.5 8 0.5 0.5 0.5 256 128 0.125 0.125 0.25
AZT 0.125 2 16 128 128 128 16 64 64 0.063
0.25 16 64 512 512 128 64 512 >512 0.063
AZT/ 0.125 0.125 0.125 0.125 0.125 16 4 0.063 1 0.063
Clav 0.125 4 0.25 4 4 128 32 0.125 0.25 0.063
IMP 0.125 0.125 0.5 0.5 0.25 2 2 0.063 1 0.25
0.5 1 0.5 1 1 >2 >2 0.5 1 0.5
IMP/ 0.125 0.063 0.125 0.125 0.125 1 1 0.063 0.5 0.125
Clav 0.5
'• 1 :: 1 0.5 0.5 2 1 0.5 1 0.5
TEM 8 8 8 8 8 32 16 4 16 2
8 8 16 16 16 64 16 8 16 4
TEM/ 4 4 4 4 4 16 16 4 8 1
Clav 8 8 8 8 8 32 32 4 8 4
CEF 16 8 8 8 8 128 64 8 64 4
32 64 16 16 16 128 64 16 8 4
CEF/ 16 8 8 8 8 128 64 64 4 4
Clav 32 64 64 32 16 128 128 8 32 4
Table 3.2: MICs for clinical isolates of ceftazidime resistant Klebsiella
pneumoniae from the Royal Free Hospital.
MIC results from Dr A. MacDonald, Dept. of Medical Microbiology, Royal Free Hospital, London. All
strains incubated overnight (18-24 hours) prior to inoculation. 24 hour aerobic incubation at 37°C
following inoculation of isosensitest agar plates containing required antibiotic concentration with 1pl
of test organism (lO^cfu/spot and 10®cfu/spot: upper and lower figures in each row respectively).
Abbreviations: AZT, aztreonam; CAZ, ceftazidime; CEF, cefoxitin; Clav, clavulanic acid (2mg/l); CTX,
cefotaxime; IMP, imipenem; NCTC, E. coli NCTC 10418; TEM, temocillin.
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2.3. Analytical isoelectric focusing
Crude P-lactamase extracts of the ten clinical strains were applied, as well as
extracts of bacteria with known and well characterised enzymes, to analytical IEF
gels in order to identify the isoelectric point of the unknown enzymes. IEF
provided the following results: nine of the isolates (KR2—>KR10) exhibited
P-lactamase bands at pi 5.4, identical to the pi of TEM-1 (Figure 3.2 page 89). All
isolates contained a pi -7.0 enzyme band (a similar value to many SHV-(>pe and
chromosomal enzymes); in seven of these isolates this enzyme band was faint. The
pi -7.0 band was strong in three preparations: KR1, KR9 and KR10. One strain
(KR10) contained a P-lactamase with pi 5.57 similar to that of TEM-E3 and
TEM-10 (see Figure 3.2 page 89). Nine of the isolates contained two enzymes, one
isolate (KR1) only exhibited a single enzyme (pi -7.0).
2.4. Relative rates of hydrolysis
Relative rates of hydrolysis of the P-lactamases from a selection of the ten Kleb.
pneumoniae, together with a range of known P-lactamases were determined for
comparison. The results of this analysis are summarised in Table 3.3 (page 90)
where the values are normalised for comparison with ampicillin (100%). These
results show that the unknown enzyme of pi 5.57, from Kleb. pneumoniae KR10,
is very similar in hydrolytic characteristics to TEM-10 or TEM-E3 (the latter
enzyme is thought to be an analogue ofTEM-10 [192]).
2.5. TRANSCONJUGATION & TRANSFER OF CEFTAZIDIME RESISTANCE
The Kleb. pneumoniae isolate producing the unidentified pi 5.57 enzyme was
conjugated with E. coli J62-2 (RifR his lac pro trp) and transconjugants counter-
selected with rifampicin, ampicillin and ceftazidime. Following IEF, two
transconjugants were shown to produce the pi 5.57, one with and one without the
pi 5.4 enzyme. The pi -7.0 enzyme was not found to be present in any recipient
strains after transconjugation (Figure 3.3 page 91).
Results Page 89
CO co CO o co O)
1 DC DC "1— LLI DC LU
lli
* DC i X. 2
H o o LU o LU
c c o h- c h-
c c c c






Figure 3.2: IEF gel showing the TEM-fype p-lactamases of Klebsiella
pneumoniae KR3, KR6, KR9 & KR10 from the Royal Free Hospital
IEF gel contained carrier ampholytes pH range 4-6. Unknown enzymes shown were from crude
extracts of the corresponding clinical strains described in the text. Standard p-lactamases shown
include TEM-E3 (pi 5.57), TEM-E4 (pi 5.61), and TEM-6 (pi 5.9).
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Strain Pi Relative rates of hydrolysis (%) §
AMP NCFN CFX CEP CAZ CTX
KR1 -7.0 100 118 3.2 47.1 0.1 3.5
KR2 5.4, (-7.0)
KR3 5.4, (-7.0) 100 0.5 0.02
KR4 5.4, (-7.0)
KR5 5.4, (-7.0)
KR6 5.4, (-7.0) 100 5.7 0.03
KR7 5.4. (-7.0)
KR8 5.4, (-7.0)
KR9 5.4, -7.0 100 33.1 2.3
KR10 5.4, 5.57, -7.0 100 43.9 2.1 88.5 17.5 2.1
TEM-1 5.4 100 18.2 UM UM
OXA-2 7.4 100 73.3 0.1
TEM-5 5.5 100 52.5 425.5 35.1 128.3
TEM-10 5.57 100 3.8 67.9 45.8 1.7
TEM-12 5.25 100 4.4 0.01 0.01
TEM-E3 5.57 100 3.0 26.7 218 0.1
J62-2 - UM UM UM UM UM UM
Strain At 5.57 100 8.2 181 56.5 8.2
Strain B* 5.57, (5.4) 100 3.6 49.6 21.2 1.2
Table 3.3: Hydrolytic characteristics of clinical isolates of ceftazidime
resistant Klebsiella pneumoniae from the Royal Free Hospital.
§ Relative rate of hydrolysis (%) with respect to ampicillin (100%). t Two ceftazidime resistant
E. coli J62-2 transconjugants (Strain A & Strain B) of Kleb. pneumoniae 1604 (KR10).
Abbreviations: AMP, ampicillin; CAZ, ceftazidime; CEP, cephaloridine; CFX, cefuroxime; CTX;













Figure 3.3: IEF gel showing the TEM-fype J3-lactamases of Klebsiella
pneumoniae KR10 from the Royal Free Hospital & transconjugants
IEF gel contained mixture of carrier ampholytes pH ranges 3.5-10 and 4-6. Standard p-lactamases
shown include SHV-3 (pi 7.0), TEM-E3 (pi 5.57), & TEM-E4 (pi 5.61). p-Lactamases labelled Strain A
and Strain B are from two E. coli J62-2 transconjugants of Kleb. pneumoniae KR10 (see text for
details).
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2.6. Gel electrophoresis of plasmid DNA
Previous work by Payne [141, 192] gave rise to the hypothesis that TEM-E3 and
TEM-10 may be the same enzyme. Electrophoresis of intact plasmid DNA and
plasmid DNA digested with EcoK I and Sea I was performed to elucidate
similarities between two TEM-E3 encoding plasmids (pUK722 and pUK723), the
TEM-1 plasmid Rl, and the plasmid encoding the unknown pi 5.57 enzyme.
Results suggested that each enzyme was present on different large plasmids.
2.7 Concluding remarks
Analysis of the MIC data (Table 3.2 page 87) showed that multiple-drug resistance
of the Kleb. pneumoniae isolated from Case 1 increased as a direct result of
therapy. Although the patient was receiving a number of (3-lactam antimicrobial
agents (including a single dose of ceftazidime), the increase in resistance to 3GCs
was not the result of P-lactamase acquisition or mutation; the strains isolated after
the instigation of aztreonam therapy had, however, acquired a pi 5.4 enzyme. The
identity of the pi 5.4 P-lactamase in the relevant isolates was probably the
ubiquitous TEM-1; the pi ~7.0/SHV-(y/?e enzyme, was probably of chromosomal
origin. The isolate from Case 2 (KR9) also probably expressed the TEM-1 enzyme.
The single isolate from Case 3 (KR10) possessed three P-lactamases: the pi -7.0
enzyme was a chromosomal SHV-(y/?e enzyme; the pi 5.57 enzyme was thought to
be TEM-E3/TEM-10.
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3. Mapping of the extended-spectrum
(3-lactamases
It is known, from the nucleotide or amino acid sequences, that many of the TEM- and
SHV-(y/?£? enzymes are very closely related. Many of these P-lactamases differ by
between one and three amino acid residues from the parental enzymes: TEM-1,
TEM-2 or SHV-1. A single exception, TEM-24, differs from the parental enzyme
TEM-2 by four amino acid substitutions (see Chapter 1, Table 1.9 page 45).The
amino acid sequences of TEM-1 (pi 5.4) and TEM-2 (pi 5.6) differ at a single
residue, amino acid 39 [149, 150], This amino acid substitution of lysine for glutamine
is the result of a single nucleotide change of cytosine to adenine at position 317
(numbering according to Sutcliffe (1978) [150]). All the other amino acid
substitutions that have been determined are the result of a single nucleotide change.
Referring to Figure 3.4a below: if the parental p-lactamase is represented by
Enzyme A a single amino acid substitution (X, represented by the arrow) could create
Enzyme B, or another substitution (Y) could create Enzyme C. Enzyme B can also
undergo substitution Y to produce a third enzyme, D. The same is true of Enzyme C,
with substitution X (see Figure 3.4b).
The series of mutations, therefore, that have created Enzyme D from Enzyme A can
occur by two distinct routes: either via Enzyme B or Enzyme C. The number of
permutations increase rapidly with the number of mutations that occur. In the latter
half of 1990 two maps were introduced [234] that identified all of the possible
intermediates of the SHV- and the TEM-derived ESBL sequenced at that time.
a) b)
Figure 3.4: Theoretical relationship of p-Lactamases
Each box represents a p-lactamase and each arrow represents a single amino acid substitution.
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3.1. The SH\j-derived enzymes
The primary structures of the SH\-derived P-lactamases SHV-1 to SHV-5, and
SHV-8 have been determined. SHV-8, an enzyme created in vitro by SDM, does
not exhibit any significant ESBL activity [235], Each of these enzymes have been
numbered chronologically according to isolation (or creation), rather than denoting
the evolutionary distances from SHV-1 (this is the same for the TEM-derived
enzymes). SHV-2 was the first SH\-derived ESBL to be sequenced, and it was
shown to differ from SHV-1 by a single amino acid change of glutamic acid at
position 238 to serine. All the clinically isolated SYSS/-\-derived ESBL sequenced
so far have possessed a serine residue at position 238 rather than a glutamic acid
residue. It is therefore, concluded that each of the subsequently identified SHV-
derived ESBL (SHV-3, -4, and -5) are derived from SHV-2, which was derived
from SHV-1; a fact that considerably simplifies the map of SHV-enzyme mutations
[234], Figure 3.5 (page 95) represents the inter-relationship of the SHV-1 -derived
P-lactamases and it is obvious from this map that the ultimate ESBL of this series,
SHV-4, can be derived through mutation from SHV-3 or SHV-5. The map of the
inter-relationships of the clinically isolated SHV-derived ESBL (Figure 3.5) has
changed little since its introduction [234] in 1990. Other SH\-derived enzymes
have been identified (e.g. SHV-6 [236]), but details of the amino acid sequences of
the enzymes have not appeared in primary journals.
3.2. The TEM-derived enzymes
The inter-relationship of the TEM-derived P-lactamases, because of the number of
enzymes that have been identified and sequenced, is more complicated than the
inter-relationships of the SHV-1 -derived enzymes. At the time the map defining the
TEM-derived inter-relationship was introduced [234], there were 17 possible
intermediate enzymes between the eight sequenced TIHM-type ESBL and the two
parental enzymes (TEM-1 and TEM-2). Many of the intermediates in the
intervening three years have been identified clinically. Determination of the amino
acid sequences of many of the T^M-type P-lactamases have filled the gaps in the
map. Table 3.4 (page 97) shows the amino acid substitutions between each of the
21 sequenced TEM-P-lactamases, and the percentage of amino acid identity
between each of the mature P-lactamases.
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Figure 3.5: Representation of the inter-relationship of the SHM-derived
p-lactamases
Each arrow represents a single amino acid change facilitated by a single nucleotide change in the
P-lactamase gene. SHV-8 has not been identified clinically, hence, is shown shaded. One-letter amino
acid notation according to the IUPAC-IUB Commission on Nomenclature [237], Numbering of the
amino acid residues is according to the recommendations of Ambler et al (1991) [158], and places the
active-site serine residue at amino acid position 70.
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Figure 3.6 (page 98) is the revised representation with all sequenced enzymes
included. Apart from one notable exception (TEM-24) all the end-point enzymes
can be connected to the parental enzymes TEM-1 and TEM-2 by a series of
clinically isolated enzymes that only differ in primary structure by a single amino
acid substitution. The missing intermediates, between TEM-7 and TEM-24, have
been called TEM-X and TEM-Y for the purposes of this thesis. TEM-X is also
possible predecessor of TEM-8, which is otherwise thought to have been derived
from TEM-2 via TEM-18 and TEM-3.
The mutation between TEM-1 and TEM-2 occurred, it can probably be assumed,
before later enzymes emerged, therefore, the change from glutamine to lysine at
position 39 does not occur within the ESBL. Two clearly separate TEM-derived
enzyme groups, therefore, exist in the TEM-derived P-lactamases: TEM-1 -derived
and THM-2-derived. The amino acid substitution table below (Table 3.4 page 97)
does not take account of the TEM-1/TEM-2 division. The final column of the table
gives the mean number of substitutions between any enzyme and the other 20
P-lactamases listed. The higher the value the more peripheral the enzyme, and
conversely, the lower values indicate the central enzymes. TEM-1, TEM-2,
TEM-17, and TEM-18 are the most 'central', and TEM-5 and TEM-24 are the
most 'peripheral'. Under this assumption it is interesting to note that all but a
single ESBL (TEM-24) of the SHY-derived, TEM-1 -derived or TEM-2-derived
enzyme groups is no more than three amino acid substitutions distant from its
respective parental P-lactamase. It has become apparent from this representation
that some of the intermediate enzymes are common predecessors for more than
one end-point ESBL, hence could be considered the more 'popular' mutations.
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Number of amino acid substitutions
TEM 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 24 26 JC
P 1 1 3 3 3 2 2 4 3 2 2 1 2 4 2 3 1 2 1 5 2 2.5
e 2 0.4 2 4 4 3 1 3 4 3 1 2 1 3 3 2 2 1 2 4 3 2.5
r 3 1.1 0.4 2 6 3 3 1 4 5 3 4 3 1 1 2 2 1 2 4 3 2.8
c 4 1.1 1.5 0.8 6 2 5 3 2 5 5 4 3 1 1 4 2 3 2 6 3 3.4
e 5 1.1 1.5 2.3 2.3 5 3 5 4 1 5 2 5 7 5 6 4 5 4 2 3 4.3
n 6 0.8 1.1 1.1 0.8 1.9 4 4 3 4 2 3 4 4 2 1 1 2 3 5 2 3.0
t 7 0.8 0.4 1.1 1.9 1.1 1.5 2 3 2 2 1 2 4 4 3 3 2 3 3 2 2.8
a 8 1.1 15 0.4 1.1 1.9 1.5 COo 3 5 4 3 4 2 2 3 3 2 3 3 2 3.1
g 9 1.1 1.5 1.5 0.8 1.5 1.1 1.1 1.1 3 5 2 3 3 3 4 2 3 4 4 1 3.2
e 10 0.8 1.1 1.9 1.9 0.4 1.5 0.8 1.9 1.1 4 1 4 7 4 5 3 4 3 3 2 3.6
11 0.8 0.4 1.1 1.9 1.9 0.8 0.8 1.5 1.9 1.5 3 2 4 4 1 3 2 3 5 4 3.3
d 12 0.4 obo 1.5 1.5 0.8 1.1 0.4 1.1 0.8 0.4 1.1 3 5 3 4 2 3 2 4 2 2.8
i 13 0.8 0.4 1.1 1.1 1.9 1.5 0.8 1.5 1.1 1.5 0.8 1.1 2 4 3 3 2 3 5 4 3.2
f 14 1.5 1.1 0.4 0.4 2.7 1.5 1.5 0.8 1.1 2.7 1.5 1.9 0.8 2 3 3 2 3 5 4 3.5
f 15 0.8 1.1 0.4 0.4 1.9 0.8 1.5 0.8 1.1 1.5 1.5 1.1 1.5 0.8 3 1 2 1 5 2 2.8
e 16 1.1 0.8 0.8 1.5 2.3 0.4 1.1 1.1 1.5 1.9 0.4 1.5 1.1 1.1 1.1 2 1 4 4 3 3.1
r 17 0.4 COo 0.8 0.8 1.5 0.4 1.1 1.1 0.8 1.1 1.1 0.8 1.1 1.1 0.4 0.8 1 2 4 1 2.3
e 18 0.8 0.4 0.4 1.1 1.9 0.8 0.8 0.8 1.1 1.5 0.8 1.1 0.8 0.8 0.8 0.4 0.4 3 3 2 2.4
n 19 0.4 0.8 0.8 0.8 1.5 1.1 1.1 1.1 1.5 1.1 1.5 0.8 1.1 1.1 0.4 1.5 0.8 11 6 3 2.9
c 24 1.9 1.5 1.5 2.3 0.8 1.9 1.1 1.1 1.5 1.1 1.9 1.5 1.9 1.9 1.9 1.5 1.5 1.1 2.3 3 4.2
e 26 0.8 1.1 1.1 1.1 1.1 0.8 0.8 COo 0.4 COo 0.8 0.8 1.5 1.5 0.8 1.1 0.4 0.8 1.1 1.1 2.6
Table 3.4: The inter-relationship of the JEM-derived p-lactamases
Number of amino acid changes between each TEM-derived p-lactamases (top right) and percentage of
amino acid sequence difference between p-lactamases (bottom left). The right hand column, X, gives
the mean amino acid substitution distance between the mature-enzyme (263 amino acids) and the
other TEM-derived enzymes. Other variations have been observed in the leader sequence of the
precursor-p-lactamase (286 amino acid residues) but are not included.
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TEM-2-der/ved TEM-1 -derived
Figure 3.6: Representation of the inter-relationship of the JEM-derived
P-lactamases
Each arrow represents a single amino acid change, facilitated by a single nucleotide change, in the
P-lactamase gene. Enzymes are divided into two groups: TEM-1 -derived and TEM-2-der/Ved along
the Q39K change between TEM-1 and TEM-2. The enzymes named TEM-X and TEM-Y in this
diagram have not been found clinically (see text for details: Section 3.2 page 96). One-letter amino
acid notation according to the IUPAC-IUB Commission on Nomenclature (1969) [237], Numbering of
the amino acid residues is according to the recommendations of Ambler et a/(1991) [158],
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4. Generation of TEM-derived (3-lactamases by
site-directed mutagenesis
After the first version of the map representing the TEM-derived P-lactamases was
drawn in Autumn 1990 [234] very few of the intermediate ESBL had been sequenced
and/or were available for study. It was proposed that some of the intermediate
enzymes between TEM-1 and TEM-5 were to be constructed by site-directed
mutagenesis (SDM). The filamentous bacteriophage M13mpl8 was chosen as the
cloning vector because of the following reasons:
• Ease with which single-stranded sequencing quality DNA could be isolated from
cell culture for the verification ofmutagenesis of the cloned fragment.
• The range of restriction sites within the multiple cloning site (MCS) of the lacT
gene.
• Lac (or Blue-white) selection of a suitable E. coli host containing DNA fragments
cloned into the MCS (disrupting the P-galactosidase activity).
The cloning vector pAT153 [170], a 3.7-kb high copy number derivative of pBR322
(4.4-kb), was also chosen as the donor of the p-lactamase gene fragment, and
recipient for the modified fragment, because of the following reasons:
• Most, if not all, of the commercially available plasmid cloning vectors that confer
ampicillin resistance (AmpR) as a selectable genetic marker carry the TEM-1
P-lactamase gene, blciT-\.
• pAT153 has had the rop gene present in pBR322 deleted, increasing the copy
number compared to the parent vector.
• Copy number can be increased from 20 to 1000 copies per chromosome per
bacterium by cultivating the bacteria in the presence of chloramphenicol.
• pAT153 is non-mobilisable because of the deletion of the bom site, constituting a
further increase in safety compared to pBR322.
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4.1. Construction of an M13mp18 SDM-vector.
pAT153 and M13mpl8 DNA were restricted separately with EcoR I and Pst I.
The resulting DNA fragments were separated by agarose gel electrophoresis, and
the 750-bp fragment of pAT153 and the large fragment (~7.2-kb) of M13mpl8
were excised and purified by adsorbtion to glass particles (Geneclean II Kit,
Bio 101). The purified M13mpl8 and pAT153 fragments were annealed and
ligated overnight and then used to transform competent E. coli TGI. Colonies of
E. coli harbouring the recombinant M13mpl8-750-bp fragment were selected by
Lac selection of plaques from a lawn of pure E. coli TGI. Mini-prep. DNA was
prepared from the selected strains and restricted with Sea I (a restriction site
present within the 750-bp pAT153 DNA fragment but not found within Ml 3
DNA). Restricted and intact DNA was then analysed by agarose gel
electrophoresis. Strains that harboured DNA of the correct size (~8-kb) and that
linearised when restricted with Sea I were selected for preparation of single-
stranded DNA templates for SDM. Orientation of the 750-bp EcoR l-Pst I DNA
fragment from pAT153 in the Ml3 phage DNA meant that single-stranded
templates contained sense sequences, therefore SDM oligonucleotides and
sequencing primers were non-sense sequences.
4.2. Construction of the recipient plasmid vector pUK3001
A plasmid vector, pUK3001 (Figure 3.7 page 101), was constructed in preparation
for the cloning of the mutant 750-bp fragment after SDM. pAT153 DNA was
restricted with EcoR I and Pst I, and after purification, was annealed and ligated
overnight with a specially designed EcoR l-Xba l-Pst I polylinker fragment
(Figure 3.8 page 101). Ligated DNA was then used to transform competent
E. coli TGI. Bacterial colonies containing plasmid DNA were selected with
tetracycline. Colonies that exhibited the tetracycline-resistant and ampicillin-
sensitive phenotype were analysed for plasmid DNA (~2.9-kb) that would cut with
Xba I but not Sea I. Bacteria harbouring the recombinant DNA required were used
in the purification of pUK3001 with the Qiagen Midi-Prep. Kit (see Chapter 2).
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Figure 3.7: Restriction map of pUK3001
The map of the plasmid shows the position of the unique restriction sites for the endonucleases
indicated according to various sources (Restriction endonuclease suppliers). Position 0 has been
arbitrarily defined as the centre of the EcoR I site (nucleotide 1 is the first thymine of the sequence
• GAATTC- ■). Restriction site positions are given relative to the first base of the recognition
sequence (except for EcoR I). Abbreviations: blaT, remainder of the TEM (3-lactamase gene (non¬
functional but codes for the last 104 amino acids of the enzyme); ori, origin of replication; tetR,
tetracycline resistance gene.
Xba\
s r:|&ATT&G GpTAGACGCTQQA| 3
3' ]©CCAG AT cjl" G C •! ,
EcoRI Pst\
Figure 3.8: EcoR l-Xba I-Pst I polylinker
Polylinker constructed from annealing two oligonucleotides (a 20-mer and a 12-mer) illustrated in
black type. The restriction endonuclease recognition sites highlighted by the shaded regions and
sites of cleavage are shown. White lettering represents nucleotide bases of recognition sequences
not present in the polylinker.
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4.3. SDM of M13mp18-750-bp fragment vector
SDM of single-stranded M13mpl8-750-bp fragment DNA was performed using
the 'Oligonucleotide-directed in vitro mutagenesis kit' from Amersham
International pic [168], The oligonucleotides listed in Table 3.5 (page 103) were
used in SDM experiments
After conducting experiments according to the SDM protocol supplied with the kit
for each oligonucleotide, E. coli TGI was transformed with the double-stranded
mutant M13mpl8-fragment DNA. Plaques were selected from a lawn of
uninfected E. coli TGI and grown overnight in LB broth. The overnight cultures
were then applied to a GeneScreen Hybridisation Membrane (NEN, DuPont) with
the Schleicher & Schuell Minifold II dot-blot apparatus. Negative controls of
unmutated single-stranded M13mpl8-fragment DNA were used. After denaturing
of the DNA and neutralisation of the denaturing solutions, DNA was cross-linked
to the hybridisation membrane with UV irradiation. Hybridisation filters were pre-
. . . . ^9
hybridised and then probed with the respective ~ P-labelled SDM oligonucleotides.
Filters were washed with increasing stringency from a 2xSSC/0. l%w/v SDS wash
solution at 37°C to a 0.5xSSC/0.1%w/v SDS wash solution at 50°C until the
negative controls gave no appreciable counts above background with a Gieger-
Miiller tube. Autoradiography of filters revealed possible mutant templates
4.4. Sequencing of M13mp18-750-bp fragment DNA
subjected to SDM
Likely mutant M13 templates were used to prepare single-stranded DNA templates
for DNA sequencing. The SDM oligonucleotides (Table 3.5 page 103) and the
sequencing oligonucleotides listed in Table 3.6 (page 103) were used as primers
for sequencing reactions. The whole of the 750-bp fragments, within the M13
vector, that gave positive probing results were sequenced. Table 3.7 (page 104)
lists the results of the SDM experiments, all SDM were attempted on the Ml3
bldY-\ template except one which used the template from the Q39K mutagenesis
(analogous to blciT-2). Each of the Ml3 templates found to have a desired
nucleotide change were sequenced on a minimum of two occasions, to check for
mutations that may have been introduced accidentally by the SDM experiment.
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Primer* Sequence? Position* Size M. Wt
Q39K 5'-GC ACC CAA CTT ATC TTC AGC-3' 327-308 20-mer 5997
E104K 5'-GG TGA GTA CTT AAC CAA GTC-3' 522-503 20-mer 6141
R164S 5'-CGG TTC CCA ACT ATC AAG GC-3' 703-684 20-mer 6062
R164H 5'-CGG TTC CCA ATG ATC AAG G-3' 703-685 19-mer 5812
R164D 5-CGG TTC CCA ATC ATC AAG GC-3' 703-684 20-mer 6931
Table 3.5: Oligonucleotide primers for Site-Directed Mutagenesis
* Primer nomenclature according to amino acid substitution envisaged. § Oligonucleotides are
non-sense strand analogues; nucleotides in bold show mismatches with sequence of b/aT-1. * 5'-»3'
binding range of non-sense oligonucleotides to sense strand of b/aT-1 (DNA sequence numbering
according to Sutcliffe (1978) [150]).
Primer* Sequence? Position* Size M. Wt
Universal 5'-GTA AAA CGA CGG CCA GT-3' - 17-mer -
383(SDM) 5'-GG AAA ACG TTC TTC GGG G-3' 400-383 18-mer 5580
561 (SDM) 5-GGC AGC ACT GCA TAA TTC-3' 578-561 18-mer 5484
Table 3.6: Oligonucleotide primers for DNA Sequencing
* Primer nomenclature refers to location of first (5') nucleotide. § Oligonucleotides are non-sense.
* 5'—>3" binding range of non-sense oligonucleotides to sense strand of b/aT-1 (DNA sequence
numbering according to Sutcliffe (1978) [150]).
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Probing identified candidates for DNA sequencing by revealing the SDM-templates
exhibiting the required point-mutations. The R164H and R164D SDM experiment
either gave false positive probing results (according to the subsequent DNA
sequencing of templates), or no positive signals were observed in the various SDM
experiments with these oligonucleotides. A summary of the results of probing and
DNA sequencing is given in Table 3.7.
4.5. Construction of mutant plasmids pUK3002, pUK3003,
pUK3004, & pUK3005
Each mutant template and the recipient plasmid, pUK3001, were restricted with
EcoR I and Pst I. The resulting DNA fragments of the mutant Ml 3 templates were
separated by agarose gel electrophoresis, the 750-bp fragments were excised and
purified by glass-milk purification. pUK3001 fragments were purified by ethanol
precipitation. The mutant fragments were annealed and ligated overnight and the






Q39K Q39 + C-317-»A CAG-xAAG K39 TEM-2
E104K E104 + G-512->A GAG-xAAG K104 TEM-17
R164S R164 + C-692-xA CGT->AGT S164 TEM-12
K39, R164 + C-692-»A CGT-»AGT S164 TEM-7
R164H R164 +(-) None - - -
R164D R164 +(-) None - - -
Table 3.7: SDM Experiments DNA Sequencing Results
t SDM oligonucleotide primer used in experiment. § Genotype (amino acid) of M13mp18-750-bp
fragment template. 1" One or more positive signals from oligonucleotide probing of SDM site.
*
Nucleotide mutations observed in DNA sequence (DNA sequence numbering according to Sutcliffe
(1978) [150]). # DNA codon modification. §§ Amino acid substitution that would result from the
observed nucleotide change. 1"! Expected recombinant enzyme.
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ampicillin and tetracycline.
Restriction analysis of plasmids harboured by AmpR TetR colonies revealed the
presence of 3.7-kb plasmids that cut with Seal but not Xba I. Re-restriction of
recombinant plasmids with EcoR I and Pst I demonstrated the presence of ~2.9-kb
and ~750-bp fragments. The plasmid containing the cytosine-692—^adenine
mutation was designated pUK3002; the plasmid with the cytosine-317—>adenine
mutation was designated pUK3003; the plasmid with the guanidine-512—»adenine
was called pUK3004; the plasmid containing the double mutation of
cytosine-317—>adenine and cytosine-692—>adenine was designated pUK3005. A
restriction map of the recombinant plasmids, based on that of pAT153, is given in
Figure 3.9 (page 106).
4.6. IEF & HYDROLYTIC CHARACTERISTICS OF THE RECOMBINANT
p-LACTAMASES
Crude extracts of each of the E. coli TGI harbouring the recombinant plasmids
were prepared. IEF of the P-lactamases produced by each strain was performed to
ascertain whether the enzymes were of the correct pi compared to clinical
isolations of the enzymes. Hydrolytic characteristics of the recombinant enzymes
were determined against nitrocefin, ceftazidime and cefotaxime and compared to
the characteristics of known P-lactamases. The summary of these verification
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Figure 3.9: Restriction map of pAT153, pUK3002, pUK3003, pUK3004,
& pUK3005
The map of the plasmids shows the position of the unique restriction sites for the endonucleases
indicated according to various sources (Restriction endonuclease suppliers). Position 0 has been
arbitrarily defined as the centre of the EcoR I site. Restriction site positions are given relative to the
first base of the recognition sequence (except for EcoR I). The plasmids vary by one or two
nucleotides. Abbreviations: blaT, TEM (3-lactamase gene; ori, origin of replication; tetR, tetracycline
resistance gene. The following (3-lactamase genes are carried by respective plasmids: b/aT-1
(pAT153), b/aT-12 (pUK3002), blal-2 (pUK3003), b/aT-17 (pUK3004), b/aT-7 (pUK3005).
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Enzyme Plasmid Isoelectric point (pi) Relative Rates of Hydrolysis (%)*
Expected Actual NCFN PEN G CAZ CTX
TEM-12 pUK3002 5.25 5.25 100 174 47 79
TEM-2 pUK3003 5.6 5.6 100 1512 UM UM
TEM-17 pUK3004 5.9 -5.5 100 1410 9.8 11
TEM-7 pUK3005 5.41 5.41 100 675 19 7.0
TEM-1 R1 5.4 5.4 100 56 UM UM
TEM-2 R46 5.6 5.6 100 512 UM UM
TEM-12 - 5.25 5.25 100 225 15 34
TEM-7 plF100 5.41 5.41 100 809 20 12
Table 3.8: Isoelectric points & hydrolytic characteristics of recombinant
P-lactamases
* Relative rate of hydrolysis relative to nitrocefin (100%). Abbreviations: CAZ, ceftazidime; CTX,
cefotaxime; NCFN, nitrocefin; PEN G, penicillin G; UM, unmeasurable.
4.7. Concluding remarks
Recombinant plasmids pUK3002, pUK3003, and pUK3005 were found to encode
analogues of TEM-12, TEM-2, and TEM-7 respectively. It is apparent, however,
from the results summarised in Table 3.8, that the recombinant plasmid pUK3004
did not encode an analogue of TEM-17 (expected pi 5.9). Unfortunately, time did
not permit the blaT gene of pUK3004 to be re-sequenced to elucidate the
nucleotide mutations with respect to blaT-1.
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5. Sequencing of the TEM-E2pUK72i P-lactamase
Payne identified the mutant P-lactamase TEM-E2 from a clinical isolate [141, 151], In
1982 the Neonatal ITU of Liverpool General Hospital had a number of deaths of
neonates as a result of infections with a gentamicin resistant (but ceftazidime sensitive
and producing TEM-1) Kleb. oxytoca 5446. Infections of Kleb. oxytoca 5446 were
subsequently eradicated until the appearance of the gentamicin and ceftazidime
resistant Kleb. oxytoca 5445 some months later. The particular strain characterised by
Payne was isolated from the blood and cerebrospinal fluid of a baby in the unit.
Ceftazidime resistance of Kleb. oxytoca 5445 was not thought to be enzymatically
mediated as TEM-1 was the only P-lactamase identified at the initial isolation. Payne
later revealed that the strain produced two P-lactamases, TEM-1 (pi 5.4) and an
additional enzyme named, TEM-E2, with a pi of 5.3. Both p-lactamases had the same
molecular weight (23.5xlO3) and were encoded by the same 141 -kb plasmid,
pUK721. It was suggested that the ceftazidime sensitive Kleb. oxytoca 5446 had
remained in areas where it had been exposed to sub-MIC levels of ceftazidime and
had led to the development of the ceftazidime resistant Kleb. oxytoca 5445. Payne had
shown that TEM-1 could readily mutate in vitro to a TEM-E2-like enzyme under the
selective pressure of ceftazidime [141, 161], It has, therefore, been concluded that the
selection of the TEM-E2 P-lactamase was a result of exposure of the TEM-1
producing strain to sub-MIC levels of ceftazidime. TEM-E2 is especially interesting
because it shows significant similarity to other clinically isolated T^iM-type enzymes
(TEM-12, and CAZ-3), but predates these enzymes by at least five years. It is,
therefore, the first example of a clinically isolated ESBL. It was decided that the
nucleotide sequence of the TEM-E2 P-lactamase needed to be determined to ascertain
its relationship to the later ESBL. If the TEM-E2 P-lactamase was analogous to
TEM-12 it would have significant bearing on the perception of the relationships and
development of the ESBL as described above (Section 3.2 page 94, and Figure 3.6
page 98).
5.1. dna SEQUENCING STRATEGY
The strategy for the cloning and sequencing of TEM P-lactamase genes was based
upon the a method designed by Dr Graham Disney and Mr Stephen Dove at Glaxo
Group Research Ltd [174], The cloning vector, pSG-2, was constructed by Disney
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& Dove by modifying the cloning vector pBGS19+ (KanR lacZ') to contain the
TEM-1 promoter from pBR322 (Tni) and the /t?/BTiT2 terminator sequence from
pKK233-2. PCR primer oligonucleotides were designed to amplify the ORFs of the
TEM P-lactamase genes. These oligonucleotides encode restriction endonuclease
recognition sequences (Xba I and Sph I) at their 5' ends to enable directional
cloning of the PCR-amplified DNA into pSG-2. Counter-selection with ampicillin
and kanamycin would select bacterial colonies containing a functional blaY ORF
inserted between the promoter and terminator of pSG-2. Recombinant ampicillin
resistance plasmids could then be sequenced for nucleotide changes within the
ORF.
It was proposed that PCR-amplified DNA fragments from not only pUK721, but
also pUK720 (TEM-E1), pUK722 (TEM-E3), pUK723 (TEM-E3) and pUK724
(TEM-E4), would be generated and cloned into pSG-2. The genes encoding
TEM-E1, TEM-E3, and TEM-E4 had also remained uncharacterised at a level of
the DNA sequence. Once PCR amplified DNA fragments were cloned, ampicillin
resistant colonies would be used for the preparation of double-stranded plasmid
DNA for sequencing. Each sequence would be determined from at least two
separate PCR-amplification and cloning experiments to eradicate the possibility of
the introduction of PCR-generated mutations being mistaken for the clinically
generated nucleotide mutations.
5.2. PCR-amplification of DNA from pUK721
Genomic DNA was isolated from overnight cultures ofE. coli J53-2 (pUK721), or
E. coli J62-2 (pUK720, pUK722, pUK723 or pUK724). Genomic DNA was then
used in the PCR reactions to amplify 900-bp fragments from the blaT ORFs of the
respective plasmids. Plasmid DNA from pSG-TEM-1 and pKK233-2 were used
regularly for control reactions. It was found that generation of PCR fragments of
TEM genes was temperamental by this method. It was suspected that mis-priming
of PCR-primer oligonucleotides was responsible for the variation in success of
PCR reactions.
A method for the generation of PCR-amplified DNA fragments direct from
overnight cell cultures was developed. It was found that 1ml of overnight culture
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of E. coli when washed once and resuspended in 1ml of 50mM Tris-Cl (pH 7 0)
provided greater consistency in generation of 900-bp PCR-amplified TEM ORF
fragments. One pi of the washed cell suspension was found to be the optimum
volume for addition to PCR reactions. Volumes less than this did not yield
optimum quantities ofDNA. Volumes greater than lpl gave temperamental results;
it was thought this was because of the interference of bacterial proteins with the
PCR reactions. PCR fragments were also generated from washed cell suspensions
prepared from overnight cultures of bacteria that had been stored at 4°C for two
days and from bacterial colonies removed from solid media after storage at 4°C for
several days. The PCR reactions employing 'old' cultures, although possible, were
found not to provide optimum quantities of PCR-amplified DNA.
5.3. Cloning of PCR-amplified DNA
The products of each PCR reaction were separated by agarose gel electrophoresis
in lxTAE buffer. The 900-bp fragments generated by successful reactions were
excised and purified with the Geneclean II Kit (resuspended in a final volume of
lOpl with TE buffer). Recovery ofDNA from the agarose gel slices was verified by
electrophoresis of lpl of each purification in agarose gels in lxTAE buffer. Five pi
of each purified PCR fragment was restricted with Xba I and Sph I and ethanol
precipitated to purify the restricted DNA from the components of restriction
enzyme buffers and the restriction endonucleases.
The vector pSG-2 was prepared for insertion of the PCR-generated TEM ORFs.
The recipient pSG-2 was restricted with Xba I and Sph I and the digested DNA
fragments separated by agarose gel electrophoresis (in lxTAE). The large
(~4.4-kb) DNA fragment was excised from the agarose gel and purified by glass-
milk purification.
The purified pSG-2 recipient fragment was then annealed and ligated overnight
with the restricted 900-bp PCR fragment. The ligated DNA was used to transform
competent Max Efficiency E. coli DH5a (Gibco BRL). Transformed bacteria were
counter-selected with ampicillin, ampicillin and kanamycin, or ceftazidime.
Colonies were screened for ampicillin, kanamycin and ceftazidime resistance
depending on the original selecting antibiotics. Colonies with the required
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phenotype (KanR AmpR) were used to prepare plasmid DNA for restriction
analysis with EcoR I, Hind III, Sph I and Xba I. Plasmid DNA exhibiting the
correct restriction characteristics was used to prepare double-stranded plasmid
DNA for DNA sequencing.
Apart from the initial problems with PCR amplification of TEM ORFs, that were
improved by substituting washed cell suspensions for total genomic DNA
preparations, there were problems with the cloning of the PCR-fragments.
Contaminating organisms were found to be a persistent problem on the solid media
used for counter-selecting transformants. The multi-resistant organisms were
partially irradicated when the source of the contamination was attributed to
surface-drying of plates in a 37°C incubator.
Ligation and transformation efficiency throughout each of the cloning experiments
was unexpectedly low (maximum of one to three colonies per plate for the
insertions that worked). Disney & Dove had similar problems with the cloning of
the blaT-\, blaT-3, b/aT-5, bldY-1, and bldT-9 ORFs. The manufacturers of the
competent E. coli DH5a recommend dilution of ligation reactions prior to
transformation, as ligation reaction components can interfere with the
transformation process. It was found that dilution of control ligation reactions did
not greatly affect the efficiency of transformation. Ligation reaction components
were, therefore, not considered responsible for the low efficiency. One of the
restriction enzymes, Sph I was therefore suspected of low cutting efficiency of
PCR-amplified DNA. The Sph I recognition sequence (•••GCATGC—) is located
very close to one end of the PCR fragment (three nucleotides from the 5'-end of
the PCR primer oligonucleotide); because of this location, digestion of PCR-
amplified DNA with this enzyme was suspected not to be as efficient as the
digestion of intact plasmid DNA. Complete digestion of pSG-2 DNA was regularly
observed with Xba I and Sph I.
The TA Cloning System (Invitrogen Corporation) was used to try and circumvent
the restriction and ligation problems encountered. The kit was designed for the
one-step cloning of PCR-amplified DNA into a specially prepared plasmid vector
(pCR II). Thermostable polymerases (such as the Taq polymerase used in the PCR
reactions) have a non-template dependent activity that adds single deoxyadenines
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to the 3'-end of all duplex DNA. The poly-deoxyadenine 'overhangs' were used to
try and clone the PCR fragment into the pCR II vector (supplied as a linear
molecule with 3'-T overhangs). An aliquot of the PCR reaction mixture was diluted
according to the TA Cloning System manufacturer's protocol and annealed and
ligated overnight with the linear pCR II DNA. The product of the ligation was then
used to transform the competent E. coli INVaF' supplied with the kit. Colonies
were counter-selected on kanamycin (the pCR II vector confers KanR & AmpR).
Presence of a PCR fragment insert within the pCR II vector was also ascertained
with concurrent Lac (blue-white) selection of colonies. The pCR II self-ligation
control yielded some white colonies together with the expected blue colonies.
White colonies from the cloning experiment were selected for isolation and
restriction analysis. Restriction analysis with EcoR I (the MCS of pCR II is
palindromic, therefore, restriction with a single enzyme will excise any inserted
DNA fragment) revealed that none of the white colonies harboured a pCR II-PCR
fragment construct as expected from the results of the self-ligation control
experiment. The use of this system was reputed to have been temperamental at the
time of the experiment.
PCR-amplified pUK721 ORF DNA was also cloned into the pBGS18+ vector.
PCR DNA amplified from pUK721 and pBGS18+ DNA were restricted separately
with Xba I and Sph I. Restricted DNA fragments were separated by agarose gel
electrophoresis and the 900-bp PCR fragment band and 4.4-kb pBGS18+ band
were excised and purified with the Geneclean II Kit (Bio 101). The purified
digested PCR DNA and pBGS18+ DNA were annealed and ligated overnight.
Aliquots of the ligation mixture were used to transform Max Efficiency E. coli
DH5a. Colonies were counter-selected with kanamycin, and insertion of the PCR
DNA into the MCS of pBGS18+ was identified by Lac selection. White colonies
were selected for isolation and restriction analysis. Restriction with EcoR I and
Hind III revealed the presence of a 900-bp insert within pBGS 18+ of one of the
selected colonies. Plasmid DNA, prepared from these colonies, was used to
re-transform Max Efficiency E. coli DH5a (Gibco BRL). All transformants
underwent Lac selection with concurrent counter-selection with kanamycin.
Transformed colonies were all white confirming the purity of the pBGS18+-PCR
fragment construct plasmid preparation.
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5.4. DNA SEQUENCING OF CLONED PCR-AMPLIFIED DNA
Sequencing grade double-stranded plasmid DNA was prepared, with the Qiagen
Midi-Prep Kit, from each of the colonies that were verified to contain a construct
with a 900-bp DNA insert. The plasmid DNA was denatured in alkaline solution
and the relevant oligonucleotide sequencing primer (see Table 3.9) annealed. DNA
sequencing of the PCR-amplified DNA insert was carried out according to the
method described in Chapter 2 for sequencing of double-stranded DNA templates.
A summary of all of the PCR-experiments and the sequencing of PCR inserts,
including the pCR II and pBGS18+ cloning experiments, is given in Table 3.10
(page 114). All the DNA sequenced was shown to be derived from the gene of the
TEM-1 (3-lactamase. No PCR-amplified TEM-ORF was successfully cloned from
fragments generated from pUK720 or pUK724. It was expected, as pUK721
encoded two TEM-P-lactamase genes, that PCR would generate equal copies of
each ORF and, therefore, there was equal probability of cloning the bldT-\ and
blciY-E2 ORF. Cloning and selection of constructs on ampicillin or ceftazidime
would have selected for plasmids containing the TEM-1 and TEM-E2 ORFs, and
the TEM-E2 ORF respectively. No ceftazidime resistant E. co/i DH5a colonies
were isolated by this procedure. Of the three plasmid-constructs sequenced (two
AmpR pSG-2 constructs and a lac~ pBGS18+ construct) no nucleotide differences
from blal-\ were observed.
Primer* Sequence? Position* Size
Bla-(S)391 5'-A GAA CGT TTT CCA ATG-3' 391-406 16-mer
Bla-(S)606 5-CC AAC TTA CTT CTG AC-3' 606-621 16-mer
Bla Seq 6 5'-TAA CCC TGA TAA ATG C-3' 167-182 16-mer
Bla Seq 7 5-CAA GAG CAA CTC GGT C-3' 464-479 16-mer
Bla Seq 8 5'-ACA ACG TTG CGC AAA C-3' 764-779 16-mer
Table 3.9: Oligonucleotide primers for DNA sequencing
4 Primer nomenclature refers to location of first (5') nucleotide. § Oligonucleotides are sense strand
analogues, * 5'->3' binding range of sense oligonucleotides to non-sense strand ofb/aT-1 (DNA
sequence numbering according to Sutcliffe (1978) [150])
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p-Lactamase Total
TEM-E1 TEM-E2 TEM-E3 TEM-E3 TEM-E4
Plasmid: Name pUK720 pUK721 pUK722 pUK723 pUK724 -
Size 31-Kb 141-kb 110-kb 100-kb 56-kb -
PCR* DNA 8 17 13 13 11 62
Cells 3 36 10 9 9 67
Successes?: DNA (%) 3 (38) 4(24) 5 (38) 5 (38) 6 (55) 23 (37)
Cells (%) 1 (33) 23 (64) 2 (20) 2 (22) 2 (22) 30 (45)
Cloningt; Purification 3 20 3 4 4 33
Ligations 7 22 5 ; 8 7 49
Colonies 2 6 4 3 3 17
Sequencing* - 3 2 2 - 7
Table 3.10: Summary of PCR-amplification experiments of blaT ORFs
from pl)K720, pUK721, pUK722, pUK723, pUK724
t Number of PCR amplifications: DNA, from total genomic DNA preparations; Cells, from whole washed
cell suspensions. § Number of PCR experiments that generated ~900-bp DNA fragments (percentage of
PCR experiments that generated a fragment in brackets), t Number of cloning experiments: Purification,
number of PCR-amplified DNA fragments purified in preparation for cloning; Ligations, number of
overnight ligation experiments to insert PCR-amplified DNA into a recipient vector; Colonies, number of
overnight ligation experiments that produced colonies (of the correct phenotype) after transformation of
E. coli DH5a. * Number of recombinant plasmids, with the correct construction, that had the blaJ ORF
DNA sequence fully elucidated.
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5.5. Single-stranded conformational polymorphism
Single-stranded conformational polymorphism (SSCP), when combined with PCR-
amplification of the target DNA sequence (called PCR-SSCP) has been used to
detect single-nucleotide changes in several hundred bases [238], In SSCP analysis
a mutated sequence is detected as a change of mobility in polyacrylamide gel
electrophoresis, as a result of an altered folded structure. Under non-denaturing
conditions, single-stranded DNA has a conformation stabilised by intra-strand
interactions. As a consequence, the conformation, and therefore the mobility, is
dependent on the DNA sequence [239], After amplification of the DNA (from
washed cell suspensions) by PCR, including 32P-a-dCTP to radio-label the product,
the amplimers were heat denatured and conformers separated by polyacrylamide
gel electrophoresis with the Mutation Detection Enhancement (MDE) Gel
(AT Biochem Inc.). Electrophoresis was carried out at constant power (8 Watts) at
room temperature for 14 hours, the recommended conditions to separate PCR
amplimers of up to 1-kb which differ by a single nucleotide. After electrophoresis
the gel was dried under vacuum for 60 minutes at 70°C then autoradiographed for
12 hours with intensifying screen at -70°C.
The developed autoradiographs showed that PCR-amplified DNA derived from
MYT-lOpjpQjoo and formed only two SSCP bands whereas
pUK721-derived PCR-DNA exhibited three bands (Figure 3.10 page 116). Other
PCR-amplimers derived from plasmids encoding a single P-lactamase also
demonstrated only two bands (not shown). The two bands produced from
blaT-I2PUK3002 corresPond to the upper two bands presented by the PCR-DNA
from pUK721.
The PCR-SSCP analysis has demonstrated that a small difference between the two
P-lactamase genes present on pUK721 exists. From the comparison with the bands
derived from the recombinant pUK3002, it would appear that one of the
conformers from pUK721 is closely related to TEM-12. The significance of the
number of bands produced, or migration distance of each conformer generated, by
PCR-SSCP has not been fully elucidated by the various pioneers of the technique.
The analysis is only useful to show that differences between closely-related DNA
species exist.
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Figure 3.10: PCR-SSCP analysis of pUK721, pUK3002 & pJPQIOO
The plasmids used for generation of 32P-labelled PCR DNA fragments for analysis encode the
following TEM p-lactamase genes: d/aT-10 (pJPQIOO), WaT-12 (pUK3002), b/aT-1 & WaT-E2
(pUK721).
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5.6. Direct DNA sequencing of PCR-amplified DNA
The results of the PCR-SSCP analysis suggest that PCR-amplification of DNA
from pUK721 generates ~900-bp fragments from both the blaTA and blaT-E2
gene. It is, therefore, an anomaly that no ceftazidime resistant clones were
produced from the insertion of PCR-fragments into pSG-2. In theory, if both
pUK721 TEM p-lactamase genes are amplified by the PCR, direct sequencing of
the PCR products should demonstrate different nucleotide bands at the same
position on a DNA sequencing gel; each band corresponding to the respective
sequence of each PCR-generated species present in the sequencing reaction.
Various strategies were tried to obtain the DNA sequence of TEM P-lactamase
genes direct from PCR-amplified DNA fragments. The major problem of
sequencing short segments of double-stranded DNA, like PCR-amplimers, is the
tendency of the templates to reanneal. Each method employed (excluding the initial
procedure of double-stranded DNA sequencing) incorporates specific steps to help
minimise the reannealing of PCR-DNA strands. All sequencing reactions included
35S-a-dATP or 33P-a-dATP to radiolabel the reaction products.
Double-stranded DNA sequencing of PCR-products
Sequencing of the purified 900-bp PCR-amplified blaT fragments was
attempted following a standard method for the sequencing of double-stranded
plasmid DNA (as described in Chapter 2 [221, 225]). After polyacrylamide gel
electrophoresis of the sequencing reaction products the dried gels were
autoradiographed overnight (-12 hours). Although control reactions employing
the plasmids pKK233-2 or pBR322 generated readable DNA sequences, no
PCR-amplimers gave any sequences after polyacrylamide gel electrophoresis of
the reaction products.
Mcpherson method for the direct sequencing of PCR-products
The method for direct sequencing of PCR-products, as described by McPherson
et al. [226], was followed with purified PCR-generated DNA from various blaT
genes. The procedure requires the heat denaturation of the double-stranded
PCR-amplimers in the presence of sequencing primer, followed by snap-freezing
of the solution on a dry-ice. After thawing the solution at room temperature, the
sequencing reactions were carried out as described in Chapter 2 following the
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method recommended by the manufacturers of Sequenase (USB). After
separation of the sequencing reaction products by polyacrylamide gel
electrophoresis the gels were dried and autoradiographed for -12 hours, but no
readable DNA sequences were observed. DNA sequences that were produced
suffered from secondary structure artefacts (see Figure 3.11 page 119). Control
sequencing reactions using double-stranded plasmid DNA (pKK233-2 or
pBR322) gave readable DNA sequences on each occasion.
Direct sequencing of PCR-products using dimethyl sulphoxide
The use of dimethyl sulphoxide (DMSO) can help overcome the problem of
reannealing of PCR-DNA strands [227], The procedure described by Winship
[227] was followed. The purified PCR-amplified DNA from each blaT gene
was mixed with 20pmoles of the required sequencing primer and denaturation
buffer to achieve final concentrations of 10%v/v DMSO, 50mM NaCl,
40mM Tris-Cl (pH 7.5) and 25mM MgCl2. The double-stranded DNA was heat
denatured and then snap-frozen on dry-ice. The solution was thawed and
sequencing reactions carried out according to the procedures recommended for
use with Sequenase Version 2.0 [225] except for the addition of DMSO to
10%Vv to the extension and termination reactions. The sequencing reaction
products were separated by electrophoresis, dried, and autoradiographed for
-12 hours. All control sequencing reactions using double-stranded plasmid
DNA (pBR322 or pKK233-2) gave readable DNA sequences. Readable DNA
sequences were obtained from the PCR-amplified DNA samples but with
considerable interference from secondary structure artefacts (see Figure 3.11
page 119). Slight alterations in the reaction procedures improved sequence
readability and reduced the number of artefacts by a small degree.
Results Page 119
PCR-amplified DNA Plasmid DNA
I —i
pKK233-2 pUK721 pKK233-2 pBR322
ATGC ATGC ATGC ATGC
I I I I I I
McPherson Method DMSO Control
Figure 3.11: Autoradiograph results from direct-sequencing of PCR-
products
Results from the direct sequencing of PCR-amplified DNA from pKK233-2 and pUK721 using the
McPherson Method [226] and DMSO method [227], The control reactions employed sequencing of
double-stranded plasmid DNA with reactions conducted as described in Chapter 2.
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Direct sequencing of PCR-products using Single-stranded DNA
binding protein
Single-stranded DNA binding protein (SSB) has a high affinity for single-
stranded DNA but does not bind to double-stranded DNA [240], The presence
of SSB in sequencing reactions helps prevent secondary structure formation and
reassociation of PCR-DNA strands. Use of SSB, less dependent on ionic
strength for binding than other single-stranded DNA binding proteins, was
tried by following the method of Wanner, Tilmans & Mischke [228].
PCR-DNA was heat denatured in the presence of sequencing primer then
snap-frozen on dry-ice. The solution was thawed and SSB (0.5pg) was added
prior to the primer extension and radiolabelling step. The SSB was inactivated
prior to running the sequencing gel by adding 0.1 pg of proteinase K and
incubating at 65°C for 20 minutes. Reaction products were then separated by
polyacrylamide gel electrophoresis, followed by autoradiography of the dried
gel for -12 hours. No DNA sequence was observed on autoradiograph films,
whereas control sequences determined from double stranded plasmid DNA
(pAT153) all worked. SSB from two different manufacturers (Pharmacia and
USB) were used in a number of sequencing experiments but with no success.
The initial denaturation and snap-freezing step was found to be the most
crucial part of the procedure, but readable sequences were still unattainable.
Direct sequencing of PCR-products with Dynabeads
A biotin ligand was incorporated into the 5'-terminus PCR-primer (Biotin-Bla 4'
had the same DNA sequence as the Bla 4' PCR-primer described in Chapter 2).
The strategy for direct DNA sequencing from PCR-amplified DNA using
Dynabeads is outlined in Figure 3.12 (page 121). Following amplification, the
double-stranded PCR-product was immobilised on Dynabeads M-280
Streptavidin (Dynal, Norway). Dynabeads M-280 Streptavidin consist of
uniform, superparamagnetic, polystyrene beads, 2.8p.m in diameter. Streptavidin
is covalently attached to the bead surface. Once the PCR-product was
selectively captured and immobilised with the Dynabeads, the DNA was isolated
by magnetic separation. Elution of the non-biotinylated amplimer, with alkali,
provided a single-stranded DNA template that was sequenced using the
Sequenase T7 DNA polymerase.
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Figure 3.12: Strategy for the direct sequencing of PCR-products using
Dynabeads
Simplified scheme for the PCR-amplification of TEM ORFs using the biotin labelled 'Biotin-BIa 4"
PCR-primer and subsequent immobilisation with Dynabeads M-280 Streptavidin (Dynal, Norway).
Once immobilised denaturation allows removal of one DNA strand. The Dynabead-labelled strand
can then be used as a single-stranded template for DNA sequencing procedures. After sequencing
reactions the template can be washed and re-used in further reactions.
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The template DNA from a single PCR reaction can be re-used: prior to loading
onto the polyacrylamide gel the template was salvaged from the sequencing
reaction mixture by magnetic separation. Re-use of the template required
stringent denaturation and washing steps to remove all of the radiolabeled
sequencing reaction products. Sequencing reaction products were separated by
polyacrylamide gel electrophoresis, and the dried gels autoradiographed for ~ 12
hours. Sequencing reactions were shown to be very successful by this method.
'Secondary bands' were observed with recycled templates if the DNA had not
been washed sufficiently after salvage.
From the DNA sequences generated from pUK721 by this method (Figure 3.13
page 123), two nucleotide bands at DNA residue number 692, corresponding to
adenine and cytosine were observed. This shows that both the codon for
Arg-164 (CGT) and Ser-164 (AGT) are present in the PCR-DNA. Relative
intensities of the two simultaneous bands were found to vary from
approximately equal to very faint A692 bands. No other anomalous adenine
bands were observed elsewhere in the DNA sequence. By separating the
adenine and cytosine lanes by at least one other nucleotide lane the possibility of
simultaneous bands resulting from leakage of reaction mixes between lanes was
eliminated. Control reactions using PCR-DNA generated from pATI53
exhibited no such duplicate bands over the same nucleotide sequence region.
This experiment has shown that both nucleotides, which separate b!aT-\ and
blaT-E2, are present on pUK721. My results suggest that TEM-E2 is the same
as TEM-12, both ofwhich would appear to vary from TEM-1 by a single amino




Figure 3.13: Results of the direct sequencing of PCR-products from
pUK721 using Dynabeads
The photographs of the autoradiographs are marked to show nucleotide position 692. From the
control sequencing reactions generated from pAT153 (right) only a single nucleotide (cytosine) was
observed at position 692. PCR-amplified DNA from pUK721 demonstrated simultaneous bands
(adenine & cytosine) at nucleotide position 692 which varied in band intensity from weak adenine
(left) to approximately equal (middle).
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6. The effect of plasmid copy number on the
MIC of P-lactam antimicrobial agents
The MICs of the P-lactam agents ampiciliin, amoxycillin, amoxycillin/clavulanic acid
(ratio 2:1), ceftazidime and cefotaxime were determined against a number of TEM-1
producing E. coli strains at three different inoculum sizes. Plasmid copy number per
chromosome varies from about one up to 100. Three inoculum sizes were used:
104 cfu/spot, 105 cfu/spot, and 106 cfu/spot. This experiment was carried out in order
to gauge the effect of the copy number of the plasmids that encode the TEM
P-lactamases upon the resistance of the host organism against the penicillins, 3GCs
and the penicillin/p-lactamase inhibitor combinations. The results of the antibiotic
susceptibilities of the organisms described in Table 3.11 are listed in Table 3.12
(page 125).
From Table 3.12 it can be seen that a decrease in inoculum size corresponds to a
decrease in MIC of the test antibiotic. In general, the decrease of inoculum size from
Plasmids Strain details
Name Size (kb) Copy No.4 Strain§ Source4
pUC8 2.7 50-100 JM108 SA1489
pUC18 2.7 50-100 JM83 SDB73
pAT153 3.7 30-60 TG1 SDB101
pBR322 4.4 -20 1009 SA473
R6K 39.9 -20 J53-2 SA471
R1 96.1 1-2 J62-2 SA17
Table 3.11: Details of plasmids & host organisms used to determine the
effect of copy number on the MIC of p-lactam antibiotics
4 Approximate copy number of plasmid per cell. § Strain of E. coli used as host organism for plasmid.
f Source of host organism (culture collection number: SA prefix refers to S.G.B. Amyes' culture
collection; SDB prefix refers to S.K. Du Bois' culture collection).
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106 cfu/ml to 104 cfu/ml only decreases the MIC of the antibiotic by a single dilution.
Susceptibilities of the host organisms to ampicillin and amoxycillin are approximately
equal for each organism tested. The addition of clavulanic acid to amoxycillin
(ratio 1:2 respectively) reduces the concentration of the penicillin required to inhibit
growth of the test organisms. Increase in the number of copies of each plasmid per
chromosome, hence a proportional rise in TEM-1 expressed, does not greatly affect
the MIC of the antibiotics examined. Increase in resistance to the 3GCs (ceftazidime
and cefotaxime) of organisms hosting high copy number plasmids (pUC8, pUC18) is
not vastly different from that of low copy number plasmids (R6K, Rl), in terms of
clinical resistance.
Plasmid Inoculum MIC (mg/l)
(cfu/spot) AMP AMX AMX/CLAV CAZ CTX
pUC8 106 >4096 >4096 32 0.5 0.125
105 >4096 >4096 16 0.5 0.063
104 >4096 >4096 16 0.25 0.063
pUC18 106 >4096 >512 32 0.5
105 3072 >512 32 0.25 N/D
to4 2048 512 16 0.063
pAT153 106 >6144 >6144 32 0.5 0.125
105 6144 5120 32 0.5 0.063
104 5120 4096 16 0.125 0.031
pBR322 106 >6144 >6144 32 0.25 0.063
105 5120 3072 16 0.25 0.031
104 4096 3072 16 0.125 0.031
R6K 106 >4096 >4096 16 0.125 0.063
105 2048 4096 16 0.125 0.031
104 2048 4096 16 0.063 0.031
R1 106 3072 3072 8 0.063 0.063
105 <512 512 8 <0.125 0.031
104 <512 512 8 <0.125 0.031
Table 3.12: The effect of plasmid copy number and inoculum on
P-lactam antibiotic susceptibility
Abbreviations: AMP, ampicillin; AMX, amoxycillin; AMX/CLAV, amoxycillin/clavulanic acid
(ratio 2:1); CAZ, ceftazidime; CTX, cefotaxime; N/D, not measured.
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7. The effect of "reverse" selective pressure
on the TEM-p-lactamases
Sowek et al. (1991) [241] described the effects of lysine substitution at amino acid
positions 104 and 240 and the substitution with serine at position 164 on the enzyme
TEM-lpTZ18R. Sowek and her colleagues found that if glutamic acid-104 or -240
were substituted with a lysine, in combination with a serine-164 substitution, the
resultant enzyme had enhanced cephalosporin hydrolysis and activity. The paper
describes a number of recombinant enzymes that are equivalent to clinically isolated
P-lactamases, namely TEM-10, TEM-12, TEM-17 and TEM-26. Analysis of the
enzymological data presented by Sowek et al. revealed some interesting features that
appear to have been ignored by the paper's authors. A summary of the relevant data is
given in Table 3.13 (page 127). The data have been arranged according to the
proposed inter-relationship of the TEM P-lactamases (Section 3.2 page 94 and Figure
3.6 page 98) in Figure 3.14 (page 128) and Figure 3.15 (page 129). The Michaelis
constant, Km, values (Figure 3.14) do not appear to show any clear trend from
TEM-1 to TEM-5 or TEM-9. It can be seen that Km for benzylpenicillin decreases,
hence affinity for the substrate increases. Michaelis constant values for the other two
substrates show a general increase, describing a lower affinity. Turnover number, kcat,
is a more sensitive gauge of enzyme efficiency. If the kcat values of each enzyme for
the three substrates are compared, (Figure 3.15) in relation to the proposed evolution
of the TEM P-lactamases, two trends are observed:
• Turnover numbers of the enzymes increase for the 3GCs with each additional
mutation away from the wild-type enzyme (TEM-1).
• As turnover number increases to the 3GCs, kcat decreases for benzylpenicillin.
This analysis of the data shows that selective pressure from a simple penicillin, for
example penicillin G, ampicillin or amoxycillin, may select out the back-mutations.
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Enzyme
TEM-1 TEM-10 TEM-12 TEM-17 TEM-26
Plasmid pTZ18R PRDD006 PRDD004 PRDD002 pRDD005
Amino acid: 104 Glu Glu Glu LYS LYS
164 Arg SER SER Arg SER
240 Glu LYS Glu Glu Glu
MIC (mg/l) PEN G >128 >128 >128 >128 >128
CAZ 0.25 32 2 0.25 64
CTX 0.03 0.25 0.03 0.03 0.25
Km (MM) PEN G vfl? 26 5.7 16 19 5.8
CAZ 80 190 260 150 150
CTX 450 32 230 470 84
kCat (sec"1) PEN G 520 17 54 370 32
CAZ 0.0016 17 3.4 0.067 57
CTX 0.25 0.39 2.4 2.5 2
l50 (nM)t CLAV 90 9.5 18 30 6.2
Table 3.13: Characteristics of the recombinant TEM-p-lactamases
described by Sowek ef al. (1991) [241].
* Enzyme and inhibitor incubated for 5 minutes at 25°C before the reaction was initiated by the
addition of cephaloridine to 1mM. Data from: Sowek et at. (1991) [241], Abbreviations: Arg, arginine;
CAZ, ceftazidime; CTX, cefotaxime; Glu, glutamic acid; Lys, lysine; PEN G, penicillin G; Ser, serine.
Amino acids annotated entirely in capital letters indicate the substituted residues in the mutant
enzymes. Numbering of amino acid residues according to the recommendations of Ambler et al.
(1991) [158]
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Figure 3.14: Comparison of the values of the Michaelis constant of
various TEM p-lactamases for three (3-lactam antibiotics
All values of Michaelis constant, Km, given in pmoles dm"3 (pM). Km values taken from
Sowek et al. [241]. Each arrow represents a single amino acid change facilitated by a single
nucleotide change in the p-lactamase gene. One letter amino acid notation according to the
IUPAC-IUB Commission on Nomenclature [237]: A, alanine; E, glutamic acid; K, lysine;
M, methionine; R, arginine; S, serine; T, threonine. Numbering of amino acid residues according to
the recommendations of Ambler et al. (1991) [158], Abbreviations: CAZ, ceftazidime; CTX,
cefotaxime; PEN G, penicillin G.
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Figure 3.15: Comparison of the turnover number of various TEM
P-lactamases for three p-lactam antibiotics
All values of turnover number, kcat, given in seconds"''. kca^ values taken from Sowek et al. [241].
Each arrow represents a single amino acid change facilitated by a single nucleotide change in the
P-lactamase gene. One letter amino acid notation according to the IUPAC-IUB Commission on
Nomenclature [237]: A, alanine; E, glutamic acid; K, lysine; M, methionine; R, arginine; S, serine;
T, threonine. Numbering of amino acid residues according to the recommendations of Ambler et al.
(1991) [158], Abbreviations: CAZ, ceftazidime; CTX, cefotaxime; PEN G, penicillin G.
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7.1. Enzyme kinetic analysis of the TEM-1, TEM-5, TEM-9,
TEM-10, TEM-12 & TEM-26 p-lactamases
The enzyme kinetics of the TEM-1R1, TEM-5pGFFl4> TEM-9pMG228,
TEM-10pjpQjoo, TEM-12 and TEM-26pjpq[oi P-lactamases were determined in
order to confirm the observations of Sowek et al. [241] and to analyse the
properties of the terminus enzymes (TEM-5 and TEM-9).
The maximum velocity of hydrolysis, Vmax, and the Michaelis constant, Km, were
determined for the substrates nitrocefin, penicillin G, ceftazidime and cefotaxime.
A summary of the results of each kinetic analysis is given in Table 3 .14 (page 131).
The (3-lactamase TEM-17 was not available for analysis. All data were determined
on the Perkin-Elmer UV/Vis 554 Spectrophotometer with partially purified enzyme
preparations (see Chapter 2). In general, the experimental results support the data
presented by Sowek et al. [241] (Table 3.13 page 127). Figures 3.16 (page 132)
and 3.17 (page 133) show the Michaelis constant and enzyme efficiency
(Vmax/Km) data in the context of the evolutionary relationships of the
TEM-derived P-lactamases. The Km values appear to show that enzyme affinity
for the substrate increases with additional ESBL mutations. Vmax values, and
therefore Vmax/Km values, for the enzymes analysed are less comparable because
of the values' dependence on enzyme concentration. Maximum velocity is a linear
function of turnover number (kcat), therefore, when compared to other data
obtained from the same enzyme preparation, it gives an indication of rate of
substrate turnover. The relative Vmax values, given in Table 3.14, infer that
substrate turnover of penicillin G decreases with improvement of 3GC turnover.
This trend is confirmed if the enzyme efficiency values (Vniax/Km) are compared.
Clavulanic acid resistant variants of the TEM p-lactamases have been described
[242, 243], and have been shown to be derived from TEM-1 by one or two
nucleotide mutations resulting in the substitution of amino acids at residue numbers
69 and 244 [243], Thomson & Amyes had successfully used 'reverse' selective
pressure, with ampicillin, to revert TRC-1 to TEM-1 [244], This work
demonstrated that selective pressure can reverse TEM P-lactamase mutations, even
in an extreme example such as this. The clavulanic acid resistance mutation












TEM-1 TEM-5 TEM-9 TEM-10 TEM-12 TEM-26
R1 pCFF14 pMG228 pJPQ100 - pJPQ101
104 Glu Glu LYS Glu Glu LYS
164 Arg SER SER SER SER SER
237 Ala THR Ala Ala Ala Ala
240 Glu LYS Glu LYS Glu Glu
265 Thr Thr MET Thr Thr Thr
PEN G 72 56 19 65 89 36
NCFN 7.7 43 162 31 2.8 31
CAZ UM 40 298 363 167 452
CTX UM 55 107 9.9 971 20
PEN G 935 130 11.7 210 3179 116
NCFN 100 100 100 100 100 100
CAZ - 93 184 1171 5964 1458
CTX - 128 64 32 34679 155
)*PEN G 11 4.7 81 2.3 115 3.6
NCFN 50 13 7.6 2.2 5.3 2.0
CAZ UM 8.7 24 4.3 0.24 3.4
CTX UM 2.5 3.1 0.06 0.13 0.06
PEN G 22.0 36 1066 105 2170 1.8
NCFN 100 100 100 100 100 100
CAZ - 67 316 195 4.5 170
CTX - 19 41 2.7 2.5 3.0
PEN G 0.16 0.084 0.50 0.036 1.9 0.099
NCFN 6.5 0.31 0.40 0.075 1.3 0.064
CAZ - 0.22 0.080 0.012 0.001 0.008
CTX - 0.046 0.029 0.006 0.0001 0.003
,§ PEN G 2.5 27 125 48 146 155
NCFN 100 100 100 100 100 100
CAZ - 71 20 16 0.08 12
CTX - 15 7.3 8.0 0.008 4.7
Table 3.14: Biochemical characteristics of the (3-lactamases TEM-1,
TEM-5, TEM-9, TEM-10, TEM-12 & TEM-26.
Abbreviations: Ala, alanine: Arg, arginine; CAZ, ceftazidime; CTX, cefotaxime; Glu, glutamic acid;
Lys, lysine; Met, methionine; NCFN, nitrocefin; PEN G, penicillin G; Ser, serine; Thr, threonine;
UM, unmeasurable. § All values relative to nitrocefin (100%). t Vmax values given as pmoles per
minute, per ml of enzyme preparation. Amino acids annotated entirely in capital letters indicate the
substituted residues in the mutant enzymes. Numbering of amino acid residues according to the
recommendations of Ambler et at. (1991) [158]
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Figure 3.16: Comparison of the Michaelis constant values of the TEM-1,
TEM-5, TEM-9, TEM-10, TEM-12 & TEM-26 (^-lactamases.
All values of the Km given in |jmoles dm"3 (pM). Each arrow represents a single amino acid change
facilitated by a single nucleotide change in the p-lactamase gene. One letter amino acid notation
according to the IUPAC-IUB Commission on Nomenclature [237]: A, alanine; E, glutamic acid; K,
lysine; M, methionine; R, arginine; S, serine; T, threonine. Numbering of amino acid residues
according to the recommendations of Ambler et al. (1991) [158], Abbreviations: CA2, ceftazidime;















PEN G = 0.036 PEN G = 0.099
NCFN = 0.075 NCFN = 0.064
CAZ = 0.012 CAZ = 0.008
CTX = 0.006 CTX = 0.003
^A237T [r265M
TEM-5 TEM-9
PEN G = 0.084 PEN G = 0.50
NCFN = 0.31 NCFN = 0.40
CAZ = 0.22 CAZ = 0.080
CTX = 0.046 CTX = 0.029
Figure 3.17: Comparison of the enzyme efficiency of the TEM-1, TEM-5,
TEM-9, TEM-10, TEM-12 & TEM-26 0-lactamases.
All values of the enzyme efficiency, Vmax/Km, given in dm3 minute"1 per ml of enzyme preparation.
Each arrow represents a single amino acid change facilitated by a single nucleotide change in the
P-lactamase gene. One letter amino acid notation according to the IUPAC-IUB Commission on
Nomenclature [237]: A, alanine; E, glutamic acid; K, lysine; M, methionine; R, arginine; S, serine; T,
threonine. Numbering of amino acid residues according to the recommendations of Ambler et al.
(1991) [158], Abbreviations: CAZ, ceftazidime; CTX, cefotaxime; NCFN, nitrocefin; PENG,
penicillin G; UM, unmeasurable.
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7.2. Application of selective pressure with ampicillin
From the analysis of the data obtained from the results of Sowek et a/. [241], my
own enzyme kinetic analysis and the results of Thomson & Ajnyes [244], the
application of 'reverse' selective pressure with a broad-spectrum penicillin would
theoretically promote back-mutations of an ESBL in a suitable host organism.
Employing a method for the continuous sub-culturing of a TEM P-lactamase
expressing E. coli, based upon that described by Thomson & Amyes [244] a
strategy was designed for a passage experiment. E. coli J62-2 harbouring the
141 -kb clinical plasmid pCFF14 encoding the TEM-5 P-lactamase was the ESBL
Enzyme Plasmid E. coli MIC (mg/l)§
Strain AMP AMX AMX/CLAV CAZ CTX
TEM-1 R1 J62-2 2048 1024 8 0.125 0.0313
TEM-12 - MG32 3072 3072 16 8 0.25
TEM-10 pJPQIOO J53-2 4096 4096 16 64 0.5
TEM-5 pCFF14 J62-2 1024 1024 8 16* 1
TEM-3 pCFF04 J62-2 2048 - - 64 8*
TEM-6 pMG226 J62-2 2048 !1|Ih|!1|: - 64 1*
TEM-9 pMG228 J62-2 2048 - - 128 2*
TEM-E2 pUK721 J53-2 5120 3072 16 16 0.25
Table 3.15: Antibiotic susceptibility of selected TEM p-lactamases.
Abbreviations: AMP, ampicillin; AMX, amoxycillin; AMX/CLAV, amoxycillin/clavulanic acid (ratio 2:1);
CAZ, ceftazidime; CTX, cefotaxime. § Inoculum of 104cfu/spot for each test organism. * The MIC
values determined against E. coli J62-2 (pCFF 14) throughout this work were consisitently atypical
compared with other workers results (usually the MIC of CAZ = 64mg/l [184]), for the purposes of the
Discussion (Chapter 4) the higher value is assummed to be the correct value. * The MIC values of
cefotaxime were not determined but the values given are taken from published sources for the
purposes of comparison: TEM-3 [183], TEM-6 [185], and TEM-9 [187],
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chosen for use in the experiment.
The antibiotic susceptibility of host organisms expressing the TEM-1 and TEM-5
P-lactamase and the intermediate enzymes TEM-10 and TEM-12 were determined
together with a number of other ESBL expressing organisms (Table 3.15). MICs
were used to ascertain variations in levels of resistance to penicillins and the 3GCs
together with penicillin/p-lactamase inhibitor combinations. The antibiotic
susceptibilities show that ceftazidime and cefotaxime MICs increase in the series
TEM-1—>TEM-12—»TEM-10->TEM-5. No similar trend was observed for the
susceptibility to ampicillin, amoxycillin or amoxycillin/clavulanic acid.
Passage experiment methodology
The passage experiment methodology was a modification of that described by
Thomson & Amyes [244]: E. coli J62-2 (TEM-5pCFF14) was cultured in three
separate 100ml aliquots of liquid media (1ST broth) containing no antibiotic
(Omg/1), 1024mg/l ampicillin and 2048mg/l ampicillin respectively. The cultures
were incubated overnight at 37°C in an orbital shaker. After incubation lOOpl of
each was subcultured into a freshly prepared 100ml aliquot of liquid media
containing the same antibiotic concentration (i.e. containing 0mg/l, 1024mg/l
and 2048mg/l ampicillin respectively). The overnight cultures were subcultured
into fresh media a total of five times (five days). Twelve colonies were purified
from each subculture on each day of the passage.
The MICs of ampicillin, ceftazidime and cefotaxime were ascertained according
to the BSAC guidelines [196] as described in Chapter 2.
IEF, employing broad-range carrier ampholytes (pH 3.5-10), was used to
examine a selection of the P-lactamases produced.
Ampicillin passage experiment results
One hundred & eighty strains were purified from the ampicillin passage
experiment. Each strain was checked for lactose utilisation, rifampicin resistance
and histidine auxotrophy to confirm that each strain was E. coli J62-2. One
hundred of the 180 purified strains were tested for antibiotic susceptibilities
together with strains expressing TEM-1R1, TEM-12, TEM-10pjpQ10o, and
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TEM-5pCppj4. A summary of the MIC results are given in Table 3.16 (page
137). Figure 3.18 (page 138) shows a plot of average MIC of the purified
colonies against the day of isolation, to demonstrate the drift of both ampicillin
and ceftazidime resistance under selective pressure. Under no selective pressure
the MICs of both ampicillin and ceftazidime remained constant, no decrease was
observed. Both the 1024mg/l ampicillin and 2048mg/l ampicillin passage
experiments show a general increase of the MICs of both ampicillin and
ceftazidime over the five days.
A number of the strains for which the ampicillin and ceftazidime MICs had been
determined were selected for more detailed examination. MICs of ampicillin,
amoxycillin, amoxycillin/clavulanic acid (ratio 2:1), ceftazidime and cefotaxime
were then determined (see Table 3.17 page 139). The isoelectric points of the
enzymes produced by the nine strains were identified from crude (3-lactamase
preparations. All strains were found to produce only a single enzyme of pi 5.5
that aligned perfectly with the single focused band of TEM-5pCFFi4
(Table 3.17). The isoelectric points of TEM-5 and the nine strains were
different from that of TEM-10pJpQ100 (pi 5.57), TEM-12 (pi 5.25) and
TEM-1R1 (pi 5.4).
Concluding remarks
No (S-lactamase mutations were observed to have been selected by the
ampicillin passage experiment on the basis of isoelectric points and antibiotic
susceptibility profiles. The increase in the MIC of the f3-lactam antibiotics tested
for the strains examined were presumed to have resulted in reduced penetration
of the drugs into the cell because of OMP changes. The OMPs of the purified
strains were not examined.
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Ampicillin No. of strains MIC (mg/l)§
Concentration* AMP CAZ
Omg/I 30 <1000 16















Table 3.16: Changes in ampicillin & ceftazidime MICs observed in the
ampicillin passage experiment.
Abbreviations: AMP, ampicillin; CAZ, ceftazidime, * Concentration of antibiotic used in passage
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-A- 1024mg/l ampicillin
2048mg/l ampicillin
Figure 3.18: Changes in ampicillin & ceftazidime MICs observed in the
ampicillin passage experiment.
The mean MIC (mg/l) of ampicillin and ceftazidime for the purified colonies isolated was plotted on a










Omg/I 3 0/27 5.5 512 1024 8 8 1
1024mg/l 1 1024/11 5.5 2048 2048 16 >64 4
2 1024/23 5.5 2048 2048 8 >64 4
3 1024/27 5.5 2048 2048 16 >64 4
2048mg/l 2 2048/25 5.5 3072 3072 16 >64 8
3 2048/36 5.5 3072 3072 16 >64 8
4 2048/41 5.5 3072 3072 16 >64 8
5 2048/55 5.5 4096 3072 16 64 8
5 2048/57 5.5 2048 3072 16 >64 8
Controls:
TEM-1R1 5.4 2048 1024 8 0.125 0.0313
TEM-12 5.25 3072 3072 16 8 0.25
TEM-10dJpq1oo 5.57 4096 6144 16 >64 0.5
TEM-5pcFFl4 5.5 512 1024 8 16 1
Table 3.17: MIC profiles of nine ampicillin passage experiment strains.
i Concentration of antibiotic used in passage experiment. § Inoculum of 10^ cfu/spot for each test
organism. Abbreviations: AMP, ampicillin; AMX, amoxycillin; AMX/CLAV, amoxycillin/clavulanic acid
(ratio 2:1); CAZ, ceftazidime; CTX, cefotaxime; pi, isoelectric point.
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7.3. The effect of clavulanic acid on the ESBL.
The effect of ampicillin upon the ESBL TEM-5 did not promote back mutations as
expected from the study of the enzyme kinetic data. Comparison of the
concentrations of the P-lactamase inhibitor clavulanic acid required to inhibit 50%
of enzyme activity, I50 values, (with cephaloridine as the substrate) [241],
demonstrated a rise in susceptibility proportional to the number of amino acid
substitutions present in each ESBL (see Table 3.13 page 127). Study of the I50
values of clavulanic acid for the enzymes TEM-1, TEM-5, TEM-9, TEM-10,
TEM-12, and TEM-26, in the presence of penicillin G, revealed a similar trend (see
Table 3.18 page 141 and Figure 3.19 page 142). I5q values for clavulanic acid were
determined by incubating the enzyme and inhibitor for 5 minutes at 37°C before the
reaction was initiated by the addition of penicillin G to a final concentration of
ImM. Successive sub-cultures of an ESBL expressing organism in the presence of
clavulanic acid and amoxycillin were then investigated. The selective pressure
exerted by a competitive and progressive P-lactamase inhibitor, such as clavulanic
acid, when combined with a broad-spectrum penicillin was suspected to be far
greater than that exerted by a broad-spectrum penicillin alone.
Passage experiment methodology
The methodology employed was the same as that described for the ampicillin
passage experiment, except for the application of selective pressure with
amoxycillin in combination with clavulanic acid (2:1 ratio). E. coli J62-2
(TEM-5pCFF]4) was cultured in liquid media at four different
amoxycillin/clavulanic acid (co-amoxiclav) concentrations: no antibiotic (Omg/1),
4mg/l co-amoxiclav, 8mg/l co-amoxiclav and 16mg/l co-amoxiclav respectively.
All concentrations of co-amoxiclav were expressed in terms of the amoxycillin
concentration within the combination. Cultures were subcultured into liquid
media containing the same antibiotic concentration, if bacterial growth was
observed. The overnight cultures were subcultured into fresh media five times
after incubation at 37°C. Ten colonies were purified from each subculture on
each day of the passage.
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Enzyme
TEM-1 TEM-5 TEM-9 TEM-10 TEM-12 TEM-26
Plasmid R1 pCFF14 pMG228 pJPQIOO - PJPQ101
Amino acid; 104 Glu Glu LYS Glu Glu LYS
164 Arg SER SER SER SER SER
237 Ala THR Ala Ala Ala Ala
240 Glu LYS Glu LYS Glu Glu
265 Thr Thr MET Thr Thr Thr
Iso
Clav/1mM Pen G 3.6 1.2 0.38 2.3 2.9 1.1
Table 3.18: l50 values for clavulanic acid of the selected TEM
P-lactamases.
Abbreviations: Ala, alanine; Arg, arginine; Clav, clavulanic acid; Glu, glutamic acid; Lys, lysine; Met,
methionine; PEN G, penicillin G; Ser, serine; Thr, threonine. * Enzyme and inhibitor incubated for
5 minutes at 37°C before the reaction was initiated by the addition of penicillin G to 1mM. Amino
acids annotated entirely in capital letters indicate the substituted residues in the mutant enzymes.
Numbering of amino acid residues according to the recommendations of Ambler et al. (1991) [158]
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Figure 3.19: Comparison of the i50 values for clavulanic acid of the
TEM-1, TEM-5, TEM-9, TEM-10, TEM-12 & TEM-26 p-lactamases.
All l50 values are given in |jmoles dm"3 (|jM) and were measured by incubating the enzyme and
various concentrations of clavulanic acid for 5 minutes at 37°C, before adding penicillin G (to 1mM).
Each arrow represents a single amino acid change facilitated by a single nucleotide change in the
P-lactamase gene. One letter amino acid notation according to the IUPAC-IUB Commission on
Nomenclature [237]: A, alanine; E, glutamic acid; K, lysine; M, methionine; R, arginine; S, serine; T,
threonine. Numbering of amino acid residues according to the recommendations of Ambler et at.
(1991) [158],
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MICs of ampicillin, amoxycillin, ceftazidime, cefotaxime and
amoxycillin/clavulanic acid were ascertained. IEF employing a broad-range
mixture of carrier ampholytes (pH 3.5-10 and pH 4-6) was used to examine a
selection of the (3-lactamases produced. (3-Lactamase activity and the effect of
clavulanic acid inhibition were determined by spectrophotometric assays.
The method of Takahashi & Nagano [213] (described in Chapter 2) was used to
extract and visualise the plasmid DNA of those strains examined by IEF. The
plasmid DNA was also digested with a number of restriction endonucleases,
none of which cut within the TEM [3-lactamase ORF. Southern blots were
prepared and were subsequently analysed by hybridisation with a non-
radioactively (biotin) labelled ^T-lpAT153 probe.
CO-AMOXICLAV PASSAGE RESULTS
The inoculum in 1ST broth containing 16mg/l co-amoxiclav failed to grow after
the first overnight incubation and was therefore discontinued. One hundred &
fifty strains were purified from the ampicillin passage experiment. Each strain
was checked for lactose utilisation, rifampicin resistance, and histidine
auxotrophy to confirm that each strain was an E. coli J62-2. Sixty-seven of the
150 purified strains (15 from the Omg/1 co-amoxiclav passage, 25 from the
4mg/l co-amoxiclav passage and 27 from the 8mg/l co-amoxiclav passage) were
tested for susceptibility to ampicillin, amoxycillin, co-amoxiclav, ceftazidime
and cefotaxime, together with strains expressing TEM-1R1, TEM-12,
TEM-lOpjpQjoo, and TEM-Sp^pp^. A summary of the MIC results is given in
Table 3.19 (page 144) together with graphical representations of the observed
change in antibiotic susceptibilities in Figures 3.20, 3.21 & 3.22
(pages 145-147).
A selection of the strains identified with anomalous antibiotic susceptibilities,
together with a selection of strains with 'modal' MIC results from each of the
three antibiotic concentration groups of the passage experiment, were analysed
by IEF to identify any abnormalities in [3-lactamase band focusing.
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Co-amoxiclav No. of MIC (mg/l)§
Cone.* strains AMP AMX AMX/CLAV CAZ CTX
Omg/I 14 <256 1024 8 8 0.5
1 <256 1024 8 16 0.5
4mg/l 1 <256 1024 4 16 0.5
4 <256 1024 8 16 0.5
4 512 1024 8 16 1
12 512 2048 8 32 0.5
1 512 2048 8 32 1
2 1024 2048 8 32 1
It 2048 2048 8 64 2
8mg/l 15 512 2048 16 32 4
1 1024 2048 16 64 2
1 1024 2048 16 64 4
2 1024 2048 16 64 8
1 1024 2048 16 128 4
4 2048 2048 16 128 8
2 2048 3072 16 128 16
1* 3072 3072 4 >128 8
Controls:
TEM-1R1 1024 2048 8 <0.0625 0.006
TEM-12 5120 4096 16 16 0.125
TEM-10pJpQ100 3072 5120 8 64 0.5
TEM-5pcFFi4 512 2048 8 16 0.5
Table 3.19: Changes in antibiotic susceptibilities observed in the
co-amoxiclav passage experiment.
t Concentration of antibiotic used in passage experiment. § Inoculum of 104 cfu/spot for each test
organism, t E. coli J62-2 strain no. 4/10. * E. coli J62-2 strain no. 8/8. Abbreviations: AMP, ampicillin;








Figure 3.20: Changes in ampicillin & amoxycillin MICs observed in the
co-amoxiclav passage experiment.
The mean MIC (mg/l) of ampicillin and amoxycillin for the purified colonies isolated plotted on a daily
basis from the co-amoxiclav passage experiment. Time expressed in days from first inoculation.
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Figure 3.21: Changes in co-amoxiclav & ceftazidime MICs observed in
the co-amoxiclav passage experiment.
The mean MIC (mg/l) of co-amoxiclav and ceftazidime for the purified colonies isolated plotted on a
daily basis from the co-amoxiclav passage experiment. Time expressed in days from first inoculation.
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Figure 3.22: Changes in cefotaxime MIC observed in the co-amoxiclav
passage experiment
The mean MIC (mg/l) of cefotaxime for the purified colonies isolated plotted on a daily basis from the
co-amoxiclav passage experiment. Time expressed in days from first inoculation.
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Some of the nine strains examined demonstrated multiple bands of P-lactamase
activity after visualisation of the IEF gel, compared with the single band (pi 5.5)
obtained from a preparation of TEM-5pCpp14 (Figure 3.23 page 149). Two
strains (numbers 4/10 and 8/8) were selected for more detailed analysis: each of
the two strains exhibited two bands in addition to a band that focused at exactly
the same point as that of TEM-5pCppj4; one of pi 5.25 and one of pi 5.57.
These two additional bands focused at the same isoelectric point as the focused
bands of TEM-10pCpF14 (pi 5.57) and TEM-12 (pi 5.25). Both strains
exhibited strong pi 5.5 and 5.25 bands, however, strain number 8/8 exhibited a
strong pi 5.57 band and strain number 4/10 showed a weak pi 5.57 band.
The graphs obtained from the results of the co-amoxiclav passage experiment
(see Figures 3.20, 3.21 & 3.22) show that the MICs of the antibiotics tested
changed in a similar manner to that observed during the ampicillin passage
experiment. In general, the antibiotic susceptibilities increased with time after
challenge with either 4mg/l or 8mg/l co-amoxiclav. The control experiment
(Omg/1 co-amoxiclav) did not raise the MIC of any of the antibiotics tested.
Analysis of E. coli J62-2 strain numbers 4/10 & 8/8
The plasmid DNA from strain number 4/10 and strain number 8/8 was isolated
and visualised by agarose gel electrophoresis, and compared with plasmid DNA
from the parent strain, E. coli J62-2 (pCFF14). Each of the strains examined
was shown to contain a single plasmid ~141-kb in size. The plasmid DNA of
strain numbers 4/10 and 8/8 was then compared to pCFF14 by restriction
analysis (Figure 3.24 page 151) with a variety of restriction endonucleases that
did not have recognition sites within the blal gene. Plasmid DNA from strain
numbers 4/10 and 8/8 were found to have identical restriction patterns for all
the restriction endonucleases used in the analysis. Comparison of the restriction
patterns of pCFF14 with that of the plasmids isolated from the mutant strains
revealed an additional EcoR I restriction fragment, about 25-30-kb in size.
Additional bands were also observed when the plasmid DNA of strain
numbers 4/10 and 8/8 were restricted with other restriction endonucleases.
Apart from the additional bands, restriction patterns of pCFF14 and the mutant
plasmids were identical.
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Figure 3.23: IEF gel showing the TEM-fype p-lactamases from
co-amoxiclav passage experiment.
The IEF gel contained carrier ampholytes pH range 4-6. Crude extracts of test organisms
were prepared, and isoelectric points of the enzymes produced by each strain determined by
comparison with preparations of enzymes of known pi. Standard p-lactamases shown
include TEM-1 (pi 5.4), TEM-5 (pi 5.5), TEM-10 (pi 5.57), and TEM-12 (pi 5.25). The TEM-12
preparation also exhibits a TEM-1 band. The pi 5.25 bands present in the enzyme
preparations in this figure were shown to be satellite bands by repeated IEF experiments
except in the TEM-12 preparation and the extracts of strain numbers 4/10 and 8/8.
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The results of the plasmid DNA analysis suggested that the mutant plasmid was
closely related to pCFF14 and was designated pUK3007.
Southern blotting and hybridisation (Figure 3.25 page 152) of the restricted
DNA fragments using a 900-bp biotin-labelled probe generated by PCR from
Z>/tfT-lpAT153, revealed that pCFF14 encoded a single TEM P-lactamase gene;
however, pUK3007 encoded two TEM P-lactamase genes. One of the blaT
genes of pUK3007 was always observed on the same restriction fragment as the
single blaT-5 gene of pCFF14. The second blaT gene from pUK3007 was
present on the additional 25-30-kb restriction fragment of the EcoR I digest.
The second blaT gene of pUK3007 was always found to be present on one of
the additional bands from the other restriction digests.
Kinetic analysis of mutant P-lactamases
The kinetic profiles of the mutant strains' P-lactamases were studied with the
Perkin-Elmer UV/Vis 554 Spectrophotometer. The Km and Vmax values of the
partially purified mixed enzyme preparations were determined for the substrates
penicillin G, nitrocefin, ceftazidime and cefotaxime and the I50 value for
clavulanic acid in the presence of penicillin G. The three enzymes from partially
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Figure 3.24: Restriction analysis comparing pCFF14 & pUK3007
The parent plasmid pCFF14 (141-kb) and the mutant plasmid pUK3007 (~170-kb) were digested with
the restriction endonucleases A/f II, BamH I, Bgl II, EcoR I and Hind III. X DNA digested with Hind III
was used as molecular weight markers. pAT153 was digested with EcoR I and EcoR \IAIf II as a
control restriction experiments. Identical mutant plasmids, designated pUK3007, were isolated from
strain numbers 4/10 and 8/8. The pCFF14/EcoR I digest was compared to that published by Chanal























Figure 3.25: Southern blot of the restriction analysis comparing pCFF14
& pUK3007
Southern transfer of restriction endonuclease digested plasmid DNA (see Figure 3.24 page 151) was
probed with a PCR-generated biotin labelled 900-bp WaT-1pAT153 fragment to reveal the DNA
fragments encoding TEM p-lactamases genes. Digested pAT153 DNA as used as a positive control.
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The three separated enzyme bands (pi 5.57, 5.5, and 5.25) were then used to
determine the kinetic profiles of each of the enzymes for the substrates
benzylpenicillin, nitrocefin, ceftazidime and cefotaxime, together with the
concentration of clavulanic acid required to inhibit 50% of enzyme activity with
penicillin G as the substrate. A summary of the kinetic analysis to the collective
enzymes and the individual enzymes is given in Table 3.20 (page 155). Each of
the separated enzyme preparations show kinetics comparable with known
P-lactamases. These results suggest that the three enzymes encoded by strain
numbers 4/10 and 8/8 were TEM-12, TEM-5 and TEM-10 respectively. The
Km of the pi 5.25 enzyme for the substrate cefotaxime was unmeasurable
because of the exceptionally low Vmax value obtained from the pure
preparation. The partially pure preparation of the pUK3007 P-lactamases
(containing the three enzymes) possessed a much broader spectrum of activity
than any of the individual enzymes. The I50 value for the combined pUK3007
enzymes (2.2pM) is approximately equivalent to the mean of the I50 values for
clavulanic acid of the three separated P-lactamases (2.8pM).
Direct DNA sequencing of PCR-amplified DNA with Dynabeads
The method developed for the sequencing of the blaT genes of pUK721 (see
under Section 5.6 page 120) was employed to obtain DNA sequences from the
pUK3007 encoded blaT genes. The target DNA was amplified by the PCR
reaction with one biotinylated PCR-primer (Biotin-Bla-4') and one non-labelled
PCR primer (Bla-31). The double-stranded PCR-product was immobilised on
Dynabeads M-280 Streptavidin and the non-biotinylated amplimer was eluted to
provide a single-stranded DNA sequencing template. The template DNA from a
single PCR reaction was re-used after salvage from each sequencing reaction
mixture prior to loading onto the polyacrylamide gel for electrophoresis. Re-use
of the template required stringent denaturation and washing steps to remove all
of the radiolabeled sequencing reaction products. Sequencing reaction products
were separated by polyacrylamide gel electrophoresis, and the dried gels
autoradiographed for -12 hours. From the sequences generated from pUK3007
samples by this method, two duplicate bands were observed (Figure 3.26
page 156):
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a) Two nucleotide bands were observed at position 1001 corresponding to
both guanine and adenine.
b) Two nucleotide bands, guanine and adenine, were present at position
1007.
This shows that the codons for Ala-237 (GCC), Thr-237 (ACC), Glu-240
(GAG) and Lys-240 (AAG) were present in the PCR-DNA. No other duplicate
bands were observed at positions simultaneous to other nucleotide bands at
other points in the PCR-generated blal genes from pUK3007. Simultaneous
bands resulting from leakage of reaction mixes between lanes of the sequencing
gel were, therefore, not a possibility. Control reactions using PCR-DNA
generated from pBR322 exhibited no such duplicate bands over the same
nucleotide sequence regions.
This experiment has shown that the bid! genes encoded by the pUK3007
plasmid(s) encode all the nucleotide changes observed in the TEM-12-^
TEM-10-»TEM-5 p-lactamase series. The presence of the wild-type (TEM-5)
genotype, together with the TEM-12 and TEM-10 genotypes, confirm the
observations from the IEF and kinetic analyses that the three P-lactamase bands
signify the presence of TEM-12, TEM-10 and TEM-5 in E. coli J62-2 Strain
numbers 4/10 and 8/8.
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Enzyme(s)





Source plasmid: pUK3007 pUK3007 pUK3007 pUK3007
Km (pM) PEN G 45 182 314 189
NCFN 26 43 12 20
CAZ 491 281 80 359
CTX 37 UM 28 19
Relative Km§ PEN G 173 423 2600 945
NCFN 100 100 100 100
CAZ 1888 653 669 1795
CTX 142 - 232 95
vmax (Mmo1 mirr1)* PEN G 7.4 0.21 0.53 0.55
NCFN 19 2.2 0.92 0.61
CAZ 17 0.33 0.50 0.37
CTX 2.8 0.066 0.39 0.08
Relative Vmax§ PEN G 39 9.5 58 90
NCFN 100 100 100 100
CAZ 89 15 54 61
CTX 15 3.0 42 13
^max PEN G 0.16 0.001 0.002 0.003
NCFN 0.74 0.05 0.08 0.03
CAZ 0.04 0.001 0.006 0.01
CTX 0.07 - 0.01 0.004
Relative Vmax/Km§ PENG 22 20 2.6 9.6
NCFN 100 100 100 100
CAZ 5.4 20 7.7 33
CTX 9.5 - 17 13
l50 G^: Clav 2.2 4.5 1.9 2.0
Table 3.20: Enzyme kinetics of the p-lactamases encoded by pUK3007.
§ All values relative to nitrocefin (100%). * Vmax values given as pmoles per minute, per ml of
enzyme preparation, t Enzyme and inhibitor (clavulanic acid) incubated for 5 minutes at 37°C before
the reaction was initiated by the addition of penicillin G to 1mM. Abbreviations: CAZ, ceftazidime;
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Figure 3.26: Results of the direct sequencing of PCR-products from
pUK3007 using Dynabeads
The photographs of the autoradiographs are marked to show nucleotide position 1001 and 1007.
PCR-amplified DNAfrom pUK3007 demonstrated simultaneous bands (guanine & adenine) at
nucleotide position 1001 and 1007.
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7.4. The effect of further "reverse" selective pressure on
E. COLI J62-2 (pUK3007).
The back-mutation of the TEM-5 ESBL to the intermediate ESBL, TEM-10 and
TEM-12, suggested the following hypothesis: continued sub-culture of the
pUK3007 harbouring strains under the selective pressure of co-amoxiclav would
select out plasmids encoding blaT-\ in preference to plasmids encoding ESBL.
In order to test this hypothesis a further passage experiment was designed. The
passage would follow the same design as the previous two passage experiments
(Sections 7.2 page 134 & Section 7.3 page 140). Modifications to the
methodology were as follows:
a) E. coli J62-2 (pCFF14) and E. coli J62-2 strain number 8/8 (pUK3007) were
sub-cultured simultaneously.
b) each strain was successively sub-cultured into 5ml liquid media (1ST broth)
containing no antibiotic (control), 512mg/l ampicillin, or 8mg/l co-amoxiclav 20
times (20 days).
c) a loopful of each overnight culture was used to inoculate fresh media containing
the required concentration of antibiotic.
d) ten colonies were purified from sub-cultures on days 5, 10, 15 and 20 and
checked for the lac his Rif R phenotype.
e) The MICs of ampicillin, co-amoxiclav and ceftazidime were determined for 96
of the 240 purified strains, together with selected control strains (a summary of
the antibiotic susceptibilities is given in Table 3.21 and in Figures 3.27, 3.28 &
3.29 on pages 159-162).
Seven strains were selected from the 96 strains, which had had their antibiotic
susceptibilities determined, for determination of the P-lactamase isoelectric points
by analytical IEF (Figure 3.30 page 163). Each of the seven strains exhibited a
single strong P-lactamase band with satellite bands of various pi values. Five of the
seven strains exhibited a strong enzyme band of pi 5.5 (identical to the pi of
TEM-5). Two of the seven strains (strain numbers 4.43 & 5.31) exhibited a strong
enzyme band of pi 5.4 (identical to the pi of TEM-1). Some of the satellite bands
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of the strains studied corresponded to the isoelectric points of TEM-10 (pi 5.57),
TEM-5 (pi 5.5) and TEM-1 (pi 5.4). No enzyme bands of equivalent pi to that of
TEM-12 were observed.
Analysis of selected E. coli J62-2 strains
The plasmid DNA of several selected strains were isolated and visualised by
agarose gel electrophoresis, and compared to plasmid DNA from the parent
strains (E. coli J62-2 (pCFF14) and E. coli J62-2 (pUK3007)). Each of the
strains examined were shown to contain a single plasmid. The plasmid DNA of
various strains were then compared to pCFF14 and pUK3007 by restriction
analysis (Figure 3.31 page 164) with the restriction endonucleases Bgl II which
has no recognition site within the blctY ORF. Digestion with the restriction
enzyme Bgl II provided maximum separation of the duplicate bid! genes of
pUK3007 (see Figure 3.25 page 152). Plasmid DNA from the selected strains
were found to have similar restriction patterns to pCFF14 and pUK3007.
Southern blotting and hybridisation (Figure 3.32 page 165) of the restricted
DNA fragments using a 900-bp biotin-labelled probe, generated by PCR from
Z>/aT-lpATi53, revealed that each mutant plasmid encoded either one or two
TEM p-lactamase genes. One of the mutant TEM-1 producing strains (Strain
number 4.43) encoded only a single TEM P-lactamase gene; whereas strain
number 5.31 encoded two blciT genes. The blaT probe hybridised with
additional bands that were present, as a result of incomplete restriction of the
plasmid DNA.
A summary of the origin, antimicrobial susceptibilities, isolectric points of
enzymes and results of the probing of the Southern transfer, for each of the






No. of MIC (mg/l)§
strains AMP AMX/CLAV CAZ
pCFF14 6 <256 8 0.25
4 <256 8 8
5 <256 8 16
1 512 8 16
pUK3007 8 <256 8 0.25
1 <256 8 0.5
1 <256 8 16
1 <256 8 64
512 8 64
1 1024 16 >64
1 2048 8 64
1 2048 64 >64
pCFF14 2048 8 64




9 4096 16 >64
pUK3007 4 2048 8 >64
4 4096 16 64
8 4096 16 >64
pCFF14 2 <256 8 0.25
4 2048 8 64
4 2048 16 >64
4 2048 32 >64
2 4096 32 >64
pUK3007 3 <256 8 0.25
3 2048 8 >64
5 2048 16 64
1 2048 16 >64
2 2048 32 64
1 4096 32 64
1 4096 32 >64
Omg/I
Controls:












Table 3.21: Changes in antibiotic susceptibilities observed in the
ampicillin/co-amoxiclav passage experiment.
t Antibiotic, with concentration used in passage experiment, t Plasmid harboured in the initial
inoculating strain of E. coli J62-2. § Inoculum of 10^ cfu/spot for each test organism. Abbreviations:







pCFF14 Control passage pUK3007 Control passage
pCFF14 512mg/l ampicillin passage -A- pUK3007 512mg/l ampicillin passage
pCFF14 8mg/l co-amoxiclav passage pUK3007 8mg/l co-amoxiclav passage
Figure 3.27: Changes in ampiciliin MiC observed in the
ampicillin/co-amoxiclav passage experiment.
The mean MIC (mg/l) of ampicillin for the purified colonies isolated, plotted on a daily basis, from the

































pCFF14 512mg/l ampicillin passage
pCFF14 8mg/l co-amoxiclav passage
pUK3007 Control passage
pUK3007 512mg/l ampicillin passage
pUK3007 8mg/l co-amoxiclav passage
Figure 3.28: Changes in co-amoxiclav MIC observed in the
ampicillin/co-amoxiclav passage experiment.
The mean MIC (mg/l) of co-amoxiclav for the purified colonies isolated, plotted on a daily basis, from
the ampicillin/co-amoxiclav passage experiment. Time expressed in days from first inoculation.
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5 10 15 20
Time (days)
Time (days)
-O- pCFF14 Control passage pUK3007 Control passage
-A- pCFF14 512mg/l ampicillin passage -A- pUK3007 512mg/l ampicillin passage
-D- pCFF14 8mg/l co-amoxiclav passage -M- pUK3007 8mg/l co-amoxiclav passage
Figure 3.29: Changes in ceftazidime MIC observed in the
ampicillin/co-amoxiclav passage experiment.
The mean MIC (mg/l) of ceftazidime for the purified colonies isolated, plotted on a daily basis, from
the ampicillin/co-amoxiclav passage experiment. Time expressed in days from first inoculation.
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Figure 3.30: IEF gel showing the TEM-fype p-lactamases from
ampicillin/co-amoxiclav passage experiment.
IEF gel contained carrier ampholytes pH range 4-6. Crude extracts of test organisms were prepared
and isoelectric points of the enzymes produced by each strain determined, and compared with
preparations of enzymes of known pi. Standard (3-lactamases shown include TEM-1 (pi 5.4), TEM-5
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Figure 3.31: Restriction analysis comparing strains from the ampicillin/
co-amoxiclav passage experiment
Plasmid DNA from a number of strains from the ampicillin/co-amoxiclav passage experiment were
digested with the Bgl\\ restriction endonuclease, and compared with the parent plasmids (pCFF14
and pUK3007). X DNA digested with Hind III was used as an indicator of molecular weight. pAT153
was digested with Hind III as a control. Migration of the various DNA species was distorted as a result
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Figure 3.32: Southern blot of restriction analysis comparing strains
from the ampicillin/ co-amoxiclav passage experiment
Southern transfer of restricted DNA (see Figure 3.31 page 164) was probed with a PCR-generated
biotin labelled 900-bp WaT-1pAT153 fragment to reveal the DNA fragments encoding TEM
P-lactamase genes. Linearised pAT153 was used as a positive control.
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Kinetic analysis of mutant (^-lactamases
The kinetic profiles of the mutant strains' P-lactamases were studied with the
Perkin-Elmer UV/Vis 554 Spectrophotometer. The Km and Vmax values of the
partially purified enzyme preparations were determined for the substrates
penicillin G, nitrocefin, ceftazidime and cefotaxime; and the I50 value for
clavulanic acid in the presence of penicillin G were determined. The results of
the kinetic studies are given in Table 3.23 (page 167). The enzyme kinetics of
the two p-lactamases from this third passage experiment, taking into account
the isoelectric points of the respective enzymes, suggested that the P-lactamases
were TEM-5 (pi 5.5) and TEM-1 (pi 5.4).
Strain Passage details Enzyme No. of MIC (mg/l)t







3.43 pCFF14 Ampicillin 15 5.5 NK 4096 16 >64
4.13 pCFF14 Co-amoxiciav 15 5.5 2 2048 32 >64
4.21 pUK3007 Co-amoxiclav 15 5.5 2 2048 32 64
4.39 pCFF14 Ampicillin 20 5.5 1 512 8 16
4.43 pUK3007 Co-amoxiclav 20 5.4 1 <256 8 0.25
5.16 pUK3007 Ampicillin 20 5.5 1 4096 16 >64
5.22 pCFF14 Co-amoxiclav 20 5.5 1 4096 32 >64
5.31 pUK3007 Co-amoxiclav 20 5.4 2 <256 8 0.25
Table 3.22: Details of selected Escherichia coli J62-2 strains from the
ampicillin/co-amoxiclav passage experiment
t Inoculum of 104 cfu/spot for each test organism. Abbreviations: AMP, ampicillin; AMX/CLAV,
amoxycillin/clavulanic acid (ratio 2:1); CAZ, ceftazidime; Co-amoxiclav, amoxycillin/clavulanic acid




Isoelectric point(s) 5.4 5.5
Source strain; 4.21 5.31
























l50 (|uM)t; CLAV 2.0 1.1
Table 3.23: Enzyme kinetics of the p-lactamases from the
ampicillin/co-amoxiclav passage experiment.
Abbreviations: CAZ, ceftazidime; CLAV, clavulanic acid; CTX, cefotaxime; NCFN, nitrocefin;
PEN G, penicillin G; UM, unmeasurable. § All values relative to nitrocefin (100%). * Vmax values
given as pmoles per minute, per ml of enzyme preparation. * Enzyme and inhibitor (clavulanic acid)







In Chapter 1 I tried to define some of the questions that required answering when this
project was started, together with the questions that have been raised by the progress
of other researchers. The aims of this thesis were to ascertain how the SHV- and
TEM-derived ESBL have evolved under the various selective pressures exerted upon
them. Every nucleotide mutation, and subsequent amino acid substitution, within an
SHV- or TEM-P-lactamase will affect the binding of the substrates to the enzyme to
some degree. Many of the mutations designated 'silent' may be found to affect
enzyme binding or stability in the future, as assay techniques become more accurate
and precise.
Chapter 3 describes the results of the experiments I performed for the completion of
this thesis. From an example of the development of clinical resistance, I went on to
describe a novel representation of the inter-relationships of very closely related
proteins. Once the inter-relationship of each P-lactamase to another has been defined
from its primary structure, a strategy for the investigation of evolutionary and
enzymatic inter-relationships could be devised. The study of the enzymatic inter-
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relationships led to the formulation of a hypothesis on the relative transient nature of
many of the ESBL investigated.
I present a discussion, in this section, of the experimental work conducted for the
completion of the aims of this thesis, together with the accumulation of the findings of
other researchers' investigations into a hypothesis, which I have presented [245, 246],
on the evolution of the SHV- and TEM-derived p-lactamases.
2. The identification of P-lactamases from
clinical isolates
Ten clinical isolates of ceftazidime resistant Kleb. pneumoniae (KR1 to KR10) from
the Royal Free Hospital (London) were characterised [233] in Autumn 1990. Eight of
the ten strains originated from a single patient, Case 1, one strain originated from
Case 2, and one from Case 3.
2.1. Identification of the P-lactamases from clinical isolates
kr1 to kr9
The original isolate of Kleb. pneumoniae (KR1) from Case 1 was shown to
express only a single P-lactamase with an isolectric point similar to that of the
SHV-type or chromosomally encoded P-lactamases. Subsequent isolates (KR2-»
KR8) from this patient expressed two P-lactamases: one of pi -7.0, hence
probably of chromosomal origin, and one of pi 5.4. The variation in expression of
the pi -7.0 enzyme, indicated by the variability of band intensity compared to the
pi 5.4 after analytical IEF, suggested that this enzyme was also of chromosomal
origin. Many Richmond & Sykes Class I P-lactamases [102] are produced only in
'basal' amounts [247]: the chromosomal p-lactamases ofKlebsiellae, classified as
Richmond & Sykes Class lb enzymes, are constitutively produced [102], The
chromosomal P-lactamases of the various Klebsiellia spp. are not considered as
clinically important as the chromosomal P-lactamases of other Enterobacteria
[102, 247],
The acquisition of the pi 5.4 enzyme (strains KR2—»KR8) coincided with the
instigation of aztreonam therapy (Chapter 3 Figure 3.1 page 84), and the
P-lactamase profile of each strain remained the same during further treatment, even
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though a number of other P-lactam antimicrobial agents were used. The MICs of
the P-lactam antibiotics provided by Dr MacDonald (Chapter 3 Table 3.2 page 87)
show that for strain numbers KR2 to KR8, in comparison with strain KR1, an
increase in all MICs were observed. The MICs of the P-lactam agents in
combination with 2mg/l of clavulanic acid was also elevated. The identity of the
pi 5.4 enzyme was probably TEM-1, because the relative rates of hydrolysis,
shown in Table 3.3 (Chapter 3 page 90), show that strain numbers KR2 to KR8
exhibit mainly penicillinase activity. Strain number KR1, however, exhibits a much
broader range of activity, hydrolysing both penicillins and cephalosporins.
The P-lactamases expressed by strain number KR9, isolated from Case 2,
demonstrate the same characteristics as those enzymes expressed by strain numbers
KR2 to KR8. The higher degree of cephalosporinase activity can probably be
attributed to greater expression of the pi -7.0 enzyme.
Comparison of the MICs of the P-lactam agents with and without the addition of
2mg/l clavulanic acid (Table 3.2) gives an indication of the contribution of the
p-lactamases to the resistant phenotype of each individual strain. If the MIC of a
particular p-lactam is not reduced in the presence of clavulanic acid, it is an
indication that the P-lactamase expressed by the strain is not contributing to an
increase of the MIC value of that drug, especially if the MIC values of other
P-lactam agents are reduced when clavulanic acid is added to the test medium. The
MICs of temocillin (a carboxypenicillin) and of cefoxitin (a cephamycin) are not
reduced in the presence of 2mg/l clavulanic acid; however, the MICs of the 3GCs
are reduced by the addition of a P-lactamase inhibitor for most of the strains. MICs
for strain number KR1, which only expresses the pi -7.0 enzyme, indicate that this
enzyme binds and hydrolyses the 3GCs but not imipenem, temocillin or cefoxitin.
The data obtained from analytical IEF, enzymatic profiles, and the MICs of the
various P-lactam agents suggest that the ceftazidime resistance phenotype
observed is the result of OMP mutations in combination with the expression of a
chromosomally encoded P-lactamase and the TEM-1 P-lactamase. The changes in
MICs of the antibiotics tested can probably be attributed to changes in the porins
of the host Kleb. pneumoniae strains. The change in the structure of the porins can
affect the penetration of many of the P-lactam antimicrobial agents through the
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bacterial cell envelope [40, 248-250]; differences in the charge of OMPs affect the
mobility of ionic compounds through the outer membrane, acting as selective
filters [251], It is unfortunate that, because of the constraints of time, the OMPs of
these strains were not studied.
2.2. Identification of the P-lactamases from clinical isolate
KR10
Kleb. pneumoniae strain number KR10 expressed three p-lactamases (isolectric
points of 5.4, 5.57, and ~7.0). The pi 5.4 enzyme was probably TEM-1 and the
pi ~7.0 enzyme was probably of chromosomal origin, as for strain numbers KR2 to
KR9. The pi 5.57 enzyme was of particular interest. The presence of the
TTLM-type pi 5.57 enzyme greatly increases the MICs of the 3GCs, hence it was
suspected that the pi 5.57 enzyme was an example of an ESBL.
The isoelectric point of the enzyme indicated that the P-lactamase was a TEM-type
enzyme, which characteristically focus between pH 5 and pH 6. The pH at which
the enzyme focused was the same as that of TEM-E3 and TEM-10, but was
slightly more basic than TEM-5. The pi 5.57 3-lactamase was shown to be
transferable after conjugation of the original Kleb. pneumonaie strain with
E. coli J62-2; however, the pi -7.0 enzyme was not observed to transfer,
supporting the hypothesis that this P-lactamase was probably of chromosomal
origin.
The comparison of the relative rates of hydrolysis of the original strain, and the
transconjugants, with those of TEM-E3 and TEM-10, revealed similarities in
profile with these P-lactamases. TEM-5 exhibits a much broader cephalosporinase
activity than TEM-E3 and TEM-10. From this data the identity of the unknown
pi 5.57 enzyme was probably TEM-10/TEM-E3. Precise identification could only
be given if the amino acid sequence of the P-lactamase was determined.
2.3. The development of resistance in clinical isolates
Case 1 represents the in vivo selection of resistance as a direct result of the
antibiotic therapy administered. Although resistance was not a consequence of
ESBL-encoding plasmid transfer, TEM-1 was shown to be acquired during
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therapy. The failure to treat, successfully, the pyrexia that this patient was suffering
from, was remedied when imipenem therapy was instigated. Imipenem was not
hydrolysed by either of the (3-lactamases present in the strains isolated from Case 1
(on the basis of the changes in MICs in the absence and presence of clavulanic
acid). The imipenem was, therefore, only subject to a reduction in penetration into
the bacterial cell, as the result of porin changes. The OMP mutations alone were
not sufficient to cause treatment failure.
Case 2 did not require antibiotic therapy, but Kleb. pneumoniae were isolated from
the urine during her stay at the RFH. This patient illustrated the possible problems
of inter-hospital transfer, especially international transfer of patients that may be
carrying resistant organisms, that may easily be disseminated to other patients if
hospital staff are not vigilant. It is fortunate that, in this case, the clinicians
involved were careful and treated Case 2 in isolation.
Kleb. pneumoniae strain number KR10 was isolated from Case 3 on the day of
admission. The ESBL expressed by strain number KR10 was probably selected by
therapy the patient had received before admission to the RFH, or as the result of
cross-infection of a resistant organism. The origin of this particular ESBL is not
clear.
All three patients could have disseminated resistant organisms within the hospital,
fortunately no resistant organisms, from any of these three sources of infection,
were transferred to other patients.
3. Analytical isoelectric focusing
TEM-10 has been reported to have various isolectric points (pi 5.55, 5.57 and 5.6)
[152, 188, 192, 252] and TEM-5 has been reported to have a pi of between pH 5.5
and 5.6 [152, 152, 184, 188, 193, 252, 253], Comparison of TEM-E3 with TEM-10
indicates that these two [3-lactamases focus at exactly the same isoelectric point,
confirming the observations on the similarity of TEM-E3 to TEM-10 [192], The
enzymes TEM-10 and TEM-5 are, however, not found to focus at the same pH (see
Chapter 3 Figure 3.23 page 149), as TEM-10 focuses at a slightly lower pH than
enzymes given a pi of 5.6.
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The ability to accurately identify the pi of an enzyme to within one hundredth of a pH
unit is dubious: a difference between pH 5.5 and pH 5.6 equates to a difference of
about 0.6pM in hydrogen ion concentration (for simple acids). The isolectric points of
enzymes can be ascertained by focusing alongside P-lactamases with similar pi values
and estimating the pi, if the unknown enzyme does not focus exactly at the same
point. The pH gradient can be determined, after focusing, by placing a surface pH
electrode on the polyacrylamide gel, at several positions, but this only provides an
estimate of pH. The only sure method of determining whether a particular enzyme has
exactly the same pi as another P-lactamase is to focus both enzymes alongside each
other. If the enzymes do not focus at the same pH an estimate of the pi value of the
unknown P-lactamase is then made. Proteins that do not co-focus will not be the
same, they must exhibit some variation in primary structure when compared to each
other. A number of the pi values of the TEM- and SHV-type P-lactamases have been
determined from the measurement of the pH gradient with a surface pH
electrode [105, 163],
The apparatus used for isoelectric focusing has a bearing on the resolution of the
technique. The LKB 2217 Ultraphor Electrofocusing unit (Pharmacia) is used by
many workers with the LKB Ampholine PAGplates (ready-made IEF polyacrylamide
gels; Pharmacia). The LKB Ampholine PAGplates are only manufactured with fixed,
linear, pH ranges. Non-linear and customised pH ranges, that provide better
separation and focusing of P-lactamases with very similar pi values, have to be
prepared according to the method described in Chapter 2 [105, 203], By combining
carrier ampholytes of different pH ranges a non-linear gradient is formed during
focusing: mixing Ampholines of pH range 3.5-10 with Ampholines of pH range 4-6
(ratio 1:1) enlarges the resolution in the pH range 4-6 and compresses the gradient at
a pH less than 4, and at a pH greater than 6. Some P-lactamases may appear to
co-focus at the same pH when separated on a linear pH gradient, however, they may
not co-focus on a non-linear gradient, showing that the pi values of the respective
enzymes are actually slightly different. A disadvantage of the non-linear gradient is
that external measurement of pH gradient (with a pH electrode) would be difficult.
The isolectric point of TEM-5 has, therefore, been taken as being pi 5.5, and
TEM-E3 and TEM-10 are assumed to focus at pi 5.57 throughout this thesis.
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4. The classification of the SHV- & TEM
extended spectrum P-lactamases
It is current practice to classify P-lactamases by their nucleotide sequence and for
most enzymes this works well; however, all the extended-spectrum P-lactamases fall
into Ambler class A [109] which encompasses enzymes whose genes share as little as
35% identity [120] but retain the same overall tertiary structure. The lack of
correlation between primary structure and enzyme function is epitomised with the
prototype enzymes TEM-1 and SHV-1: these enzymes are impossible to distinguish
enzymologically. The TEM-5 P-lactamase gene, blaT-5, encodes only three amino
acid changes from that of TEM-1 [160], The expanded substrate profile of the
TEM-5 P-lactamase, compared to TEM-1, confers a resistant phenotype of immense
clinical importance [254], A classification scheme based entirely on the structure is,
therefore, unhelpful.
4.1. The extension of the Payne & Amyes classification
The Payne & Amyes categorisation scheme [152] is based on the biochemical
properties and the resistances that the enzymes confer show that the mutations
produce three major changes in function (described in Chapter 1). ESBL in
Group 1, which give low level resistance to cefotaxime or ceftazidime, possess
amino acid substitutions that increase the ability of the enzyme to hydrolyse
ceftazidime faster than cefotaxime. Groups 2 and 3 will produce high levels of
resistance to ceftazidime and/or cefotaxime. ESBL in Group 2 hydrolyse
ceftazidime to a greater extent than cefotaxime, whereas Group 3 enzymes
hydrolyse cefotaxime better than ceftazidime. Professor Amyes and I have
suggested an additional group (group zero) [255]; the enzymes of which are
virtually indistinguishable from the prototype enzymes TEM-1, TEM-2 and SHV-1
on the basis of resistance profile, for example TEM-13 [157], TEM-17 [157, 241],
TEM-18 [157] and SHV-8 [235], Often the in vitro ability to hydrolyse cefotaxime
is greater than that required to hydrolyse ceftazidime, but the fast penetration of
cefotaxime ensures that this hydrolysis is insufficient to overcome the drug's
antibacterial activity. These changes seem to work in concert with previous
mutations.
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A universally recognised indicator of bacterial sensitivity to antibiotics is the
minimum inhibitory concentration, the lowest concentration required to inhibit
bacterial multiplication. This can be used to compare each clinically observed
mutation inserted into the maps of the ESBL inter-relationships (Chapter 3
Figures 3.5 & 3.6, pages 95 & 98 respectively) with the biochemical properties of
the enzyme and the resistance profile that it confers [234], allowing a
structure-function relationship to be devised and suggestions for evolution to be
proposed.
4.2. The SHV-derived P-lactamases
The relationships of the SHy-derived enzymes are well defined and are shown in
Figure 4.1. Sequence data show that all clinical SHV-derived ESBL have the same
change of amino acid at position 238 and thus must have all derived from SHV-2.
This first mutation from SHV-1, changing glycine to serine, gives a Payne &
Amyes Group 3 enzyme with significant hydrolysis of both cefotaxime and
ceftazidime. This produces a very large increase in the MIC of cefotaxime but only
a moderate increase in the MIC of ceftazidime [153, 155] (Table 4.1).
Enzyme MIC(mg/l)§
Cephalothin Ceftazidime Cefotaxime
SHV-1 p453 16 0.2 0.01
SHV-2pBP60 256 2 4
SHV-3pUD18 128 2 2
SHV-4pUD21 256 64 4
SHV-5pAFF2 256 32 4
Table 4.1: Resistance profiles of the SH\I-derived p-lactamases
Data taken from Philippon, Labia & Jacoby (1989) [153] and presented as representative MIC






Figure 4.1: The inter-relationships of the SHV-derived p-lactamases
Each arrow represents a single amino acid change. Boxes, each representing a (3-lactamase, are
shaded according to the enzyme's substrate profile (see the legend below), based upon the Payne &
Amyes classification [152]. One letter amino acid notation according to the IUPAC-IUB Commission
on Nomenclature (1969) [237], Amino acid numbering according to the recommendations of Ambler
etal. (1991) [158],
Parental enzyme with no ESBL activity
Group 0: Very low or non-existent ESBL activity
Group 3: High ESBL activity (ceftazidime < cefotaxime)
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SHV-4 was derived from SHV-2 by substitution of two amino acids, either
through SHV-3 or SHV-5. Study of the MICs of cefotaxime and ceftazidime, for
bacteria harbouring these intermediate SHV-derived P-lactamases [153], shows
that the change of the amino acid at position 205 from arginine (SHV-2) to leucine
(SHV-3) does not increase cefotaxime or ceftazidime resistance. On the other
hand, a change in the amino acid at position 240 from glutamic acid (SHV-2) to
lysine (SHV-5) has little effect on the MIC of cefotaxime, but considerably
increases the MIC of ceftazidime. Further challenge of an SHV-2 producing strain
with a 3GC, particularly ceftazidime, is likely to select the SHV-5 mutation rather
than the SHV-3, which gives no apparent further selective advantage.
Furthermore, when the SHV-5 enzyme has an additional substitution of arginine by
leucine at position 205, these changes work in concert and there is a further
increase of both cefotaxime and ceftazidime resistances. Huletsky et al. [235]
corroborate the evidence presented by Sowek et al. [241], who found that the
E240K change in the TEM-derived p-lactamases raised the MIC of ceftazidime
slightly, but had no effect on the MIC of cefotaxime. Huletsky et al. [235] found
that the glutamic acid-240—>lysine resulted in a small increase in the MIC of
ceftazidime, but a very nominal rise in the MIC of cefotaxime.
This analysis suggests that a single change from glycine to serine at position 238
vastly increases cefotaxime resistance, with a more limited rise in the MIC of
ceftazidime. An isolated change at position 205 does not improve the resistance
profile of an extended-spectrum SHV enzyme; however, the same substitution at
position 205, in addition to a change at 240, has a co-operative effect on
cefotaxime and ceftazidime resistance. A co-operative effect also exists between
amino acid 238 and residue 240.
For a mutation encoding a Glu-240—>Lys change to be evolutionary viable, the
Gly-238—>Ser change must have already occurred. Some co-operative spatial
effect between the two amino acids must therefore occur. The same appears to be
true of the residue at position 205. The Arg-205—>Leu change does confer a slight,
if small, increase in 3GC resistance when combined only with the glycine to serine
mutation at residue number 238 (SHV-3). I suspect that a nucleotide mutation in
the SHV-1 gene that encoded leucine-205, instead of arginine, would exhibit no
increase in resistance to the 3GCs.
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Another deduction from this data is that the glycine-238—>serine substitution is
most likely to be selected by an antibiotic like cefotaxime, whereas the remaining
two mutations are more likely to be selected by ceftazidime treatment, provided
that the glutamic acid-240—»lysine change occurs before the arginine-205—^leucine
substitution. A probable sequence of changes under clinical selection is, therefore,
likely to have been SHV-l->SHV-2->SHV-5-*SHV-4.
4.3. The TEM-derived P-lactamases
The mutation relationships are well defined amongst the TEM enzymes and are
shown in Figure 4.2 (page 179), although they are more complex. It can probably
be assumed that the mutation between TEM-1 and TEM-2 occurred before later
enzymes emerged, and that the glutamine-39—»lysine change does not occur with
the ESBL. Two clearly separate TEM-derived enzyme groups, therefore, exist in
the TEM-derived enzymes: TEM-1 -derived and TEM-2-derived.
A three-dimensional structure of the TEM-1 P-lactamase has been published
[126, 127], Analysis of the tertiary structure (Figure 4.3 page 180) of the
P-lactamases place the sites of amino acid variation adjacent to the proposed
position of the respective P-lactam 6(7)-substituents when bound at the active site
of the enzyme. The amino acid mutations alter the shape of the active-site, either
directly or indirectly, and reduce hindrance of P-lactamase-cephalosporin binding.
In some cases changes may promote binding through additional charge-charge
interactions with the drug moieties. In other cases, binding of a substrate may be




Figure 4.2: The inter-relationships of the TEM-derived 0-lactamases
Each arrow represents a single amino acid change. Boxes, each representing a (3-lactamase, are
shaded according to the enzyme's substrate profile (see the legend below), based upon the Payne &
Amyes classification [152], The enzymes denoted TEM-X and TEM-Y have not been isolated clinically
(see Chapter 3, Section 3.2 page 94 for details) One letter amino acid notation according to the
IUPAC-IUB Commission on Nomenclature (1969) [237]. Amino acid numbering according to the
recommendations of Ambler et at. (1991) [158],
■i Parental enzyme with no ESBL activity
Group 0: Very low or non-existent ESBL activity
[llllfll Group 1: Low ESBL activity (ceftazidime > cefotaxime)
Group 2: High ESBL activity (ceftazidime > cefotaxime)
Group 3: High ESBL activity (ceftazidime < cefotaxime)
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Diagram showing the amino acids important in substrate binding which lie close to the TEM-1 active
site, based upon the crystal structure described by Jelsh et al. (1992 & 1993) [126, 127], Numbering
of amino acid residues according to the recommendations of Ambler et al. (1991) [158],
Abbreviations I v , salt-bridge ; Ala, alanine; Arg, arginine; Asp, aspartic acid; Glu, glutamic
acid; Lys, lysine; Met, methionine; Ser, serine.
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Considering the MIC values of various [3-lactam antimicrobial agents for the
TEM-l-VTEM-5 and the TEM-1—>TEM-9 (3-lactamases from my results and
published sources, some interesting observations can be made (Chapter 3: Table
3.13 page 127 [241] and Table 3.15 page 134). The first alteration from TEM-1 to
the enzymes TEM-5 or TEM-9, is the alteration of arginine-164 to serine. The
resultant P-lactamase, TEM-12, has a limited capability to hydrolyse either
ceftazidime or cefotaxime and is classified as Du Bois, Payne & Amyes Group 1.
The presence of this enzyme increases ceftazidime resistance but hardly affects
susceptibility to cefotaxime. The same substitution can take place with the TEM-2
(3-lactamase to give TEM-7, which has similar properties [186, 189], The increased
capability to hydrolyse oxyimino cephalosporins does not arise from the acquisition
of serine at position 164, but from the loss of arginine. The Arg-164->His change
in TEM-2 also gives an enzyme (TEM-11) with the same properties [256], It is
interesting that, in spite of the fact that the loss of arginine at position 164 appears
so often in the TEM enzymes, this substitution is not found amongst the SHV
group. The unusually short a-7 helix of the TEM-1 enzyme [126, 127], compared
to other Class A enzymes, may explain the lack of substitution in the SHV group.
As with the SHV-4 enzyme (Figure 4.1 page 176) the development of TEM-9 can
be accomplished by two distinct routes (Figure 4.2 page 179). The TEM-17
mutation, substituting glutamic acid-104 with lysine, is a potential alternative to
TEM-12; however, this change does not significantly increase the MIC of
cefotaxime and has no effect on the MIC of ceftazidime. Combination of the
lysine-104 and serine-164 substitutions, as seen in TEM-26, results in a synergistic
effect, increasing the MIC of ceftazidime out of proportion to the contribution of
each separate mutation. The MIC of cefotaxime for TEM-26 is the same as that
obtained for TEM-17. The TEM-26—»TEM-9 transition (threonine-265->
methionine) increases the MIC of cefotaxime to a greater extent than the MIC of
ceftazidime [179, 180], The TEM-12 to TEM-10 change (glutamic acid-240-»
lysine) greatly increases the ceftazidime resistance conferred. A further substitution
of threonine for alanine at position 237 (TEM-5) further increases the laboratory
resistance to cefotaxime but not to ceftazidime.
It is possible to plot and compare the development of TEM-5 and TEM-9; both
enzymes have similar substrate profiles, the latter slightly more resistant to the
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action of cefotaxime, but the MICs of ceftazidime remain equivalent for both. In
their respective selections, the arginine-164-»serine change appears to be the
crucial first stage; it is a fairly common mutation, both with TEM-1 and TEM-2
and thus has a pivotal position in the development of over half the TEM-derived
ESBL. The second step mutations, TEM-26 and TEM-10, do not differ in their
abilities to confer resistance to cefotaxime; however, TEM-26 has a greater ability
to confer resistance to ceftazidime. For both TEM-5 and TEM-9 the first two
mutation events are likely to have been selected by ceftazidime, or a similar drug,
and the final stage is likely to have been selected by cefotaxime, or similar
antibiotic. Study of the threonine-265 and alanine-237 mutations show that the
latter is more potent in conferring cefotaxime resistance than the former. This
progression ofmutations shows that the arginine to serine substitution at position
164 and the glutamic acid to lysine change at position 240 both increase
ceftazidime resistance. The glutamic acid to lysine mutation at position 104 has a
minimal effect on substrate profile, except in combination with the removal of
arginine at position 164, when it promotes a further increase in ceftazidime
resistance. The mutations at positions 237 and 265 both raise the MICs of
ceftazidime and cefotaxime, although they have a more significant effect on the
latter. The substitution of methionine for threonine at position 265, in the absence
of other mutations (TEM-13), is effectively silent as it has no effect on MIC
values [157],
5. Spatial effects of point mutations
Figure 4.3 (page 180) shows the latest representation of the three-dimensional
structure of the active-site of the TEM-1 P-lactamase, together with the location of
each of the point mutations and other residues important in substrate binding. The
arginine-164 residue is situated on the f2-loop, part of which is made up by the short
a-7 helix. A major difference between the structure of TEM-1 and other Ambler
Class A P-lactamases appears to be the very short a-7 helix in the former [126, 127],
The arginine-164—»serine change would disrupt the two salt bridges formed between
the basic arginine-164 and the acidic residues aspartic acid-171 and aspartic acid-179
[127], Other Ambler Class A P-lactamases with an arginine at position 164 only form
a single salt-bridge [123], The ionic bond across the H-loop retains the shape of the
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back of the active-site, ideally sized for the earlier (and smaller) P-lactam
antimicrobial agents. Prevention of salt bridge formation, by replacing the basic
guanidine group of arginine with the neutral alcohol group of serine, results in the
active-site cavity becoming less rigid. The movement of the a-7 helix, increasing the
size of the oxyanion hole that forms the active-site, allows the tighter binding of
3GCs, especially ceftazidime.
Glutamic acid-104 is situated adjacent to the a-3 helix, and is partially obscured from
full participation in substrate binding by the Q-loop in the TEM-1 P-lactamase. A
mutation to substitute lysine at this position does not contribute greatly to substrate
binding, unless arginine is lost from position 164 and the salt bridges were not
formed. The synergy that exists between the substitutions at positions 164 and 104
would be explained by this model. The increase in size of the active-site cavity, as a
direct result of a change preventing salt bridge formation, will also expose residue 104
and allow full contribution to substrate binding.
The residues at positions 237, 238, and 240 are situated at the end of P-3 sheet
(Figure 4.4 page 184). Mutation of these residues enlarges the active-site by the
movement of the P-3 sheet away from the a-2 helix [235, 257], Enlargement of this
region of the P-lactamase active-site creates an enzyme with a higher affinity for the
7-oxyimino cephalosporins; substitutions at positions 237 and 238 favour cefotaxime
resistance, whereas substitution at 240 favours ceftazidime resistance. The spatial
contribution, if any, of changes observed at residue 265, situated at the end of the
P-5 sheet, remain unclear.
5.1. Analysis of biochemical data
The conclusions drawn from the MIC values are confirmed by the biochemistry.
Vmax, Km, kcat, and Vmax/Km all support the MIC data. The turnover number,
kcat, reveals that an increase in the capacity of a specific enzyme to hydrolyse a
7-oxyimino cephalosporin is usually concurrent with a decrease in the turnover of
the simpler penicillins, such as ampicillin and amoxycillin, in comparison with
either TEM-1 or SHV-1 respectively. This observation suggests that the ESBL are
less efficient at hydrolysing the earlier p-lactams than their ubiquitous prototypes.
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P3 p4
Figure 4.4: Schematic representation of {3-lactam binding to the
active-site of the SHM-derived p-lactamases
Diagram is based on the crystal structure of the Bacillus licheniformis 749/c p-lactamase. Electrostatic
and hydrogen-bonding interactions, which can attract p-lactam drugs are indicated by the
arrows (• : ). The dotted line (♦«♦»♦) to aspartic acid-104 indicates the hydrogen bond present
in the B. licheniformis 749/c enzyme, and in the TEM-derived lysine-104 mutants, but not the
SHM-derived p-lactamases. The mutation of residues number 237 and 240 moves the p-3 sheet away
from the a-7 helix in the manner indicated. Amino acid numbering according to the recommendations
of Ambler et al. (1991) [158], Abbreviations: Arg, arginine; Asn, asparagine; Asp, aspartic acid; Gly,
glycine; Lys, lysine; Ser, serine; Thr, threonine. Illustration after Knox (1993) [257],
Discussion Page 185
5.2. The evolution of TEM-derived P-lactamases
The biochemical development of TEM-5 and TEM-9 from the prototype TEM-1
P-lactamase was examined above in terms of resistance. The data presented in
Chapter 3 (from [241]) show that, while the turnover numbers for cefotaxime and
ceftazidime increase, the kcat for benzylpenicillin decreases. The greater the
efficiency of 7-oxyimino cephalosporin hydrolysis, the slower the turnover of
benzylpenicillin. The kcat values for both ceftazidime and cefotaxime reflect the
MIC results. Comparison of the benzylpenicillin turnover number of TEM-17 with
that of TEM-12 shows that, although the latter enzyme hydrolyses the 3GCs with
greater efficiency than the former, TEM-17 has a greater ability to degrade the
early penicillins than TEM-12. The only time that such a situation would be an
advantage would be if the host organism was challenged with a penicillin. Thus, if
TEM-26 had been selected from TEM-12 by the clinical use of the 3GCs and the
host was subsequently challenged with a penicillin, a mutation to TEM-17, rather
than back to TEM-12, would theoretically have a selective advantage.
Simple selective pressure with ampicillin does not appear to induce such a
mutation. The use of a p-lactamase inhibitor, for example clavulanic acid, would
provide a much stronger selective pressure than amoxycillin or ampicillin on their
own. Comparison of the Rvalues of clavulanic acid for the enzymes suggested
that the use of this inhibitor may induce back mutations, and experimental results
seem to support this hypothesis (see below). The back mutation of TEM-26 to
TEM-17 would allow the forward mutation to TEM-15, then subsequently TEM-4
(Figure 4.2 page 179), or to TEM-26 if re-challenged with a 7-oxyimino
cephalosporin, whilst still providing a higher level of penicillin and clavulanic acid
resistance for the host organism compared to some other first-step mutations (e.g.
TEM-12 or SHV-5).
When considering the evolution of TEM-8 from those enzymes identified from
clinical isolates, the progression would seem to be TEM-2—»TEM-18-»TEM-3->
TEM-8. However, TEM-18, a TEM-2 derived analogue of TEM-17, is a Group 0
enzyme (very low or non-existent 7-oxyimino cephalosporin resistance). TEM-7,
equivalent to TEM-12, belongs to Du Bois, Payne & Amyes Group 2 (low level
3GC resistance), and as illustrated in the TEM-1—»TEM-9 progression described
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above provides a much greater selective advantage over TEM-18 as a first step
mutation. Substitution of glutamic acid-104 for lysine in TEM-7 to create a
TEM-2-derived clinical analogue of TEM-26, TEM-X, would appear to be the
logical link to TEM-8. TEM-X has not been identified from a clinical isolate, but
its existence is supported by the identification of TEM-24. TEM-8 is probably the
progeny ofTEM-X, rather than of that ofTEM-3 via TEM-18.
6. Site-directed mutagenesis of to/aT-1pati53
When the first version of the map describing the inter-relationships of the SHV- and
TEM-derived P-lactamases was introduced [234], only eight of the TEM-derived
P-lactamases had been sequenced at either an amino acid or DNA level. Many of the
possible intermediates had not even been identified as possible candidates on the basis
of phenotype, but it was only a month or so before Mabilat & Courvalin published
details of the 'missing links' [157], The development of a method for the rapid
screening of clinical isolates for point-mutations in the TEM gene allowed the
identification of TEM-1 and TEM-2 variants that did not necessarily confer a
clinically significant phenotype. The technique, called 'oligotyping', probed five loci
of the bid! genotype with 17-mer oligonucleotides to discriminate point mutations on
the basis of a single nucleotide mismatch between oligonucleotide and gene. From the
screening of 222 strains expressing a TEM-type P-lactamase, nine novel genotypes
were identified. Seven of the new P-lactamases were named TEM-13, TEM-14,
TEM-15, TEM-16, TEM-17, TEM-18, and TEM-19 [157], The previously unknown
A/tfT-8 and blaY-\\ genotypes were also identified for the known TEM-8 and
TEM-11 phenotypes. Mabilat & Courvalin [157] provided a great deal of information
on the molecular epidemiology of the TEM-derived P-lactamases, but little
information on the biochemical characteristics of the enzymes. A major failing of the
oligotyping technique for identification of genotype is that mutations not occurring at
the loci probed would not be identified. The clinical isolates that were 'oligoytyped'
originated from many different French hospitals, and have remained unavailable for
other researchers to examine. The biochemical characteristics of the enzymes
described by Mabilat & Courvalin [157] have still not been elucidated. It has remained
for other researchers either to create the genotype with recombinant techniques and
then study the biochemistry of the enzyme, or to identify examples of the enzymes
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from clinical enzymes. Many of the genotypes have now been correlated with a
phenotype by one of these two approaches, or been assigned through analogy to other
Ambler Class A P-lactamases.
Thus, a strategy for the creation of some of the TEM-derived intermediate enzymes
by site-directed mutagenesis was designed. The construction of six recombinant
enzymes was attempted over a period of nine months. Of these six experiments, four
yielded mutants with apparently the correct genotype (TEM-12pUK3002,
TEM-2pUK3oo3, TEM-17pUK3004, and TEM-7pUK3005). In the initial strategy these
recombinant enzymes were to be used as the basis of further SDM experiments to
create more TEM-derived intermediate enzymes. All of the P-lactamases created by
SDM, except for TEM-17, had been well characterised by other researchers, and the
enzymes were available for study. The pUK3004 enzyme did not have the phenotype
expected: the pi of the recombinant P-lactamase (pi-5.5) was lower than expected
(pi 5.9 [157, 241]); the rate of hydrolysis of 3GCs was higher than found by other
workers for the same point mutation [241], It was, therefore, concluded that the
pUK3004 P-lactamase gene did not encode the TEM-17 P-lactamase. The DNA
sequence ofblal would have to be reassessed in order to categorically define
the genotype of the enzyme expressed; unfortunately, the constraints of time
prevented such measures. The major criticism of the 'oligotyping' method of Mabilat
& Courvalin [157] was that, although probing a 17 to 20-bp region of a specific gene
can efficiently detect a point mutation within that region, it does not present any
information on mutations of the DNA sequence remote from that site.
I suspect that, as quite commonly occurs with this technique, at least one point
mutation was inadvertently inserted into the 750-bp fragment present in the M13
vector during SDM. When the mutant fragment was cloned back into pUK3001 and
the P-lactamase expressed, the additional point-mutation(s), in combination with the
Glu-104-»Lys change, encoded a functional protein with altered biochemical
characteristics.
Other researchers had managed to create mutants or identify clinical examples of the
missing enzymes, hence as a result of the slow progress of the SDM approach, time




The first ESBL was identified by Kliebe et al. in 1985 [155] and was later shown to
be derived from the SHV-1 P-lactamase by a single amino acid mutation [258], This
ESBL (SHV-2) is classified as a Du Bois, Payne & Amyes Group 3 enzyme, and
confers high level resistance to the 3GCs. Du Bois, Payne & Amyes Group 2 and 3
P-lactamases all confer significant clinical resistance to the 3GCs. Groups 0 and 1,
however, confer low level resistance to the 7-oxyimino cephalosporins which may not
cause treatment failure in the clinical setting. Under these conditions the identification
of the novel genotype would be missed, and such an omission would have no bearing
on the outcome of the antibiotic therapy of the infection concerned. The omission
would become a problem if cross-infection of the bacterium expressing the mutant
P-lactamase were to occur and subsequent challenge with 3GCs selected a Group 2
or 3 enzyme. Even if treatment failure does occur, partly as the result of a strain
expressing a Group 0 or 1 enzyme, the presence of such a P-lactamase may pass
unnoticed, as the phenotypes of these enzymes are often similar to those observed for
the prototype P-lactamases TEM-1 and TEM-2. Treatment failure may be attributed
to other factors, when in reality the mutant P-lactamase is one of, possibly, two or
three factors; for example, decreased permeability of the bacterial cell envelope as a
result of OMP mutations. Group 0 and Group 1 enzymes often confer low resistance
levels and the MICs of the 3GCs for the strains concerned are below the break-points
recommended in the BSAC guidelines [196],
Another factor that delayed the identification of ESBL before 1985, especially those
conferring low level resistance, was the belief that the development of plasmid-
mediated resistance to the 3GCs was impossible. This belief was the result of the
information disseminated by the pharmaceutical companies that marketed the 3GCs at
this time. Indeed, the consensus beliefwas that, at the time, these claims were valid. It
is unfortunate, but after the introduction of any novel compound, many of the initial
claims turn out to be untrue, mainly because of the lack of clinical data on the new
drugs.
Payne [141] conducted a retrospective study of ceftazidime resistant isolates stored in
the Glaxo Group Research Ltd. culture collection (Greenford, Middx) and identified a
TEM-type P-lactamase that conferred low level ceftazidime resistance on the host
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organism [141, 151], The strain in which the TEM-E2 P-lactamase was identified was
isolated in 1982 and, therefore, pre-dated any other known ESBL by three years.
TEM-E2 showed considerable similarity in substrate profile to the recombinant
P-lactamase TEM-101 [162], which was created by point-mutation of the
arginine-164 codon to code for a serine residue at position 164. Later, Weber etal.
[189] described a clinical example of a TEM-1 -derived P-lactamase, designated
TEM-12, that encoded the arginine-164-»serine substitution which also showed
remarkable similarity to the TEM-E2 enzyme. TEM-12 was chromosomally encoded,
but was shown to be present on a transposon [259], and only conferred clinically
significant resistance to the 3GC ceftazidime in combination with decreased
permeability of the outer membrane of the host organism [189], Furthermore,
TEM-E2-like mutant P-lactamases could be selected from TEM-1 in vitro with
ceftazidime [161, 162], hence the evidence strongly suggested that TEM-E2 was
derived from TEM-1 by substitution of arginine-164 with serine. The TEM-12
P-lactamase holds a pivotal position in the evolution of the lliM-derived ESBL
(Figure 4.2 page 179), hence the characterisation of the amino acid sequence of the
first known example of an ESBL is essential.
The methodology described in Chapter 3 eventually led to a clear indication that
pUK721 encoded two P-lactamases; one with an arginine residue at position 164 and
one with a serine residue at position 164. pUK721 was known to produce two
P-lactamases, TEM-1 (pi 5.4) and TEM-E2 (pi 5.25) [151], hence as bldT-\ encodes
for arginine-164, it can be deduced that the second P-lactamase gene encodes for a
serine at position 164. No other nucleotide changes were observed from the DNA
sequencing gels, therefore it is concluded that the TEM-E2 P-lactamase has an
identical genotype to that ofTEM-12.
8. ESBL "BACK-MUTATIONS"
The purification of p-lactamases to sufficient purity to be able to determine
P-lactamase concentration accurately is a difficult operation. Other researchers have
successfully completed the purification and the determination of detailed enzyme
kinetics on a number of P-lactamases previously [260, 261], but it was not until
Sowek et al. [241] published the kinetic profiles of a number of closely related
recombinant TEM-1 -derived p-lactamases that the true relationships became
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apparent. The 'Sowek paper' was published in late 1990 and provided the catalyst for
the hypothesis that is described here. As mentioned previously, Sowek and
colleagues, although presenting a mass of information, failed to realise the full
implication of the data. It was not until the data were arranged in an evolutionary
context (Figure 4.2 page 179) that the trends became apparent: as capability to
hydrolyse the 3GCs increased with a concurrent increase in the number of ESBL
mutations, the turnover of the pencillins decreases. The less efficient that a
TEM-derived P-lactamase is at hydrolysing the early penicillins, the lower the I50
value of clavulanic acid becomes, i.e. the more tightly clavulanic acid is bound to the
enzyme. It would appear that such a scenario would be evolutionary disadvantageous,
especially since the host organisms of ESBL would be challenged with penicillins, or
pencillins in combination with the p-lactamase inhibitors in general practice. The
Darwinian approach to the evolutionary implications of these findings would explain
the relative rarity of the ESBL with respect to the prototype enzymes.
A second finding from the kinetic data was that some of the alternative intermediates,
such as TEM-17 and, I suspect, SHV-3, presented no significant selective advantage
over the parental enzymes when conferring 3GC resistance. These intermediate
enzymes, conversely, did not present a significant disadvantage over the parental
species of P-lactamase when conferring resistance to the penicillins (Figure 4.2
page 179). Back-mutation to an alternative intermediate, TEM-17 instead of TEM-12
for example, from TEM-26 would create an enzyme closer to the prototype TEM-1
P-lactamase in its ability to hydrolyse penicillins. This observation would explain the
existence of many of the extraneous ESBL that have been identified but, on first
inspection, appear to have no evolutionary function.
8.1. The effect of ampicillin
In order to test the hypothesis, after repeating the kinetic studies of Sowek and
co-workers, the terminus enzyme TEM-5 was passaged against ampicillin at
various concentrations. Passage with ampicillin over a short period of time (five
days in the first passage experiment) and a relatively long period of time (20 days
in the third passage experiment) did not select any backward mutations. No novel
p-lactamases were observed as the result of either ampicillin passage.
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Comparison of the MICs of the simple penicillins for the various TEM-derivatives
reveals that resistance is similar or may actually increase. Other factors, however,
influence the MIC values: host organism, gene promoter, plasmid copy number,
and permeability barriers [248, 250], The strains passaged with ampicillin by this
method, or any clinical strain challenged with a penicillin, would all be equal in
these respects compared to the other bacteria in the culture, if they all harbour the
same plasmid. Transfer of plasmid DNA to other organisms, for instance in the
gastro-intestinal tract, will probably occur [262], or there may be mutations in the
OMPs [189, 248] or the PBPs [263], This may provide a greater selective
advantage than back mutation to an enzyme with a relatively low increase in
penicillin hydrolysis compared to the 'terminus' ESBL. The P-lactam antimicrobial
agents are known to alter the properties of the bacterial cell envelope at sub-MIC
concentrations [264], The application of a selective pressure with a penicillin was,
therefore, not sufficiently severe for a strain harbouring a plasmid encoding a back-
mutation. The difference in kinetic profile of a 'terminus' ESBL compared to the
prototype p-lactamase, with respect to the early penicillins, does not appear to be a
disadvantage. Any organism expressing an SHV- or TEM-derived ESBL would
confer a level of penicillin resistance that has no clinically significant difference to
that conferred by the parental enzymes, TEM-1, TEM-2 or SHV-1.
The effect of plasmid copy number was examined in order to calibrate the MICs of
P-lactamases encoded on different clinical plasmids. Although the MICs of the
P-lactams tested did increase with copy number, and therefore with P-lactamase
expression, the increase is out of proportion with the differences in copy number.
A five-ten fold increase in plasmid copy number increased the MIC of the
penicillins, ampicillin and amoxycillin, by about three fold but this was quite
variable. The MICs of amoxycillin/clavulanic acid, ceftazidime, and cefotaxime are
not increased to such an extent with copy number. The MIC of
amoxycillin/clavulanic acid, for instance, only doubled for a five to 10 fold increase
in copy number. The MICs of ceftazidime and cefotaxime are affected in a similar
manner, with the MIC of cefotaxime affected to the least extent of all the
P-lactams tested. From this data it can, therefore, be surmised that copy number
does influence the MIC of the P-lactams but not by a significant degree. All ESBL
identified so far have been encoded by large clinical plasmids [180], which are
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invariably present in a low copy number. The effect of the copy number of the
clinical plasmids will, therefore, be minimal.
Disney & Dove [174] cloned a number of ESBL into an isogenic expression
vector, then determined the MICs of a number of P-lactam antibiotics hosted in
two isogenic E. coli strains: DCO and DC2 [249], E. coli DC2 is isogenic with
strain DCO, except for an abs mutation, rendering the strain hyperpermeable to
most antibiotics: the effect of permeability of the various P-lactam antibiotics was
assessed (see Table 4.2). The MIC values examined in this manner are not subject
to variation in plasmid copy number or variability in expression as each TEM ORF
is under the regulation of the same promoter, P3, from the bldX gene of Tn3. The
MICs of cefuroxime, ceftazidime and cefotaxime decrease concurrently with a
0-Lactamase E. coli strain MIC (mg/l)t
CFX CLAV CAZ CTX
TEM-1 DCO 8 31 0.5 0.13
DC2 1 62 0.5 <0.03
TEM-3 DCO >62 31 62 >62
DC2 16 62 >62 >62
TEM-5 DCO >62 31 >62 >62
DC2 >62 62 62 16
TEM-6 DCO 32 31 >62 16
DC2 2 62 >62 2
TEM-7 DCO 8 31 >62 2
DC2 1 62 >62 2
TEM-9 DCO 31 31 >62 62
DC2 2 62 >62 16
Table 4.2: The effect of outer-membrane permeability on the MIC of
various p-lactam antimicrobial agents
f Inoculum of 104 cfu/spot for each test organism. Abbreviations: CAZ, ceftazidime; CFX,
cefuroxime; CLAV, clavulanic acid; CTX, cefotaxime. Data from Disney & Dove (1991) [174],
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decrease in permeability for every ESBL examined. The MIC of clavulanic acid is
somewhat anomalous, increasing with decreasing permeability.
One conclusion from all the MIC determinations presented is that the technique is
not subtle enough to be able to discern the differences in resistance conferred by a
group of exceptionally closely related enzymes such as the SHV- and
TEM-derived ESBL.
8.2. The effect of amoxycillin/clavulanic acid
Amoxycillin in combination with clavulanic acid, in the ratio 2:1, provides a
stronger selective pressure as a result of the joint progressive and competitive
nature of the inhibition of the P-lactamase inhibitor [265], The effect of the
clavulanic acid on the ESBL TEM-5 was clearly shown to promote the selection of
back mutations. The passage of an E. coli strain harbouring TEM-5, at limiting
concentrations of amoxycillin/clavulanic acid for five days, promoted back
mutation of blaT-5 to blctT-\0, and then blaT-\2. No TEM-1 variants were
observed. Further passage of the mutant plasmid, pUK3007, for 20 days selected
strains that either expressed TEM-5 or TEM-1 only. The TEM-5 and TEM-1
P-lactamases represent the two extremes of function of the evolutionary series;
TEM-1—>TEM-12—>TEM-10—>TEM-5. A culture, therefore, expressing both
TEM-1 and TEM-5 will have the advantages of both enzymes: the broad-spectrum
of TEM-5 and the lower P-lactamase inhibitor susceptibility of TEM-1. A strain
expressing TEM-5 will be protected against its deficiencies, to some degree, by
surrounding strains expressing TEM-1 [2], The reverse would also be true. The
presence of any other intermediate enzyme, for example TEM-12 or TEM-10,
would be surplus to requirements. The intermediates are not good at conferring
3GC resistance or low susceptibility to clavulanic acid compared to the prototype
TEM-1, or the 'terminus' TEM-5 P-lactamase. The combined effect of expression
of the three P-lactamases (TEM-5, TEM-10, and TEM-12) was shown to have a
broader range of activity than TEM-5 or TEM-1 alone. The presence of TEM-1
and TEM-5 within a culture would also have a broad spectrum of activity, and only
requires the expression of two enzymes rather than three.
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Following this hypothesis, the intermediate P-lactamases, TEM-12 and TEM-10,
are only expressed during the transition of TEM-5 back to TEM-1. This would
explain why only a finite number of strains, after the five day passage with
amoxycillin/clavulanic acid, exhibited multiple P-lactamase expression and why
strains only expressed TEM-1 or TEM-5 after a further 20 days.
The effect of clavulanic acid on its own needs to be mentioned. Table 4.2
(page 192) illustrates the findings of other workers [30], that the MIC of clavulanic
acid is a significant factor at higher concentrations. The MIC of clavulanic acid
alone appears to be about 31mg/l [30, 174]; therefore, at higher concentrations of
amoxycillin/clavulanic acid (ratio 2:1) the antibacterial action of the clavulanic acid
is a contributing factor to the overall MIC. This is why, when determining the
MICs of a P-lactam in the presence of a P-lactamase inhibitor, a fixed
concentration of the inhibitor is included in the medium: 2mg/l of clavulanic acid
with varying p-lactam concentrations. For the purposes of the passage experiment
a ratio of amoxycillin and clavulanic acid of 2:1 was employed, as the commercially
available preparations of this combination (Augmentin, SmithKline Beecham) are
formulated in this ratio. The physiological levels of the two components would,
therefore, approximate to a ratio of 2:1.
8.3. blaT GENE DUPLICATION
The Southern transfer of plasmid DNA after restriction analysis, and the
subsequent probing for the presence of blaT genes, revealed that multiple
P-lactamase expression within a single strain corresponded to the presence of
multiple TEM P-lactamase genes on a single plasmid. This suggests that
back-mutation has been facilitated by intramolecular gene duplication. Duplication
of the blaT-5 gene would, firstly, increase p-lactamase expression. In the second
instance, when two P-lactamase genes are present, a point mutation within one of
the genes may be selected without loss of the ESBL activity encoded by the
TEM-5 gene. Mutations that code for the P-lactamase intermediates would confer
a broader-spectrum of activity upon the host organism, hence, present a selective
advantage. Further back-mutations would be selected in a similar manner. Whether
one of the duplicate genes is deleted prior to a second duplication/mutation event,
or one of the two genes has another point mutation selected without deletion, is
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not known. The host strain, however, does harbour a heterogeneous population of
plasmids encoding a number of combinations of the blaT-\2, blaT-\0 and b/aT-5
genes. Examples of strains that express either combinations of intermediate
TEM-derived ESBL, or a combination of parental TEM P-lactamase and an
intermediate ESBL have been isolated from clinical samples [151, 266], These
reports help to validate the in vitro observations.
After the 20 day passage, strains harboured plasmids which expressed either
TEM-1 or TEM-5, that were derived from the mutant pUK3007, encoded one or
two TEM P-lactamase genes. I suspect that the presence of two blciX genes on a
single plasmid of a strain expressing only a single P-lactamase was a transitional
phase before deletion of one of the identical genes. Hence, if the passage were
continued with amoxycillin/clavulanic acid, a heterogeneous population of bacteria
would exist that expressed a single p-lactamase, TEM-1 or TEM-5, encoded by
plasmids harbouring a single P-lactamase gene.
Transpositional duplication of P-lactamase genes
The TEM-derived P-lactamases have been found on a number of transposons
[267, 268], identified as Tn7, Tn2, Tn3, and their relatives. Tn3 and Tn2/ are
class II, or complex, transposons, and represent two of the three related families
of this class that have been identified [269]. TEM-1 is usually present on a
Tn3-like element [180], and some of the enzymes have been found on Tn2/-like
transposons [259], Studies on Tn3 have suggested that transposition proceeds
via a cointergrate intermediate [270], where replicon fusion facilitates
transposition. If the whole transposon harbouring the blaT gene is being
duplicated under the selective pressure of amoxycillin in combination with
clavulanic acid, an alternative method of replication is suggested by my results:
the analysis of the mutant plasmid, pUK3007 (~170-kb), showed a duplication
of a relatively small region of DNA, about 25-30-kb in size, when compared to
the parent pCFF14 (~141-kb). Analysis of the plasmid DNA suggests that
transposition occurs via a mechanism of inversion [270], This mechanism of
replication is, however, not regularly associated with class II transposons,
implicating that gene duplication may not be the result of transposon
duplication.
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Intramolecular duplication of P-lactamase genes
Another possible method of P-lactamase gene duplication is that the gene itself
is duplicated within a transposon. Duplication by this method would probably
follow the normal mechanism of resistance gene acquisition employed by
class II transposons [111, 269, 271], The presence of two identical, or nearly
identical, genes within the same transposon would somehow interfere with
transposition and, therefore, present an evolutionary disadvantage for the
transposon. In a stable environment one of the duplicates would be deleted, and
the presence of two blciT genes on the same transposon would only be present
during the transition of an ESBL to a parental enzyme.
This area of the study would be interesting to elucidate further, and probing of
the plasmid DNA for specific transposons would help answer some of the new
questions raised by these passage experiments.
9= Conclusions
Conservative mutations, or mutations remote from the active site, do not affect
biological parameters in a measurable manner. Evolutionary implications of the single
mutations may be relatively minor, as seen in the enzyme TEM-17, and may not be
detected during the normal course of events. Unless the resistance profile has been
altered some mutations would be difficult to identify. A number of silent mutations, or
minimally important mutations, occur frequently with little functional consequence,
but prepare bacteria for a more drastic change when challenged further with
7-oxyimino cephalosporins. Substitutions that result in significant changes in the
phenotype of the producing organism would not necessarily be observed unless a
specific cephalosporin was used during clinical treatment. Most of the first step
mutations observed in the TEM P-lactamases would fall into this category; indeed
most of them would pass undetected in diagnostic laboratories as they fail to reach the
threshold of resistance recommended for break-point sensitivity testing [196], So the
acquisition of a single innocuous mutation may create an enzyme which is poised to
confer high levels of resistance after a second, more dangerous mutation.
Although innocuous mutations may exist in the unchallenged population, treatment
with a penicillin, as often occurs in general practice, would result in the selection of
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the parental enzymes (TEM-1, TEM-2 and SHV-1) over the progeny. Challenge with
the 7-oxyimino cephalosporins would select the most resistant p-lactamase in the host
population. Only when such an event has occurred will a second mutation event occur
to expand the spectrum of the enzyme further. A third mutation may occur during
continued treatment with 7-oxyimino cephalosporins to create a more effective
extended-spectrum P-lactamase. Cross-infection to other patients, or escape into the
environment, may result in the challenge of the host organism with a penicillin and a
P-lactamase inhibitor. Such a biological pressure would select against the
extended-spectrum p-lactamases and may induce back mutations to the more
innocuous enzymes, TEM-17 or SHV-3, for example. Extended-spectrum
P-lactamase evolution can be mapped through careful biochemical analysis and the
use of molecular biology techniques, and it seems that such evolution of the parent
P-lactamase to broad-spectrum activity consists of a series of both forward and
backward mutations.
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Summary: During an 8-month period, Klebsiella pneumoniae resistant to
cefotaxime and ceftazidime were isolated from 18 elderly patients in two
closely-situated UK hospitals. Amongst these 18 patients, the organisms
were isolated from urine samples of 17, from blood cultures of two and from a
wound swab f one. The infected patients were located in nine different
wards and several of the patients had been transferred between wards, within
and between the two hospitals. All the bacterial isolates belonged to serotype
K62, were non-typable or reacted only weakly with bacteriophage, showed
similar plasmid profiles and were resistant to tetracycline and trimethoprim,
thus indicating they were the same strain. Resistance to cefotaxime and
ceftazidime was inhibited by clavulanic acid suggesting the involvement of
extended-spectrum P-lactamase (ESBL) enzyme activity. This was con¬
firmed by analytical isoelectric focusing, which showed that isolates each
produced two P-lactamases with isoelectric points of 7-0(SHV-3) and
7-6 (SHV-1/2) respectively.
Keywords-. Klebsiella pneumoniae-, resistance to cefotaxime and ceftazidime;
extended-spectrum p-lactamase.
Introduction
When the third-f eneration cephalosporins cefotaxime and ceftazidime were
introduced into clinical use in the early 1980s, they offered the advantage of
being stable to the then known plasmid-mediated P-lactamases.1,2 However,
there have since been a number of reports of the isolation of bacteria, (in
particular Klebsiella spp.), which are resistant to third-generation
cephalosporins due to the production of extended-spectrum P-lactamases
(ESBLs) capable of hydrolysing these compounds.3,4 Although the earliest
known example of an organism resistant to third generation cephalosporins,
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due to production of an ESBL, is a strain of Klebsiella oxytoca isolated in
Liverpool in 1982,5 such organisms have presented few significant problems
in the UK to date. Early in 1991, a review of resistance to third-generation
cephalosporins noted that only 10 UK isolates had been reported in the
literature4 in contrast to the situation in some other countries, particularly
France, where a number of hospital outbreaks involving organisms
producing ESBLs have been reported.3,4 Shortly after this review was
published, a small outbreak in the Intensive Care Unit of a UK hospital
involving eight patients infected or colonized with K. aerogenes serotype
K16 resistant to third generation cephalosporins, probably due to
production of an ESBL, was reported.6 In addition, with other workers we
have recently reported three patients in a London hospital infected with
distinct strains of Klebsiella spp. resistant to cefotaxime and ceftazidime due
to production of ESBLs.7 In this paper, we report an outbreak of
nosocomial infection involving elderly patients in two closely situated UK
hospitals which was caused by a cephalosporin-resistant strain of Klebsiella
pneumoniae producing at least one ESBL.
Methods
Hospital setting
Hospital A is a 600-bed district general hospital in the UK and hospital B is
an acute and long-stay hospital for elderly care patients, situated 8 miles
away. Hospital A provides the pathology service for patients in hospital B.
Elderly care patients are often transferred between the two hospitals.
In November 1990, Klebsiella pneumoniae was isolated from the blood of a
74 year-old male patient in hospital A. The patient had been in hospital for
2-5 months during which time he had been nursed on two different wards.
The source of the bacteraemia was thought to be the catheterized urinary
tract, though this was not confirmed microbiologically at the time. On disc
testing (30 pg discs), the isolate showed reduced sensitivity to cefotaxime
and ceftazidime. The isolate was referred to the Central Public Health
Laboratory (CPHL) where resistance (minimum inhibitory concentration
[MIC]> 16 mg 1_1) to both antimicrobial agents was confirmed. Following
this probable urinary tract-associated bacteraemia, cefotaxime was added to
the antibiotic set tested routinely against urinary tract isolates from all
urines submitted from inpatients in both hospitals. Between January and
June 1991, a further 19 isolates of cephalosporin-resistant K. pneumoniae
recovered from 17 patients were referred to CPHL where they were
examined in detail as outlined below.
Antimicrobial susceptibility testing
MIC values for a number of antimicrobial agents were determined by an
agar dilution method, using Isosensitest agar (Oxoid) supplemented by 2%
(v/v) lysed horse blood (Advanced Protein Products Ltd.), with an
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inoculum of 104-105 organisms per spot. For nine isolates, the MIC values
for cefotaxime and ceftazidime were determined with and without the
addition of clavulanic acid to the medium at a final concentration of
2 mg 1_1.
Serological and bacteriophage typing
The capsular (K) antigen of each isolate was typed by counter-current
immunoelectrophoresis (CIE).8 Bacteriophage typing was performed as
described previously.9
Plasmid analysis
Plasmids were extracted according to the method of Kado and Liu10 and
subjected to electrophoresis in 0-8% (w/v) agarose gels.
Attempts to transfer cephalosporin resistance
Attempts were made to transfer cefotaxime resistance from K. pneumoniae
to E. coli strain J62-2 (lac~rifr). Equal volumes of broth-grown K.
pneumoniae and E.coli J62-2 (at a concentration of 108—10V colony forming
units [cfu] ml-1) were mixed together and incubated at 37°C overnight.
Serial 10-fold dilutions were then plated out on Isosensitest agar containing
cefotaxime (8 mg l-1) and rifampicin (50 mg 1_1), and incubated at 37°C for
up to 3 days.
P~lactamase identification
Nine isolates were referred to the University of Edinburgh for identification
of P-lactamase activity. The P-lactamase enzymes present in sonicated
extracts of bacteria were identified by analytical isoelectric focusing.11
Results
Description of the outbreak
Between January and June 1991, K. pneumoniae organisms resistant to
cefotaxime and ceftazidime were isolated from urine (nine catheter
specimen samples and eight mid-stream urine samples) from 14 female and
three male elderly patients (age range 67-102 years old). Identical
organisms were also isolated from the blood of one of the patients and from
a wound swab of another. Eleven of the patients had urinary catheters at the
time of isolation or had been catheterized previously.
Four of the patients were in three different wards in hospital B at the time
that the organisms were isolated, and the others were in hospital A. The
relatively insidious and widely spaced nature of the outbreak is shown in
Table I. For 16 of the patients, the interval between admission to hospital
and the isolation of cephalosporin-resistant K. pneumoniae ranged between
two and 12 weeks. Two patients, one in a medical ward and one in an elderly
care ward in hospital A were found to have cephalosporin-resistant K.
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Table I. Patient location and date when Klebsiella pneumoniae K62 resistant to cefotaxime and
ceftazidime was first isolated
No. of patients in indicated month
Hospital Ward type Ward Nov. Dec. Jan. Feb. Mar. Apr. May. June Total
90 90 91 91 91 91 91 91
A Elderly care 11 — 1- - 2* 116
Elderly care 2----1- - -1
A Orthopaedic 1 — — — — — If 1 - 2
Orthopaedic 2 — - — - - 1 2-3
A Surgical ]
A Medical i _____ _ 1 l
B Elderly care 1 — — 1 — — — — — 1
Elderly care 2 — — 1 - 1 — — -2
Elderly care 3 — — — — — 1 — — 1
Totals 1 0 3 1 2 5 4 2 18
* One patient had isolates from blood and urine, f Isolates from wound swab and urine.
pneumoniae in urine samples collected within one day of admission. Each of
these patients had previously been admitted into the same elderly care ward
in hospital A in September and November 1990 respectively. All of the
patients from whom cephalosporin-resistant f. pneumoniae was isolated
had received antibiotics for treatment or prophylaxis following their
hospital admission. Twelve patients had received one or more
cephalosporins (cefotaxime, ceftazidime or cephradine), 11 patients had
received a fl-lactam (amoxycillin or flucloxacillin) and three patients had
received trimethoprim, a drug to which the organism was also resistant (see
below). Three patients had been transferred between the two hospitals
during the course of their,admission and six patients had been transferred
between wards within hospital A.
Antimicrobial susceptibility
All the isolates were resistant to a range of p-lactam antimicrobial agents
including ampicillin (MIC > 64 mg l-1), carbcnicillin (MIC > 256 mg l-1),
piperacillin (MIC> 64 mg 1_1), cefuroxime (MIC> 32 mg l-1), cefotaxime
(MIC > 16 mg P1) and ceftazidime (MIC> lo mg P1). For nine isolates
tested, (six were from patients in five different wards in hospital A and three
were from patients in two wards in hospital B), the MIC value for
cefotaxime was reduced from 512 mg P1 to 10 mg P1 or less in the presence
of clavulanic acid, while the MIC value for ceftazidime was reduced from
more than 128 mgP1 to 4mgl~1 or less. This observation suggested that
resistance to these agents was due to ESBL activity. Analysis of these nine
isolates by analytical IEF revealed identical ^-lactamase activity, with two
bands of pi 7 0 and 7 6 being detected. The former band most probably
reflected production of the ESBL SHV-3, while the band with a pi of 7 6
indicated the production of either SHV-1 or the ESBL SHV-2 (the two
enzymes have identical pi values). Attempts to transfer cefotaxime
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resistance from six of those isolates to E. coli in vitro were unsuccessful.
All the isolates were additionally resistant to tetracycline (MIC = 8 mg l-1)
and trimethoprim (MIC>8mgl-1) but susceptible to amikacin
(MIC^2 mg l-1), gentamicin (MIC^ 1 mg l_l), tobramycin (MIC^ 1 mg l1)
and ciprofloxacin (MIC = ^0-25 — 1.0 mg 1_1).
Evidence for spread of a single strain
All the isolates exhibited a number of common phenotypic characteristics
indicating that they were related epidemiologically. They all belonged to
serotype K62, were non-typable or reacted weakly with bacteriophage and
had the same antibiogram, as described above. The first 15 isolates referred
to CPHL were examined for plasmids and were all found to contain a
plasmid of c. 100 Md in size, with two of these isolates containing an
additional plasmid of 40 Md and two containing two additional plasmids of
40 Md and 2 Md. The two isolates harbouring an additional 40 Md plasmid
only were isolated from the first case in November 1990 and from a patient
in an elderly care ward in hospital A in January 1991. The two isolates
harbouring additional plasmids of 40 Md and 2 Md were isolated from a
patient in an elderly care ward in hospital B in March 1991, and from a
patient in the orthopaedic ward in hospital A in April 1991, respectively.
The latter two patients had not been transferred between wards prior to the
date that these organisms were isolated from them.
Discussion
This report describes an outbreak of infection (including two bacteraemias)
in two UK hospitals involving K. pneumoniae resistant to the third
generation cephalosporins cefotaxime and ceftazidime. The mechanism of
cephalosporin resistance involved ESBL activity, as shown by inhibition of
cephalosporin resistance by clavulanic acid and by IEF analysis of bacterial
extracts which demonstrated the presence of SHV-3 together with a second
enzyme which was either SHV-1 or SHV-2.
The evidence for nosocomial transmission of a single strain is that isolates
from each of eighteen infected patients belonged to the same serotype
(K62), were non-typaKe or reacted only weakly with bacteriophage, and
exhibited identical patterns of susceptibility or resistance to a range of
non-P-lactam antimicrobial agents. In addition, each of nine isolates
examined exhibited identical P-lactamase activity when analysed by IEF.
Although each of the 15 isolates examined harboured a plasmid of c. 100 Md
in size, there was some variation with regard to the presence or absence of
other plasmids, with two isolates harbouring a plasmid of c. 40 Md, and two
harbouring plasmids of about 40 Md and 2 0 Md. There was no obvious
epidemiological link between isolates containing more than one plasmid.
Although ESBL activity is frequently encoded on transferable plasmids,4
repeated attempts to transfer cephalosporin resistance from the outbreak
strain to E. coli in vitro were unsuccessful. The observation that resistance
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to cefotaxime and ceftazidime was not detected in other serotypes of K.
pneumoniae or in other bacterial species in the hospital suggests that the
gene encoding cephalosporin resistance may not be readily transferable
either in vitro or in vivo.
At present the epidemiology of the outbreak has not been defined.
Information concerning factors such as faecal or skin carriage by patients
and staff is not yet availabie. It is likely, however, that spread of the strain
between a total of 10 wards in two hospitals is related to the frequent
transfer of patients between wards. In addition, the observation that all the
patients from whom the strain was isolated had received one or more
courses of antimicrobial agents to which the strain was resistant, suggests
that usage of such agents may provide a selective pressure for the spread of
such strains. Although detailed epidemiological data are not available, it is
reasonable to assume, for the time being, that the underlying epidemiology
of the outbreak is likely to resemble that suggested previously for
nosocomial Klebsiella spp.12
Attempts to control the outbreak included re-inforcement of standard
infection control procedures. In addition, clinicians were advised to avoid
monotherapy with injectable cephalosporins in the empirical therapy of
bacteraemia pending microbiological confirmation. Selective digestive tract
decontamination, as reported by Taylor and Oppenheim6 in relation to an
ITU outbreak is not a suitable option for relatively long-stay elderly care
patients.
The origin of the strain of K. pneumoniae causing the present outbreak is
not known. Organisms of serotype K62 are relatively uncommon in the UK
comprising only 3 5% of strains of K. pneumoniae submitted to CPHL for
typing (B. Ayling-Smith, unpublished). A strain of K. pneumoniae K62
resistant to cephalosporins has been described in a hospital in Ghent,
Belgium but differed from the strain described here in that it did not
produce the ESBL SHV-3, but produced either an enzyme with a pi of 6 5
designated CAZ-hi or an enzyme with a pi of 7-5 designated FUR-2.'3 A
strain of K. pneumoniae producing SHV-3 has been described in a hospital
in Paris, but the serotype of the strain was not reported.14 Irrespective of the
origin of the strain described in the present report, microbiologists and
clinicians need to be aware that cephalosporin-resistant K. pneumoniae
capable of intra- and inter-hospital spread is now to be found in the UK.
Elderly care patients, intermittently or continuously catheterized for
urinary drainage and who are often transferred between wards and hospitals
may be a special risk group for the acquisition and dissemination of such
organisms.
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words such as "You can be sure that I will be giving you all the
results as soon as I receive them and I will tell you only the truth".
Truth leads to trust. Touching leads to trust. Trust is never more
critical than in the optimum managment ofpatients who have had to
be given bad news. I would also emphasise the importance of never
withholding the bad news from any mentally competent adult, no
matter what advice may be received from relatives or others.
Alan McGuinness Gastroenterology Unit,
Sydney Hospital,
Sydney. NSW 2000. Australia JOHN R. GRAHAM
Compliance and tuberculosis treatment
Sir,—Your April 6 editorial (p 823) states that "Doctors no
longer have the right—if, indeed, they ever had—to expect patients
to comply with their advice, whether proscriptive or prescriptive".
We strongly support this tenet; however, we suggest one major
exception. Tuberculosis is spread almost exclusively by human-to-
human aerogenic transmission: when a patient with pulmonary
disease coughs, he generates an aerosol containing tubercle bacilli
which may then be inhaled by others. We contend that doctors have
not only the right but also the obligation to see that the patient
adheres to the prescription (chemotherapy) or the proscription
(quarantine). On the premise that the tubercular patient potentially
infringes the right of a citizen to be free of disease, laws throughout
the US strictly constrain public access for patients with
communicable (untreated) pulmonary tuberculosis. Failure on the
part of physicians to be assertive in ensuring regular administration
ofantituberculosis medications has dire consequences: high rates of
treatment failure/relapse, continued contagion, and acquired drug
resistance.
With the closure ofsanatoria and the abolition ofmost specialised
tuberculosis clinics, tuberculosis treatment in North America and
Europe has been "mainstreamed" into the general health care
system over the past three decades. Unfortunately, during this era
non-compliance has become the major impediment to the
successful treatment of these patients.1 A major element in this
trend has been the laisser-faire policy represented by your editorial
position on the care of these patients. Medication cannot be forced
upon unwilling patients by the practitioner or the state; however,
aggressive, large-scale programmes of directly observed or
supervised therapy should be used for those proven to be or at high
risk of being non-compliant with therapy. Every effort should be
made to induce adherence to treatment—and if this cannot be
accomplished and the patient(s) remain contagious, public agencies
should be willing to quarantine such individuals. Although this
always has been a defensible proposition, it is even more compelling
in an era of HIV which has seen a substantial increase in
tuberculosis case rates in many regions, including epidemics of
multiply resistant disease in several locations in the United States.
Clinical Mycobactenology Service,
Division of Infectious Diseases,
National Jewish Center
for Immunology and Respiratory Medicine.
Denver, Colorado 80206, USA;
and University of Colorado School of Medicine \ilCHAEL D. ISEMAN
University of Colorado School of Medicine.
Denver. Colorado • JOHN A. SBARBARO
1. Fox W. Compliance of patients and physicians: experience and lessons from
tuberculosis, I. Br MedJ 1983; 287: 33-35.
Frequency of rhodopsin codon 23 mutation
and retinitis pigmentosa
Sir,—Although those of us with an interest in retinitis
pigmentosa fRP) welcomeDr Sorscher and Dr Huang's description
(May 11, p 1115) of a rapid method to detect a particular rhodopsin
mutation, we feel that they make several misleading statements that
should be clarified. Firsdy, they state that the frequency of
autosomal dominant RP (ADRP) in the general population is
"about 1 in 3500". The prevalence ofall types ofRP is indeed in this
region, but the ADRP subgroup represents only 19-26% of the
total, which includes autosomal recessive and X-linked forms as
well as a sizeable sporadic group.1 Secondly, Sorscher and Huang
ambiguously state that the rhodopsin codon 23mutation was seen in
17 of 148 individuals "with the disease"—referring to a series of
unrelated ADRP patients of North American origin.2 It should be
noted, however, that this point mutation was not found in
ninety-one unrelated European ADRP families-1 and that many
other rhodopsin mutations have since been found in ADRP
families.-15 A large number of ADRP families are unlinked to this
region and therefore represent mutation(s) at other remote
gene(s).6"
We welcome the ingenious methods that Sorscher and Huang
present for mutation detection, but they have unintentionally
inflated both the frequency ofADRP and of the rhodopsin codon 23
mutation, which is responsible for the disease in a small proportion
of RP patients.
MRC Human Genetics Unit, ._ TT ▼
Western General Hospital, DOUGLAS H. LESTER
Edinburgh EH4 2XU, UK ALAN F. WRIGHT
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Sir,—The incidence of Enterobacteriaceae with resistance to
third-generation cephalosporins due to plasmid-mediated,
expanded-spectrum P-lactamases (ESBL) may be underestimated.
We report here three ceftazidime-resistant Klebsiella pneumoniae
strains isolated in a London hospital during 1990.
Case 1 (16, F; Guillain-Barre syndrome). She had been
transferred from an Athens hospital. Her urine grew Kpneumoniae
(serotype K69) but antibiotics were not required during her
2-month hospital stay in London. Minimum inhibitory
concentrations (MICs) were estimated on 'Isosensitest' agarwith an
inoculum of 104 colony-forming units and aerobic incubation for
18 h. An MIC above 2 mg, 1 is taken as indicating resistance to
ceftazidime.1 The MIC of ceftazidime was 64 mg;l, falling to 0-25
mg/1 on addition of 2 mg; 1 clavulanic acid, which inhibits ESBL.
Case 2 (28, M; quadriplegia). He was admitted with urinary
retention and fever. K pneumoniae (non-typable) was isolated from
both urine and blood. The MIC of ceftazidime was 512 mg/1,
reduced to 4 mg/1 by clavulanic acid. The strain was also resistant to
gentamicin and netilmicin. He was successfully treated with
intravenous amikacin after a lack of response to 24 h of intravenous
cefotaxime 2 g three times daily. He had been an inpatient in two
other London hospitals in the previous 5 years, with no history of
foreign travel.
Case 3 (17, M; neutropenia after bone-marrow transplantation
for acute myeloid leukaemia). He became febrile a week after the
graft (day 1) and the fever persisted despite empirical antibiotic
therapy. Kpneiononiae was isolated from blood culture on days 8,
12, and 15. By day 15 theMIC of ceftazidime was 32 mg 1, reduced
by clavulanic acid to 1 mg. 1. Imipenem 500 mg lour times a day was
started on day 15, the organism being sensitive by Stokes' method,
and he became apyrexial within 24 hours. On day 21 fever returned,
with profound hypotension, and K pneumoniae was again isolated
from blood culture. The MIC of ceftazidime was now 512 mg 1,
reduced to 4 mg/1 by clavulanic acid. Doubling the dose of
imipenem resulted in a second defervescence and a slow clinical
recovery. All isolates were serotype K48.
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All patients were nursed in isolation and no secondary cases
occurred. The klebsiella strains showed resistance to cefotaxime and
aztreonam, and up to five further classes ofantibiotics. Resistance to
third-generation cephalosporins was successfully transferred to
Escherichia coli J62 from the Kpneumoniae strains from the first two
cases, consistent with these ESBLs being plasmid-mediated; and
plasmids of 60 and 70 MD, respectively, were found on agarose gel
electrophoresis.
These three cases illustrate the possible origins of organisms
producing ESBLs—namely, international transfer with the patient,
inter-hospital transfer, and selection of the resistant strain within
a hospital. Nosocomial outbreaks of ESBL-producing
Enterobacteriaceae withmultiple resistance2 to a range of antibiotic
classes have occurred in Europe3 4 and the USA.5 The continued use
of third-generation cephalosporins exerts substantial selection
pressure in favour of ESBL-producing organisms and also for the
evolution6 ofESBLs. This, togetherwith the introduction ofsimilar
oral cephalosporins, such as cefixime, into the community, should
prompt laboratory surveillance for such strains. We suggest a
variauon of the double-disc synergy test3 on isolates showing
moderate resistance to cefotaxime. Should the use of third-
generadon cephalosporins be restricted?7
We thank Dr T. L. Pitt, Central Public Health Laboratory, for serotvping
the isolates, and Prof J. M. T. Hamilton-Miller and Dr S. H. Gillespie for
advice and comments.
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In-vivo monitoring of neuronal loss in
Creutzfeldt-Jakob disease by proton
magnetic resonance spectroscopy
Sir,—The advent of bovine spongiform encephalopathy has
renewed interest in novel approaches to the clinical diagnosis of
spongiform encephalopathies such as Creutzfeldt-Jakob disease
(CJD). We have seen a case of sporadic CJD where the only
magnetic resonance imaging abnormalities were mild cortical
atrophy and hyperintensities in the lentiform nuclei, as noted
previously.1 By contrast, proton magnetic resonance spectroscopy
(MRS) demonstrated significant metabolic alterations in cortical
grey matter and white matter and in striatum. Right frontal lobe
biopsy, done 2 days alter these scans, revealed fine vacuolation of
the neuropil (spongiform change; in the deep grev-matter with a
slight loss of neurons and gliosis, consistent with CJD.
After a cold in August, 1990, a 53-year-old woman had difficulty
sleeping and complained of dizziness. When cycling she found it
hard to keep her balance. A neurologist noted trunk and gait ataxia
and a tremor of her right thumb. By October she had become
forgetful, had difficulty expressing herself, and her speech was
NAA
Cho
4.0 3.5 3.0 2.5 2.0
Chemical shift / ccm
Fig 1—Localised proton MR spectra of parietal white-matter.
Upper; Patient with CJD, exhibiting reduction of NAA and PCr Cr and
increase in Ins.
Lower: control.
Major metabolites include N-acetylaspartate (NAA), glutamate (Glu),
creatine (Cr), and phosphocreatine (PCr), choline-containing
compounds (Cho), and myo-inositol (Ins). Volume of interest 1 2 ml.
slurred. Nocturnal anxiety and paraspasticity ensued and she was
admitted to hospital in November. Her ataxia worsened as did her
memory. Paranoid-hallucinatory states required treatment with
haloperidol for a week. In December a progressive left-sided
spasticity developed. Dysarthria further impeded her speech and
she became demented. CSF analysis revealed oligoclonal banding.
EEGs revealed diffuse slow and a-range complexes with temporo-
occipital sharp wave 0 and 6-complexes. No 1-2 Hz periodic sharp
wave complexes (PSWC) were seen. In February, 1991, the patient
was in a coma and showed spontaneous myoclonus, predominantly
in her right arm. An EEG showed PSWCs, supporting the
diagnosis of CJD.2 In March localised proton MRS was done with
20 ms echo-time stimulated-echo sequences (2 0 T Siemens
'Magnetom').3 Measuring times were 6-5 min with 128
accumulations and repetiuon times of 3 s.
Fig 1 shows the proton MR spectrum of the left parietal
white-matter of the parient, compared with that of a 56-year-old
healthy female control. The N-acetylaspartate (NAA peak was
reduced (40%), as was the creadne, phosphocreatine rario (10%);
there was an increase in inositol (30%). Similar findings were
observed contralatcrally and in frontal white-matter except for
slightly lower values of cholinc-containing compounds. Two
volumes of interest in predominantly grey-matter were investigated
in paramedian frontal and parietal locauons; only NAA was
diminished (30%) (fig 2). MRS in the hyperintense region of the
striatum showed a fourfold loss of metabolites. The remaining
metabolite pattern exhibited a further reduction ofNAA relative to
creatines and cholines.
A. A. MacDonald
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Can clavulanic acid reverse extended-spectrum P-lactamase mutations?
S.K. Du Bois1*, M.S. Marriott2, and S.G.B. Amyes1
Edinburgh University, Edinburgh, U.K., 2Glaxo Group Research Ltd, Greenford, U.K.
The SHV- and TEM-derived extended-spectrum P-lactamases (ESBL), have emerged as a
response to the clinical use of the third-generation cephalosporins (3GCs), and have become an
enormous clinical threat to this class of pharmaceuticals. Escherichia coli J62-2
(TEM-5pCFpi4) was cultured in liquid media containing limiting concentrations of amoxycillin
and clavulanic acid (ratio 2:1) (co-amoxiclav). The cultures were sub-cultured five times into
fresh media containing the same antibiotics. Ten colonies were purified from each sub-culture.
Minimum inhibitory concentrations (MICs) of ampicillin, amoxycillin, ceftazidime, cefotaxime
and co-amoxiclav revealed a few strains with increased resistance to co-amoxiclav, ceftazidime
and cefotaxime. Isoelectric focusing demonstrated that the increased resistance corresponded
with multiple p-lactamase expression (pi 5.57, 5.5 & 5.25). Electrophoresis of plasmid DNA
confirmed that each organism contained a single plasmid, of similar size to pCFF14 (150-kb).
Analysis of enzyme kinetics of each P-lactamase compared to TEM-1 (pi 5.4), TEM-5
(pi 5.5), TEM-10 (pi 5.57) and TEM-12 (pi 5.25) suggested that the unknown p-lactamases
were TEM-5, TEM-10 and TEM-12. Southern blotting of restricted plasmid DNA showed
gene duplication in the mutant plasmid (pUK3007) when compared to the parent plasmid
(pCFF14). E. coli 362-2 (pUK3007) was cultured in liquid media containing limiting
concentrations of co-amoxiclav. The cultures were sub-cultured 20 times into fresh media
containing the same antibiotics. Analysis of strains revealed that anomalous MICs of
co-amoxiclav, cefotaxime and ceftazidime corresponded to the presence of two one of two
P-lactamases (pi 5.5 & 5.4). Plasmid DNA was of similar size to pUK3007, and Southern
blotting showed the presence of one or two TEM P-lactamase genes. Enzyme kinetics of each
p-lactamase suggested that the unknown enzymes were TEM-5 and TEM-1. Our results
suggest that clavulanic acid, in combination with amoxycillin, selects back mutations from
ESBL to TEM-1 by a mechanism of gene duplication.
J. Med. Microbiol. — Vol. 36 (1992), 4-29
© 1992 The Pathological Society of Great Britain and Ireland
REVIEW ARTICLE
Antibiotic resistance in bacteria
—a review based on a symposium held on 5 January 1991 atAddenbrookes Hospital, Cambridge and chaired by
Professor J. T. Smith
Edited by S. G. B. AMYES and C. G. GEMMELL*
Department of MedicalMicrobiology, The Medical School, University ofEdinburgh, Teviot Place, Edinburgh EH8 9AG
and *Department of Bacteriology, The Medical School, University of Glasgow, Royal Infirmary, 86 Castle Street,
Glasgow, G4 OSF
Introduction
Antibiotic resistance tends to be discussed by groups who
work on related antibiotics. The symposium, which provided
the basis for this review, was a rare opportunity for scientists
working on quite different aspects of resistance to present
and discuss their results. Much emphasis has been placed on
the mechanisms of resistance and the first five papers reflect
this. They demonstrate the quite different resistance prob¬
lems encountered with each class of antibacterial drug. The
remaining four papers take a different, and often less
expressed approach, examining the impact that resistance
has on clinical populations and our ability to treat the
patient. These papers examine the effect that resistance has
on the virulence and pathogenicity of bacteria and how the
host is affected by resistant strains. This section ends with
views about the future of antibiotics.
Resistance to antifoliate antibacterial
agents
K. J. Towner
DepartmentofMicrobiology andPHLS Laboratory, University
Hospital, Nottingham NG7 2UH
The folate pathway occupies a central metabolic role
leading to protein and nucleic acid synthesis (fig. 1). Two
types of antifolate agent have gained wide acceptance and
are ofclinical importance: (i) the sulphonamides, that inhibit
the bacterial enzyme dihydropteroate synthetase (DPS),
which catalyses the reaction ofp-aminobenzoic acid (PABA)
with a pteridine derivative and are selectively toxic for
bacteria because man does not require this enzyme; (ii)
trimethoprim, that inhibits the ubiquitous enzyme dihydro-
folate reductase (DHFR), and is selectively toxic because its
affinity for the bacterial enzyme is some 10 000-fold greater
than that for the mammalian enzyme. Following its initial
introduction, trimethoprim was prescribed originally only
in combination with a sulphonamide, usually sulphamethox-
azole, for reasons which, at the time, seemed justified, but
upon which, for many applications, substantial doubt was
subsequently cast.1,2 In this paper, acquired resistance to
sulphonamides and trimethoprim is summarised with partic¬
ular reference to recent developments in molecular biology



















Fig. 1. Reactions involve in the folate pathway.
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Although a prime requirement is to distinguish between
intrinsic and acquired resistance, other difficulties have been
caused in the past by the use of different definitions for the
term "resistant". In addition to the fact that clinically
relevant resistance is not the same as laboratory-determined
resistance, particular problems arise in susceptibility to
sulphonamides and trimethoprim in relation to choice of
resistance breakpoints, inoculum size and the correct
medium.3 Other local factors, such as the occurrence of
epidemic strains, or selection and choice of particular
specimens and patients, may greatly influence the "inci¬
dence"of resistant strains. Therefore, assessmentsofchanges
4
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number is inadvertently used by different investigators
for different enzymes or genes. Gene probes for each
of the existing recognisedDHFR types can be supplied
so that investigators can ensure that they are not
duplicating previous work. We would also request that
when each investigator is ready to confirm the
identification of a new gene, a copy of the new gene,
or the appropriate probe, should be donated for future
distribution. By this approach, although DHFR type
numbers will gradually less reflect biochemical prop-
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Table I. Incidence of resistance to sulphonamides (Su) or trimethoprim (Tp), or both, among
isolates of enterobacteria causing urinary tract infection from the Nottingham area
Species
Percent of isolates that were Total per cent that were
SuRTps SuRTpR SusTpR SuR TpR
E. coli Hosp. 20-2 14-3 5-1 34-5 19-4
Comm. 18-3 13-3 4-3 31-6 17-6
Klebsiella/Entero- Hosp. 7-6 10-2 5-7 17-8 15-9
bacter spp.
Comm. 9-8 110 8-2 20-8 19-2
Proteus spp. Hosp. 4-0 7-7 14-3 11-7 220
Comm. 3-7 6-3 15-5 100 21-8
R, resistant; S, sensitive.
* Resistance was defined as described previously,7 with breakpoints of trimethoprim lactate 8 /tg/ml and
sulphamethoxazole 16 tig/ml.
in resistance are more significant if they are made from long-
term follow-up surveys in a single centre, and several such
surveys have been performed with isolates of Enterobacter-
iaceae from different parts of the world.4
Table I summarises the latest available data (1989) on the
incidence of resistance to sulphonamides and trimethoprim
among isolates of Enterobacteriaceae causing urinary infec¬
tion from the Nottingham area. The incidence of sulphon-
amide resistance has remained stable for many years, but
the incidence of resistance to trimethoprim has increased
considerably since surveillance commenced in 1978.5 With
the exception of localised outbreaks of infection with
resistant strains, comparable incidences of resistance in
Enterobacteriaceae are also found generally in other devel¬
oped countries.4 In contrast, the incidence of resistance to
sulphonamides or trimethoprim, or both, in developing
countries tends to be considerably higher (30-60% in general
hospital isolates of Escherichia coli ).4'6 These higher
incidences probably reflect the epidemic spread ofparticular
resistant strains, plasmids or transposons in response to the
continuous selection pressure imposed by the careless or
unregulated use of trimethoprim and other antibiotics.
Table I also provides an interesting illustration of the
effect of changes in selection pressure. Trimethoprim was,
originally, prescribed always in combination with a sulphon-
amide. Consequently, all strains resistant to trimethoprim
were also resistant to sulphonamides. Trimethoprim became
available for use alone in the UK in 1979 and, since then,
the proportion of strains resistant to trimethoprim and
susceptible to sulphonamides has increased steadily7 to the
levels shown in table I. In the light of earlier controversy,1'2
it is interesting, although rather academic, to speculate as to
whether the same overall incidence of trimethoprim resist¬
ance in Enterobacteriaceae would have been reached so
rapidly had trimethoprim continued to be prescribed only in
combination with a sulphonamide.
The situation in gram-positive bacteria is somewhat
different. Although resistance to sulphonamides has been
known for many years, the incidence of acquired trimetho¬
prim resistance remained negligible until the advent of
methicillin-resistant staphylococci (MRS) in the early 1980s.
A considerable number of MRS are resistant also in
trimethoprim,4 but the overall frequency of strains with
resistance to both methicillin and trimethoprim varies
widely among strains of different origin, depending largely
on the occurrence of outbreaks of infection involving
particular resistant strains, but is generally low.4
Mechanisms ofresistance to sulphonamides
Resistance to sulphonamides may be encoded either by
the chromosome or by plasmids. Chromosomal mutations
leading to hyper-production of PABA occur and these
overcome the metabolic block imposed by the inhibition of
DPS by sulphonamides, but they seem to be of relatively
minor clinical importance. The commonest mechanism of
resistance is the production of an altered form of DPS for
which sulphonamides have a reduced affinity. Although
chromosomal mutations leading to the production of such
altered enzymes may occur, most clinically significant
sulphonamide resistance is associated with the production
of altered forms of DPS encoded by antibiotic resistance
plasmids.
Two distinct types of DPS (I and II) encoded by plasmids
have been characterised in gram-negative bacteria; DPS-I
(encoded by the gene sull), has only 57% nucleotide sequence
homology with DPS-II (encoded by sulll), and their deduced
polypeptides show only c. 50% similarity.8 The sull gene is
often located on transposons related to Tn21, or on large
self-transmissible plasmids that show similarities to Tn21 in
the resistance region.9 In contrast, the sulll gene not only
encodes a different enzyme, but is associated with different
types of plasmids. The DPS-II enzyme is somewhat more
stable in a cell-free extract than DPS-I, and the sulll gene is
carried mainly on small non-conjugative plasmids.8'10 Both
of these plasmid-encoded enzymes can be distinguished
readily from the resistant DPS encoded by the sulA gene on
the chromosome of Streptococcus pneumoniaewith 43%
DNA similarly between sulA and sullor sulll, respectively.8
Mechanisms ofresistance to trimethoprim
Acquired resistance to trimethoprim may also be encoded
by the chromosome or by antiobiotic resistance plasmids.
There is in-vitro evidence that trimethoprim can select for
chromosomal mutants of pathogenic bacteria that lack the
enzyme thymidylate synthetase.11 Such "thy" mutants have
lost the normal ability to synthesise thymidylate and, in
order to grow, require exogenous supplies of thymine or
thymidine to enable them to synthesise thymidylate via the
"salvage" pathway.12 The action of trimethoprim would be
adversely affected by the presence ofsuch exogenous supplies
under pathological conditions, but very few clinical isolates
with this mechanism of resistance have been reported,3
perhaps because of failure to recognise them.
An alternative type of resistance is observed when
mutations lead to overproduction of the normal chromo-
somally encoded DHFR. Mutants of this type have been
obtained from several gram-positive and gram-negative
species in vitro,3 but, again, seem to be relatively rare among
clinical isolates.13 Impermeability mutants have also been
reported in a various genera, and are of particular interest
because of the reported cross-resistance between trimetho¬
prim and other antibiotics such as the quinolones.14
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However, as with the sulphonamides, the commonest
mechanism of acquired resistance to trimethoprim results
from the production of an insusceptible target enzyme.
Mutant forms of the normal susceptible DHFR encoded by
the chromosome have been found occasionally in clinical
isolates,13 but by far the most important and commonest
mechanism of resistance is associated with the production
of an additional, insusceptible, form of DHFR encoded by
genes located on self-transmissible or mobilisable plasmids
and transposons.4 The remainder of this section is devoted
to a brief description of these enzymes and the possible
evolutionary relationships between them.
Plasmid-mediated trimethoprim resistance was domi¬
nated initially by the spread of genes encoding DHFR types
I and II, but seven major groups (types I—VII) of DHFRs
insusceptible to trimethoprim have now been characterised
in gram-negative bacteria. Several of these major groups are
further divided into subtypes, and an additional insuscepti¬
ble DHFR (type SI) has been characterised in staphylococci.
The identification of each of these enzyme types on the basis
ofbiochemical and biophysical properties has been reviewed
previously4 and, as with the plasmid-encoded ^-lactamases,
further DHFR types probably await discovery. Indeed, it
should be noted that two DHFRs isolated independently in
the UK and Scandinavia have both been designated "type
Vii" is,i6 remaincier 0f this article refers to the UK
enzyme, but further adjustments in nomenclature may be
required when the precise relationship between these two
enzymes, and the other DHFRs characterised previously,
has been investigated fully.
The time-consuming nature of biochemical identification,
involving the extraction and purification of each individual
enzyme, has encouraged the development of a set of DNA
probes which are capable of distinguishing between the
genes encoding the different enzymes. These probes are
particularly useful for epidemiological studies17 and are
available currently for DHFR groups I-V, VII and SI ,4,18'19
When used in combination with high stringency wash
conditions, the probe set is capable of distinguishing clearly
between the major enzyme groups. One anomaly concerns
DHFR group III, which had originally been thought to
contain three directly related subtypes—Ilia, Illb and IIIc.
Each subtype has similar biochemical properties, albeit with
markedly different iso-eiectric points, and confers only a
moderate level of trimethoprim resistance.4 However, no
hybridisation has been detected between the standard group
III probe (constructed from the type Ilia gene) and the genes
encoding types Illb and IIIc (C. J. Thomson and S. G. B.
Amyes, personal communication). Therefore, it seems
probable that enzymes belonging to these subtypes, although
similar biochemically, may have evolved independently (see
below).
Further investigations of the possible evolutionary rela¬
tionships between the different DHFR groups have been
stimulated, in part, by observations that some of the group-
specific DHFR probes can, when used under conditions of
reduced stringency, react with genes encoding enzymes
belonging to other DHFR groups.4 Several of the enzymes
and genes involved have now been sequenced, with
particular attention being paid to the amino terminal (N-
terminal) region which forms most of the active site for all
DHFRs.
The two subtypes within group I (la and lb) share 71%
amino acid homology and 65% nucleic acid homology with
each other (H.-K. Young, personal communication), but
only 29% amino-acid homology with the susceptible chro¬
mosomal DHFR.4
The three subtypes within group II (Ha, lib and lie) share
extensive (> 78%) amino-acid sequence homology with each
other,4 but are quite unlike any other plasmid or chromo¬
somal DHFR; it has been postulated that they may be
derived from an oxidoreductase which acted originally on a
completely different substrate.
The type Ilia DHFR shares 51% homology with the E.
coli chromosomal enzyme, perhaps suggesting that they may
have shared a common evolutionary origin.4 In contrast, the
type Illb enzyme is clearly distinct from the type Ilia
enzyme, sharing only 15 of the first 47 amino acids in the N-
terminal sequence, and differs also from the E. coli
chromosomal enzyme and the types I, II, V and SI.20 These
observations support the hypothesis, referred to above, that
the subtypes Ilia and Illb, although biochemically similar,
have evolved independently.
The type IV enzyme, like subtype Ilia, shows most
homology (40%) with the E. coli chromosomal enzyme, but
is clearly distinct from the other plasmid-encoded DHFRs.21
The type V enzyme, in contrast, is closely related to the
types la9 and lb (H.-K. Young, personal communication),
with 75% and 87% homology respectively. There is a similar
close relationship between the type VI enzyme and types la
(63% homology) and V (61% homology).22 Sequencing
results for the type VII enzyme are not available yet, but
hybridisation experiments have indicated a close relation¬
ship between the the V and VII genes.19
All of the plasmid-encoded DHFRs from gram-negative
bacteria seem to be unrelated to DHFR type SI from gram-
positive bacteria.4
Envoi
Genes encoding resistance to the main antifolate antibac¬
terial agents, sulphonamides and trimethoprim, are now
distributed widely among bacteria in most environments.
The precise incidence of resistance in local ecosystems is
probably related closely to the extent of the selection pressure
exerted by local usage of antibiotics. Most clinically
significant resistance to antifolates is associated with
plasmid-carried genes, often transposable, which encode
alternative drug-insusceptible target enzymes. Two major
types of plasmid-encoded DPS conferring resistance to
sulphonamides have been characterised, and trimethoprim
resistance is conferred by at least seven major groups of
plasmid-encoded DHFR in gram-negative bacteria, with an
additional plasmid-encoded DHFR in gram-positive bacte¬
ria. Among the gram-negative DHFRs, groups I, V, VI and
VII seem to be closely related, groups Ilia and IV show
some similarities to trimethoprim-susceptible chromo-
somally-encoded enzymes, and group II enzymes seem to be
completely distinct from all other types. The combined use
of biochemical and molecular biological techniques has
enabled the inter-relationships between the different genes
and enzymes to be investigated, and is now providing us
with an insight into the evolutionarymechanisms underlying
the emergence of resistance to the antifolate antibacterials,
and perhaps to antibiotics in general.
Plasmid-mediated ^-lactamases responsible
for penicillin and cephalosporin resistance
S. G. B. Amyes, D. J. Payne* and S. K. du Bois
Department of Medical Microbiology, The Medical School,
University of Edinburgh. *Present address: SmithKline Bee-
chams Pharmaceuticals, Brockham Park, Betchworth, Surrey
RH3 7AJ
Alexander Fleming's major contribution to medical
science was the recognition of the potential of pencillin. He
could not have known that he had stumbled upon a group of
antibiotics that were not only going to prove to be the most
extensively used antibacterial agents throughout the world
but also prove to be the most durable. As with almost every
other group of antibacterial drugs, the emergence of bacterial
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resistance soon threatened their future value. The 50th
anniversary of Abraham and Chain's first discovery of an
enzyme capable of destroying penicillin,23 a /(-lactamase,
has just passed and there is still much debate as to whether
/(-lactamases really do compromise our reliance on this group
of drugs.
If we had had only pencillin G, this battle may have been
lost. The strategy used to overcome /(-lactamase attack was
to modify the antibiotic so that it was no longer capable of
fitting into the active site of the enzyme. This proved
successful for a period with the /(-lactamases produced by
staphylococci. The ability to prepare 6-amino penicillanic
acid and substitute functional groups, which do not allow
the binding of the antibiotic at the active site of the enzyme,
to produce methicillin and the oxacillins, kept the staphylo¬
cocci under control for more than 10 years. However, the
adaptability of the /(-lactamases and the acquisition of a
gene capable of changing the penicillin binding protein
(PBP) 2, has now put many staphylococci beyond the reach
of /(-lactams. Neu demonstrated that, in the developed
world, more than 95% ofnosocomial staphylococci possessed
/(-lactamases.24
The substitution of functional groups on 6-amino penicil¬
lanic acid led to the development of ampicillin, amoxycillin
and carbenicillin and allowed the large Gram-negative rods
to be controlled by penicillins. The widespread use of
ampicillin resulted in the emergence of resistance in 1962.
Anderson and Datta25 showed that resistance to ampicillin
could be plasmid-mediated and thus became freely transfer¬
able from one species to another. However, little distinction
was made between plasmid and chromosomally-determined
/(-lactamases. In 1973, Richmond and Sykes divided all /(-
lactamases into five groups based on the substrate profile
and response to inhibitors.26 The substrate profiles were, at
best, Vmax determinations and often were merely determi¬
nations of rates of hydrolysis at a single fixed substrate
concentration. This value was usually expressed relative to
that obtained with a standard /(-lactam substrate, i.e.,
penicillin G, ampicillin, or cephaloridine. The rate of
hydrolysis allowed a preliminary classification into oxacilli-
nases, carbenicillinases or broad-spectrum drugs. However,
this method of classification had a number of drawbacks. It
did not take account of the affinity of the /(-lactamase for the
substrate (i.e., the Km) nor did it consider amino-acid
sequence homology. It classified all plasmid encoded /?-
lactamases into just two of the groups, based on the
inhibitory activity of cloxacillin.
Ambler27 introduced a scheme based on sequence homol¬
ogy of the amino acids. He identified two classes ofenzyme—
Class A enzymes have a serine group at their active site and
have a mol. wt of c. 29 000. They are either penicillinases or
broad spectrum. These enzymes show considerable homol¬
ogy with D-alanine carboxypeptidase and may have a
common evolutionary origin. Both chromosomal and plas-
mid-determined enzymes fall into the group. Class B enzymes
include metallo-enzymes and have no amino acid homology
with Class A enzymes. Class C was added by Jaurin and
Grundstrom,28 to include /(-lactamases with serine involved
in the active site but very different in structure from Class A
proteins. These enzymes determine cephalosporin resist¬
ance, showing no sequence homology with Class A enzymes.
Huovinen et al., having sequenced the enzyme PSE-229 and
compared its structure with the OXA-2 /(-lactamase,30
proposed a fourth class D; enzymes ofquite distinct substrate
specificities had related structures. The final class, E, was
created for the /(-lactamases from Xanthomonas maltophilia,
metallo-enzymes like Class B but with no sequence homology
with Class B.31 This scheme again classified all plasmid-
encoded /(-lactamases into two groups, which were still very
broad. Indeed, some of these enzymes within a class show
less than 40% homology with other /(-lactamases.
Huletsky et al.32 recently reported the phylogenetic
relationships between the Class A /(-lactamases that have
been sequenced. His cladogram showed a vast diversity in
amino acid structure, with as little as 35% homology,
although the basic shape of the molecule is conserved.
Whereas this scheme may indicate how related enzymes
may be, it cannot be extended to allow comparison of /(-
lactamases in the clinical situation. This is demonstrated
with three enzymes in this group, TEM-1, TEM-3 and SHV-
1. TEM-1 and SHV-1 are very similar biochemically; they
hydrolyse penicillins and early cephalosporins, but not later
cephalosporins. However, they are phylogenetically so far
apart that a gene probe for one will not hybridise with the
other as there is only 65% homology. On the other hand,
TEM-1 and TEM-3 have 99% sequence homology,33 but
TEM-3 has the distinction that it can hydrolyse, and confer
resistance to, ceftazidime and cefotaxime. This difference
has immense clinical significance. Gene probing with a
TEM-1 gene probe cannot distinguish it from the TEM-1
gene.
In the clinical environment, change in enzyme structure
is a relatively slow occurrence and happens in small stages.
Therefore, a scheme distinguishing enzymes or genes must
be very sensitive. This problem was ameliorated by the
development of iso-electric focusing by Matthew and
colleagues.34 This technique, relying on the characteristic
iso-electric point (pi) of enzymes, can, at its highest degree
of sophistication, detect single amino acid differences in
certain parts of the molecule. An equally sensitive technique,
still much in its infancy, is the use of oligonucleotides
designed to identify one nucleotide change. However, its
success relies on the correct choice of probes. Iso-electric
focusing has been the technique universally used and it has
been combined with substrate profiles for finer distinction.
At first, these compared relative rates at fixed substrate
concentrations but, more recently compared relative Vmax
values or relative rates of efficiency (Vmax/Km).
Several surveys performed in Europe during the 1980s,
employing these techniques,35-37 demonstrated that the
TEM-1 /(-lactamase was by far the most prevalent plasmid-
encoded enzyme, responsible for up to 80% of the ampicillin
resistance mediated by plasmids in gram-negative rods. The
next most prevalent enzyme was TEM-2, which varies by
one amino acid change from glutamine to lysine at position
37 (on the Sutcliffe numbering scheme). This change
produces no apparent alteration in biochemical properties
or resistance phenotype. Thus, we can assume that, as far as
/(-lactam substrates are concerned, these enzymes are
identical, and that their relative distributions of about 8:1
come from the relative success of the transposons on which
the genes are carried. An equally prevalent enzyme, SHV-1,
though phylogenetically distinct, again has very similar
properties. The proportion of gram-negative bacteria resist¬
ant to ampicillin can vary in the developed world but is
usually quite high. A survey in Scotland showed that the
proportion was 45% isolates from Edinburgh, but was 70%
in similar strains from Glasgow. India has the highest
incidence of plasmid-mediated resistance. In 1984, 81% of
all Enterobacteriaceae were ampicillin-resistant including
77% of strains E. coli.38 In this study, there was a wide
distributionofplasmids ofmany different types. An epidemic
of one plasmid type was not being observed and the
proportions of individual /(-lactamases was significant.
Again, the TEM-1 enzyme was most prevalent, found in
>70% of strains. Surprisingly, OXA-1 was more common
than TEM-2. However, even in an area where resistance
was so prevalent, the number of diffent /(-lactamases was
quite small. Most of the plasmid-mediated /(-lactamases
capable of hydrolysing just ampicillin and first-generation
cephalosporins have been found on very few occasions.
About 30 of these plasmid-encoded /(-lactamases capable
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of hydrolysing penicillins and early cephalosporins have
been described; however, only five or so are found with any
regularity.39
The prevalance of the TEM-1 //-lactamase has forced
pharmaceutical companies to seek alternative strategies.
This has largely been achieved in two ways: (i) the concurrent
use of //-lactamase inhibitors; (ii) the development of drugs
which are resistant to //-lactamase attack, //-lactam//?-
lactamase inhibitors have proved remarkably successful.
There are few reports of plasmid-mediated resistance and
these have largely been confined to reports of hyperproduc-
tion of TEM //-lactamases.
Ceftazidime and cefotaxime were considered, at their
launch, to be as close to perfection in the design of //-lactam
drugs as was possible to achieve. In one area, it was virtually
guaranteed that they would not fail—there would never be
plasmid-mediated resistance. In 1982, a change took place
which destroyed this guarantee. It was so small that it was
missed at the time. A Klebsiella oxytoca strain, originally
isolated from the blood and CSF of a baby in a neonatal
intensive care unit in Liverpool, was gentamicin-resistant
but ceftazidime-sensitive and it produced the TEM-1 //-
lactamase. A subsequent isolate of K. oxytoca from this unit
showed that it had now become ceftazidime-resistant. In a
series of experiments performed 6 years afterwards, the
ceftazidime resistance was found to be carried on a 141-kb
auto-transferable plasmid. Biochemical analysis showed
that the enzyme hydrolysed ceftazidime at a low, but
significant, efficiency. The equivalent enzyme could be
obtained by a single-step mutation from the TEM-1 //-
lactamase and the Liverpool enzyme was designated TEM--
E2.40 Most of these enzymes have been found in continental
Europe. In 1983, three strains of K. pneumoniae and one of
Serratia marcescens were isolated which conferred resistance
to cefotaxime. The //-lactamase was plasmid-mediated and
a modification of the ubiquitous klebsiella enzyme, SHV-
1,41 A glycine residue at position 236 had changed to serine.
There followed an explosion of reports of new, plasmid-
mediated extended-spectrum //-lactamases.
There are now nearly as many plasmid-mediated ex¬
tended-spectrum //-lactamases as there are plasmid-me¬
diated //-lactamases capable ofhydrolysingmerely ampicillin
or early cephalosporins. Almost all of them are derivatives
of TEM-1/2 or SHV-1 //-lactamases. The maximum number
of mutations is three amino acids from TEM-1, TEM-2 or
SHV-1 //-lactamases.
It is difficult to assess whether these enzymes are clinically
of great significance. Certainly, there have been outbreaks
of resistance caused by these //-lactamases. The best
documented was the epidemic of TEM-3 in K. pneumoniae
strains isolated in French hospitals. This enzyme was found
in nearly 500 strains.42 Recently, there has been an
equivalent epidemic of bacteria containing TEM-like en¬
zymes in the USA.43 Generally, the emergence of these //-
lactamases has been sporadic and localised, the vastmajority
of enzymes being found on very few occasions. This may
reflect different localised usages of extended spectrum //-
lactam agents, in particular those related to ceftazidime and
cefotaxime.
Payne and Amyes44 have grouped these //-lactamases
according to their hydrolysis properties (table II), in a similar
manner to the Richmond and Sykes Scheme.26
In Group 1, there are enzymes which hydrolyse both
ceftazidime and cefotaxime poorly. In most cases, they
hydrolyse cefotaxime with slightly greater efficiency than
ceftazidime—this is paradoxical as they confer greater
resistance to ceftazidime, which probably results from the
superior penetration of cefotaxime.
Group 2 consists of those enzymes capable of hydrolysing
ceftazidime more efficiently than cefotaxime and, generally,
confer much higher levels of resistance to this drug. Some
would not produce clinically significant resistance to cefotax¬
ime as the level of resistance is insufficient.
Group 3 is the largest group and comprises those enzymes
that hydrolyse cefotaxime more efficiently than ceftazidime.
However, probably for reasons similar to those with the
Group 1 enzyme, resistance to cefotaxime is rarely higher
than ceftazidime. We have divided this group into (a) those
derived from TEM enzymes, (b) all the SHV-derived
extended-spectrum //-lactamases, and (c) two enzymes—one
from Japan and one from India—of unknown origins.
All these enzymes confer little, ifany, significant resistance
to the combination of a //-lactam agent and //-lactamase
inhibitor, particularly clavulanic acid. Therefore, such
combinations should remain effective. However, a new
plasmid-mediated //-lactamase which confers resistance, not
only to extended-spectrum //-lactam agents but also to //-
lactam///-lactamase inhibitor combinations, has recently
been identified. This enzyme, called BIL-1, appeared in a
clinical isolate ofE. coli in Pakistan.45 The pi of this enzyme
was extraordinarily high at pi 8-8 and thus it could have
been confused with the induced //-lactamase ofE. coli, which
is believed to account for the CEP-1 enzyme.46 The CEP-1
//-lactamase has a pi of 8-2 and was shown to be quite
distinct from BIL-1. On the other hand, the BIL-1 /?-
lactamese does have a very similar pi to the Enterobacter
Table II. Plasmid-mediated extended-spectrum //-lactamases
Group 1 Group 2 Group 3 Group 4 Unassigned
TEM-E1 TEM-E3 TEM-derived BIL-1 FUR
TEM-E2 TEM-6 TEM-3 MJ-1
TEM-E4 TEM-9 TEM-4 MJ-2
TEM-7 TEM-10 TEM-5 Unamed 1










Group 1, poor hydrolysis of cefotaxime and ceftazidime.
Group 2, better hydrolysis of ceftazidime than cefotaxime.
Group 3, better hydrolysis of cefotaxime than ceftazidime.
Group 4, confers resistance to all cephalosporins and clavulanic acid.
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cloacae type A chromosomal /i-lactamase. In any case, this
enzyme appears to result from a chromosomal gene, encoding
a Bush class 1 /i-lactamase, migrating into a plasmid vector.
The BIL-1 /i-lactamase has virtually no hydrolytic activity
against cefotaxime, ceftazidime, cefuroxime or even ampi-
cillin. It does possess activity against nitrocephin and
cephaloridine. It has approximately the same relative
efficiency of hydrolysis against these two substrates as the
ubiquitous TEM-1. The inhibition properties of BIL-1 are
much more interesting. It is readily inhibited, and, therefore,
binds ampicillin cefuroxime and ceftazidime. It is 4000
times less sensitive to inhibition by clavulanic acid.
There are five enzymes that do not fit into the classification
scheme, mainly because there are insufficient data. It is not
yet known from where many of these enzymes are derived,
and only one has been found on more than two occasions.
New enzymes are being discovered constantly and will be
entered into this scheme. It is, of course, vital to know the
biochemical relationships, because this probably reflects the
selective pressures. However, with most resistance mecha¬
nisms, classification often takes account of similarities in
nucleotide or amino-acid sequences. This requires full gene
sequencing to identify the relationships and will be of
particular interest with the SHV- and TEM-derived en¬
zymes.
With the SHV-1 enzymes, the relationships are well-
defined and are shown in fig. 2. Each box represents a single
amino-acid mutation. Therefore, it is easy to see how SHV-
1 led to SHV-2 and that SHV-4 was derived either through
SHV-3 or SHV-5. All the intervening enzymes have been
found in the clinical environment.
The relationships between the TEM-enzymes are much
more complicated (fig. 3). Again, each box represents a
single amino-acid mutation. It can probably be assumed
that the mutation between TEM-1 and TEM-2 occurred
before the later enzymes emerged and that the change at
amino-acid position 37 does not occur with the extended-
spectrum /1-lactamases. Therefore, all those mutations in the
top half arose from TEM-1 and those in the bottom half
from TEM-2. Unlike the SHV enzymes, most of the
intermediates have not yet been identified. The laboratory-
selected /^-lactamase, TEM-101,47 a mutation of TEM-1,
may well be the TEM-E2 we found in the Liverpool K.
oxytoca isolate;40 but whether TEM-9, for instance, is
derived from intermediate A or D is not known.
Plasmid-mediated /Macatamases are a vast array of
Fig. 2. Diagrammatic representation of the relationships between















Fig. 3. Diagrammatic representation of the relationships between
the TEM-derived /^-lactamases. Each box represents a single amino-
acid change.
enzymes; there are nearly 60 distinct enzymes. It is almost
certain that many more will be identified. The immediate
potential clinical threat comes from the extended-spectrum
^-lactamases; however, we must wait to see which, if any,
of these enzymes will emerge as the successor to TEM-1.
Resistance to the 4-quinolones
C. S. Lewin
Department ofMedical Microbiology, University ofEdinburgh
Medical School, Teviot Place, Edinburgh, EH8 9AG
The 4-quinolones are chemically synthesised compounds
whose principal target is the enzyme DNA gyrase (E.C.
number 5.99.1.3), the only bacterial enzyme capable of
introducing negative supercoils into DNA.48 DNA super-
coiling plays an important role in bacterial metabolism—it
compacts the chromosome and is involved in the regulation
of gene transcription49 as well as the bacterial response to
the environment.50 The enzyme is a tetramer consisting of
two A and two B subunits.48 The A subunit cuts both strands
of DNA simultaneously at intervals four base pairs apart
and holds the strands apart but covalently bound to the
enzymes. The B subunit, using ATP for energy, then
introduces a negative supercoil into the DNA and the A
strand then reseals the two strands.
The first 4-quinolone, nalidixic acid, was synthesised
almost 30 years ago. Its antimicrobial spectrum is limited to
the Enterobacteriaceae; it is useful for the treatment of
urinary tract and enteric infections. The antimicrobial
spectrum of the 4-quinolones was extended by the discovery
that the addition of a piperazine at C6 and fluorine at C7 to
the common 4-oxo-l,4-dihydroquinolone skeleton caused a
1000-fold improvement in antimicrobial activity. Bacterial
species intrinsically resistant to nalidixic acid are susceptible
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to these new fluoroquinolones and, in the 1980s, compounds
such as pefloxacin, norfloxacin, ciprofloxacin, enoxacin and
ofloxacin, active against a wide range of bacterial species,
became available for clinical use.
The increasing therapeutic potential of these antimicro¬
bial agents has caused considerably interest in the mecha¬
nisms by which bacterial resistance to the 4-quinolones is
mediated. Bacterial resistance to antimicrobials can be
mediated either via a plasmid or a chromosomal mutation.
Plasmids often carry several genes conferring resistance
to several antimicrobial agents, therefore, in clinically
important bacteria, tend to be the main reservoirof resistance
to most antimicrobial agents. This is not the case with the 4-
quinolones as, unlike other commonly used antimicrobial
agents, plasmid-mediated resistance to the 4-quinolones has
yet to be identified in clinical isolates. It should be noted
that plasmids have been associated with nalidixic acid
resistance in shigellas isolated from the Indian subcontinent,
but they did confer resistance to the 4-quinolones.51,52
Although plasmid-mediated 4-quinolone resistance has yet
to be found clinically, a potential mechanism of resistance,
which may involve drug accumulation, has recently been
reported.
The norA gene identified in Staphylococcus aureus codes
for a 50-Kda protein which appears to be membrane
associated and confers high-level resistance to hydrophilic
fluoroquinolones.53,54 This gene has been cloned into
plasmid pBR322.53,54 When a quinolone-susceptible strain,
Escherichia coli HB101, was transformed with the recombi¬
nant plasmid, it developed resistance to the 4-quinolones.
The MICs of hydrophilic drugs such as enoxacin, norfloxa¬
cin, ciprofloxacin and ofloxacin increased 8 to 64 fold
whereas only a two-fold increase was observed for the
hydrophobic 4-quinolones nalidixic acid and sparfloxa-
cin.53,54 Kaatz et al. have also recently identified a mutation
similar to norA in an isolate of S. aureus which conferred
resistance on an E. coli recipient strain when it was cloned
on to a plasmid (unpublished results). Thus, a mechanism
by which a plasmid could confer resistance to the 4-
quinolones has been identified although it has yet to be
found in a clinical isolate.
The probability of plasmid-mediated 4-quinolone resist¬
ance arising via the two other two mechanisms that have
been identified for other classes of antibacterial agents seems
low. A drug destruction mechanism appears unlikely as the
4-quinoiones are synthetic agents. A 4-quinolone resistant
DNA gyrase coded by a plasmid would also seem an unlikely
candidate because genetic studies have shown that quinolone
sensitivity is dominant over quinolone resistance in gyrase
genes.55 Indeed, transformation of quinolone resistant
strains with plasmids carrying quinolone susceptible gyrase
genes have been used to identify alterations in DNA gyrase
as the cause of resistance to the 4-quinolones in gram-
negative bacteria.55-57
As plasmid-mediated quinolone resistance has yet to be
identified in a clinical strain, chromosomal mutations are
the only mechanism by which bacteria are able to develop
resistance to the 4-quinolones during therapy. Chromo-
somally-mediated resistance to the 4-quinolones can occur
by one of two mechanisms—either an alteration in the target
enzyme, DNA gyrase, or a mutation that reduces drug
accumulation.
In most species investigated so far, high-level resistance
to all 4-quinolones appears to be conferred by mutations in
the gyrA gene which codes for the A subunit of DNA gyrase.
GyrA mutations confer high-level cross-resistance to all 4-
quinolones but do not seem to be associated with resistance
to other, unrelated antibacterial agents. Such mutations have
been identified in E. coli (cfxA, gyrA, nalA, nfxA),55,58,59
Pseudomonas aeruginosa (nalA, cfxA),60-62 Haemophilus
influenzae,63 Citrobacterfreundii6Aand Serratiamarcescens.65
The gyrA genes of E. coli, Bacillus subtilis, S. aureus and
Klebsiella pneumoniae have been sequenced revealing close
homology between the gyrases of different species.66-68
Nucleotide sequence analysis performed on 10 spontaneous
quinolone-resistant gyrA mutants of E. coli KL1669 showed
that quinolone resistance appeared to be conferred by point
mutations within a small region between amino acids 67 and
106 near the N terminus of the A subunit. Six of the 10
mutants possessed a substitution at amino acid 83, a serine.
This mutation has also been identified in a clinical isolate of
E. coli that developed resistance during enoxacin therapy.70
In 5. aureus, this serine is located one amino acid further on
at position 84. There is also a serine at amino acid 85 (aa 84
is alanine in E. coli) and substitution of either amino acid
was found to be the cause of quinolone resistance in clinical
isolates ofS. aureus.11 Furthermore, high level ciprofloxacin
resistance in 5. aureus (MIC > mg/L) was found to be
associated with substitution ofboth serines.71 It is interesting
to note that all of the mutations conferring quinolone
resistance are situated close to the tyrosine at amino acid
122 of the A subunit that is covalently bound to DNA when
the enzyme breaks the phosphodiester bonds of DNA.48
Although little is known about the quinolone-gyrase-DNA
complex, it would seem that the alterations in amino acid
residues result in disruption of key interactions of the
complex.
Mutations in the B subunit of DNA gyrase coded by the
gyrB gene have been shown to cause 4-quinolone resistance
in E. coli and P. aeruginosa.55,56 However, unlike gyrA
mutations, these do not always cause cross-resistance to all
4-quinolones. The nal31 mutation in E. coli72 confers
resistance to the 4-quinolones lacking a C7 piperazine while
rendering bacteria hypersensitive to 4-quinolones possessing
this substituent. This phenomenon results from the mutation
increasing the negative charge of the B subunit, increasing
its attraction for the positively charged piperazine group.73
The 4-quinolones must penetrate bacteria to gain access
to their target DNA gyrase. Therefore, a reduction in the
ability of the 4-quinilones to enter bacteria results in
decreased bacterial susceptibility. The 4-quinolones pene¬
trate bacteria by diffusion through porins in the outer
membrane of gram-negative bacteria. The hydrophobic 4-
quinolones such as nalidixic acid are also able to penetrate
the bacterium through the phospholipid bilayer.73,74 Active
transport may also play a role in bacterial accumulation of
the 4-quinolones as endogenous active efflux of norfloxacin
has been demonstrated at the inner membrane of E. coli and
P. aeruginosa.75-76
In gram-negative bacteria, mutations affecting 4-quino-
lone permeability have been identified in E. coli (nalB, nfxB,
norB, cfxB), Salmonella, Pseudomonas (nalB, cfxB and nfxB,
qrl, qr2), Klebsiella and Serratia spp. and have been reviewed
recently.52,77 Unlike alterations in DNA gyrase, which
confer only cross-resistance to other 4-quinolones, resistance
caused by the reduction in 4-quinolone accumulation can be
associated with decreased sensitivity to unrelated antibac¬
terial agents. Mutations in E. coli which confer resistance to
the 4-quinolones by an impermeability mechanism are
associated with alterations in outer-membrane porin F
(ompF). Both inactivation of the ompF gene and mutations
in regulatory genes controlling expression of ompF at a post-
transcriptional level can cause 4-quinolone resistance; e.g.,
cfxB appears to be an allele of the marA gene which confers
resistance to tetracyclines and chloramphenicol as well as to
the 4-quinolones.78.
In P. aeruginosa, resistance to the 4-quinolones resulting
from reduced drug accumulation has been associated with
alterations in a wide range of outer-membrane proteins.52
Resistance to the 4-quinolones can be associated with cross-
resistance to other antibacterial agents; e.g., the Qrl and
Qr2 mutations associated with a reduction in ompG and an
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antigenically related 40-Kda outer-membrane protein con¬
ferred resistance to some /^-lactam agents, chloramphenicol
and tetracycline, as well as to the 4-quinolones.76 However,
this is not always the case as, for example, unstable low-level
resistance to the 4-quinolones in this species associated with
the alteration or loss of a 31-32-Kda outer-membrane protein
did not confer cross-resistance to antibacterials unrelated to
the 4-quinolones.79
Fukuda et al.s0 have recently identified a new resistance
mechanism in P. aeruginosa strain PAO associated with
reduced drug permeability. The nfxCmutation mapped near
catA (46 min) on the PAO chromosome and caused a 10- to
32-fold decrease in susceptibility to ciprofloxacin, ofloxacin,
norfloxacin and fleroxacin. It was associated with increased
expression of a 50-Kda protein and decreased expression of
a 46-Kda protein. The nfxC mutation was associated with
cross-resistance to imipenem and chloramphenicol but
rendered bacteria highly susceptible to other extended
spectrum cephalosporins and to aminoglycosides. This
mutation was thought to be clinically significant as quino-
lone-resistant P. aeruginosa that are resistant to imipenem
but susceptible to other /J-lactam agents have been isolated
from patients.80
In E. coli and P. aeruginosa, resistance to the 4-quinolones
has been associated with alterations in the expression of
lipopolysaccharides.52,77 Hence, resistance manifested by
reduced drug accumulation does not result solely from
changes in the outer-membrane proteins. The discovery of
an active efflux system for the 4-quinolones suggests that
another class of drug mutations, which confer resistance by
reducing 4-quinolone accumulation, may exist, although
they have yet to be identified. This might be similar to
tetracycline resistance, in which the drug efflux system works
with enhanced efficiency. Finally, much less information
exists about resistance to the 4-quinolones resulting from
reduced drug accumulation in gram-positive bacteria. The
best characterised mutation is the norA mutation in S. aureus
discussed previously.54'55
The development of resistance to the modern fluorinated
4-quinolones during therapy has been shown to have
occurred in a wide range of bacterial species.52'77 These
clinical reports indicate that it is possible for most bacterial
species to develop resistance to the 4-quinolones during
therapy. However, extrapolation of the frequency at which
resistance to the fluoroquinolones is likely to develop
clinically from these isolated reports is not possible. The
monitoring of bacterial susceptibility to the 4-quinolones
once they have been introduced serves to provide such
epidemiological information. Several large scale studies
have monitored the susceptibility of bacterial pathogens to
the 4-quinolones since they have become available and,
generally, very little resistance to the modern 4-quinolones
has been observed.52,81,82
Kresken and Wiedemann81 monitored nalidixic acid
resistance in the Federal Republic of Germany, Austria and
Switzerland from 1975 to 1986, with particular emphasis on
the period between 1983 and 1986 when ofloxacin and
norfloxacin became available in these countries. Despite a
marked increase in the use of the 4-quinolones during this
period, resistance in Enterobacteriaceae, S. aureus or
Enterococcus faecalis did not increase. P. aeruginosa was an
exception; between 1983 and 1986, the percentage of 4-
quinolone-resistant strains increased from 3% to 10%.
Another survey performed in the Federal Republic of
Germany by Grimm,82 testing over 100 000 bacterial strains
isolated from both hospitals and general practice between
1986 and 1987, found similar results to those of Kresken and
Wiedemann81 for Enterobacteriaceae. However, Grimm82
report a significant increase in the incidence of 4-quinolone
resistance in staphylococci, particularly amongst multi-
resistant S. epidermidis. There have also been other reports
of high incidence of ciprofloxacin resistance in methicillin-
resistant S. aureus (MRSA) isolated in hospitals.52,83 This
resistance does not necessarily appear to develop during
therapy of the MRSA infection may be associated with use
of ciprofloxacin for treatment of a pathogen other than
MRSA.52,83 It has been suggested that ciprofloxacin
resistance can develop in colonising MRSA which then
subsequently spread to other patients in the hospital.83
Problems may also exist in other bacterial species. The
frequencyof resistance to the 4-quinolonesmay be increasing
in Bacteroides fragilis and Ser. marcescens. Surveys in Japan
have reported high incidences of quinolone resistance in
these species.66,84
In conclusion, the clinical incidence of 4-quinolone-
resistant bacteria is still relatively rare, although it seems to
be occurring with increasing frequency in certain species
such as P. aeruginosa and staphylococci (particularly multi-
resistant organisms). Resistance is not plasmid-mediated at
present although a potential mechanism involving reduced
accumulation has now been identified. Resistance to the 4-
quinolones occurs through chromosomal mutations resulting
in an altered target (DNA gyrase) or reduced drug
accumulation (particularly associated with alterations in the
outer-membrane porins).
Mechanisms and epidemiology of
aminoglycoside resistance
N. M. Brown and D. S. Reeves
Department of Medical Microbiology, Southmead Hospital,
Westbury-on-Trym, Bristol
Introduction
The aminoglycoside-aminocyclitol antibiotics have re¬
mained valuable agents for treating serious infections since
their introduction, despite the development of newer broad
spectrum and less toxic antibiotics. The emergence of
resistance to them has followed their widespread use and,
although generally it still remains at a low level for most
organisms, is important for the increased mortality, morbid¬
ity and expense it causes. This is particularly true for
resistant strains having the ability to spread rapidly in
institutions causing outbreaks of nosocomial infection.85
The uptake of the aminoglycoside antibiotics by the
bacterial cell and their mechanisms ofaction has been shown
to be a complex process, as yet incompletely understood.
Nevertheless, some discussion of these events is helpful in
understanding the different mechanisms of aminoglycoside
resistance.
Aminoglycoside uptake and action
The uptake of aminoglycosides by bacterial cells has been
most extensively studied with streptomycin and gentamicin.
It differs from the uptake of most antibiotics in that it is
active (energy-dependent), and has been divided into three
phases. The first phase of uptake is the attraction and
binding of the antibiotic to the cell outermembrane ofgram-
negative rods, and is rapid and passive. The second and
third phases have been named energy-dependent phases I
(EDP-I) and II (EPD-II). The initial passive uptake of
aminoglycoside is thought to depend on the electrical
potential across the outer membranes. Aminoglycosides are
cationic and are, therefore, attracted to anions on the cell
surface and across the outer membrane by the internally
negative electrical potential, passing through the porin
channels of gram-negative cells or water filled interstices of
gram-positive cells. In Pseudomonas aeruginosa, which has a
less permeable outer membrane, a model has been proposed
whereby the aminoglycoside binds to the negatively charged
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magnesium binding sites on the membrane surface, causing
disruption of the membrane barrier and facilitating entry
into the cell of aminoglycoside.86 The extent and rate of
ionic uptake depends on the size of the electrical potential
gradient across the outer membrane, and a number of
inhibitors which reduce ionic binding and diffusion have
been described.87
The EDP-I appears to be comparatively slow, and is
thought to represent the transport of the aminoglycoside
across the cytoplasmic membrane to come into contact with
the ribosome, perhaps on transporter molecules. It precedes
any of the intracellular events leading to cell death and
appears to be the rate limiting step in uptake.
The EDP-II occurs as the aminoglycoside binds to specific
binding sites on the 30S ribosome and the initiation of
protein synthesis is disrupted. This leads to changes in the
permeability of the cell membrane and a secondary, rapid
escalation in antibiotic uptake, cell disorganisation and,
ultimately, cell death.
In aerobic gram-negative bacteria, the kinetics of cell
killing has been shown to be biphasic.88 An initial phase of
cell death occurs soon after the aminoglycoside is adminis¬
tered and is thought to be associated with the ionic binding
to the cell. It appears to be very rapid and related to the
concentration of the antibiotic. A second phase of killing is
much slower and independent of drug concentration. Such
findings show the importance of obtaining adequate peak
aminoglycoside concentrations and have been used as an
argument in favour of single, large, once-daily dosage
regimens. However, despite this, the slower energy-depend¬
ent phases of uptake are the most important phases in the
bactericidal action of aminoglycoside antibiotics.89 Many
antibiotics acting on protein synthesis, e.g., chlorampheni¬
col, are bacteriostatic. They do not have the same complex
energy-dependent uptake mechanisms as the aminoglyco¬
sides, and the interference in protein synthesis by many of
these agents is reversible. The uptake of aminoglycosides is
irreversible in vitro unless the cell membrane is destroyed by
an agent such as toluene, and the rapid influx of antibiotic
occurring in EDP-II appears to be the important step in the
irreversible disruption of protein synthesis conferring cidal
activity.90
Mechanisms ofresistance to aminoglycosides
There are three mechanisms by which resistance of
bacteria to aminoglycoside antibiotics may occur—enzymic
modification, deficiency of uptake or accumulation, and
modification of the ribosomal target site.
Enzymic modification. This is the most common and
clinically important cause of acquired aminoglycoside
resistance. Enzymes may modify the aminoglycoside by
various mechanisms—particularly N-acetylation, O-nucleo-
tidylation or O-phosphorylation. A number of different
aminoglycoside modifying enzymes (AME) have been
identified and the nomenclature for their description consists
of a three letter code according to their mode of action—
aminoglycoside acetyltransferase (AAC), aminoglycoside
phosphoryl-transferase (APH) and aminoglycoside adenyl-
transferase or nucleotidylase (AAD or ANT). The site of
action of the enzyme on the aminoglycoside molecule is
denoted by a number in parenthesis, e.g., AAC(2") represents
acetylation of the 2"-amino group. Further characterisation
may be given by the addition of roman numerals to
differentiate enzymes of similar actions. Thus, potentially,
an aminoglycoside may be modified at more than one site
and, therefore, be a substrate for more than one enzyme.
Similarly, an enzyme may have several different substrates.
Most genes coding for AMEs are plasmid specified, and
many are known to be carried on transposons. Plasmid
transfer may occur by conjugation, transduction or transfor¬
mation and a single plasmid may carry more than one AME
gene. More rarely, the enzyme is chromosomally specified,
and this has been described in Serratia spp., Acinetobacter
spp., Pseudomonas spp., Staphylococcus aureus and some
streptococci.
In contrast to some other antibiotic-modifying enzymes,
e.g., the /i-lactamases, AMEs appear to be virtually
completely intracellular. Very little enzyme or modified
aminoglycoside can be found outside the cell; therefore,
extracellular antibiotic is still active. Although the exact
location of the AME within the cell is not known, it is
thought to be closely associated with the cytoplasmic
membrane.91 Modification of the aminoglycoside substrate
at this site could confer resistance by preventing binding to
the specific ribosomal binding sites or by interfering with
aminoglycoside accumulation. As has been discussed, these
processes are closely related.
Enzymes are thought to be constitutively expressed.
However, the amount of enzyme produced and the rate of
substrate action may be variable. It has been postulated that
within each bacterial cell there is competition between the
rate of aminoglycoside modification and the rate of transport
of aminoglycoside across the cytoplasmic membrane during
EDP-I; this being the rate limiting step.91 If uptake exceeds
modification the cell may be killed even though it possesses
a mechanism of resistance. With exposure to aminoglyco¬
side, resistant bacterial cells with a higher rate of substrate
modification may emerge, perhaps due to selection of
bacteria with higher gene copy numbers and hence sufficient
enzyme so that modification exceeds aminoglycoside accu¬
mulation. At present it is not thought that true enzyme
induction occurs.
Deficiency of uptake or accumulation. Because of the
complex nature of aminoglycoside uptake there is great
potential for resistance to occur by this mechanism. Mutants
with altered cell-membrane structure or cellular metabolism
could interfere with the aminoglycoside accumulation
described above. It is becoming increasingly recognised that
isolates that are resistant to aminoglycosides by these
mechanisms exist and may have clinical importance.
Most organisms intrinsically resistant to aminoglycosides
are unable to accumulate sufficient antibiotic. Strict anaer¬
obes that respire without a functioning electron-transport
chain, for example, are unable to drive the energy-requiring
phases of uptake and cannot maintain an adequate negative
internal potential for uptake to occur. Likewise, some
fermentative bacteria, such as streptococci, may exhibit low
level resistance due to incomplete electron-transport sys¬
tems.92 In some clinical isolates of P. aeruginosa showing
resistance, an altered lipopolysaccharide structure in the cell
membrane has been described ;92 similar findings have been
reported with other organisms, particularly Klebsiella pneu¬
moniae. Such resistance, as described in P. aeruginosa, is
chromosomally specified and non-transferable. It is stable in
vitro and independent of exposure to aminoglycoside. In
general, resistance of this type affects a wide range of
aminoglycosides and is of low level. High concentrations of
aminoglycoside may overcome the permeability barrier and
render the organism sensitive. This is in contrast to enzymic
modification, which tends to affect specific aminoglycosides
and usually produces high-level resistance.
Recently, there has been considerable interest in adaptive
resistance as a result of exposure to low levels of aminogly¬
cosides. This has been described both in vitro and in vivo.93
Exposure to one dose of aminoglycoside may produce
resistant variants of an organism that have altered metabo¬
lism and, consequently, impaired aminoglycoside accumu¬
lation. This has been shown to occur most readily with P.
aeruginosa, but also with Escherichia coli and S. aureus, and,
as with the impermeability resistance described above,
affects a wide range of aminoglycosides and is of low level.
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However, such isolates quickly revert to susceptibility when
exposure to the aminoglycoside is removed. This suggests
that they are not simply resistant mutants selected by
antibiotic exposure. Often, colonies are readily identifiable
by their small size, slow growth and atypical morphology,93
which could also reflect intracellular metabolic changes.
Such adaptive resistance may have clinical relevance to
cases of treatment failure in conditions requiring prolonged
or repeated aminoglycoside therapy, e.g., endocarditis and
cystic fibrosis, and could be difficult to detect in the
laboratory as isolates may revert to susceptibility at initial
isolation.
Modification of ribosomal target site. Aminoglycosides
interfere with the initiation of protein synthesis by binding
to specific binding sites on the 30S ribosome. As yet,
mutations affecting this specific target site do not appear to
have great clinical importance. Experimental and clinical
isolates showing resistance to streptomycin and spectino-
mycin by this mechanism have been described, and are
thought to arise by single step mutations at the StrA locus.
Although mutations near to this site may produce resistance
to other aminoglycosides, this has not been seen in clinical
isolates.93
The epidemiology ofaminoglycoside resistance
It is not surprising that resistance to aminoglycosides is
becoming increasingly recognised, as these agents have been
widely used in hospitals for more than 20 years, not only for
treatment but also for prophylaxis. They are also used in
veterinary practice and in commercial processes involving
animals.94 Several multicentre study groups have docu¬
mented the prevalence of aminoglycoside resistance and
also the mechanisms of resistance. These include groups in
the UK,95 Europe96,97 and the USA.98 Such collaborative
studies are essential as the prevalence of aminoglycoside
resistance in each individual hospital is low, but they have
generally only been able to give a single snapshot of patterns
of resistance (the point prevalence). More information can
be obtained from studies of the prevalance of resistance over
a period time,99'100 or studies that have been repeated, such
as the European Study on Antibiotic Resistance (ESGAR)
reports of 1987 and 1990.96'97 A summary of some of these
reports is shown in table III. Variations in the resistance
level can be found, not only between countries, but also
between laboratories participating in individual studies.
One striking difference is the increasing resistance from
Northern to Southern Europe (table IV). The USA has
resistance levels approaching those of Southern Europe.
However, care must be taken when comparing these studies
as the isolates examined come from a variety of clinical
sources. The majority of studies have looked at consecutive
blood-culture isolates, but some have included all clinical
isolates or urine isolates. Also, the distribution of organisms
varies between studies; those finding a higher incidence of
Providencia, Serratia and Acinetobacter spp. and coagulase-
negative staphylococci have reported a high level of
aminoglycoside resistance. Differences in the geographical
pattern of resistance may reflect different patterns of
aminoglycoside usage. Similarly, the isolation of organisms
more likely to be aminoglycoside-resistant, such as those
listed above, may reflect selection secondary to antibiotic
exposure.
In all studies, the most common mechanism of aminogly¬
coside resistance is modification by enzymes. Impermeabil¬
ity resistance accounts for < 10% of resistant isolates and is
seen most frequently in non-aeruginosa Pseudomonas spp.95
The distribution of AMEs varies from country to country.
In Europe as a whole, the most common AMEs in gram-
negative bacilli are ANT(2"), AAC(3)V and ACC(6')II, and
in staphylococci the double-acting AME APH(2")/AAC(6')
combined and ANT (4').96 Combinations of AMEs are
common and a wide variety of different enzymes is seen,
especially in isolates from Southern Europe where AAC(6')I,
either alone or in combination, is responsible in part for
higher resistance levels. In the UK, the most common
enzymes are AAC(3) and ANT(2") in gram-negative bacilli
and APH(2")/AAC(6') in staphylococci.95'99 Similar find¬
ings have been described from the USA and Australia. This
differs from the Far East, where AAC(6") is most common,
and Chile, where > 90% of aminoglycoside-resistant isolates
possess ACC(3).101 Again, these differences may reflect
pressure due to antibiotic usage. In Japan, for example, the
high usage of kanamycin and dibekacin may have encour¬
aged the selection of AAC(6'), which causes resistance to
this group of antibiotics, whereas AAC(3), which confers
resistance to gentamicin, sisomycin and netilmicin, is rarely
seen. The presence of a single enzyme in resistant Chilean
isolates may represent the distribution of a single R-plasmid
in a hospital.101 In studies from other countries, however,
there has been a tendency in more recent surveys to find an
increasing number of different AMEs, often in combina¬
tion.102,103 Although selection pressure from hospital ami¬
noglycoside usage may be the most important factor
controlling this, other factors, such as spread of resistance
through animals may also be significant.94
Table III. Gentamicin resistance (%) described in some recent studies
Study reference Finland102 Sweden100 Hospita^LfK99 Saudi Arabia103 Europe97 UK95 Europe96
Number of isolates 633 2027 7264 5001 2578 2463 970 4146 3440
Source of isolates Blood Blood All clinical All clinical Blood Urine Blood Urine Blooc
Escherichia coli 0 0-6 2 3 3 1-6 0-6 4
Klebsiella spp. 5-5 3 9 j 1 8-5 j
Citrobacter spp. 0-5 8 > 14 r 15 0 30 r10
Enterobacter spp. 3 15 J J 6 4 J
Serratia spp. 0 21 30 54 6 28 28
Providencia spp. 73 53 79
Acinetobacter spp. 13 37 56 50 65
Pseudomonas spp. 50 3 27 28 26 6 6 33
Total all gram-negative 1 5 12 12 3-3 2-4 12
bacilli
Staphylococcus aureus 0-7 1 3 12 20 2 5 12
Coagulase-negative 20 20 26 28 29 16 53
staphylococci
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Table IV. Aminoglycoside resistance from European blood-culture isolates
Percentage of gram-negative isolates resistant to Percentage of gram-positive isolates resistant to
Region
Gent Tob Net Ami Gent Tob Net Ami
Northern Europe 3 2 4 3 15 18 6 10
Central Europe 8 7 8 7 32 34 19 28
Southern Europe 24 22 23 15 30 31 17 17
Northern Europe: Sweden Finland, Denmark, Great Britain; Central Europe: Belgium, Netherlands, West Germany, Austria, Switzerland;
Southern Europe: France, Spain, Portugal, Italy, Greece.
Gent, gentamicin; Tob, tobramycin; Net, netilmicin; Ami, amikacin.
Methods for identification ofresistance mechanism
Some idea as to the mechanism of resistance of an
aminoglycoside-resistant isolate can be obtained from the
resistance pattern, level of resistance, colonial morphology,
and growth, as described above. Most isolates will be
resistant by enzymic modification. Identification of the
AME is rarely necessary clinically, but may be useful for
epidemiology or research. Identification may be presumed
by testing susceptibility to the aminoglycoside substrates for
the enzyme, and simple methods have been described based
upon either MICs101 or inhibition zone diameters.104 It is
likely that results of these tests will become increasingly
difficult to interpret as the frequency of combinations of
enzymes increases. Furthermore, some of these methods use,
ideally, aminoglycosides not in clinical use and therefore
difficult to obtain.
Most other methods for enzyme identification are unlikely
to be used by clinical laboratories. Radiolabelled co-factors
have been widely used to measure the binding of modified
aminoglycoside to cellulose phosphate paper but can give
confusing results with some enzyme combinations. High
performance liquid chromatography of the reaction products
may also be used; this has the advantage of specifically
identifying reaction products. Most recently, techniques
have concentrated on the genes coding for AMEs. Specific
probes have been developed for detecting AME genes, and
the polymerase chain reaction can further facilitate this. As
techniques improve, these methods will become more
sensitive and may prove to be very useful for identifying
combinations of AMEs.
Glycopeptide resistance in gram-positive
bacteria
P. E. Reynolds
Department of Biochemistry, University of Cambridge, Tennis
Court Road, Cambridge, CB2 1QW
Introduction
Some of the most used antibiotics in clinical medicine are
those that affect the bacterial cell wall which is composed of
a variety of macromolecules, some of them found uniquely
in bacteria. The majority of clinically-important bacteria
contain peptidoglycan, which confers rigidity on the bacter¬
ium and is the main molecular determinant of cell shape. It
is a large, polar molecule which is assembled on the outside
surface of the bacterium in three main stages from subunits
manufactured inside the cell. The subunits are transferred
across the membrane, polymerised to form short polysac¬
charide chains substituted with unusual peptides which are
finally cross-linked to the existing wall by the transpeptida-
tion reactions. This series of reactions leading to the
formation of cross-linked peptidoglycan affords a plethora
ofpotential targets for antimicrobial agents.105 The presence
of a unique amino-sugar and the un-natural d-isomers of two
amino acids ensures that these targets are unique to bacteria
and that antibiotics interfering with the biosynthetic
pathway are likely to be selectively toxic to bacteria. The
last two reactions in the pathway (polymerisation and
transpeptidation) occur outside the cytoplasmic membrane
and, consequently, antibiotics that interfere with these stages
of synthesis do not require a transport system to reach the
target site. Glycopeptide antibiotics (vancomycin and
teicoplanin) inhibit the first of these two reactions (and
would also block transpeptidation) by binding tightly to the
unique acyl-d-alanyl-d-alanine arrangement of amino acids
in the membrane-bound nascent peptidoglycan.106
Mechanism ofaction ofglycopeptide antibiotics
Glycopeptide antibiotics are effective at low concentra¬
tions against the majority of gram-positive bacteria, but
toxicity problems in the early years of their application
precluded their widespread use in spite of their selective
action against the peptidoglycan. The introduction of /?-
lactamase-stable penicillins resulted in a temporary reduc¬
tion in the clinical use of vancomycin, but the acquisition of
alternative mechanisms of resistance to /Mactam antibiotics
in particular, and an improvement in the purity of the
vancomycin preparations, witnessed a resurgence in the use
of glycopeptides, particularly against multiresistant staphyl¬
ococci that are intrinsically resistant to all /1-lactam
antibiotics. Glycopeptide antibiotics, including vancomycin
and teicoplanin, are large, rigid molecules; they adopt a
bracelet-like configuration with a substantial cleft or pocket
into which peptides ending in d-alanyl-d-alanine bind
firmly, though non-covalently, with almost computerised
precision.107 It is the mechanism of action of this group—
interaction with a structural component of the cell wall
rather than with a target protein—that makes this class of
antibiotics unique and reduces the possibility of large-scale
resistance emerging in clinical strains. Definitive studies of
the interaction of glycopeptides with the target peptides
were elucidated with the use of nuclear magnetic resonance
spectroscopy, by mass spectrometry followed by model
building, and by 3-dimensional reconstruction of the binding
sites.108 The wall subunit, either attached to its lipid carrier
or as part of the growing peptidoglycan chain to which the
new subunit will be added, is held firmly by hydrogen
bonding to the peptide backbone of the glycopeptide (fig. 4).
The space-filling model of the glycopeptide-pentapeptide
complex indicates that the sugars in the wall subunit are not
immediately adjacent to the glycopeptide molecule, but the
peptidoglycan polymerase whose active site must be located
close to the sugars is a large molecule in comparison with
both the antibiotic and the wall subunit. Presumably, the
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presence of the antibiotic on the subunit prevents the enzyme
from being located precisely in the correct position so that it
can no longer catalyse the transglycosylation reaction that
polymerises the peptidoglycan backbone chain.109 In addi¬
tion to the inhibition of the peptidoglycan polymerase by
steric hindrance (fig. 5), binding of glycopeptides to the D-




Fig. 4. Diagrammatic representation of the interactions between a
peptide terminating in D-alanyl-D-alanine and the aglycone of a
glycopeptide: five hydrogen bonds are formed.
the vital transpeptidation reaction that links the growing
peptidoglycan chain to the mature cell wall. As the result of
the inhibition of these two sequential reactions wall,
synthesis is frozen.
Resistance to glycopeptides
The structure of glycopeptides, as well as their unique
mechanism of action, is likely to ensure that any resistance
mechanism acquired by a bacterium will be unusual
compared to conventional mechanisms such as destruction
or inactivation of an antibiotic or drastic modification of the
target site. Other possible resistance mechanisms include
sequestration of the antibiotic molecule by non-specific
binding and altered accessibility of the target site. Some
bacteria are naturally insensitive to glycopeptides, either
because entry through the outer membrane is prevented
(gram-negative bacteria) or for an unknown reason (some
lactobacilli, leuconostocs, pediococci), though inactivation
of the antibiotic molecule has not yet been detected in any
instance of resistance.110
Sequestration of the available glycopeptide as the result
of non-specific binding is also unlikely for various reasons:
vast over-production of suitable peptides to complex with
the antibiotic molecules would be necessary to raise the MIC
of a sensitive strain so dramatically. Such an increase in
non-specific binding could occur through secretion of wall
precursors into the medium, an enhanced rate of wall
turnover involving loss of material into the medium, a
substantial increase in the amount of wall peptidoglycan
present (and consequent wall thickening) or a decrease in
degree of cross-linking in the peptidoglycan with resultant
increase in specific binding to non-essential target sites. As
yet, none of these scenarios has been detected in investiga¬
tions of resistant coagulase-negative staphylococci or other
resistant (or insensitive) strains;109 if any of these situations
arose there would be a dramatic decrease in the amount of
free glycopeptide in the culture medium of resistant strains
in comparison with that of their isogenic sensitive strains


























Fig. 5. Diagrammatic representation ofglycopeptide molecules bound to D-alanyl-D-alanine sequences in a new wall subunit and the growing
nascent glycan chain; these molecules may prevent, by steric hindrance, the transglycosylase reaction that links the nascent chain to the new
subunit. The shaded area represents the approximate extent of the glycopeptide. The transglycosylase enzyme is not directly inhibited so
resistance cannot result from mutation of the gene encoding the enzyme. Prevention of binding of glycopeptide molecules to the target acyl-
D-alanyl-D-alanine grouping could be brought about by inactivation of glycopeptides (not detected); sequestration of antibiotic in the growth
medium (not detected); enzymic modification of the target site (difficult for the subsequent essential transpeptidation reaction to occur); or
protection of the target site by another molecule (i.e., changing the accessibility to glycopeptides).
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bacteria or in complex formation in the culture medium has
yet been reported.
Genetic studies
The recently reported resistance in coagulase-negative
staphylococci and in enterococci is likely to result either
from a change in accessibility of the target or from
modification of the target. The resistant enterococci have
been studied intensively in several laboratories and at least
two types have been identified (table V): high-level resistant
strains are resistant to both vancomycin and teicoplanin
whereas low-level resistant strains are initially susceptible to
teicoplanin and moderately resistant to vancomycin.111-115
Resistance is inducible by vancomycin and teicoplanin in
the high-level resistant isolates, but only by vancomycin in
the low-level resistant strains; however, once resistance to
vancomycin is induced, these strains become resistant to
teicoplanin as well suggesting that a common factor is
involved. The two types of strains differ also with respect to
the transferability of resistance to other related or unrelated
bacteria. Plasmids encoding resistance have been detected
and isolated from some but not all the high-level resistant
enterococci116 and have been transferred by conjugation to
glycopeptide-sensitive strains of the same or related species.
In one instance, a plasmid has been transferred from its host
of Enterococcus faecium to a range of other gram-positive
bacteria including Streptococcus sanguis, Str. lactis, Str.
pyogenes and Listeriamonocytogenes but not to Staphylococcus
aureus or Bacillus subtilis :114 if transfer to, and expression
of, glycopeptide resistance in 5. aureus had been achieved,
clinical microbiologists would have been very concerned at
the prospect of glycopeptide resistance being added to the
growing list of antibiotic resistances in multiresistant strains
of staphylococci.
Purified plasmid DNA from resistant E. faecium has been
used to transform Str. sanguis Challis to glycopeptide
resistance; subsequently a 4-Kb EcoRl fragment containing
the gene (vanA) encoding resistance was cloned in Escherichia
coli on a conjugative gram-negative-gram-positive shuttle
vector and transferred by conjugation of Ent.faecalis and B.
thuringiensis, which became resistant to glycopeptides.117
Transferable resistance in high-level resistant strains is
not always associated with plasmid DNA; plasmids were
not detected in either the donor or transconjugants in one
report of transfer, and in another a strain cured of
glycopeptide resistance retained all three plasmids present
in the resistant parent.116 It has been suggested that, in these
instances, the resistance gene may have a chromosomal
location, possibly in association with a transposon. Such a
location has also been postulated for the gene encoding
resistance in low-level glycopeptide-resistant strains because
resistance is not transferable and no plasmids have been
detected. Sequencing of the N-terminus of the VANA
protein which is present in high-level resistant strains that
have been induced (see below) has enabled the vanA gene to
be identified and sequenced.118 The deduced amino-acid
sequence corresponded to a protein of calculated Mr 37-4 x
103, similar to that of the protein seen by sodium dodecyl
sulphate (SDS)—polyacrylamide gel electrophoresis
(39 Kda). The protein encoded by the vanA gene appears to
be structurally related to the D-alanyl-D-alanine ligases of E.
coli and Salmonella typhimurium (28% and 36% amino acid
identity respectively). Furthermore, the vanA gene, when
introduced into an E. coli mutant strain with a thermosensi-
tive D-ala-D-ala ligase, was able to achieve complementation
at 42°C.118
Biochemical studies
The presence of the vanA gene in high-level glycopeptide-
resistant strains and its introduction into sensitive strains is
associated with the production of a membrane-associated
protein of approximately 39 Kda following induction with
glycopeptides.112'119'120 The amounts of the protein in
sensitive strains or in uninduced resistant bacteria are very
low or non-existent. All high-level resistant enterococcal
strains that have been examined contain the vanA gene as
demonstrated by probing with a 290-bp probe specific for
vanA, whereas DNA from the low-level resistant strains did
not hybridise with this probe.121 Also, hybridisation was
not detected with DNA of the teicoplanin-resistant coagu¬
lase-negative staphylococci or the intrinsically resistant
leuconostocs, pediococci and lacotobacilli.121 The presence
Table V. Characteristics ofglycopeptide-resistant gram-positive bacteria
Acquired resistance in
Resistance enterococci Intrinsic resistance*
property staphylococci (Lactobacilli, leuconostocs,
High level Low-level pediococci)
MIC (mg/L)
vancomycin >64 16-32 1-2 (S) >1000
teicoplanin >16 0-5 (S) 8-32 > 250
Transferability + - - -
Plasmid-mediated + (some) — — —
Inducibility by
vancomycin + + — Constitutive
teicoplanin + — Constitutive Constitutive
Mass of resistance protein
(Kda) 39 39-5 NDf ND
Hybridisation to vanA
probe + — — -
Reaction with antibody to
39-3-Kda protein - -F - -
(S), sensitive.
ND, not determined.
* This group includes the two glycopeptide-producing strains Actinomyces orientalis ATCC 19795 (vancomycin) and
A. teichomyceticus ATCC 31211.
t Teicoplanin-resistant strains of S. epidermidis contain an additional membrane protein (39 Kda) in comparison
with a non-isogenic sensitive strain.
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of the 39-Kda protein in high-level resistant strains only has
been confirmed by immunoblotting with an antibody raised
against the purified protein.122 Low-level resistant strains
also synthesise an inducible membrane protein of similar
molecular mass (39-5 Kda) which appears to perform a
similar function in conferring resistance;113 although the
gene encoding it (designated vanB has not yet been
sequenced, the N-terminal sequence of the protein was
different from that of the 39-Kda protein, and antibodies
against the purified protein did not cross-react with the
"resistance" protein from high-level resistant strains.119 A
summary of the characteristics of glycopeptide-resistant
organisms is given in table V.
Mechanism ofresistance—hypotheses
The balance of evidence suggests that resistance in the
enterococci results from altered accessibility ofglycopeptide
molecules to their target sites. A reduction in accessibility
could be due either to production of the target cell-wall
peptides (acyl-d-ala-d-ala) by another molecule so that
glycopeptide molecules are prevented from binding, or to
enzymic modification of the target so that glycopeptides no
longer recognise the target and cannot bind to it (or bind
with much lower affinity).
Modification of target. The product of the vanA gene has
considerable homology with d-ala-d-ala ligases from gram-
negative organisms. The specificity of these enzymes is not
absolute and, with appropriate substrate pressure, it is
conceivable that a wall precursor could be synthesised in
which the terminal d-ala-d-ala was replaced with a different
dipeptide.121 Theoretical considerations render this sugges¬
tion unlikely: the introduction of cross-bridges between
peptides in the peptidoglycan depends on transpeptidation,
which in turn requires the two C-terminal amino acids of
the wall precursor to be in the d-configuration. Even if one
or both amino acids could be altered to other d-amino acids
under normal physiological conditions, it is doubtful if the
binding affinity of glycopeptides to the peptide would be
changed substantially.
Strong experimental evidence for a different type of
modification comes from investigations in which it was
shown that wall-membrane fragments of both high- and low-
level resistant enterococci prevented the binding of vanco¬
mycin and teicoplanin to a soluble pentapeptide terminating
in acyl-d-ala-d-ala.123 In the absence of the wall-membrane
fragments, or with an identical preparation from sensitive
or uninduced resistant enterococci, binding of vancomycin
to the added peptide was not prevented. This is an excellent
model system for studying the binding of glycopeptides to
their target sites and it was shown that prevention of binding
was time dependent; it could be blocked by adding a large
excess of the dipeptide d-ala-d-ala (which does not itself
bind to glycopeptides), and it was destroyed by heating the
wall-membrane preparation—these observations are con¬
sistent with the involvement of an enzyme in the protection
phenomenon.123 Furthermore, in these experiments there
was a high molar excess of pentapeptide to induced 39-Kda
protein which rules out simple binding as a resistance
mechanism. It was postulated that enzymic modification
may have involved the release of d-alanine from the
pentapeptide,123 though such an activity would prevent
subsequent transpeptidation if it occurred in vivo. There are
two lines of evidence not in accord with this hypothesis: the
resistant enterococci are susceptible to some derivatives of
vancomycin,122 suggesting that the binding site for glyco¬
peptides has not been changed substantially, and, more
significantly, treatment of the wall-membrane preparation
of the resistant enterococci with SDS at 100°C permitted
binding of vancomycin to the residual wall whereas no
binding occurred to the native preparation.123 This suggests
that no drastic modification of the glycopeptide binding site
has occurred.
Protection of target. Two lines of evidence suggest that the
additional membrane protein present in resistant strains of
enterococci that have been induced with glycopeptides
recognises d-ala-d-ala, the binding site of glycopeptides.
The VANA protein has considerable homology with d-ala-
d-ala ligases118 (as discussed above) and the prevention of
binding of vancomycin to a synthetic pentapeptide termi¬
nating in d-ala-d-ala by a wall-membrane preparation
containing either the 38-Kda or the 39-5-Kda protein was
eliminated by an excess of d-ala-d-ala.123 However, simple
binding of the additional membrane protein to the glycopep¬
tide binding sites is unlikely in view of the large number of
these sites (2 x 107 in a staphylococcus), unless the topograph¬
ical distribution of the protein in the membrane protects the
wall precursors as they are extruded through the membrane
and until they are fully incorporated into the mature wall.
Glycopeptide resistance in coagulase-negative
staphylococci
The degree of resistance to glycopeptides in coagulase-
negative staphylococci, particularly S. epidermidis and S.
haemolyticus, is not as great as with the enterococci.
Furthermore, these isolates are resistant to teicoplanin but
not to vancomycin.124 This implies that the resistance
mechanism will be different from that in the enterococci and
could be accounted for by slightly altered accessibility. An
additional membrane protein of 39 Kda has been found in
resistant isolates of S. epidermidis in comparison with
sensitive isolates (non-isogenic) but there is no direct
evidence that this protein is involved with resistance except
by analogy with the enterococci (M. D. O'Hare and P. E.
Reynolds, unpublished observations).
Summary
Selective antibiotic pressure due to the increased use of
glycopeptide antibiotics for the control of infections caused
by gram-positive bacteria has resulted in the emergence of
resistance in enterococci and coagulase-negative staphylo¬
cocci. It is of particular concern that resistance is mediated
in some enterococcal strains by self-transferable plasmids
with a wide hose range; such a situation may lead to the
transfer of this type ofglycopeptide resistance to other gram-
positive pathogens.121
Although glycopeptide antibiotics have been used for 30
years, cases of resistance have been slow to emerge. This is
probably due to the unique interaction between a compact
and relatively rigid antibiotic molecule and its target, which
is, unusually, a substrate for peptidoglycan synthesis rather
than an enzyme involved in catalysis. For this reason, any
mechanism of resistance is likely to be unusual: diminished
accessibility of glycopeptides to their target sites is the most
likely possibility in both enterococci and coagulase-negative
staphylococci but whether this results from target protection
ormodification has not yet been demonstrated convincingly.
Surveillance of antibiotic resistance in
England and Wales
R. C. George, P. B. Norbury and Dorothy James
Antibiotic Reference Laboratory, Division ofHospital Infection,
Central Public Health Laboratory, 61 Colindale Avenue,
London NW9 5HT
Surveillance of antibiotic resistance may be done at both
local and national levels. At local level, the compilation of
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results of routine diagnostic work for surveillance purposes
is readily achieved, particularly if the work of the laboratory
is computerised.125-126 The data derived may be used in the
formulation of local prescribed guidelines and poli¬
cies.127,128 Special studies and surveys are also undertaken
at local level and may involve additional susceptibility
testing and investigation of the mechanisms and genetics of
particular resistance markers detected. Such studies may
relate to local experience with particular pathogens, e.g.,
enterococci in Nottingham,129 or cover prolonged periods
of study for organisms isolated from particular sites of
infection, such as blood, e.g., Phillips and co-workers
reported recently on the antibiotic susceptibility of bacter-
aemia at St Thomas' Hospital over a 20-year period.127
For the definition of national trends in antibiotic resist¬
ance, cultures isolated in different laboratories may be
referred to one centre, where they can be examined for
antibiotic susceptibility with standardised methods. Such
studies may be specifically organised for this purpose130,131
or result from the examination of cultures submitted to
reference laboratories for typing or other specialised stud¬
ies.132,133 The number of different cultures, participating
centres, and time periods of study that may be included in
specially organised surveys are necessarily restricted by
resource and staffing implications. Similarly, data derived
from reference laboratory studies may be biased because the
criteria for submission of status for reference work are not
standardised.
An alternative approach to national surveillance is
provided by the referral of results ofsusceptibility tests (done
for diagnostic and therapeutic purposes) from diagnostic
laboratories to one or more centres where they are compiled
and analysed. Large multi-centre studies spanning several
years have been performed in the USA134 and the UK.135
The recent UK report by Spencer and co-workers utilised a
computer-based reporting scheme called Microbase136 to
collect susceptibility data on nearly 367 000 isolates from 61
medical microbiology laboratories distributed throughout
much of the UK.135
The remainder of this paper describes an approach to the
continuous surveillance ofantibiotic resistance which utilises
and expands the existing scheme for reporting bacterial
isolates from cases of bacteraemia and meningitis to the
PHLS Communicable Disease Surveillance Centre (CDSC).
The CDSC operates a voluntary, confidential, laboratory
reporting scheme for a wide range of infections in England
and Wales. Within the CDSC reporting scheme, laboratories
are requested to report significant bacterial isolates from
cases of bacteraemia and meningitis. During 1988, a major
re-organisation of this reporting scheme was initiated
involving the introduction of new computers, software and
report forms. This re-organisation suggested to staff within
the Division of Hospital Infection (DHI) of the Central
Public Health Laboratory (CPHL) an opportunity to
undertake continuous surveillance of antimicrobial suscep¬
tibility data for bacteraemia and meningitis isolates reported
to CDSC. Accordingly, after consultation with colleagues in
CDSC, the new Communicable Disease Report (CDR)
Form 2 was modified to include a request to the reporting
laboratories to list the antimicrobial susceptibility test results
obtained from routine diagnostic work on the cultures being
reported. This approach has several advantages. Firstly, the
data collected relates to organisms judged responsible for
significant infection. Secondly, the only additional workload
required in the reporting laboratory is to add their own
susceptibility test results to the form they are already
completing. Thirdly, the majority of all diagnostic micro¬
biology laboratories in England and Wales participate in the
reporting scheme giving very wide coverage. Fourthly, the
results obtained can be analysed geographically and by
clinical and epidemiological features (where these data are
available); and finally the surveillance scheme can run
continuously over many years providing a unique database
providing trends in antibiotic resistance. The new report
forms, with the request to include susceptibility test results,
were introduced at the beginning of 1989. This paper
presents some of the results obtained for bacterial isolates
reported during the first half of the 1989.
Reporters were asked to enter antibiotic susceptibility test
results as susceptible, intermediate or resistant (using their
own definitions), for the bacterial isolates they were
reporting. The susceptibility test results were added to the
existing CDSC computer database records of individual
patient infections (containing details of the source labora¬
tory, and clinical and epidemiological features) by staff of
the Division of Hospital Infection. As only those agents to
which clinical isolates were routinely tested in the individual
laboratories were included in the reports, there was consid¬
erable variation in the total number of tests for each
antibiotic. Generally, we have selected for inclusion those
antibiotics for which a result appears in > 40-50% of reports
for a particular species. When positive isolation was reported
from both blood and CSF in cases of meningitis, infection
was counted only once. Therefore each organism included
in these totals relates to an individual patient's infection.
In this preliminary report it is not feasible to present the
wealth of data that is being generated by this surveillance
system. Therefore, we have chosen for inclusion data relating
to four pathogens commonly reported to CDSC as causing
bacteraemia or meningitis, or both. Tables VI-IX show the
reported susceptibility test results for Escherichia coli,
Staphylococcus aureus, Streptococcus pneumoniae and Pseu-
domonas aeruginosa. The number of different laboratories
from which the reports were received is also shown. In
reports of these four bacterial infections, 84-87% included
results of antimicrobial susceptibility tests and 87-92% of
individual reporting laboratories included such data in their
reports.
For those agents most likely to be used therapeutically for
E. coli bacteraemia (table VI)—the cephalosporins and
aminoglycosides—full susceptibility was reported for > 98%
of isolates with the exception of cefuroxime, for which full
susceptibility was reported for 92-6%. Susceptibility to
ampicillin or amoxycillin was reported for 45% and
susceptibility to trimethoprim for 80% of the isolates tested.
Amongst the 2366 S. aureus bacteraemias reported from
249 laboratories, susceptibility test results were included for
87% (table VII). Apart from the 85% of isolates resistant to
penicillin, little antibiotic resistance was reported for the
agents tested, with 92% sensitivity to erythromycin, 98% to
methicillin, and 97% to gentamicin and fusidic acid.
The pneumococcus was the third most common organism
reported. Of these reports, 85% included susceptibility test
results. Full susceptibility to penicillin was reported for
almost all; with only three of 1701 isolates were reported to
be resistant or of intermediate sensitivity to penicillin. Of
nearly 1600 isolates for which reports included details of
erythromycin susceptibility, 2-5% were reported as resistant
or of intermediate susceptibility. Nearly 99% of the 385
isolates for which chloramphenicol susceptibility was re¬
ported were recorded as sensitive. This total includes
virtually all those from meningitis but relatively few of those
from bacteraemia.
Susceptibility test results were received for 86% of 499
cases of bacteraemia due to Pseudomonas aeruginosa reported
from 184 laboratories (table IX). Susceptibility to gentamicin
was noted in 91% of 338 reports, 1-5% were reported to be of
intermediate susceptibility and 7-4% resistant to gentamicin.
Susceptibility to ciprofloxacin, ceftazidime, piperacillin and
azlocillin was reported for 95%, 94%, 95% and 90% of
isolates respectively amongst reports that included results
for these antibiotics.
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The results obtained to date and the continuing support
that the surveillance scheme is receiving from microbiolo¬
gists in England and Wales suggest that this approach to
surveillance is likely to be useful and relevent for the
foreseeable future. It should be possible to monitor and
report trends and shifts in antibiotic susceptibility for a wide
range of common pathogens causing bacteraemia and
meningitis.
The accuracy of results reported in such a surveillance
study could be questioned. However, the results received are
those generated during normal laboratory testing for diag¬
nostic and therapeutic purposes. Such tests are subject to
both internal and external quality control. Results from the
National External Quality Assurance Scheme for micro¬
biology show that, for most organism and antibiotic
combinations examined within the scheme, agreement with
the designated correct result is achieved on 80-100% of
occasions, (Personal Communication, J.J.S. Snell). Thus, it
seems reasonable to accept the reported results as valid.
For E. coli, the results obtained for gentamacin suscepti¬
bility are identical to those obtained in the 3-year survey
reported by Spencer135—1% resistance—and very similar to
the 1-6% gentamicin resistance amongst 371 blood-culture
isolates reported from the Bristol survey in 1986.131 The
latter two studies reported 97% and 98% of E. coli strains to
be sensitive to cefuroxime, compared with the 92-6%
reported here. It remains to be seen whether there is any
significant trend towards resistance to cefuroxime in isolates
Table VI. Antimicrobial susceptibility ofE. coli isolates from cases of bacteraemia reported




Number (%) of strains that were
S I R
Ampicillin/Amoxycillin 3070 (97-5) 1400 (45-6) 119(3-9) 1551 (50-5)
Cefotaxime 1554 (49-4) 1542 (99-2) 3(0-2) 9 (0-6)
Ceftazidime 1046 (33-2) 1036 (99 0) 4(0-4) 6 (0 6)
Cefuroxime 2189 (69-6) 2027 (92-6) 72 (3-3) 90(4-1)
Ciprofloxacin 1572 (50) 1568 (99-7) 3(0-2) 1 (0-1)
Gentamicin 3015 (95-8) 2958(98-1) 27 (0-9) 80(1-0)
Trimethoprim 2261 (71-8) 1816(80-3) 19(0-8) 426(18-8)
Total number reported
Number of reporting laboratories
Number (%) with one or more sensitivity results
Number (%) of laboratories reporting sensitivity results





Table VII. Antimicrobial susceptibility of 5. aureus isolates from cases of bacteraemia




Number (%) of strains that were
S I R
Penicillin 1995(96-6) 292 (14-6) 1703 (85-4)
Erythromycin 1981 (95-9) 1830 (92-4) 4(0-2) 147 (7-4)
Methicillin 1962 (95 0) 1920 (97-9) 42 (2-1)
Gentamicin 1623 (78-6) 1571 (98-8) 14(0-9) 38 (2-3)
Fusidic acid 1659 (80-3) 1618(97-5) 5(0-3) 36(2-2)
Total number reported
Number of reporting laboratories
Number (%) with one or more sensitivity results





TableVIII. Antimicrobial susceptibility ofpneumococci isolated from cases of bacteraemia
and meningitis reported to CDSC/DHI from England and Wales, Jan.-June 1989
Antibiotic Number (%)
tested
Number (%) of strains that were
S I R
Penicillin 1701 (98-5) 1698 (99-8) 2(0-1) 1 (0-06)
Tetracycline 756 (43-8) 735 (97-2) 9(1-2) 12(1-6)
Erythromycin 1596 (92-4) 1551 (97-2) 4(0-3) 41 (2-5)
Chloramphenicol 385 (22-3) 380 (98-7) 1 (0-3) 4(1-0)
Total number reported
Number of reporting laboratories
Number (%) with one or more sensitivity results
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Table IX. Antimicrobial susceptibility of P. Aeuruginosa isolates from cases of bacteraemia




Number (%) of strains that were
S I R
Azlocillin 174 (49-6) 156 (89-7) 6(3-4) 12(6-9)
Ceftazidime 247 (70-4) 233 (94-3) 3(1-2) 11(4-5)
Ciprofloxacin 288 (82-1) 275 (95-5) 7 (2-4) 6(2-1)
Gentamicin 338 (96-3) 308 (91-1) 5(1-5) 25 (7-4)
Piperacillin 169 (48-1) 160 (94-7) 3(1-8) 6 (3-6)
Total number reported
Number of reporting laboratories
Number (%) with one or more sensitivity results





of E. coli from bacteraemia. The presence in these data of a
small number of reports of resistance or intermediate
sensitivity to cefotaxime and ceftazidime at 0-8% and 1%,
respectively, of isolates tested against these antibiotics is
suggestive of emerging resistance to these agents. As this
survey continues it should be possible to plot any such
changes in susceptibility to cephalosporins and, indeed, to
other antimicrobial agents over time.
Amongst the isolates of S. aureus from bacteraemia,
susceptibility to gentamicin and methicillin was reported in
97% and 98% respectively. These results are similar to the
98% sensitivity to gentamicin for 204 blood-cultures isolates
of S. aureus reported in Bristol131 and the 98% sensitivity to
methicillin reported for Spencer.135
Amongst pneumococci, very low levels of resistance to
penicillin and chloramphenicol were reported. However, it
should be noted that strains resistant to these agents are
responsible for significant infections in patients in England
and Wales, albeit in very low numbers. Resistance to
erythromycin was noted in 2-5% of nearly 1600 reports of
isolates from blood or CSF, compared with the 1% of > 7000
pneumococci from various clinical sources reported by
Spencer.135 Whether this small difference represents a
change in overall susceptibility to erythromycin may become
apparent as the survey continues.
The 7-4% incidence of resistance to gentamicin amongst
338 bacteraemia isolates of P. aeruginosa is notably higher
than the 1 % resistance reported for Pseudomonas spp.135 and
a little higher than the 4% resistance reported for 23 blood
isolates in Bristol.131 A survey of 1866 isolates of P.
aeruginosa collected from 24 British hospitals noted resist¬
ance in 5-5%.137
With a few exceptions the results reported here present a
reasonably reassuring picture of continued bacterial suscep¬
tibility to a wide range of antibiotics. Comparison of these
results with those obtained from culture-based surveys shows
reasonable concordance. The continuous surveillance of the
antibiotic susceptibility of bacteraemia isolates by the
present system, supplemented with occasional culture—
based surveys of particular species to define precisely the
genetics and mechanisms of resistance, offer a simple and
cost effective approach to national surveillance.
Is THERE ANY RELATIONSHIP BETWEEN BACTERIAL
RESISTANCE AND VIRULENCE?
L. Gutmann and G.S. Tillotson*
Service de Microbiologic, Hopital St Joseph, Paris Cedex 14,
France, and *Research and Development Department, Bayer
(UK) Ltd, Newbury, Berkshire, RG13 IJA
To access the association between virulence and antibiotic
resistance, it is essential to examine the interaction from two
aspects—firstly, in relation to plasmid encoded resistance
and secondly for chromosomally mediated resistance and
virulence; the interplay may be demonstrated by the use of
appropriate animal models. Many questions on this topic
have been raised and a multitude remain unsolved. For an
organism to be virulent it must possess some features or
factors which may include: (i) the ability to adhere to other
cells (via pili, fimbriae or adhesins); (ii) the production of an
extracellular toxin; or (iii) the ability to penetrate the tissues
or cells by virulence factors (once inside the cell the bacteria
may multiply and destroy it). Several of these features are
exquisitely plasmid mediated, others are only chromosomal.
Many virulence or pathogenicity factors are known to be
encoded by plasmids. Some are toxins that cause diarrhoea;
some are factors responsible for the adhesion of bacteria to
other cells; some are components that allow bacteria to
penetrate HeLa cells and then multiply; and some are
features that enable salmonellae to persist in various organs.
Many of these virulence factors happen to be associated
with antibiotic resistance markers carried on plasmids. One
of the best known instances of a linkage between resistance
and virulence conferred by a plasmid is that of enterotoxin
production amongst antibiotic-resistant Escherichia coli
isolates in the Far East.138 Toxigenic E. coli produce either
a heat-labile, antigenic, large-molecular-weight toxin (LT)
or a heat-stable, non-antigenic toxin (ST), or both. These E.
coli strains contain plasmids that carry the genetic informa¬
tion necessary for the production of these toxins. Several
conflicting reports suggested that E. coli may or may not be
able to carry together plasmids conferring enterotoxin
production and antibiotic resistance, but Echeverria et al.
collected 176 enterotoxigenic E. coli (ETEC) strains for the
Far East, of which 72% were resistant to one or more
antibiotic; 44% were resistant to four or more agents. In
transfer experiments, 80% of 31 ETEC strains transferred
part of their resistance pattern and 35% also transferred
their toxigenicity profile. None of the recipients acquired
toxigenicity without antibiotic resistance. These workers
concluded that ETEC isolated from the Far East in 1978
were frequently resistant to antimicrobial agents, and that
genes coding for resistance and enterotoxin production could
be transferred together in vivo. It was not known if this
phenomenon could occur in the human gastrointestinal
tract.
This type of association has also been observed by other
workers. Wachsmuth et al)39 found that 36% of a multi-
resistant E. coli population produced ST and that all
toxigenic strains were resistant to antibiotics. Smith and
Linggood140 examined ETEC isolates from pigs and found
that toxin-conferring plasmids were transmitted with resist¬
ance plasmids and, although not linked, the plasmids were
transferred together. Because interbacterial transfer of
antibiotic resistance occurs more efficiently in animals when
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antimicrobial agents are used, caution was advocated against
"the widespread use of antibiotics because it might result in
an increased incidence of bacteria possessing pathogenic
plasmids in the environment ofman and domestic animals".
The precise mechanisms of virulence of enteropathogenic
E. coli (EPEC) are not known. However, work by Laporta
et al.141 has shown that EPEC adhere to HeLa cells in two
different ways. These are termed localised adherence (LA)
and diffuse adherence (DA). The bacteria demonstrating
LA stick to localised areas of the cells in which they form
distinct microcolonies or clusters, whereas the isolates
showing DA adhere to the whole surface of the HeLa cells.
The LA characteristic has been shown to be consistent in
EPEC serotypes and focal adherence of E. coli Ol 11: H cells
to small bowel epithelia and packed aggregates on HEp-2
cells have been described previously by Clausen and
Christie.142
Laporta et al.xi2 confirmed that naturally occurring
plasmids encoding both LA and antibiotic resistance have
been recognised in E. coli. These workers examined six
strains of EPEC possessing transferable drug resistance;
two strains possessed the characteristic of joint factor
expression. One strain carried two plasmids, one coding for
ampicillin (Ap) resistance and the other for LA, whereas the
other strain contained only one plasmid coding for resistance
to four antibiotics and LA. Curing by acridine orange of an
ApLA + transconjugant showed that both features were lost
simultaneously.
The situation is different in bacteria possessing chromo¬
somal mutations conferring antibiotic resistance. One of the
best known examples of this is an alteration in a porin, a
protein component (Omp) of the outer membrane of gram-
negative bacteria responsible for the movement into the
bacterial cells ofmany chemicals such as nutrients, ions and
certain antibiotics. A very complex control mechanism
regulates the quantitative production of porins and affects
their sensitivity to different families of antibiotics such as //-
lactams, chloramphenicol, tetracycline and the quinolones.
The porins span the outer membrane as protein trimers that
admit small hydrophilic molecules to the cytoplasm. In E.
coli, Omp F has been shown to be larger than Omp C (1-2 nm
compared with IT nm). Thus, the ratio of Omp F. Omp C
affects the range of chemicals and antibiotics admitted to
the cell. Genes coding for the control of Omp F and Omp C
are under the transcriptional regulation of the Omp R gene,
which itself is part of the component regulatory system Omp
R and env Z. The env Z gene encodes a transmembrane
sensory component which acts as a donor for the product of
Omp R, a transcriptional regulator. Dorman et a/.143
introduced, via transposon-generated mutation, into a
mouse-virulent strain of Salmonella typhimurium, various
Omp changes, which included Omp C, Omp D (another
porin present in salmonellae), Omp F and Omp R. Once
characterised, the mutated strains were inoculated into
BALB/c mice by either the oral or intravenous route. In
comparison with the parent strain, Omp C- or Omp F-
deficient strains were identical in virulence. The Omp D
mutant was slightly less virulent whereas the mutant Omp
R failed to kill the mice after oral challenge and showed a
markedly reduced intravenous LD50. Furthermore, the Omp
R mutants persisted for several weeks in murine tissues, and
appeared to protect against subsequent challenge by the
parent strain.
Cyclic AMP (cAMP) and the cAMP receptor protein
(CRP) are essential for the transcription of many genes and
operons involved in catabolite transport and breakdown.
The cAMP levels in cells influence various factors related to
virulence or pathogenicity, such as synthesis of fimbriae and
flagella and manufacture of at least one Omp. Deficiency in
cAMP and CRP can also be associated with //-lactam
resistance. Curtis and Kelly144 developed strains of Salmon¬
ella typhimurium which were unable to synthesise adenyl
cyclase and CRP and thus were deficient in cAMP. The
parent strain of S. typhimurium possessed a virulence
plasmid, pStSRIOO, which enabled it to attach to, invade
and persist in Peyer's patches but was defective in traversing
to the mesenteric lymph nodes and spleen. With several
different genotypic mutant derivatives, studies were per¬
formed to assess the following properties; carbohydrate,
metabolism, flagellum synthesis, colony size, virulence in
BALB/c mice, genetic stability, tissue tropism, persistence
of avirulent mutants and immunogenicity. All of the mutant
strains were less virulent and induced a high level of
protective immunity. Tissue tropism and persistence were
not markedly different in the cAMP and CRP mutants.
However, the genetic mutations created appeared to be
stable. The infective dose required for the mutants was
significantly higher than that of the parental strain, whereas
the colony size and generation times of the mutant strains
were smaller and longer than the wild type. Thus, mutations
causing loss of adenyl cyclase or loss ofCRP lead to avirulent
but immunogenic strains of S. typhimurium.
Shigella flexneri causes dysentery in man by penetrating
and multiplying inside human colonic epithelial cells. This
invasive process has been demonstrated in vitro by showing
HeLa cell invasion and a subsequent cytopathic effect. The
expression of genes located on the chromosome is required
for full virulence, but loci encoding for entry into epithelial
cells are located on a 220-kb virulence plasmid. Bernadini et
al,145 constructed mutants of the Omp B locus which
contains the Omp R and env Z genes, which in turn are
responsible for regulatory changes in accordance with
environmental stimuli. Deletion of the Omp B locus via an
allelic exchange yielded a mutant that expressed a low level
of entry into cells and a limited capacity to survive
intracellularly. Other virulence assays confirmed that the
virulence of the mutant was severely impaired.
These three examples of chromosomal mutations which
were associated with decreased virulence have shown that
genetic changes which are known to be related to antibiotic
resistance (although it was not tested in these particular
mutants) may have a price in terms of viability, persistence
and invasiveness. Two examples follow, in which sensitive
clinical isolates of bacteria resistant in vitro have been
investigated with respect to virulence in a mouse infection
model.
Resistance to //-lactam and aminoglycoside antibiotics in
Pseudomonas aeruginosamay be conferred either by enzymes
(plasmid or chromosomal) or by a change to permeability.
When aminoglycoside resistance is present it may result
from either a complete loss or significant reduction of the O-
antigenic subunits of lipopolysaccharide. Bryan et al.xi6
examined the virulence ofa series ofmutant and transductant
strains of P. aeruginosa that expressed //-lactamase and
aminoglycoside resistance, in a mouse model of peritonitis
and septicaemia (table X). The mechanisms of resistance of
these mutant strains included (1) for /Mactam antibiotics,
the production of a constitutive //-lactamase, a decrease in
permeability and a decreased affinity for penicillin-binding
proteins, and (2) for aminoglycoside antibiotics, a decrease
in cytochrome and nitrate reductase as the absence or
reduction in the subunits of LPS. The results for these
various mutant strains in the mouse peritonitis model
revealed that bacteria showing mechanisms of resistance to
//-lactam antibiotics all retained virulence properties similar
to the parent. This is consistent with observations of these
isolates that showed no change of morphology, growth rate
or production of exotoxin A. However, the aminoglycoside-
resistant strains showed a significant decrease in virulence.
Three strains with altered cytochrome demonstrated slower
growth rates and two mutant strains had "uncapped" LPS.
Thus, in contrast to strains resistant to //-lactam agents,
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Table X. Strains, properties and features of P. aeruginosa strains1
MIC (me/11
GrowthStrain Resistance Virulence LD50
no. mechanism rate
Piperacillin Gentamicin
PA 0503 None 1 1 — 7x 105 Normal
P-lactam resistant




>120 1 5-5 x 105 Normal
PCC 45 Permeability de¬
crease
4 1 6x 105 Normal
PCC 17 Decreased affinity to
PBP
80 1 5x 105 Normal
PCC 2 Decreased affinity to
PBP 3
4 1 6 x 105 Normal
Aminoglycoside resistant
PAO 2401 Cytochrome and
N03 reduction
1 15 i 72-1 x 106 I
PAO 2402 No cytochrome and
N03 reduced
1 4 1 72-1 xlO6 i
PAO 2403 No cytochrome and
N03 reduced
1 16 i 72-1 x 106 i
PAO 503-18 Absence of LPS sub-
unit
1 4 i 72-1 x 106 Normal
PAO 503-16 Marked reduction in
LPS subunit
1 4 1 72-1 x 106 Normal
those with reduced aminoglycoside sensitivity manifested
reduced virulence. Similar mutant strains have been isolated
from cystic fibrosis patients, almost all ofwhom had repeated
intensive courses of aminoglycosides. It is probable that
these strains may persist during antibiotic therapy despite
their reduced virulence.146
A further group of antimicrobial agents is the 4-fluoro-
quinolones, ofwhich ciprofloxacin is one of the most active.
Despite broad spectrum and rapid bactericidal activity,
ciprofloxacin-resistant bacteria are isolated particularly
amongst P. aeruginosa and staphylococci. As ciprofloxacin is
available for both oral and parenteral administration, it has
been used extensively in the treatment of patients with cystic
fibrosis. However, resistant strains ofP. aeruginosa have been
isolated during such treatment. Ravizzola et al.147 examined
two routine clinical isolates and their in-vitro ciprofloxacin-
resistant variants whose MICs were > 200mg/L and 50mg/L
respectively. These strains were injected intraperitoneally
into mice and the LD50s were calculated. The authors
concluded that these ciprofloxacin-resistant strains were less
virulent than the susceptible parent strains. A change in
colony form (from large/rough to small/rough) was observed.
The results suggested that resistance may be associated to a
decrease in virulence.
In conclusion, since resistance and virulence genes can be
harboured on plasmids and, occasionally, on the same
plasmid, excessive use of antibiotics may favour (i) the
spread of such plasmids harbouring these two types of genes,
and (ii) the formation of such plasmids harbouring the two
kinds of markers. Conversely, bacteria exhibiting changes
usually associated with chromosomal mutations showed a
reduction in virulence and infectivity but rarely a change in
immunogenicity. Clearly agents able to select such resistance
mechanisms should be used cautiously in circumstances
where such mutations may be readily expressed because,
although the strains appear to be less virulent, they are still
resistant to therapy. Nevertheless, these chromosomally
resistantmutant strains may be useful in the development of
new bacterial vaccines in the light of their immunogenic but
non-pathogenic properties.
Sensitivity of antibiotic resistant bacteria
to opso nophagocytosis IN VITRO: implications
for clinical infections and therapy
C. G. Gemmell
Department of Bacteriology, Medical School, University of
Glasgow, Royal Infirmary, Glasgow
Since the advent of penicillin in 1940 and its subsequent
use in the treatment of staphylococcal and other infections,
concurrent resistance to the drug has been recognised
amongst a hitherto susceptible bacterial population. In
particular, the development of methicillin as a therapeutic
drug followed the recognition that Staphylococcus aureus
readily developed resistance to penicillin by the induction of
a /^-lactamase enzyme. Stereochemical features ofmethicillin
prevented destruction of the antibiotic by the enzyme.
However, resistance to this drug is now possible through
alteration in the drug target proteins andmethicillin-resistant
5. aureus (MRSA) are now a clinical problem world-wide.148
Cross-resistance to other penicillins and cephalosporins, as
well as resistance to drugswith different biochemical actions,
is now found amongst this group of organisms.
MRSA strains are important nosocomial pathogens. They
were first described in the early 1960s and outbreaks of
MRSA infection were described subsequently in Great
Britain, Europe, the USA and Australia. With the exception
of a single strain causing clinical problems in London and
the South-East of England (named EMRSA-1)149 most
outbreaks of infection with MRSA have been readily
contained. This has led to the suggestion that such strains
are generally less virulent than their methicillin-sensitive
counterparts (MSSA). Isolates of S. aureus from patients
with primary staphylococcal sepsis are still rarely multi-
resistant whereas those patients with MRSA usually have
underlying disease, e.g., MRSA strains isolated from patients
in a Burns Unit succeeded in colonising the most severely
burned individuals but rarely spread elsewhere in the
hospital.150 In terms of patient management, it would be
useful to be able to distinguish strains that are potentially
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epidemic from non-epidemic or sporadic strains. One study
has shown that production of low levels of protein A and
high levels of coagulase may be predictive of potentially
epidemic strains.151 Some corroboration of these findings
has been shown by others, who also demonstrated production
of similar amounts of a, y and <5 haemolysins in MRSA and
MSSA.152
With this background, it seemed logical to look for
differences in host response to infection as a predictor of
susceptibility to infection by MRSA. Measurement of
various parameters of neutrophil function in vitro is possible
and by so doing the expression or otherwise or surface
components inimical to opsonophagocytosis might be
detected. In addition, it is possible to compare neutrophil
functions in normal and immunocompromised hosts.
Since 1985, the Royal Infirmary, Glasgow, has witnessed
a succession ofmulti-resistant S. aureus strains with differing
antibiotic susceptibility patterns. Patients admitted to the
Burns Unit became colonised with a strain resistant to
penicillin, erythromycin and fucidin (PEF). Sometime
thereafter, a strain resistant to penicillin, erythromycin,
methicillin and gentamicin (PEMG) appeared in these
patients to the exclusion of the former strain. Strains with
different antibiotic sensitivity patterns were chosen for
measurement of their susceptibility to serum opsonisation
and subsequent phagocytosis by neutrophils. However, no
significant differences between the strains were found.153
Similar results have been reported also by others.152
suggesting that the observed changes in protein A expression
are not in themselves sufficient to alter bacterial susceptibility
to phagocytosis or that some compensation has taken place
in the MRSA strains deficient in protein A.
Extension of these methods to neutrophils obtained from
immunocompromised (i.e., burned) patients revealed that
the host status was important in determining how MRSA
were handled. Immediately after burn injury, patients'
neutrophils were markedly depressed in terms of their ability
to phagocytose MRSA and this change lasted for several
days before normal phagocytic efficacy returned. To some
extent, these differences could be attributed to difference in
the opsonic activity of the patients' serum (table XI).
Therefore, these findings would support the concept that
drug resistance per se does not predetermine virulence in vivo
except amongst immunocompromised patients, in whom
humoral and cellular defects can be recognised.
It is realised that the drug-resistant S. aureus strains used
in the preceding studies may or may not have had a common
genetic background and cannot, therefore, be properly
compared to each other or to antibiotic-sensitive strains. In
an attempt to answer this criticism, a different approach has
been followed with regard to the development of fluoroquin¬
olone resistance in S. aureus and Pseudomonas aeruginosa.
The primary action of the quinolones is on DNA gyrase,
although the cidal mechanism may involve a series of
events.154 Resistance to drugs of this type is based upon the
possession of an altered DNA gyrase, with the A sub-units
being intimately involved. Mutations affecting synthesis of
a particular outer membrane protein and permeability have
been described also. Many of these mutant strains have
appeared during therapy and have constituted a risk to the
patient as well as a threat to the choice of the quinolones in
therapy.
Serial subculture ofmany bacterial species in the presence
of sub-inhibitory concentrations of norfloxacin, ciprofloxa¬
cin, ofloxacin, enoxacin or pefloxacin results in the selection
of resistance; Escherichia coli may be an exception. Cross-
resistance between the five drugs was readily demonstra¬
ble.155 This technique has been used to provide quinolone-
resistant variants derived from an original quinolone-
sensitive strain as targets for measurement of their compar¬
ative susceptibility to phagocytosis. Ciprofloxacin and
ofloxacin were used as selector drugs. No differences were
recognisable in ingestion by neutrophils between the
quinolone-resistant offspring and the S. aureus or P.
aeruginosa parent strains.156 However, when their ability to
induce a respiratory burst in the neutrophils was measured,
some differences were found between the strains. Variants
of S. aureus expressing low or intermediate level resistance
to the quinolones were less able to generate a respiratory
burst than the original strain. In contrast, similar strains of
P. aeruginosa appeared more capable of stimulating the
neutrophils in this assay. In addition, there was considerable
strain-to-strain variation in neutrophil interaction which
could not be explained either by their innate susceptibility
to phagocytic ingestion or their level of drug resistance.
Table XII illustrates some of these results. It remains to be
seen whether the drug-induced variants differ in other
respects from their parent strains. Preliminary evidence
with S. aureus suggests that their ability to elaborate various
exotoxins (e.g., a-haemolysin, coagulase) may be altered.
Whether their structural topography is also modified during
the development of drug resistance is still to be investigated.
On the basis of current experimental approaches there is
little evidence to suggest that development of drug resistance
results in "superbugs" capable of initiating more serious
infections than their drug-sensitive counterparts, except,
perhaps, in causing nosocomial infection among immuno¬
compromised patients. In this context, it would be appropri¬
ate to extend the studies to bacterial pathogens in which
drug resistance has developed during antibiotic therapy.
The selective pressure provided by the antibiotic ciproflox¬
acin used in the treatment of peritonitis in patients
undergoing chronic ambulatory peritoneal dialysis has
provided drug-sensitive and drug-resistant strains of S.
epidermidis and S. haemolyticus. However, no differences in
bacterial susceptibility to opsonophagocytosis were detected.
The clinical implications of acquired
bacterial resistance
R. N. Griineberg
Department of Microbiology, University College Hospital,
London WC1E6AU
The general implications of acquired bacterial resistance
to antimicrobial agents are very great. The explosive growth
of a new industry of bacterial genetics has been given a
Table XI. Differences between serum from burned patients A and B and
normal serum in opsonisation of strains of S. aureus
Percentage ingested by PMNL after opsonisation with
Target
normal serum patient A serum patient B serum
strain
1% 10% 1% 10% 1% 10%
PRF 12-5 23-1 3-9 10-8 1-6 3-6
PEMG 17-2 22-5 13-2 25-2 10 9-5
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Table XII. Induction of repiratory burst in PMNL following exposure to
quinolone-sensitive and quinolone-resistant strains of S. aureus
Strain Drug
resistance
Peak chemiluminescence (cpsc) after
opsonisation with serum
1% 10%
bro, None 0-27 0-27
Ciprofloxacin 019 0-36
Ofloxacin 0-41 0-45
lh4 None 0-40 0-36
Ciprofloxacin 0-24 0-35
Ofloxacin 010 019
powerful impetus by the stimulus of enquiry into the
mechanisms of acquired bacterial resistance and has
generated considerable activity in academic departments of
medical microbiology and research laboratories. A second
consequence has been to make medical microbiologists
much more "clinical" and much less laboratory based. In
the UK, there are approximately 400 consultant medical
microbiologists with an infrastructure of junior medical
staff, specialised laboratory staff and whole sections of
laboratories, for the basis of development has been the
existence of antibiotics and the linked relationship with
antibiotic resistance. Before the antibiotic era there were
hardly any specialist microbiologists in hospitals in the UK;
there were relatively small numbers in University depart¬
ments whose functionswere related to teaching and research.
The development of antibiotic resistance has added
greatly to the interest of medical microbiology and has
provided opportunities for international links, often through
the support of the pharmaceutical industry for conferences
at home and abroad. The development of the antimicrobial
part of the pharmaceutical industry has been very striking.
Had there been no need to develop this industry because
bacteria had not acquired resistance, there would be very
different patterns of prescribing within hospitals, where one
fifth of the drugs budget is now allocated to antimicrobial
agents, and a corresponding reduction in the interest of the
industry in microbiologists.
All drugs have certain common limitations on their use—
the nature and frequency of side effects, and cost. Antimicro¬
bial agents have a third problem which has generated the
antibiotics industry and medical microbiology as a special¬
ity—acquired bacterial resistance to antibiotics.
Selection ofresistant organisms
In the early days of the antimicrobial era, most infections
were caused by organisms, such as staphylococci, strepto¬
cocci, and, very occasionally, coliform organisms, which
were inherently antibiotic-sensitive. Over subsequent dec¬
ades, selection pressures produced by the widespread use of
antibiotics, whether for appropriate or inappropriate rea¬
sons, have resulted in the emergence of new groups ofmajor
pathogens as causes of infections. Often this has led to the
emergence oforganisms ofwhichmicrobioligistswere barely
aware before the advent of antimicrobial agents; infections
caused by Pseudomonas aeruginosa, and even by other
Pseudomonas spp., by Klebsiella, Enterobacter, Serratia,
Arizona and Citrobacter spp. and by many other gram-
negative species, by enterococci, and by resistant staphylo¬
cocci, whether coagulase-negative or coagulase-positive, are
now common. The pressures for the emergence of these
oragnisms as pathogens have been, on the one hand
technological change, such as the increasingly widespread
use of indwelling vascular catheters or prosthetic devices, or
more heroic surgical procedures, and, on the other hand, the
attempt to prevent these ever more exposed patients
succumbing to infections by the widespread use of antibiot¬
ics, whether given prophylactically or therapeutically.
New drugs
In the classical era of the development of new antimicro¬
bial agents, extending to the late 1950s, although antibiotic
resistance was emerging it has not done so to any great
extent and several powerful agents were available that
covered nearly all the pathogens that were commonly seen
in clinical practice at that time; penicillin, streptomycin,
tetracycline, chloramphenicol, sulphonamide, erythromy¬
cin, ampicillin, carbenicillin, methicillin, the first generation
cephalosporins and metronidazole were all available.
However, many of those drugs, useful though they were,
had limitations on their use because of difficulty of
administration or, in cases such as streptomycin, toxicity.
There would, perhaps, have been some development of new
drugs even in the absence of bacterial resistance, as attempts
to develop more convenient versions of existing drugs which
would have been easier to administer and perhaps less toxic.
It is reasonable to speculate that there would not have been
the development of the semi-synthetic /1-lactam agents—the
cephalosporins, monobactams, augmentin, etc—or of tri¬
methoprim and co-trimoxazole, and that the massive
development of the aminoglycosides, and the quinolones
and glycopeptide antibiotics, would not have occurred
without the major stimulus of bacterial resistance. If it were
not for the problem of resistance, most of these relatively
new antimicrobial agentswould have offered little to improve
patient management.
Implicationsfor patients
The response of the medical profession to the problem of
resistance has been to use higher doses of the older drugs
than would otherwise have been the case, or to combine
drugs, as in the treatment of tuberculosis, to overcome the
actual or perceived risk of resistance to single agents, or,
alternatively, to use more recently developed drugs which
may be difficult to administer, toxic and costly.
Some drugs are difficult to administer because they have
to be given intravenously, commonly in substantial doses,
generally necessitating the positioning of long intravenous
catheters, which essentially ties the patient to a hospital bed
and makes him or her immobile; there is also the
administration, in some cases, of a heavy sodium load. There
are well documented risks of morbidity and mortality
relating to the length of time for which an intravenous
catheter has to remain in place.
Toxicity and side effects present considerable problems in
relation to monitoring levels of the agents in serum and the
cost of thismonitoring, both in terms of laboratory costs and
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in terms of potential litigation when patients have semi-
predictable side effects related either to unusual sensitivity
to the drug or to long administration of the drug for good
clinical reasons. The cost of monitoring and of litigation is
substantially under-estimated by the medical profession.
The direct cost of the drug also may be very considerable.
Pencillin G, 600 mg given 6 hourly, costs a few pence per
day. The cost of replacing penicillin G by alternatives such
as vancomycin, cephalosporins, etc., may be tens of pounds
per day, with the result that excess money spent on the new
drugs cannot be spent on more desirable objectives. There
are also associated costs in giving drugs, both for the giving
system and for the labour of administering the treatment.
Examples ofcurrent clinicalproblems
A recent problem concerns a 6-month-old child with
meningitis caused by a pneumococcus with diminished
sensitivity to penicillin. Initially, penicillin was given, before
it was recognised that the pneumococcus was not fully
sensitive, and there was no significant clinical response.
Once the problem was recognised, chloramphenicol treat¬
ment was instituted but this has caused considerable anxiety
because of the need to give a potentially toxic drug to a child
who would otherwise not have received it.
In another specialty, cardiac surgeons have used /Madam
antibiotics combined with an aminoglycoside, prophylacti-
cally, to reduce post-operative sternal would infection. Such
infections are most commonly caused by coagulase-negative
staphylococci, which are resistant to methicillin in 60% of
cases, or by Staphylococcus aureus. Because even very short
courses of aminoglycosides given prophylactically may give
rise to toxicity, there is increasing pressure to use glycopep-
tide antibiotics prophylactically.
Doomwatch
There is steadily progressive erosion of the usefulness of
antibiotics by rising tide of acquired resistance in pathogenic
bacteria. Total inability to control resistant bacteria is, so
far, a rarity. However, doctors being driven to use second-
or third-line drugs, or antibiotic combinations, rather than
the first choices of previous years. A heavy cost in side
effects, ecological damage, preventable hospitalisation,
morbidity and mortality, and in money, is being paid and
will increasingly be paid.
Concluding remarks by J. T. Smith
In the "good old days", a single lecture describing bacterial
resistance to antibacterial agents would nicely encompass
all there was to know on the subject. However, as clinical
isolates exhibiting resistance tomore andmore drugs became
more frequent (more often than not resulting from R-
plasmids), whole conferences on resistance to but a single
class of antibacterial agent became normal. Although such
a fashion had technical merit, discussion of bacterial
resistance became so fragmented that few indeed could
retain an overview of the problem. The meeting that
provided the basis for this review article brought together
investigators with a wide range of expertise across the full
spectrum of antibiotic resistance and helped speakers and
audience alike to stay abreast of this most important topic.
We thank Bayer UK for supporting the meeting on which this
article is based, which has permitted a forum where problems of
antibiotic resistance could be frankly discussed.
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Comparison of Clostridium sordel/ii toxins HT and LT with
toxins A and B of C. difficile
R. D. MARTINEZ* and T. D. WILKINS
Department of Anaerobic Microbiology, Virginia Polytechnic Institute and State University, Blacksburg, I/A 24061,
USA
Summary. Clostridium sordellii produces two toxins, designated HT (haemorrhagic toxin)
and LT (lethal toxin), that are similar to toxins A and B of C. difficile. The physicochemical
properties of toxins HT and A were remarkably similar. The specific biological activities of
toxin HT were almost the same as those of toxin A, and their NH^-terminal sequences
shared close homology. The properties of toxins LT and B were similar, as were their NH2-
terminal sequences, but toxin B was much more cytotoxic than toxin LT. Immunodiffusion
analysis with specific antibodies showed that although toxins B and LT shared major
antigenic determinants, each had unique epitope^. The results suggest that toxins B and LT
have diverged more than toxins A and HT. Immunoblotting with antibodies to the toxins of
C. difficile showed that toxins HT and LT had common antigenic determinants.
Introduction
Several studies have implicated Clostridium sordellii
as a cause ofdiarrhoea and enterotoxaemia in domestic
animals,1-3 and, more recently, as an agent of toxic
shock-like syndrome in man.4,5 This species was once
suspected to be the cause of pseudomembranous colitis
(PMC) in man because the cytotoxicity of faecal
filtrates from PMC patients was neutralised by C.
sordellii antitoxin.6-8 However, C. sordellii could not
be isolated from the faeces ofpatients with PMC. This
discrepancy was clarified when C. difficile was isolated
from faecal samples of patients with PMC,9-11 and it
was shown that the toxins produced by this organism
are neutralised by C. sordellii antitoxin.6'8,12'13 Two
toxins, A and B, have been purified from culture
supernate of toxigenic strains of C. difficile.14-16 Both
are large proteins that are lethal to animals and
cytotoxic. Toxin A is a potent enterotoxin that
produces a haemorrhagic fluid response in the rabbit
ileal loop assay.17-19
C. sordellii produces two toxins that are similar to
toxins A and B, which explains why C. sordellii
antitoxin neutralises the toxins of C. difficile. The
production of two distinct toxins by C. sordellii was
first described by Arseculeratne et al.,20 who extracted
a haemorrhagic toxin from sporulating cells and an
oedema-producing toxin from vegetative cells. The
oedema-producing toxin was more lethal than the
Received 7 Aug. 1990; revised version accepted 28 March 1991.
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haemorrhagic toxin and the toxins are now referred to
as LT (lethal toxin) and HT (haemorrhagic toxin)
respectively. We have already described the purifica¬
tion of toxin HT by ultrafiltration and immuno-affinity
chromatography with a monoclonal antibody (MAb)
to toxin A, and have shown that toxin HT has
biological activities and immunological properties
similar to those of.toxin A.21 Popoff has purified toxin
LT and shown that it is immunologically related to
toxin B.22 The toxins produced by C. difficile and by
C. sordellii have similar physicochemical as well as
immunological and biological properties but they are
not identical. Therefore, it was of interest to compare
the properties of these toxins in more detail.
Materials and methods
Protein determination
Protein concentration was estimated by the method
of Bradford23 with the BioRad Protein Assay Kit
(BioRad Laboratories, Richmond, CA, USA). Bovine
y-globulin (BioRad) was the standard.
Bacterial strains and medium
C. difficile VPI 10463 (Tox + ), C. sordellii VPI 9048
(Tox + ), VPI 2013 (Tox-) and VPI 7319 (Tox-) were
obtained from the culture collection of the Department
of Anaerobic Microbiology, Virginia Polytechnic
Institute and State University (Blacksburg) and were
identified by L. V. Holdeman, E. P. Cato and W. E.
C. Moore by methods described in the Virginia.
Polytechnic Institute Anaerobe Laboratory Manual.24
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DOES CLAVULANIC ACID SELECT
EXTENDED-SPECTRUM (3-LACTAMASES?
SK Du Bois1, MS Marriott2 and SGB Amyes1
1 Edinburgh University, Edinburgh, UK
2Glaxo Group Research Ltd, Greenford, UK
ABSTRACT
Escherichia coliJ62-2 (TEM-S^^J was cultured in liquidmedia containing limiting concentrations of ampicillin
or amoxycillin and clavulanic acid (2:1 ratio). The cultures were subcultured five times into fresh media
containing the same antibiotics. Ten colonies were purified from each subculture (300 strains in total).
Minimum inhibitory concentrations (MICs) of ampicillin, amoxycillin, ceftazidime, cefotaxime, and amoxycillin/
clavulanic acid revealed a few strains with increased resistance to not only amoxycillin/clavulanic acid but also
ceftazidime and cefotaxime. Isoelectric focusing demonstrated that the increased resistance corresponded
with multiple p-lactamase expression (pi 5.57,5.5, and 5.25). Electrophoresis of plasmid DNA confirmed that
each organism contained a single plasmid, the same size as pCFF14 (150-kb). Analysis of enzyme kinetics
of each p-lactamase (pi 5.57, 5.5, and 5.25) compared to TEM-1 (pi 5.4), TEM-5 (pi 5.5), TEM-10 (pi 5.57),
and TEM-12 (pi 5.25) suggests that the unknown p-lactamases are TEM-5, TEM-10 and TEM-12 respectively.
Our results suggest that amoxycillin in combination with clavulanic acid selects back mutations to TEM-1 and other
extended-spectrum p-lactamases. The host organism will contain a heterogenous population of a clinical plasmid.
INTRODUCTION
The third-generation cephalosporins (3GCs), which possess a 7-oxime side-chain, epitomise our ability to
overcome antimicrobial resistance, especially of the plasmid-encoded TEM-1 and SHV-1 p-lactamases.
Unfortunately the TEM- and SHV-derived extended-spectrum p-lactamases (ESBL) have developed as the
direct result of the selective pressure imposed by the use of 3GCs.
The biochemical data published by Sowek and colleagues in 1991 [1 ] show that as cefotaxime and ceftazidime
turnover, kCAT, increases, the benzylpenicillin turnover decreases. The greater the efficiency of 3GC hydrolysis
the slower the turnover of benzylpeniciliin.
When considering the mutations required to transform TEM-1 into TEM-5 (Figure 1): comparison of the
benzylpenicillin turnover number of TEM-12 to that of TEM-10 shows that, although the latter enzyme
hydrolyses the 3GCs with greater efficiency than the former, TEM-12 hydrolyses penicillins faster than TEM-
10. Biological pressure from a penicillinwould select against the ESBL and may induce back mutations to the
more innocuous enzyme, TEM-12. We have proposed the hypothesis that the evolution of the parent
p-lactamase to broad-spectrum enzyme can consistof both forward and backwardmutations atwell defined locations.
FIGURE 1
METHODS
The passage experiment methodology was a modification of that by described by Thomson & Amyes [2]:
Escherichia coliJ62-2 (TEM-S^^J was cultured in liquidmedia containing limiting concentrations of ampicillin
(AMP-selection) and amoxycillin and clavulanic acid (2:1 ratio) (CO-AMOXICLAV-selection). The cultures
were subcultured five times into fresh media containing the same antibiotic. Ten colonieswere purified from each
subculture (300 strains in total).
Minimum inhibitory concentrations (MICs) of ampicillin, amoxycillin, ceftazidime, cefotaxime, and amoxycillin/
clavulanic acid were performed according to the BSAC guidelines [3].
Isoelectric focusing (IEF), based on the method of Matthews et al [4], employing a broad-range ampholine
mixture (pH 3.5-10) was used to examine a selection of the p-lactamases produced.
The method of Takahashi & Nagano [5] was used to extract and visualise the plasmid DNA of those strains
examined by IEF. The plasmid DNAwas also digested with a number of restriction endonucleases, none of
which were known to cut within the TEM p-lactamase gene. Southern Blots were prepared according to the
method ofSouthern [6] andwere subsequently analysed by hybridisationwith a non-radioactively labelled blaT-
1 probe (generated by PCR and Biotin-7-dATP) [7].
p-lactamase activity and the effect of clavulanic acid inhibitionwere determined by spectrophotometric assays
[8,9,10],
RESULTS
MICs of the colonies from the AMPICILLIN-selection group revealed a few strains with increased resistance
to all of the antibiotics (ampicillin, amoxycillin, ceftazidime, cefotaxime, and amoxycillin/clavulanic acid) used
in the challenge. Isoelectric focusing demonstrated that all the p-lactamases were identical and had an
isoelectric point (pi) of 5.5 corresponding to that of TEM-5. Specific activity of the crude enzyme preparations
suggested that enzyme production in the cellwas raised. No p-lactamasemutationswere observed as a result
of the ampicillin.
MICs of colonies from the CO-AMOXICLAV-selection to ampiciilin, amoxycillin, ceftazidime, cefotaxime, and
amoxycillin/clavulanic acid revealed a few strains with increased resistance not only to amoxycillin/clavulanic
acid but also ceftazidime and cefotaxime. Isoelectric focusing demonstrated that the increased resistance
corresponded with multiple p-lactamase expression (pi 5.57,5.5, and 5.25). Electrophoresis of plasmid DNA
confirmed that each organism contained only a single plasmid of similar size and EcoR I restriction pattern to
pCFF14(150-kb).
Comparison of the restriction patterns of pCFF14 and one of the mutant strain's plasmid (named pUK3007)
revealed an additional EcoR I restriction fragment, approximately 25-30-kb in size. Additional restriction
fragments are seen in the restriction patterns with some of the other endonucleases used.
Intragenic gene probing revealed a blaT gene was only ever present on a single restriction fragment from a
digest of pCFF14. However, aTEM gene was shown to be present on two restriction fragments ofmany of the
pl)K3007 digests.
Specific activity of the crude enzyme preparations ofTEM-5^^ and the enzyme(s) of pUK3007 suggested
that the latter preparation possessed a much greater spectrum of activity than would be exhibited by a single
enzyme, TEM-1, TEM-12, TEM-10, orTEM-5. This is in agreementwith the IEF results showing the presence
of more than one TEM p-lactamase.
Our results show that ampicillin does not induce point-mutations in the ESBL. However, the use of amoxycillin
and clavulanic acid in combination causes gene duplication and point mutations in the bla genes to occur in
the clinical plasmid, pCFF14. The resulting plasmid exhibits the production of three p-lactamases: TEM-5,
TEM-10, and TEM-12. TEM-10 and TEM-12 are one and two pointmutations different fromTEM-5 respectively.
FIGURE 2
MIC'S OF p-LACTAMS & HYDROLYTIC CHARACTERISTICS OF TEM-DERIVED p-LACTAMASES
Enzyme Benzylpenicillin Ceftazidime Cefotaxime
MIC* kCAT(S"1) MIC* kcAT(s"1) MIC* kCAT (S'1)
TEM-1 >128 520 0.25 0.0016 0.03 0.25
TEM-12 >128 54 2.0 3.4 0.03 2.4
TEM-10 >128 17 32 17 0.25 0.39
TEM-5 - - 128 - 4 -
* Minimum inhibitory concentration in pg/ml for plasmid-containing Escherichia coli
DISCUSSION AND CONCLUSIONS
Conservative mutations or mutations remote from the active site do not affect biological parameters in a
measurable manner. Evolutionary implications of the single mutations may be relatively minor and may not
be detected during the normal course of events. Silent mutations, or minimally important mutations, occur
frequently with little functional consequence but may prepare bacteria to be ready for a more drastic change
when challenged with a 3GC. Acquisition of a single innocuous mutation facilitates the occurrence a more
dangerous double mutation.
Although innocuous mutations may exist in the unchallenged population, treatment with a penicillin, as often
occurs in general practice, would result in the selection of the parental enzymes, TEM-1, TEM-2 and SHV-1,
rather than the progeny. Challenge with the 3GCs would select the most resistant p-lactamase expressed in
the bacterial flora. Only when such an event has occurred will a second mutation event occur to expand the
spectrum of the enzyme further. A third mutation may occur during continued treatmentwith 3GCs to expand
the spectrum of the p-lactamase further.
Cross-infection to other patients or escape into the environment may result in the challenge of the host
organism with a penicillin and a p-lactamase inhibitor. Such a biological pressure would select against the
extended-spectrum p-lactamase andmay induce backmutations to themore innocuous enzymes, TEM-17 or
SHV-3 for example.
We suggest the hypothesis that the evolution of the parent p-lactamase to broad-spectrum enzyme can consist
of both forward and backward mutations at well defined locations.
Our results suggest that amoxycillin in combination with clavulanic acid selects back mutations to TEM-1 and
other extended-spectrum p-lactamases. The back mutations are facilitated by gene duplication. The host
organism will also contain a heterogenous population of a clinical plasmid. We believe that point-mutations
occur in the TEM-gene during duplication of the gene. In a non-selective environment one of the duplicate
genes is usually deleted. However, the results of this experiment show thatthe selective pressurewhich results
from the combination of a penicillin, such as amoxycillin, with clavulanic acid preserves the presence of
duplicate genes on the same plasmid.
The acquistion of more than one ESBL by the cell broadens the resistance profile of the bacterium allowing
significant 3GC, penicillin, and p-lactamase inhibitor resistance. A subsequent challenge with amoxycillin/
clavulanic acid may promote further back-mutation towards TEM-1, away from ESBL activity. However, the
use of a 3GC may select novel ESBL, not necessarily the ancestral ESBL.
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